<SEC-DOCUMENT>0001280776-23-000018.txt : 20231114
<SEC-HEADER>0001280776-23-000018.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114072704
ACCESSION NUMBER:		0001280776-23-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		231401578

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20230930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051,d:d5353bfea53f4d57897f6da50a88ea3b--><html xmlns:vtl="http://vitaltherapies.com/20230930" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-28">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="c-82" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-333">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-353">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-354">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-515">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" xsi:nil="true" name="us-gaap:SubsequentEventsTextBlock" id="f-597"></ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-17</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financialinstitution"><xbrli:measure>vtl:financialInstitution</xbrli:measure></xbrli:unit><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>vtl:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-28</xbrli:startDate><xbrli:endDate>2023-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-27</xbrli:startDate><xbrli:endDate>2023-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id5353bfea53f4d57897f6da50a88ea3b_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">332</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On October 31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">45,145,383</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_10">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_10">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_10">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_13">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_16">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_19">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_61">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_73">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_76">35</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_82">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_85">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_88">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_94">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_97">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id5353bfea53f4d57897f6da50a88ea3b_100">37</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">59,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-34">9,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">65,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">125,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-41">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-43">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-44">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">66,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">13,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-51">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-52">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">17,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-55">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-56">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="f-57">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="f-58">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-59">18,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-60">14,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-61"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-62"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-63"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-64">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-66">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-70">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at September 30, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-78">44,595,383</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-80">39,307,286</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-81">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-82">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-83">433,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-85">3,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-86">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-87">389,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-88">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">48,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">66,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:49.696%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">19,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-94">16,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-95">63,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-96">50,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">3,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-98">3,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">11,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">11,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-101">23,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-102">20,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">75,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-104">62,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">23,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">20,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">75,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">62,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-109">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-110">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-111">2,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-112">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-113">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">1,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">1,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">2,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-117">801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">1,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">3,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">1,772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">22,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">21,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">72,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">63,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-125"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-126">0.51</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-127"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-128">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-129"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130">1.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-132">2.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-134">44,574,377</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">30,564,995</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-138">44,227,264</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-139"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-140">29,655,946</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:55.298%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">22,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">21,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">72,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">63,933</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-145">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-146">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-147">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-148">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">22,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-150">20,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-151">71,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-152">64,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_19"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of  Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:43.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153">39,307,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-154">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-163">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-164">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued from exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-165">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-166">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-167">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">44,403,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">429,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">342,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">91,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">23,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">23,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-176">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-178">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-179">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-180">84,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-181">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-182">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">44,488,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-184">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">431,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">366,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">69,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">22,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">22,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-191">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-192">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-193">9</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-194">107,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-195">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-196">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-197">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-198">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-199">44,595,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-200">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">433,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">3,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">389,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">48,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:42.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-205">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-206">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-208">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">196,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-212">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-213">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-214">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-215">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-216">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="f-217">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-218">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-219">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-220">918</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-221">2,904,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-222">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-223">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-224">29,240,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-225">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">355,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-227">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-228">217,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">137,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-230">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-233">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-234">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-235">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-236">24,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-237">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-238">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-239">308</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-240">1,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-241">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-242">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-243">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-244">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">368,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-246">660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-247">239,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">127,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-249">21,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-250">21,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-251">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-253">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-254">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-255">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-256">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">369,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-258">386</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-259">260,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">108,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_25"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"></td><td style="width:79.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-261">72,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-262">63,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-263">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-264">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-265">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-266">4,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-267">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-268">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-269">3,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-270">2,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-271">951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-272">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-273">5,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="f-274">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-275">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-276">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-277">56,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-278">50,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-279">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-280">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of investments - Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-281">9,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:fixed-zero" scale="3" id="f-282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-283">9,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-284">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-285">9</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-286">1,226</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-287">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-288">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-290">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-291">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-293">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-294">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-295">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-296">39,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-297">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-298">3,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-299">47,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-300">14,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-301">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-302">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-303">59,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-304">72,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-305">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-307" continuedAt="f-307-1" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="f-307-1" continuedAt="f-307-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="c-3" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="f-308">80</ix:nonFraction> employees.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:NumberOfDevelopmentPrograms" format="ixt-sec:numwordsen" id="f-309">three</ix:nonFraction> development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-310">389.3</ix:nonFraction> million as of September 30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-311">317.3</ix:nonFraction> million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2023, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-312">355.9</ix:nonFraction> million from private and public offerings of preferred and common stock. As of September 30, 2023, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-313">59.7</ix:nonFraction> million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital and such actions are not solely within the control of the Company.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-314" continuedAt="f-314-1" escape="true">Basis of Presentation and Consolidation</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-314-1">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</ix:continuation> </span></div><div style="margin-top:12pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-307-2">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation> </span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-315" continuedAt="f-315-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-315-1" continuedAt="f-315-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-316" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-317" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" id="f-318" continuedAt="f-318-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-319">35.4</ix:nonFraction>&#160;million, Germany of approximately $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-320">22.4</ix:nonFraction>&#160;million and Australia of approximately $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-321">1.9</ix:nonFraction>&#160;million as of September 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="c-3" decimals="INF" name="vtl:NumberOfFinancialInstitutionsUsedForCashDeposit" format="ixt-sec:numwordsen" scale="0" id="f-322">two</ix:nonFraction> large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of September 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-77" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-323">5.0</ix:nonFraction>%. Cash and cash equivalents in Germany were earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-78" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-324">2.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-325">3.25</ix:nonFraction>% during the period ended September 30, 2023.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-315-2" continuedAt="f-315-3"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="f-318-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentTableTextBlock" id="f-326" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:56.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="f-327">0</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-328">9,629</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="f-329">0</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-330">9,629</ix:nonFraction></span></td></tr></table></ix:nonNumeric></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-331" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-332" continuedAt="f-332-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-332-1">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-333">three</span> to <ix:nonNumeric contextRef="c-83" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-334">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-335">34,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-336">17,000</ix:nonFraction> for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-337">88,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-338">58,000</ix:nonFraction> for the nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-339" continuedAt="f-339-1" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-339-1">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-340"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-341"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-342"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-343">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses during the three and nine months ended September 30, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-344" continuedAt="f-344-1" escape="true"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-344-1">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-315-3" continuedAt="f-315-4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-345">33.0</ix:nonFraction>&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-346" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-347" continuedAt="f-347-1" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-347-1">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="f-348" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="vtl:GovernmentAssistanceRate" scale="-2" id="f-349">43.5</ix:nonFraction>% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to <ix:nonFraction unitRef="eur" contextRef="c-85" decimals="INF" name="us-gaap:GovernmentAssistanceAmount" format="ixt-sec:numwordsen" scale="0" id="f-350">one million</ix:nonFraction> Euros per year. We recognized $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-351">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-352">2.3</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-353"><span style="-sec-ix-hidden:f-354">other income</span></span> related to research activities performed during the three and nine months ended September 30, 2023, respectively and  $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-355">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-356">2.0</ix:nonFraction>&#160;million  related to research activities performed during the three and nine months ended September 30, 2022, respectively.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-357" continuedAt="f-357-1" escape="true">General and Administrative Expenses</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-315-4" continuedAt="f-315-5"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-357-1">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-358" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-359" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="c-82" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-360">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="c-83" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-361">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" id="f-362">three</ix:nonFraction> existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-363" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-364" continuedAt="f-364-1" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-315-5"><ix:continuation id="f-364-1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-365" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-366">5,096,552</ix:nonFraction> pre-funded warrants were exercised in January 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-367" continuedAt="f-367-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-367-1">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-368" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-369">6,263,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-88" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-370">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-371" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="id5353bfea53f4d57897f6da50a88ea3b_37"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-372" continuedAt="f-372-1" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="f-372-1"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="f-373" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-374">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-375">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-376">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="f-377">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" scale="3" id="f-378">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-379">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-380">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-381">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-382">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-383">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-384" continuedAt="f-384-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-385">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-386">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-387">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-388">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-389">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-390">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-391">3,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-392">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:continuation id="f-384-1"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-393">12,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-394">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-395">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-396">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedCompensationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-397">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="f-398">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-399">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-400">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-401">13,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-402">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-403" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-404">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-405">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-406">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-407">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-408">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-409">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-410" continuedAt="f-410-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-410-1" continuedAt="f-410-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional <ix:nonNumeric contextRef="c-89" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-411">27</ix:nonNumeric> months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="c-90" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-412">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="c-91" name="vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-413">six month</ix:nonNumeric> rent holiday at the beginning of the lease as well as a <ix:nonNumeric contextRef="c-1" name="vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-414">three month</ix:nonNumeric> rent holiday upon the <ix:nonNumeric contextRef="c-89" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-415">27</ix:nonNumeric> month extension starting May 2023. There were net additions of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-416">544,000</ix:nonFraction> related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-417">6</ix:nonFraction>% for the original leases and <ix:nonFraction unitRef="number" contextRef="c-89" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-418">8</ix:nonFraction>% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-419">209,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-420">232,000</ix:nonFraction> for the three months ended September 30, 2023 and 2022, respectively and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-421">642,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-422">498,000</ix:nonFraction> for the nine months ended September 30, 2023 and 2022, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-423" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:84.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-424">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-425">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-426">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-427">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-428">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="f-429">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-430">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-431">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-432">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="f-433">5.1</ix:nonFraction>&#160;million, all of which is expected to be paid in the next twelve months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-410-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="id5353bfea53f4d57897f6da50a88ea3b_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-434" continuedAt="f-434-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-434-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-435" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-436">35,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-437">35,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-440">35,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-441">35,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-444">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-445">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-449">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-74" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-452">5.0</ix:nonFraction>% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of September 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-453" continuedAt="f-453-1" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="f-453-1" continuedAt="f-453-2"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-454">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="vtl:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="f-455">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement. This 2020 Shelf Registration Statement will expire on November 24, 2023. The Company plans to file prior to that expiration date, a new shelf registration statement to replace the expiring Form S-3, which would permit the Company to: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expiring Form S-3; and (ii) offer and sell additional securities to be registered on the new Form S-3.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-456">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners LLC) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-112" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="f-457">ten</ix:nonFraction> days&#8217; prior notice, or by Leerink Prtners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-458">8.1</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-459">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC (now Leerink </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LLC)  as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-115" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="f-460">ten</ix:nonFraction> days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of October 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-461">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="f-462">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and nine months ended September 30, 2023, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-463"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-464">0.3</ix:nonFraction></ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-465"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-466">107,012</ix:nonFraction></ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="f-467"><ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="f-468">2.72</ix:nonFraction></ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-469"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-470">0.3</ix:nonFraction></ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="f-471"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="f-472">9,000</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-473">40.9</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-474">4,204,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="f-475">9.72</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-476">39.6</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="f-477">1.2</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-478">8,696,552</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-479">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-480">4.35</ix:nonFraction> per Share, and (ii) <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-481">5,096,552</ix:nonFraction> pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-482">4.34</ix:nonFraction> per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-453-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-483">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-484">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="c-3" decimals="INF" name="vtl:NumberOfVotesPerEachShareOfCommonStock" format="ixt-sec:numwordsen" id="f-485">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through September 30, 2023, <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="f-486"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="f-487">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-488">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-489">0.0001</ix:nonFraction> par value preferred stock, having rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-490">No</ix:nonFraction> preferred shares were outstanding as of September 30, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="f-491" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-492">32,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-493">6,263,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-494">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-495">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-496">4,085,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-497">10,471,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_49"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-498" continuedAt="f-498-1" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="f-498-1" continuedAt="f-498-2"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-499">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-500">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-501">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This maximum number was increased by <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-502">1</ix:nonFraction>&#160;million shares in September 2023, subject to approval by stockholders of the Company at the Company's Annual Stockholders meeting to be held in 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-503">167,642</ix:nonFraction> shares life-to-date under the ESPP.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-504">19,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-505">102,000</ix:nonFraction> of expense related to the plan during the three and nine months ended September 30, 2023, respectively.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-506">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-507">74,000</ix:nonFraction> of expense related to the plan during the three and nine months ended September 30, 2022, respectively.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-498-2" continuedAt="f-498-3"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-508">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="c-138" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="f-509">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-510">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-511">4,408,871</ix:nonFraction> shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-512">4,440,000</ix:nonFraction> shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="c-141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="f-513">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="c-142" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-514">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-515">three</span> or <ix:nonNumeric contextRef="c-144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-516">four years</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-517" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-518">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-519">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-520">2,740,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-521">1.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-524">268,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-525">7.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-526">6,263,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-527">7.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-528">8.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-529">119,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-530">6,263,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-531">7.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-532">8.27</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-533">119,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-534">2,393,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-535">11.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-536">7.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-537">6,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:51.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-538">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-539">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-540">1,837,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-541">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="f-542">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-543">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-544">194,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-545">11.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-546">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-547">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-548">8.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-549">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-550">3,799,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-551">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-552">8.59</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-553">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-554">1,248,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-555">13.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-149" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-556">7.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-498-3" continuedAt="f-498-4"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-558">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-559">1.32</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-560">6.94</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-561" continuedAt="f-561-1" escape="true">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="f-561-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-562">4.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-563">2.04</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-564">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-565">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-151" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-566">96.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-152" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-567">97.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-568">6.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-152" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-569">6.00</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-570" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-571">815,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-572">831,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-573">2,607,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-574">2,392,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-575">872,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-576">1,081,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-577">2,857,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-578">3,651,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-579">1,687,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-580">1,912,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-581">5,464,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-582">6,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-583">12.7</ix:nonFraction> million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-584">2.90</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-498-4"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-585">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-586">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="f-587"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="f-588"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="f-589"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt-sec:numwordsen" scale="0" id="f-590">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_52"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="vtl:ChangesInBoardOfDirectorsDisclosureTextBlock" id="f-591" continuedAt="f-591-1" escape="true">Changes in Board of Directors</ix:nonNumeric></span></div><ix:continuation id="f-591-1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s initial term lasted until the 2023 Annual Meeting of Stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held on June 28, 2023, at which meeting he was elected to a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-171" name="vtl:RelatedPartyTransactionBoardOfDirectorTerm" format="ixt-sec:durwordsen" id="f-592">three year</ix:nonNumeric> term expiring at the 2026 Annual Meeting of Stockholders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for MS. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#8216;s extensive leadership in clinical research and development of MS treatments provides valuable clinical, strategy and management skills to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Director Resignation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Vincent Ossipow retired from the Board of Directors on June 28, 2023. Dr. Ossipow&#8217;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies or practices.</span></div></ix:continuation><div><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-593" continuedAt="f-593-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-593-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-594">30,250</ix:nonFraction> per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#8217;s monthly base salary to $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-595">32,368</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-596">30,250</ix:nonFraction> (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_61"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item 1 &#8220;Financial Statements&#8221; in this Quarterly Report and audited Consolidated Financial Statements for the years ended December 31, 2022 and 2021 of Immunic, Inc. filed with the Securities and Exchange Commission ("SEC"), in our Annual Report on Form 10-K on February 23, 2023. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors&#8221; and in the section headed &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the SEC on February 23, 2023, and the differences may be material. These risk factors include, but are not limited to statements relating to our three development programs and the targeted diseases; the potential for vidofludimus calcium, IMU-856 and IMU-381 to safely and effectively target diseases; preclinical and clinical data for the Company&#8217;s development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; the Company&#8217;s expected cash runway; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 80 employees.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="margin-top:12pt;text-align:justify"><img src="vtl-20230930_g1.jpg" alt="pipeline_20231018_2000px.jpg" style="height:277px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) are ongoing. On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium&#8217;s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential. Top-line data from the CALLIPER trial, for which the recruitment of in total 467 patients was completed in August 2023, is expected to be available in April of 2025. Moreover, we currently expect to report an interim futility analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials at the end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium, with combined anti-inflammatory, antiviral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Recently published preclinical data showed that vidofludimus calcium activates the neuroprotective transcription factor nuclear receptor related 1 (&#8220;Nurr1&#8221;), which is associated with direct neuroprotective properties and may enhance the potential benefit for patients. Additionally, vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and antiviral effects of vidofludimus calcium. We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting MS patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&#8220;NfL&#8221;), an important biomarker of neuronal death. Vidofludimus calcium has shown in clinical trials reported to date a consistent pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,400 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (&#8220;SIRT6&#8221;), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications and may allow the potential for combination with available treatments in gastroenterological diseases.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data from the final portion of a Phase 1 clinical trial in celiac disease patients during periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We are currently preparing clinical Phase 2 testing of IMU-856 in ongoing active celiac disease, while also considering further potential clinical applications in other gastrointestinal disorders.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic has selected IMU-381 as a development candidate to specifically address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with new antiviral molecules. We are exploring several options to possibly support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to perform research and development activities in the Australasia region. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $389.3 million as of September 30, 2023 and $317.3 million as of December 31, 2022. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to advance our clinical pipeline of product candidates.  We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of clinical development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2023, Immunic has raised net cash of approximately $355.9 million from private and public offerings of preferred and common stock. As of September 30, 2023, the Company had cash and cash equivalents of approximately $59.7 million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital and such actions are not solely within the control of the Company.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Strategy </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in MS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial, in patients with ongoing active celiac disease.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Continuing preclinical research to complement the existing clinical activities, explore additional indications for future development, and where appropriate, generate additional molecules for future development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2023, we announced that we have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/391,442, entitled, &#8220;Treatment of Multiple Sclerosis Comprising DHODH Inhibitors,&#8221; covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium and other salt as well as free acid forms for the treatment of RMS. The claims are expected to provide protection into 2041, unless extended further.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 9, 2023, we announced positive interim data from our phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. The predefined interim analysis examined the change from baseline to 24 weeks in serum NfL and glial fibrillar acidic protein ("GFAP") levels among approximately the first half of patients enrolled in this trial.   We believe that this data showed biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Serum NfL responses were consistently observed for vidofludimus calcium across progressive MS disease and all subpopulations. In the overall PMS population at 24 weeks (N=203), vidofludimus calcium was associated with a 6.7% reduction from baseline in serum NfL, compared to a 15.8% increase over baseline in placebo (p=0.01, post hoc). At 48 weeks (N=79), vidofludimus calcium reduced serum NfL by 10.4% from baseline, compared to a 6.4% increase in placebo. Substantial reductions were also seen across all PMS subtypes, as well as in patients that show or do not show disease and/or magnetic resonance imaging ("MRI") activity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although early, interim GFAP data also showed a promising signal: at 24 weeks (N=203), GFAP increased by 3.7% for vidofludimus calcium, and 4.4% for placebo. At 48 weeks (N=79), the change was only 2.7% for vidofludimus calcium, with a 6.4% increase for placebo. Progression of GFAP response is generally thought to evolve more slowly than NfL, and we believe that a longer follow-up may further strengthen this signal.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Completion of Enrollment of Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2023, we announced completion of enrollment of our phase 2 CALLIPER trial of vidofludimus calcium in patients with PMS. In total, 467 patients with primary PMS, or active or non-active secondary PMS have been randomized to either 45mg of vidofludimus calcium or placebo.  A top-line data readout of the full 467 patients is expected in April of 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in MS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2023, we announced the publication of preclinical data showing that vidofludimus calcium acts as a potent Nurr1 activator, in addition to its known mode of action as a DHODH inhibitor. Activation of Nurr1 could be responsible for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the drug&#8217;s postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in MS patients. Specifically, preclinical data shows potent Nurr1 activation by vidofludimus calcium at low concentrations in several test systems. The data was published in the peer-reviewed, high impact Journal of Medicinal Chemistry, in a paper entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Development of a potent Nurr1 agonist tool for in vivo applications.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2023, we announced the presentation of clinical and preclinical data for IMU-856 as a virtual e-poster at Digestive Disease Week 2023. Included in this presentation were new data on IMU-856&#8217;s mode of action as a potent modulator of SIRT6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, we announced positive results from the part C portion of our Phase 1 clinical trial of IMU-856 in patients with celiac disease. The data demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this data set provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture. The data provides first clinical evidence that IMU-856&#8217;s ability, observed in preclinical studies, to re-establish proper gut cell renewal translates into clinical benefits for patients with celiac disease. Most importantly, the observed protection of intestinal villi from gluten-induced destruction, independent of targeting immune mechanisms involved specifically in celiac disease, appears to be unique among proposed therapeutic approaches and may be applicable to other gastrointestinal diseases such as UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, we announced the appointment of Dr. Richard Rudick as a member of our Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s initial term lasted until our 2023 Annual Meeting of Stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held on June 28, 2023, at which meeting he was elected to a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three year term expiring at the 2026 Annual Meeting of Stockholders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for MS. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#8216;s extensive leadership in clinical research and development of MS treatments provides valuable clinical, strategy and management skills to the Board.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Director Resignation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Vincent Ossipow retired from the Board of Directors on June 28, 2023. Dr. Ossipow&#8217;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe UC</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, we reported positive data from the maintenance phase of our Phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe UC. The data showed a dose-linear increase in clinical remission as compared to placebo at week 50. Moreover, an exploratory statistical analysis confirmed the 30 mg dose of vidofludimus calcium to be statistically superior (p=0.0358) in achieving clinical remission at week 50, with a 33.7% absolute improvement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over placebo. A similar effect on clinical remission rates at week 50 was also found among those patients who received corticosteroids during the induction phase. Finally, a dose-linear increase in endoscopic healing was observed, with the 30 mg dose of vidofludimus calcium being associated with a 37.8% absolute improvement over placebo and also achieving statistical significance in an exploratory statistical analysis (p=0.0259).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the maintenance phase data of CALDOSE-1 confirms vidofludimus calcium's activity in the absence of chronic corticosteroid co-administration. Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in the maintenance phase of this trial was observed to be safe and well-tolerated.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deprioritization of Izumerogant (IMU-935) Development Program</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to focus on the rapidly advancing vidofludimus calcium and IMU-856 programs, and considering the totality of available data for izumerogant, including changes in expected time to market and increased complexity of potential further development in this competitive field, we announced on April 5, 2023 to focus our resources and, therefore, deprioritized the clinical portion of our izumerogant development program in psoriasis and castration-resistant prostate cancer.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $278.8 million in research and development expenses through September 30, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $726,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $726,000 of income in total of which $67,000 and $100,000 were recorded in the nine months ended September 30, 2023 and 2022, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. The funding of this grant is now completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2022 and 2023 as global interest rates have been increasing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia, a German Government research and development grant and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future. The intercompany loan between Immunic, Inc. and Immunic AG was settled on September 28, 2022 through an equity infusion from Immunic, Inc. to Immunic AG.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2023 and 2022 </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended September 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,454&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,116)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,454)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,108)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,769)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,224)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses increased by $3.3 million during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase reflects (i) a $2.8 million increase in external development costs related to the Phase 3 clinical program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $1.2 million increase in drug supply costs for vidofludimus calcium to support our ongoing trials, (iii) a $1.0 million increase in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $0.5 million increase in personnel expense in research and development related to an increase in headcount and (v) a $0.9 million increase in related costs across numerous categories. The increases were partially offset by (i) a decrease of $2.5 million resulting from deprioritizing the izumerogant program in psoriasis and castration-resistant prostate cancer and (ii) a $0.6 million decrease in external development costs related to the Phase 1 clinical trial of IMU-856. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $0.2 million during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. This increase was spread across numerous categories.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income increased by $1.9 million during the three months ended September 30, 2023, as compared to the three months ended September 30, 2022. The increase was primarily attributable to (i) a $1.8 million decrease in foreign exchange losses and (ii) a $0.5 million increase in interest income as a result of higher interest rates. The increase was partially offset by a $0.4 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia primarily for IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Nine Months Ended September 30, 2023 and 2022 </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the nine months ended September 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,842&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,161&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75,842)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,681)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,802&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,574&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,040)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,933)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,107)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $13.4 million during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase reflects (i) a $10.1 million increase in external development costs related to the Phase 3 clinical program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $2.9 million increase in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in progressive multiple sclerosis, (iii) a $2.3 million increase in drug supply costs for vidofludimus calcium to support our ongoing trials, (iv) a $1.8 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, (v) a $1.6 million increase in personnel expense in research and development related to an increase in headcount, $0.2 million of which was due to non-cash stock based compensation and (vi) a $0.5 million increase in related costs across numerous categories. The increases were partially offset by (i) a decrease of $4.0 million from deprioritizing the izumerogant program in psoriasis and castration-resistant prostate cancer and (ii) a decrease of $1.8 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $0.3 million during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily due to (i) a $0.2 million increase in travel expense, (ii) a $0.2 million increase in legal and consultancy expense and (iii) a $0.5 million increase across numerous categories. The increases were partially offset by a decrease of $0.6 million in personnel expense in general and administrative which was primarily due to non-cash stock based compensation decrease.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income increased by $5.6 million during the nine months ended September 30, 2023, as compared to the nine months ended September 30, 2022. The increase was primarily attributable to (i) a $2.2 million increase in interest income as a result of higher interest rates, (ii) a $3.2 million decrease in foreign exchange losses and (iii) a $1.1 million research allowance attributable to tax year 2021 from the German Federal Ministry of Finance. The increase was partially offset by a $0.9 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016.  We have an accumulated deficit of approximately $389.3 million at September 30, 2023 and $317.3 million as of December 31, 2022.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2023, Immunic has raised net cash of approximately $355.9 million from private and public offerings of preferred and common stock. As of September 30, 2023, the Company had cash and cash equivalents of approximately $59.7 million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital and such actions are not solely within the control of the Company.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of October 31, 2023, there is $75.0&#160;million remaining on this shelf registration statement. The 2020 Shelf Registration Statement expires on November 24, 2023. The Company plans to file prior to that expiration date, a new shelf registration statement on Form S-3 to replace the expiring 2020 Shelf Registration Statement, which would permit the Company to:  (i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expiring 2020 Shelf Registration Statement; and (ii) offer and sell additional securities to be registered on the new Form S-3</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners LLC) as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2023, $8.1&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Securities LLC (now Leerink Partners LLC)   as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of October 31, 2023, $80.0 million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and nine months ended September 30, 2023, we raised gross proceeds of $0.3&#160;million pursuant to the December 2020 ATM through the sale of 107,012 shares of common stock at a weighted average price of $2.72 per share. The net proceeds from the December 2020 ATM were $0.3&#160;million after deducting underwriter commissions of $9,000. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, we did not raise any proceeds under our ATM facilities.  In the nine months ended September 30, 2022, we raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. We expect our expenses to continue to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, duration, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of all the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of izumerogant in moderate-to-severe psoriasis. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have to curtail our product development programs and liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, we had cash and cash equivalents of approximately $59.7 million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of the financial statements in this Form 10-Q without raising additional capital, which the Company believes could be very challenging, as well as highly-dilutive.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the nine months ended September 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,801)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,040)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, operating activities used $56.8&#160;million of cash. The use of cash primarily resulted from (i) our net loss of $72.0 million adjusted for non-cash charges of $6.3 million related to $0.7 million for an unrealized foreign currency loss and $5.6 million related to stock-based compensation and depreciation and amortization and a $9.0&#160;million net increase in operating assets and liabilities. Changes in our operating assets and liabilities during the nine months ended September 30, 2023 consisted primarily of (i) a $3.9 million increase in our other current assets and prepaid expenses and (ii) an increase of $5.1 million in our other current liabilities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, operating activities used $50.0&#160;million of cash. The use of cash primarily resulted from (i) our net loss of $63.9 million adjusted for non-cash charges of $10.3 million related to $4.2 million for an unrealized foreign currency loss and $6.1 million related to stock-based compensation and depreciation and amortization and a $3.6&#160;million net increase in operating assets and liabilities. Changes in our operating assets and liabilities during the nine months ended September 30, 2022 consisted primarily of (i) a $2.0 million increase in our other current assets and prepaid expenses and (ii) an increase of $1.6 million in our other current liabilities.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, net investing activities provided $9.6 million of cash, primarily due to the sale of $9.8 million of time deposits partially offset by the purchase of $169,000 of property and equipment. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $113,000 during the nine months ended September 30, 2022, which was related to the purchase of property and equipment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $0.4 million during the nine months ended September 30, 2023 consisting primarily of net cash proceeds from the sale of common stock under our 2020 ATM facility. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $39.7 million during the nine months ended September 30, 2022 consisting primarily of net cash proceeds from the sale of common stock under our 2020 ATM facility. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September 30, 2023, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2023:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:84.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, we have non-cancelable contractual obligations under certain agreements related to our development programs IMU-838, IMU-935 and IMU-856 totaling approximately $5.1 million, all of which is expected to be paid over the next twelve months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2023, there were no significant changes in our critical accounting policies or in the methodology used for estimates. Our significant accounting policies are described in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) our audited consolidated financial statements for the years ended December 31, 2022 and 2021 filed in our Annual Report on Form 10-K on February 23, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $59.7 million as of September 30, 2023, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $22.4 million of these funds are held in German bank accounts that were earning between 2.00%-3.25% interest as of September 30, 2023.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our condensed consolidated balance sheets. As of September 30, 2023, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $12.8 million. A decrease of approximately $1.3 million in net current assets would result as of September 30, 2023, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the nine months ended September 30, 2023, would have impacted our net loss by approximately $6.3 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934 ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the nine months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_79"></div><div><span><br/></span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. It is not uncommon for lawsuits to be filed alleging lack of process or breach of fiduciary duties by directors, and we may face such suits in the future. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which we strongly encourage you to review. Other than as set forth below, there have been no material changes to the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, transactional counterparties, or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have recently led to market-wide liquidity problems. In March 2023, Silicon Valley Bank, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although financial regulators have taken measures to prevent further bank closures, these risks remain. If we were to borrow money in the future and if any of our lenders or counterparties to any such instruments were to be placed into receivership, or if we had cash deposits at any such banks, we may be unable to access our funds. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we assess our banking and financing relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations, clinical programs and product development could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit, or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and stricter financial and operating covenants, or limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws if, for example, we were unable to obtain access to deposits used for payroll. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our clinical trials have been delayed as a result of the ongoing military action by Russia in Ukraine and may also be delayed by the recent outbreak of war in the Middle East. The continuation of these conflicts could have further adverse effects on our business.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our clinical trials of vidofludimus calcium were originally planned to be conducted at more than 60 sites in Ukraine and Russia, but most had to be relocated to other countries because of the invasion of Ukraine by Russia in February 2022 and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">resulting sanctions imposed on Russia by the United States and other countries. These disruptions delayed our clinical development program, increased our costs and may disrupt future planned clinical development activities in these two countries. This military action has continued for more than a year and its future course and effects on our Company are highly unpredictable. We currently have 19 active sites in western Ukraine and the ongoing conflict could put the data associated with these patients in jeopardy as well as extend patient recruitment timelines. We anticipate that Ukraine will make up approximately 15%-20% of our ENSURE- 1 and ENSURE-2 phase 3 patient population. In addition, no clinical sites in Russia have been activated or are intended to be used in the future. Alternative sites to fully and timely compensate for our clinical trial activities in Ukraine may not continue to be available. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The recent outbreak of war between Israel and Hamas may also result in delays or suspensions of our clinical trials in the Middle East.  We have already and plan to open in the next few months additional clinical trial sites in Lebanon and Jordan..  Attacks on northern Israel by Hamas allies from Lebanon have resulted in retaliatory strikes in Lebanon by Israel.  Hostilities could escalate further and involve other countries in the Middle East where we have or plan to have clinical trial sites. </span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If our clinical trials are further interrupted, our clinical development program could experience further delays and increased costs and we may have insufficient data to support regulatory approvals of vidofludimus calcium, and any commercialization may be delayed or not approved, which could limit our potential revenue and hurt the competitive position of our potential products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id5353bfea53f4d57897f6da50a88ea3b_100"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 21, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-1.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-2.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-3.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231202311.htm">Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-93023xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-9x3023xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-9x30x23xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-93023xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="id5353bfea53f4d57897f6da50a88ea3b_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;14, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit231202311.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac611201f19c44c5be59f56f21b26608_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements on Form S&#8209;3 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">225230, 333-250083, 333-255303, and 333-268737), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Form S&#8209;4 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">229510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">), and Form S-8 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">233864 and 333-258235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">) of Immunic, Inc. of our report dated February 23, 2023, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s&#47; Baker Tilly US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minneapolis, Minnesota </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">February 23, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>imux-93023xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i08ddf1951e21430d885ab1bdbbc72bef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 14, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>imux-9x3023xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idaf29f944a7e4bacaed23c0480e2236d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 14, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>imux-9x30x23xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic861766b4d424961a7e70b557264b2d2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 14, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>imux-93023xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaecc62c983da450499665db2770cb9e1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 14, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtl-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000010 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>0000012 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>0000014 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>0000015 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinBoardofDirectors" roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectors">
        <link:definition>0000017 - Disclosure - Changes in Board of Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>0000018 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vitaltherapies.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>9954473 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954474 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>9954475 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>9954476 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>9954477 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>9954481 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>9954482 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>9954483 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>9954484 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>9954485 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9954486 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>9954487 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>9954487 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954488 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalInformationDetail" roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail">
        <link:definition>9954489 - Disclosure - Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityOfferingDetails" roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails">
        <link:definition>9954491 - Disclosure - Common Stock - Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>9954492 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>9954493 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>9954494 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>9954495 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>9954496 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>9954497 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ChangesinBoardofDirectorsDetails" roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails">
        <link:definition>9954499 - Disclosure - Changes in Board of Directors (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>9954500 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_GovernmentAssistanceRate" abstract="false" name="GovernmentAssistanceRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" abstract="false" name="ChangesInBoardOfDirectorsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PlaneggGermanyMember" abstract="true" name="PlaneggGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_RelatedPartyTransactionBoardOfDirectorTerm" abstract="false" name="RelatedPartyTransactionBoardOfDirectorTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="vtl_NumberOfVotesPerEachShareOfCommonStock" abstract="false" name="NumberOfVotesPerEachShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_AustraliaAndGermanyMember" abstract="true" name="AustraliaAndGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtl-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_433730ae-818f-4d4e-8dfc-ab4d94d8aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7adc1fce-c8ee-4580-934c-6fcad2255593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_433730ae-818f-4d4e-8dfc-ab4d94d8aa03" xlink:to="loc_us-gaap_LiabilitiesCurrent_7adc1fce-c8ee-4580-934c-6fcad2255593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9c3f952d-2674-4640-95bc-2212f8105e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_433730ae-818f-4d4e-8dfc-ab4d94d8aa03" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9c3f952d-2674-4640-95bc-2212f8105e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_7c3f5420-e314-422a-a6fb-c7c03f94152c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2db821d7-c18d-4e56-89cc-46536bad5ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_7c3f5420-e314-422a-a6fb-c7c03f94152c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2db821d7-c18d-4e56-89cc-46536bad5ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_baf6e8cb-2c74-483a-92b5-5b3714b7455d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e98a9e6f-dd7b-475c-bd36-2320ea1f0fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_baf6e8cb-2c74-483a-92b5-5b3714b7455d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e98a9e6f-dd7b-475c-bd36-2320ea1f0fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_bf0efdd9-3fd6-4b9d-9062-c2c6307d571f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_baf6e8cb-2c74-483a-92b5-5b3714b7455d" xlink:to="loc_us-gaap_OtherShortTermInvestments_bf0efdd9-3fd6-4b9d-9062-c2c6307d571f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f30d841-0c43-40c8-a8e8-045b0fcf0be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_baf6e8cb-2c74-483a-92b5-5b3714b7455d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4f30d841-0c43-40c8-a8e8-045b0fcf0be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26a6a7b5-f426-4725-b315-bba57275ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e71d8e86-f11f-4236-90ec-aaa242e7e57b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26a6a7b5-f426-4725-b315-bba57275ffc1" xlink:to="loc_us-gaap_AssetsCurrent_e71d8e86-f11f-4236-90ec-aaa242e7e57b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_948cec7c-d898-4ccd-ac26-41c397cee407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26a6a7b5-f426-4725-b315-bba57275ffc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_948cec7c-d898-4ccd-ac26-41c397cee407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f18a920f-1f70-413f-acfe-cce418d0d204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26a6a7b5-f426-4725-b315-bba57275ffc1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f18a920f-1f70-413f-acfe-cce418d0d204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3902af7-3f29-4dad-a775-d138ac287608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26a6a7b5-f426-4725-b315-bba57275ffc1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3902af7-3f29-4dad-a775-d138ac287608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f08edf7f-8d02-40e8-b976-3fdc39dbf2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_84a3f788-0459-4cbf-bb73-63b8ad839467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f08edf7f-8d02-40e8-b976-3fdc39dbf2c9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_84a3f788-0459-4cbf-bb73-63b8ad839467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c404f4d-58ec-4bed-9103-4ce45fbbf462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f08edf7f-8d02-40e8-b976-3fdc39dbf2c9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c404f4d-58ec-4bed-9103-4ce45fbbf462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c9d5b95a-2df8-4ff4-85ff-ffd7398daae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f08edf7f-8d02-40e8-b976-3fdc39dbf2c9" xlink:to="loc_us-gaap_AccountsPayableCurrent_c9d5b95a-2df8-4ff4-85ff-ffd7398daae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9577528-73b9-4204-b098-20d844fada80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f957fbb0-e74e-4e24-b030-7300c6151fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9577528-73b9-4204-b098-20d844fada80" xlink:to="loc_us-gaap_StockholdersEquity_f957fbb0-e74e-4e24-b030-7300c6151fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_036d8e75-5c21-4c90-b39f-c5238654779d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9577528-73b9-4204-b098-20d844fada80" xlink:to="loc_us-gaap_Liabilities_036d8e75-5c21-4c90-b39f-c5238654779d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fab4b8b4-a5f6-4a78-9650-4e41a70778f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9577528-73b9-4204-b098-20d844fada80" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fab4b8b4-a5f6-4a78-9650-4e41a70778f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0e8fd2cc-533c-49eb-9954-f4c82596ffcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:to="loc_us-gaap_PreferredStockValue_0e8fd2cc-533c-49eb-9954-f4c82596ffcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a6c1701f-e85a-4007-8944-ed2b7863df10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:to="loc_us-gaap_CommonStockValue_a6c1701f-e85a-4007-8944-ed2b7863df10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bea1b3e8-16aa-4f23-9993-d9f4fe3fd136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bea1b3e8-16aa-4f23-9993-d9f4fe3fd136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e4c435e-ee72-4255-b5e0-1ea14e866e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e4c435e-ee72-4255-b5e0-1ea14e866e09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_84e1d86f-2d4d-41b9-b1a4-1e61fe82c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_960b2e7f-4b4e-4bd2-80a2-660096b0822d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_84e1d86f-2d4d-41b9-b1a4-1e61fe82c42d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7845f0a5-1aba-45b1-b09b-6fdd7cd731e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fe893e20-8fc6-4017-a5e1-5e82885c5979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7845f0a5-1aba-45b1-b09b-6fdd7cd731e9" xlink:to="loc_us-gaap_OperatingIncomeLoss_fe893e20-8fc6-4017-a5e1-5e82885c5979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ee5469a8-dd94-4e0e-b80b-04d11b0cfe42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7845f0a5-1aba-45b1-b09b-6fdd7cd731e9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ee5469a8-dd94-4e0e-b80b-04d11b0cfe42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f13bb9f6-ee06-497c-baaa-27306b152130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b6200923-0fbf-4c62-af7a-9a045da4f8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f13bb9f6-ee06-497c-baaa-27306b152130" xlink:to="loc_us-gaap_OperatingExpenses_b6200923-0fbf-4c62-af7a-9a045da4f8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2e5ee00f-5e77-41ee-89f2-9320ebc93ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_94852ebd-8881-4cc6-8d8d-b0a412233cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2e5ee00f-5e77-41ee-89f2-9320ebc93ddd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_94852ebd-8881-4cc6-8d8d-b0a412233cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bf71fd65-2f63-45cd-9e68-a2507674c03d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_2e5ee00f-5e77-41ee-89f2-9320ebc93ddd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bf71fd65-2f63-45cd-9e68-a2507674c03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_27104bce-384f-42d5-8eb5-56c19855db29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f965274c-ed8a-4ac0-b4f6-8c6e7f2486a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27104bce-384f-42d5-8eb5-56c19855db29" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f965274c-ed8a-4ac0-b4f6-8c6e7f2486a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3f38e229-4fbf-4427-a2e9-7bfdf7ad133e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27104bce-384f-42d5-8eb5-56c19855db29" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3f38e229-4fbf-4427-a2e9-7bfdf7ad133e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_035e78e3-a032-4fe7-ad83-af2c5e4f9974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4cf6b194-f123-4963-9dfa-90a6b6869822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_035e78e3-a032-4fe7-ad83-af2c5e4f9974" xlink:to="loc_us-gaap_NetIncomeLoss_4cf6b194-f123-4963-9dfa-90a6b6869822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_abec9b94-bfe3-4724-adcf-567626082273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_035e78e3-a032-4fe7-ad83-af2c5e4f9974" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_abec9b94-bfe3-4724-adcf-567626082273" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2f4fc278-f6c6-4e95-8350-9952481b4db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_NetIncomeLoss_2f4fc278-f6c6-4e95-8350-9952481b4db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_03089342-daaf-4391-99ff-fa0cd839335f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_03089342-daaf-4391-99ff-fa0cd839335f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d855175a-151c-4fd1-96b8-b426fa781694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_ShareBasedCompensation_d855175a-151c-4fd1-96b8-b426fa781694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbc0348e-a801-465e-b403-440d560ea5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fbc0348e-a801-465e-b403-440d560ea5c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_99e99952-0dbe-402b-a7d1-a6f3a93dee37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_99e99952-0dbe-402b-a7d1-a6f3a93dee37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b99338d7-79cf-43de-a42c-47eea68452b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_b99338d7-79cf-43de-a42c-47eea68452b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_81f1e643-30d4-4705-95d5-b7bf639cb029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_81f1e643-30d4-4705-95d5-b7bf639cb029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_4abbd6d8-90a1-4446-9bc4-9c7c32fa4047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_670e67c3-439f-4654-97ab-12c95fb4f9c0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_4abbd6d8-90a1-4446-9bc4-9c7c32fa4047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdef3143-7faf-4bc7-99c9-8fe1bd0b1f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d638a38d-c736-41d7-ba1f-9681feabd8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdef3143-7faf-4bc7-99c9-8fe1bd0b1f3a" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_d638a38d-c736-41d7-ba1f-9681feabd8bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d803328b-e36d-44b1-a7fa-6f31c784f894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdef3143-7faf-4bc7-99c9-8fe1bd0b1f3a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d803328b-e36d-44b1-a7fa-6f31c784f894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b011b00c-5fd7-45bd-bdc8-bf8a015956c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9e6955f1-466f-4066-9168-fc12ae063263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b011b00c-5fd7-45bd-bdc8-bf8a015956c9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9e6955f1-466f-4066-9168-fc12ae063263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657972b8-043b-4d12-b51a-9b3b7551554d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b011b00c-5fd7-45bd-bdc8-bf8a015956c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657972b8-043b-4d12-b51a-9b3b7551554d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_09ad93e5-468d-4301-8301-0340463061d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b011b00c-5fd7-45bd-bdc8-bf8a015956c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_09ad93e5-468d-4301-8301-0340463061d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_301ebe41-a2d8-4dc5-a748-19dac9093c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b011b00c-5fd7-45bd-bdc8-bf8a015956c9" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_301ebe41-a2d8-4dc5-a748-19dac9093c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c639ec3b-f2c8-428d-ba29-edb245f7f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9297757-7b81-468a-8f81-f5d0a4bf5bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c639ec3b-f2c8-428d-ba29-edb245f7f75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9297757-7b81-468a-8f81-f5d0a4bf5bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f43855-3e95-404e-bef5-7bfa41d62651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c639ec3b-f2c8-428d-ba29-edb245f7f75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f43855-3e95-404e-bef5-7bfa41d62651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_724edd44-e725-4650-99c5-d21e5f940f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c639ec3b-f2c8-428d-ba29-edb245f7f75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_724edd44-e725-4650-99c5-d21e5f940f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6b0dd0d-2755-4418-9d7e-68d75d38b249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c639ec3b-f2c8-428d-ba29-edb245f7f75d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6b0dd0d-2755-4418-9d7e-68d75d38b249" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ee9fe73-6ed2-4f61-ad93-0bf9b3812ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f1ac3dcf-2130-4fae-8ed6-0b2aea553f33" xlink:href="vtl-20230930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ee9fe73-6ed2-4f61-ad93-0bf9b3812ea3" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_f1ac3dcf-2130-4fae-8ed6-0b2aea553f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_05177780-8059-42ff-9994-4d4373af515a" xlink:href="vtl-20230930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ee9fe73-6ed2-4f61-ad93-0bf9b3812ea3" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_05177780-8059-42ff-9994-4d4373af515a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_0fdcf4d2-d875-4ee3-8fa4-04c801205146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ee9fe73-6ed2-4f61-ad93-0bf9b3812ea3" xlink:to="loc_us-gaap_OtherAssetsCurrent_0fdcf4d2-d875-4ee3-8fa4-04c801205146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_83cc962d-44ae-4634-9506-e3b11f0a0a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5ee9fe73-6ed2-4f61-ad93-0bf9b3812ea3" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_83cc962d-44ae-4634-9506-e3b11f0a0a65" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_91677add-8081-4077-a432-61b379d22775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_779e5d55-145e-43d9-8aac-4d1232be25bb" xlink:href="vtl-20230930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_91677add-8081-4077-a432-61b379d22775" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_779e5d55-145e-43d9-8aac-4d1232be25bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_6dd3a1b0-f2cc-4d03-a96c-459db0601bdd" xlink:href="vtl-20230930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_91677add-8081-4077-a432-61b379d22775" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_6dd3a1b0-f2cc-4d03-a96c-459db0601bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_5b58adcd-0b39-4417-8c3f-df0772577318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_91677add-8081-4077-a432-61b379d22775" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_5b58adcd-0b39-4417-8c3f-df0772577318" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_946119aa-11b1-4f29-97b9-06e9f65dea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_915670bb-71ba-40ab-ba8b-29d47af9834e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_946119aa-11b1-4f29-97b9-06e9f65dea4d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_915670bb-71ba-40ab-ba8b-29d47af9834e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_b2efe264-0ac8-4870-82f6-0c6c087848f1" xlink:href="vtl-20230930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_946119aa-11b1-4f29-97b9-06e9f65dea4d" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_b2efe264-0ac8-4870-82f6-0c6c087848f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_491883e7-cffa-4ac7-81f0-87297e4b1a81" xlink:href="vtl-20230930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_946119aa-11b1-4f29-97b9-06e9f65dea4d" xlink:to="loc_vtl_AccruedCompensationCurrent_491883e7-cffa-4ac7-81f0-87297e4b1a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_bad79979-be6a-457a-ad38-eb1fcf23f0c8" xlink:href="vtl-20230930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_946119aa-11b1-4f29-97b9-06e9f65dea4d" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_bad79979-be6a-457a-ad38-eb1fcf23f0c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e4ec13c4-bd55-424b-948f-94e6adc04ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_d14cd6d0-b763-48f0-8235-ce0b4b8b56f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e4ec13c4-bd55-424b-948f-94e6adc04ca7" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_d14cd6d0-b763-48f0-8235-ce0b4b8b56f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2974989c-2f91-4eb9-a651-be9fa3f92464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e4ec13c4-bd55-424b-948f-94e6adc04ca7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2974989c-2f91-4eb9-a651-be9fa3f92464" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5a88ef9-eb03-48c7-b874-860850653f46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e7da2826-2050-426d-af38-8ee776d355f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5a88ef9-eb03-48c7-b874-860850653f46" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e7da2826-2050-426d-af38-8ee776d355f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d66af954-530d-42e8-845e-1881a0d2716a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f5a88ef9-eb03-48c7-b874-860850653f46" xlink:to="loc_us-gaap_OperatingLeaseLiability_d66af954-530d-42e8-845e-1881a0d2716a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6172461f-22d7-445c-b069-7d4ef50f60c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6172461f-22d7-445c-b069-7d4ef50f60c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7d413e00-d903-48c7-a75c-f9af9d3e03b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7d413e00-d903-48c7-a75c-f9af9d3e03b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_e4c3021f-6fe0-4067-a656-4645eaa53f00" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_e4c3021f-6fe0-4067-a656-4645eaa53f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_22ef76b9-bf9e-44ca-a126-09f033a1b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_22ef76b9-bf9e-44ca-a126-09f033a1b3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6f15018a-0ff3-41eb-be73-432fe587e71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6f15018a-0ff3-41eb-be73-432fe587e71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f604b1a5-2154-4a73-803b-14b1e5192b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_79fe967d-824e-456f-88ed-698b8e1c5c52" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f604b1a5-2154-4a73-803b-14b1e5192b66" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtl-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6b2e1a1-65e8-4d75-897d-9c993eeaea48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6b2e1a1-65e8-4d75-897d-9c993eeaea48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_182eabfb-398d-4c38-bcd4-08bb332f7f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockholdersEquity_182eabfb-398d-4c38-bcd4-08bb332f7f8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adce9e39-fede-4bb0-a1b5-85aa744a3795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_NetIncomeLoss_adce9e39-fede-4bb0-a1b5-85aa744a3795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_09a592a6-7e70-4e60-8747-585061037c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_09a592a6-7e70-4e60-8747-585061037c9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66382c5a-88f4-4466-b5e1-f8f2d6c842de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66382c5a-88f4-4466-b5e1-f8f2d6c842de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb57d3ee-6e2a-4eb9-88cd-54fb5f4b650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb57d3ee-6e2a-4eb9-88cd-54fb5f4b650a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b32b53f2-716a-4713-afae-a9d6e2d74475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b32b53f2-716a-4713-afae-a9d6e2d74475" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b33bd17-42a8-4b92-8d57-68c8af2af1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b33bd17-42a8-4b92-8d57-68c8af2af1fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_92512e9b-3301-4b04-ba6b-c481623f5fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_92512e9b-3301-4b04-ba6b-c481623f5fbd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_beea34ee-aedc-41ab-934d-df295fe63b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_beea34ee-aedc-41ab-934d-df295fe63b6e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c042660-7a9b-45d4-8d01-e031c7e32081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c042660-7a9b-45d4-8d01-e031c7e32081" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0be0652d-11a7-4f4a-a13f-f262c020d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43be24e4-0e12-48e8-b866-3f3050390962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:to="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_81165421-bc26-4adb-b8ae-551650cf6ed8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:to="loc_us-gaap_EquityComponentDomain_81165421-bc26-4adb-b8ae-551650cf6ed8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:to="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b8e8376-7766-44f7-bf14-899dcf8a90bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_CommonStockMember_8b8e8376-7766-44f7-bf14-899dcf8a90bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4616ce83-8719-45e5-b722-afe4922e3e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4616ce83-8719-45e5-b722-afe4922e3e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7751e2b6-6763-4e53-bd65-50ffe4e19256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7751e2b6-6763-4e53-bd65-50ffe4e19256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1201af95-e2d2-4e22-bf5a-16c27ed072cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_RetainedEarningsMember_1201af95-e2d2-4e22-bf5a-16c27ed072cb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_a5b5bd3a-592b-4376-863e-5407fc03a56a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_dei_EntityNumberOfEmployees_a5b5bd3a-592b-4376-863e-5407fc03a56a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_1f60693d-179d-4ffe-923d-fcba9dea005c" xlink:href="vtl-20230930.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_1f60693d-179d-4ffe-923d-fcba9dea005c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f20ee4d-ceef-4094-b18c-435b6cda3de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f20ee4d-ceef-4094-b18c-435b6cda3de3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a730cf3c-0720-45ba-a455-f1449f7729cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a730cf3c-0720-45ba-a455-f1449f7729cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9b9f3f0-6368-4211-bd91-386c1452fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9b9f3f0-6368-4211-bd91-386c1452fdc5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4464166d-010a-4d10-a60f-a6d3f379604a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4464166d-010a-4d10-a60f-a6d3f379604a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c7d1a130-eb73-4507-92f9-993daa038129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:to="loc_us-gaap_SubsequentEventMember_c7d1a130-eb73-4507-92f9-993daa038129" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7a22670-7818-4d78-976f-c6f964d84975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7a22670-7818-4d78-976f-c6f964d84975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_c1ad408b-b617-46b9-b5ab-01f201c521e2" xlink:href="vtl-20230930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_c1ad408b-b617-46b9-b5ab-01f201c521e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_44337701-1efc-42ff-be61-0aa868c50418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_InvestmentInterestRate_44337701-1efc-42ff-be61-0aa868c50418" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8cbf559-20d6-4fc7-93c1-337e77d06c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8cbf559-20d6-4fc7-93c1-337e77d06c6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_547817e0-3a65-461f-b289-e602640a3360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_Depreciation_547817e0-3a65-461f-b289-e602640a3360" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_3c249d47-64dd-453a-be78-bb00d0dbaef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_3c249d47-64dd-453a-be78-bb00d0dbaef0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_79027644-a737-40d9-8fbd-900b0fe2f205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_79027644-a737-40d9-8fbd-900b0fe2f205" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_57c7fb48-511e-4236-8cec-fc8eff8d74a0" xlink:href="vtl-20230930.xsd#vtl_GovernmentAssistanceRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_GovernmentAssistanceRate_57c7fb48-511e-4236-8cec-fc8eff8d74a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_e856ab2a-a92b-46f5-a8a0-cf2135894751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_e856ab2a-a92b-46f5-a8a0-cf2135894751" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1f36f909-eac3-45e1-a76d-59489cc4cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1f36f909-eac3-45e1-a76d-59489cc4cf97" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_24d0b7c6-49f0-410e-81cb-c105d51c0c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_24d0b7c6-49f0-410e-81cb-c105d51c0c77" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_8d8c7941-75fa-40aa-8f79-90fced4bf737" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_8d8c7941-75fa-40aa-8f79-90fced4bf737" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1eb002bd-7395-4588-aec2-341d5b5785a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1eb002bd-7395-4588-aec2-341d5b5785a5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_49db0569-95fb-4062-8668-b17ea19cf974_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:to="loc_srt_SegmentGeographicalDomain_49db0569-95fb-4062-8668-b17ea19cf974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:to="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4cc2394a-2a6a-4772-a566-a4a232f5ff2e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_US_4cc2394a-2a6a-4772-a566-a4a232f5ff2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1b31505a-d89c-472a-a19a-5a3b34f0fc19" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_DE_1b31505a-d89c-472a-a19a-5a3b34f0fc19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_0f68179a-0d85-46a9-8865-6d22ce22317b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_AU_0f68179a-0d85-46a9-8865-6d22ce22317b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_5cbe6659-2dac-48ff-853f-035edbb00968" xlink:href="vtl-20230930.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_vtl_AustraliaAndGermanyMember_5cbe6659-2dac-48ff-853f-035edbb00968" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2f760cc-4d10-40e5-86f7-15c670959a79_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:to="loc_srt_RangeMember_d2f760cc-4d10-40e5-86f7-15c670959a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:to="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d943b8a9-86aa-4472-864d-b6f0725c275a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:to="loc_srt_MinimumMember_d943b8a9-86aa-4472-864d-b6f0725c275a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6aee9afe-d365-49fc-b0c4-73a4781d8ac4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:to="loc_srt_MaximumMember_6aee9afe-d365-49fc-b0c4-73a4781d8ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_80dde5b1-cdff-4fc8-8249-a842b14ec226_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_80dde5b1-cdff-4fc8-8249-a842b14ec226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0a35c9ca-a9d2-45b1-8b85-7a6601d22b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0a35c9ca-a9d2-45b1-8b85-7a6601d22b16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_32b0f0e1-c792-44da-b86e-a3feef303a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:to="loc_us-gaap_BankTimeDepositsMember_32b0f0e1-c792-44da-b86e-a3feef303a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_a614308c-d9ab-4fb2-9391-dc545493a0a8" xlink:href="vtl-20230930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:to="loc_vtl_PreFundedWarrantsMember_a614308c-d9ab-4fb2-9391-dc545493a0a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_b1454610-4128-41f8-8768-876d1aab8c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:to="loc_us-gaap_OtherShortTermInvestments_b1454610-4128-41f8-8768-876d1aab8c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_94b31d08-6723-49b1-9e99-f7cc933677bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_94b31d08-6723-49b1-9e99-f7cc933677bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_60538a1d-741f-42b6-950a-ccb5648e7dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:to="loc_us-gaap_BankTimeDepositsMember_60538a1d-741f-42b6-950a-ccb5648e7dbe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e30961d-f360-478e-9080-dfc3ee2d6c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e30961d-f360-478e-9080-dfc3ee2d6c27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d68d0d0b-6d4b-4574-b77a-4e382279c2ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d68d0d0b-6d4b-4574-b77a-4e382279c2ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_10dc39f9-3db3-4c56-b7c7-3e3ef1d57690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:to="loc_us-gaap_StockOptionMember_10dc39f9-3db3-4c56-b7c7-3e3ef1d57690" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ea7ab4e6-7843-4243-8a1d-c1a8679f4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ea7ab4e6-7843-4243-8a1d-c1a8679f4c0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0cd83ec1-14c9-4bf1-88fa-bd3d85332807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0cd83ec1-14c9-4bf1-88fa-bd3d85332807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_7c3bff73-8fbc-40e3-aade-d531754d7985" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_7c3bff73-8fbc-40e3-aade-d531754d7985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_44d37540-9a10-411e-a883-cca95bd01a1e" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_44d37540-9a10-411e-a883-cca95bd01a1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d7cba373-8d53-40ae-b67b-ed77e4272265" xlink:href="vtl-20230930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d7cba373-8d53-40ae-b67b-ed77e4272265" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_ba4673a5-e29a-49cf-88d7-559f071b2b77" xlink:href="vtl-20230930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_ba4673a5-e29a-49cf-88d7-559f071b2b77" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_8bb2020f-3302-4c07-ac44-269967eac1af" xlink:href="vtl-20230930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_8bb2020f-3302-4c07-ac44-269967eac1af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_759c2baf-3176-4b42-abb0-63485bb24be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_ContractualObligation_759c2baf-3176-4b42-abb0-63485bb24be4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:to="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b10bce13-8b48-44bf-acd9-47bbfd2b4620_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:to="loc_srt_SegmentGeographicalDomain_b10bce13-8b48-44bf-acd9-47bbfd2b4620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:to="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_677cc038-e09b-4492-8c97-597faeddcc7d" xlink:href="vtl-20230930.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_NewYorkCityMember_677cc038-e09b-4492-8c97-597faeddcc7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_786949bc-3678-4fed-b423-b39b088cc796" xlink:href="vtl-20230930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_GrafelfingGermanyMember_786949bc-3678-4fed-b423-b39b088cc796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_6cc2d4a6-1f38-4263-87b5-1b641d168e32" xlink:href="vtl-20230930.xsd#vtl_PlaneggGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_PlaneggGermanyMember_6cc2d4a6-1f38-4263-87b5-1b641d168e32" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b18b00d1-88dd-44f0-847a-efbd7651c872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b18b00d1-88dd-44f0-847a-efbd7651c872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_510f177e-8558-4b30-acb1-af1b74f3df02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_510f177e-8558-4b30-acb1-af1b74f3df02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33a84aad-8e06-4656-a3f5-76a93476de8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33a84aad-8e06-4656-a3f5-76a93476de8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e937ead-54e7-49a2-b0ed-55c65dd085df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e937ead-54e7-49a2-b0ed-55c65dd085df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bdd7ba2e-8e0b-4633-a98c-e432178dc4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bdd7ba2e-8e0b-4633-a98c-e432178dc4e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5fd9e7d5-ad21-448c-bf53-db24388ffa01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5fd9e7d5-ad21-448c-bf53-db24388ffa01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6129855a-a522-4a8c-8452-2ffa1dad9e55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6129855a-a522-4a8c-8452-2ffa1dad9e55" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_8b45b053-1e16-4c56-98d5-ff501b9570b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:to="loc_us-gaap_InvestmentInterestRate_8b45b053-1e16-4c56-98d5-ff501b9570b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:to="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7afd28a3-a674-420d-b05d-160d645f5680_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:to="loc_srt_SegmentGeographicalDomain_7afd28a3-a674-420d-b05d-160d645f5680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:to="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac6d1d4e-f453-4c7e-9823-c84447e9f497" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:to="loc_country_US_ac6d1d4e-f453-4c7e-9823-c84447e9f497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:to="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_255983ef-e4a2-4413-bd62-3ea678026915_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_255983ef-e4a2-4413-bd62-3ea678026915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05ea3a58-a3d8-42ec-a07c-d092479da005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05ea3a58-a3d8-42ec-a07c-d092479da005" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_53a8ed8f-066f-41af-97ed-fe8b45488068" xlink:href="vtl-20230930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_53a8ed8f-066f-41af-97ed-fe8b45488068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_79320fb3-8264-4fb0-92ec-fe2ed78bb84e" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_79320fb3-8264-4fb0-92ec-fe2ed78bb84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_fe3ebe44-48f6-47ec-b2cb-d7bc1f03be47" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_fe3ebe44-48f6-47ec-b2cb-d7bc1f03be47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_6068dd7a-690a-4f9e-bfaf-b53aa2d2986d" xlink:href="vtl-20230930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_6068dd7a-690a-4f9e-bfaf-b53aa2d2986d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_ca8e5ff4-f590-4d59-abb4-e104b359fa9e" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_ca8e5ff4-f590-4d59-abb4-e104b359fa9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_643edf7b-5c44-4d76-b1f0-0ad08f209aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_643edf7b-5c44-4d76-b1f0-0ad08f209aea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1a5049-3858-4553-97b1-a1a4b4797a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1a5049-3858-4553-97b1-a1a4b4797a74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_21386ea2-2a7b-470f-b786-4befccc2506c" xlink:href="vtl-20230930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_21386ea2-2a7b-470f-b786-4befccc2506c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7bbd7f6b-9663-400d-a78f-3e1dae0833f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7bbd7f6b-9663-400d-a78f-3e1dae0833f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_8e380462-fe46-4555-a7b7-aece4ac5faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_PaymentsForCommissions_8e380462-fe46-4555-a7b7-aece4ac5faf2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52099669-d5dc-4f51-9169-434857a5051c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52099669-d5dc-4f51-9169-434857a5051c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_40cbba2a-3953-4378-b705-02d680bce5d5" xlink:href="vtl-20230930.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:to="loc_vtl_December2020ATMMember_40cbba2a-3953-4378-b705-02d680bce5d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_a63c8ddb-f1d6-4ad9-9114-4433bb45a7f8" xlink:href="vtl-20230930.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:to="loc_vtl_May2022ATMMember_a63c8ddb-f1d6-4ad9-9114-4433bb45a7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_73e0d400-fb3f-43ec-9b78-370759b2b375_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_73e0d400-fb3f-43ec-9b78-370759b2b375_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_58296295-7c9b-499a-b63c-01b25550cc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:to="loc_us-gaap_SubsequentEventMember_58296295-7c9b-499a-b63c-01b25550cc4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_057cdcf3-5fc0-40a8-b316-614c166b15a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_057cdcf3-5fc0-40a8-b316-614c166b15a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_06efea59-894e-4b5e-b446-282664ddd050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_06efea59-894e-4b5e-b446-282664ddd050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_314947e3-a646-4780-835c-4c6e5f0578f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SharePrice_314947e3-a646-4780-835c-4c6e5f0578f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0b04e6e-18a8-4f05-906c-04bd427edc58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0b04e6e-18a8-4f05-906c-04bd427edc58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6267ca47-e0c9-47e0-b098-3608be105f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:to="loc_us-gaap_CommonStockMember_6267ca47-e0c9-47e0-b098-3608be105f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_5f349c3e-184f-43a1-a40d-eb0b7990cd85" xlink:href="vtl-20230930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:to="loc_vtl_PreFundedWarrantsMember_5f349c3e-184f-43a1-a40d-eb0b7990cd85" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18ec550e-7074-4a95-88b7-9c30dd6b7953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18ec550e-7074-4a95-88b7-9c30dd6b7953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:to="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1bbd660-6e87-45da-bdd1-06971dc0f0a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1bbd660-6e87-45da-bdd1-06971dc0f0a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d305b9cb-7a50-45ef-affd-c39afb613c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d305b9cb-7a50-45ef-affd-c39afb613c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_b3502b17-1546-4a19-85aa-361587fac490" xlink:href="vtl-20230930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_b3502b17-1546-4a19-85aa-361587fac490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:to="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2fd11683-8050-4791-9ebc-d440f331c061_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:to="loc_us-gaap_PlanNameDomain_2fd11683-8050-4791-9ebc-d440f331c061_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:to="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_447975ab-3b73-4faf-aedd-0dc5804a45a4" xlink:href="vtl-20230930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_447975ab-3b73-4faf-aedd-0dc5804a45a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_55e3ef16-dcc4-42ed-b950-75f13d1c5edc" xlink:href="vtl-20230930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_55e3ef16-dcc4-42ed-b950-75f13d1c5edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_9b2a8cb8-243b-4d8a-a991-5c7cccf77773" xlink:href="vtl-20230930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_9b2a8cb8-243b-4d8a-a991-5c7cccf77773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_e0126b52-0558-4f82-bd87-58e60452b26f" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_e0126b52-0558-4f82-bd87-58e60452b26f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f6a07abf-022b-4775-a28e-217e595fb89a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f6a07abf-022b-4775-a28e-217e595fb89a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb5f0ea9-59de-4033-8838-ccc729f9f93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb5f0ea9-59de-4033-8838-ccc729f9f93d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2a8da2c-85df-4095-a20d-a755dd672eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2a8da2c-85df-4095-a20d-a755dd672eaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85c69c4a-17aa-45f1-9dc8-6fd478b06abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85c69c4a-17aa-45f1-9dc8-6fd478b06abb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_759ecfee-822c-49eb-87e3-e049c85209ec" xlink:href="vtl-20230930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_759ecfee-822c-49eb-87e3-e049c85209ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a08774f3-6d31-4023-b93c-ce5daaf22523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a08774f3-6d31-4023-b93c-ce5daaf22523" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_8123fa07-0bdb-44ff-8711-084cc547ba36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_8123fa07-0bdb-44ff-8711-084cc547ba36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e7703aa-4016-4a85-b37c-8f8f6ef991ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e7703aa-4016-4a85-b37c-8f8f6ef991ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_974b98a5-b6e7-4b77-bb99-190aab62356e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_974b98a5-b6e7-4b77-bb99-190aab62356e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22510dfd-7f71-4b14-bbe0-75d2e6b1bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22510dfd-7f71-4b14-bbe0-75d2e6b1bca2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4c0057f-895b-418f-a0c8-4a6feda1e261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4c0057f-895b-418f-a0c8-4a6feda1e261" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_112fbbe2-74f4-47ac-83bb-48b44c2dca05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_112fbbe2-74f4-47ac-83bb-48b44c2dca05" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_af3df2db-6d17-405d-9bc1-bc486a411b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_af3df2db-6d17-405d-9bc1-bc486a411b40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8c90f997-7e69-448e-94d6-bc945548589f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8c90f997-7e69-448e-94d6-bc945548589f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_438797d0-0d2b-4622-ae8d-3a85635f4da7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:to="loc_us-gaap_PlanNameDomain_438797d0-0d2b-4622-ae8d-3a85635f4da7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:to="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_c4bf62e4-ed4a-4fb8-83f1-6c54506d66ff" xlink:href="vtl-20230930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_c4bf62e4-ed4a-4fb8-83f1-6c54506d66ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:href="vtl-20230930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_b9e95078-c249-471b-ab31-bdb9d5be3125" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_b9e95078-c249-471b-ab31-bdb9d5be3125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_812e55a2-3b1b-4168-82cc-1416291faa2e" xlink:href="vtl-20230930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_812e55a2-3b1b-4168-82cc-1416291faa2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_966fc097-195f-4583-ac1f-e2882bceae81" xlink:href="vtl-20230930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_966fc097-195f-4583-ac1f-e2882bceae81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_77e365bb-9937-4fa3-8559-a2ea9517065a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:to="loc_srt_RangeMember_77e365bb-9937-4fa3-8559-a2ea9517065a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:to="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_870eedd9-c1e6-4c88-96f1-f441eb255d9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:to="loc_srt_MinimumMember_870eedd9-c1e6-4c88-96f1-f441eb255d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31e2b508-a848-4a88-8241-07d11c0a1a8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:to="loc_srt_MaximumMember_31e2b508-a848-4a88-8241-07d11c0a1a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_e62977d7-9219-45b8-9771-c8c3dc45f6ec" xlink:href="vtl-20230930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_e62977d7-9219-45b8-9771-c8c3dc45f6ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_dff2aee1-f319-46b1-95ca-4203d0312cf0" xlink:href="vtl-20230930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_dff2aee1-f319-46b1-95ca-4203d0312cf0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_060ac493-d567-4da0-ab31-2c752fc36cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_060ac493-d567-4da0-ab31-2c752fc36cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_54718896-673c-4fb3-b17c-5cc9f01bf289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_54718896-673c-4fb3-b17c-5cc9f01bf289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d09a8dfd-2565-47f0-8731-865beb2de5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d09a8dfd-2565-47f0-8731-865beb2de5ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_488ac2fd-a1fd-47ce-8b5b-da1f2ede149f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_488ac2fd-a1fd-47ce-8b5b-da1f2ede149f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5a876844-f818-4cdc-8e18-880bad71dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a6e5f70-b231-49d5-b6a6-50ad84ddea97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a6e5f70-b231-49d5-b6a6-50ad84ddea97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ef11d89e-5015-4543-a97f-298b9083f657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ef11d89e-5015-4543-a97f-298b9083f657" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a7a7064-57c4-42e5-972c-ea11e1449b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a7a7064-57c4-42e5-972c-ea11e1449b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb8dc5a6-22bd-4146-81e5-2d71cb3a6cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb8dc5a6-22bd-4146-81e5-2d71cb3a6cf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761d2556-9605-46cf-85e9-81a3a7c60234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761d2556-9605-46cf-85e9-81a3a7c60234" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e5b80a2a-18fb-4ed2-bcd9-1457725550f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e5b80a2a-18fb-4ed2-bcd9-1457725550f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eeff2ba-2378-4ab3-bdab-7bdcfdf6acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4467fb28-b676-4aef-a324-5034b7c98553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4467fb28-b676-4aef-a324-5034b7c98553" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_43595a6b-3746-4442-9244-054a70f48e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_43595a6b-3746-4442-9244-054a70f48e09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e5fc1f-0458-4e4c-a310-e3f8475379c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e5fc1f-0458-4e4c-a310-e3f8475379c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8253f992-77dc-4c86-b2f2-f155c8f95fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8253f992-77dc-4c86-b2f2-f155c8f95fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_007a5aae-be6a-43ea-8fca-d63a5e5a592c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_007a5aae-be6a-43ea-8fca-d63a5e5a592c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_203f031c-34a1-401c-aeb6-6a6a55ded52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_203f031c-34a1-401c-aeb6-6a6a55ded52c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05f0a76c-1166-4001-b027-f56b9912ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05f0a76c-1166-4001-b027-f56b9912ddeb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2447a27c-4c67-445f-8b1d-85a6b17708fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2447a27c-4c67-445f-8b1d-85a6b17708fb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:to="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b9f762d-6c76-488c-b9a7-5dc306211733_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:to="loc_us-gaap_PlanNameDomain_9b9f762d-6c76-488c-b9a7-5dc306211733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:to="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_3950469c-d891-4e37-b363-f1b254c9f041" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_3950469c-d891-4e37-b363-f1b254c9f041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:to="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_442f5b4e-fb0c-4154-ba06-7c9fe4873126_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_442f5b4e-fb0c-4154-ba06-7c9fe4873126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65f40fcb-ba7e-4c9d-ba0c-8a2e163786d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65f40fcb-ba7e-4c9d-ba0c-8a2e163786d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_485e03cb-e98d-44c3-a683-b978d4720714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_485e03cb-e98d-44c3-a683-b978d4720714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352f20cf-251c-4d51-95c5-f6bcbaed8774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352f20cf-251c-4d51-95c5-f6bcbaed8774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7f43603c-b743-4bfd-aea4-b6cf60734c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7f43603c-b743-4bfd-aea4-b6cf60734c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89d821f7-337d-4e3f-9aab-0b8130c2d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89d821f7-337d-4e3f-9aab-0b8130c2d22b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:to="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_660bf230-d1bd-4c33-9a79-297803798814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:to="loc_us-gaap_PlanNameDomain_660bf230-d1bd-4c33-9a79-297803798814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:to="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_bba71310-1eb7-43eb-b633-9ad8346192bd" xlink:href="vtl-20230930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_bba71310-1eb7-43eb-b633-9ad8346192bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2c814749-063b-40d3-8d42-83040133f18c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:to="loc_us-gaap_ShareBasedCompensation_2c814749-063b-40d3-8d42-83040133f18c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:to="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1cc0df2c-6347-4e21-97b6-aec61ffe8926_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1cc0df2c-6347-4e21-97b6-aec61ffe8926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_73c7c35c-93bc-486e-a2ac-9dc61ea7f8fd" xlink:href="vtl-20230930.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:to="loc_vtl_EmployeeMember_73c7c35c-93bc-486e-a2ac-9dc61ea7f8fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8ea1c19c-b2aa-4d88-bae4-f7407861908e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8ea1c19c-b2aa-4d88-bae4-f7407861908e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e02e363a-441e-4746-85be-fba20aafb8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e02e363a-441e-4746-85be-fba20aafb8fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a9b90dc-197c-461d-ad1d-65219c4deb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a9b90dc-197c-461d-ad1d-65219c4deb1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#ChangesinBoardofDirectorsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm_d54235ce-02ab-49d1-bc25-065f35d3d96e" xlink:href="vtl-20230930.xsd#vtl_RelatedPartyTransactionBoardOfDirectorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:to="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm_d54235ce-02ab-49d1-bc25-065f35d3d96e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:to="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a7161601-e366-485a-927a-2820db0470a9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a7161601-e366-485a-927a-2820db0470a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_08f5b46c-5cb9-414e-bfc8-8053f39b1e6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:to="loc_srt_DirectorMember_08f5b46c-5cb9-414e-bfc8-8053f39b1e6e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_9ca547b4-2b17-4fe4-ba57-6c2cf446b66d" xlink:href="vtl-20230930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_9ca547b4-2b17-4fe4-ba57-6c2cf446b66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ebea2128-a280-4d2e-98bc-940f51a4c721_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ebea2128-a280-4d2e-98bc-940f51a4c721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_ec004adb-f80a-4f9b-ada7-01f84f0a93af" xlink:href="vtl-20230930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_ec004adb-f80a-4f9b-ada7-01f84f0a93af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a493ce56-d15d-41dc-a672-a7d7743d7ff2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a493ce56-d15d-41dc-a672-a7d7743d7ff2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_423dc5a6-2e68-4376-a331-450b3dda98ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:to="loc_srt_ScenarioForecastMember_423dc5a6-2e68-4376-a331-450b3dda98ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4a187a3c-4725-4603-af73-d20793bc7334_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4a187a3c-4725-4603-af73-d20793bc7334_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_baff2855-a590-4869-8a0e-bbd92f0d735d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_baff2855-a590-4869-8a0e-bbd92f0d735d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_97ea3a8d-f230-4339-bc3f-5f2075602fe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_97ea3a8d-f230-4339-bc3f-5f2075602fe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_eb800197-8526-46a8-a05f-29890daaca6c" xlink:href="vtl-20230930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_eb800197-8526-46a8-a05f-29890daaca6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_02d07cdd-475e-43fd-b8a0-b238dc3d1303_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:to="loc_us-gaap_RelatedPartyDomain_02d07cdd-475e-43fd-b8a0-b238dc3d1303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:to="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_9ff665f3-49a1-4ae5-b002-cd4035812ace" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:to="loc_srt_AffiliatedEntityMember_9ff665f3-49a1-4ae5-b002-cd4035812ace" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtl-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherShortTermInvestments_6282668a-29c4-4009-ae6a-8b18356a6462_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - other</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_81ae59d4-7d6e-4506-ab2b-0d93d44d4900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other share (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_bbe0eb2b-fb51-436e-bcf9-9ec0eafff99c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_99685381-d54e-4e6b-96f6-1e6b3b595d8d_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9f6a2861-f7d0-4466-8300-2670aed20854_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f08249e4-b725-4358-bac3-132f3ef0a3e3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_99f99818-a999-4f50-be3a-59625a09602a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9d3cdabc-8104-49c6-92dc-2d7447ba48b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_d97ab59a-0f0a-4009-ad6e-512d841e7bbb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_800888e6-e28f-4b83-b7bb-b71912c5bf90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_10d25b76-ed8d-478c-9648-9a7897a0da3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8f0fff99-8870-4810-be2c-a476dd1ac2e8_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9a4cac72-3fb4-4a2a-a8dc-dcce5c1bfff9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7d894bb7-0d7b-4d1c-a48e-486d6d83f016_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_678899b8-4cda-457d-89ec-e1159a487d39_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a495671f-521c-4e70-b4bc-3a9bc4bce6d8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6d34d49f-5b7b-474b-92fb-e52ac6183686_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbf8a349-26fc-4d71-bae6-3f7da14dd7bc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_91c41453-0bbd-4f5c-a5d1-bddf3026d7b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_54efecff-efed-4dad-905e-e38351efe132_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_25fc75dc-92bf-461d-a0be-b9f9ab6cffed_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_ae420f91-5ae3-4731-bd29-4068013a4e0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_e654dd43-d4cd-4654-8875-22ae47f3d1a1_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cbe099dc-87d0-478c-bd3c-8f7a08991b52_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_ddbfcc74-6cd5-4a95-a70f-53ea841cfb98_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20230930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5e50ab84-7712-41fc-a487-251b97ff09c4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e493c8ba-affa-4e48-a7b6-c9190fb728e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7ce16c96-8bb9-47ec-abe9-64e599b0509a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_5713e73e-c51c-4b27-aab8-ae159cd9ac46_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_326ada29-3df1-46a2-a115-313dffc484d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_c797f533-54d0-4ab2-9c3e-6e0bc76f5a90_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5899e105-e40f-461d-955e-16f3d08b771d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f93ca43d-1597-426e-a3a3-2bd4e1406e7c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8cb1b7d1-a5f6-4608-a1c1-82bc47d88fce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_677b891c-76ac-4e8a-8580-57108b676efb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $9 and $1,226, respectively</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b840c04d-b841-4f20-b782-ee697d65632f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock at premium</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_92e3c258-9674-4169-8876-edf5f2477f84_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1bc99f8e-8755-49fd-aa8c-6889241a508c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ae507f4a-8e43-4815-ade2-81131b26ea87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7d79618f-00d8-4255-ba51-e4c2cab2da56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_61d66422-97a4-48c0-8111-8743df450e60_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20230930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_35054043-4f37-4e19-86b6-bde0130c8315_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_c2463857-4a20-4a3e-84f2-9d7e7b7c5770_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_63be9d3b-789e-47c5-a493-3704b8dfe833_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_330836d3-71de-4fc2-8c99-3f4e2bfcc8b5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f850695b-71d7-4cf1-99ef-9a710e829973_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_4ba758dd-7354-4ffa-91f6-9e037b47a417_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20230930.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_9beb0af0-f59e-4ab4-99f8-b5604838294f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1c8fb790-67f6-46df-9a9f-c7c6b31a90e1_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20230930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6203f6b2-0c59-422a-9a6d-6cda5e93a746_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2280154f-1104-4459-956c-1352f9fabc2c_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7e601ec6-ce3f-4f58-bdd5-74f73a93b413_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7d206efe-0d7b-4862-8bbe-b49959f54a7e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_58702aa3-6f11-452b-8b24-621ba685601c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1be87868-aaf7-44b6-9383-786faa7005f1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5638784e-8efa-4ff7-b19c-683d5c4b2533_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bb1d46d5-c28c-44c9-8218-14e955e54e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_bcb1f679-533e-4ad7-85a2-e0df2f13480d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment charge</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_0f77d258-652d-4378-984a-acf1715a9db4_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2f56d8ae-78d8-4d2a-b30f-584c4db1e34e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b452c28-8df6-4911-8896-20218c03c79c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9e87c3c6-a529-4a1b-a39a-10d4305c5192_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_94b405d2-5be4-43b1-9566-5f4513b291c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_eb1f5011-78e1-4f98-aa87-35557adc3fde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f6b3bf34-984f-46ff-b9e8-fe72f0614adf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9ebe9dfb-cd27-4319-b1bd-5db8e7665deb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_b6d80bc5-f410-40bd-b5fc-67a6d625ce05_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20230930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9d9dd94b-a748-4c74-ad45-dc7955ae1f5c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_496d32f1-9f8b-42e7-bbac-2a6ae01ced68_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d244840f-2020-4321-b3ea-6af64f4ca048_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_4cd7164e-869b-4b9a-9273-194b781a348a_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20230930.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_3d103947-00f8-4ae3-afab-dfb3c2996f5e_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cdb0ac1e-bfdf-4288-b231-1733b437416c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_04b3acfd-aaff-4708-b6e3-20c02d542488_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_27298710-e6f7-4a9f-ac1a-e2c46d2dc2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_3f89ac4a-1d1c-4216-8bb3-e8fabbb2c712_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_89b7a1bd-12e3-42bf-95bc-8fa9afe9e562_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b0db472a-5a8b-418d-8d8b-2093e5d79f92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0e3d7b77-eceb-427f-b6fa-cdd72c8d761c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8d3537a1-c973-4fdd-8d1a-1f476e2f3c04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7daa4ab2-aa55-49c2-aa15-6d394aa8aa22_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5b9e1716-d951-468d-9af7-a1d453956ddf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_df6d4693-dba3-465f-996f-5b98b16e4b32_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b3acc444-92c1-4ea6-9131-90e6ebe576a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d92a9827-89e6-4de8-862e-f98448206d2c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_db4166d0-550d-438b-b458-364fd86beff7_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_208d423c-e6f2-4606-9a15-c58ca8089a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_e0c51d96-7aec-4851-8776-b29ce1881dff_terseLabel_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_label_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposit</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_documentation_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:href="vtl-20230930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:to="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a83e32b-d49b-41ae-8c9b-f8489b623797_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1f719d06-44e7-46d8-a718-1080b7be9c6d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7cf9f63a-6976-4443-ad58-12e7d99fd005_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b0e879e2-8e37-41a2-a16e-a187e4b1b908_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26dd0a4a-3375-430f-ad04-fcdbbd5d5333_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_df341cb8-2072-47c2-ae2a-ebf181d7671d_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20230930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a267b236-30f8-4732-92ca-16d706c3d563_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6549977-5bd3-448a-8f28-947b1a4c93aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f12e8e82-9f27-426d-9d54-918caaf90e6e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e492e4aa-e643-4fd0-9876-ae76751c2467_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_a87eb755-5bfe-40e2-8f3c-724fdfb4720b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_10689425-ed36-40bd-9295-f23e27b94996_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e48d87f-ce3c-4364-a60b-28a7509e3c6d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_04200aaf-5694-4211-a82b-957728c74b5e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_98d46c13-1d56-41ed-bfe3-36ffb15f9f6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of investments - Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b76ab291-011d-4a57-b2b8-f819153bb434_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e44cc6b4-5118-4db7-bbe7-a96530ebc5d2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PlaneggGermanyMember_a95cd554-9e49-4b3c-99b9-572261e293d1_terseLabel_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_label_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany [Member]</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_documentation_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember" xlink:href="vtl-20230930.xsd#vtl_PlaneggGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PlaneggGermanyMember" xlink:to="lab_vtl_PlaneggGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_78d6caf1-8ce2-4372-a044-d07de493c351_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_8aa1e49d-0403-4a4c-b181-7fe7331e75be_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20230930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_907e4f4a-d291-4bc1-b6b0-7610f31af245_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0550c9f4-f28d-43ae-a07a-f732f51d207c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_68517a97-2cf6-4613-8dbd-adcf7d5d9e75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_23e3488f-713e-4716-8cae-99500779d4de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_90abbdca-fd06-48e4-a5b7-e402861c7e43_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_553995dc-1a32-4be8-bad1-0d7d6d88349f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c0f5de5d-9231-4ed2-a249-a8d4f81d3458_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_412790cf-69ac-4e19-ab76-16688c956358_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_9be041c3-eb0d-4f27-9d71-2657f77108e9_terseLabel_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Board of Directors</link:label>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_label_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Board of Directors Disclosure [Text Block]</link:label>
    <link:label id="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_documentation_en-US" xlink:label="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Board of Directors Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:href="vtl-20230930.xsd#vtl_ChangesInBoardOfDirectorsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:to="lab_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_280cedc6-bdb5-424b-a6dc-bbd90d1aa6ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2603fe10-cc60-484a-99b0-0f6ae4f7b575_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_fcc82763-a0de-4cab-bd64-5473208405a9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_bc66612e-962e-4888-a80d-3ff6c7449aaa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_77990963-079c-4fb3-9b28-1d12e8692381_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_659d85e7-f71f-482f-9f50-d80cca8be272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3a0c1496-6e25-4fc7-9437-e509b19f6fa7_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ca82502c-8b2e-427e-8e8a-870fcdcb6f0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2fde87f0-f8dd-4a72-900e-39a1b926f9de_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_c3f27696-dace-415f-b990-a7e1dba7b18a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4bb5c777-6e42-427b-92f9-95134395f55b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c06530de-f728-4034-a349-aa03f712c577_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GovernmentAssistanceRate_54fd31f2-9060-4f8e-97ba-fd39ea7cc0b2_terseLabel_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_label_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_documentation_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate" xlink:href="vtl-20230930.xsd#vtl_GovernmentAssistanceRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GovernmentAssistanceRate" xlink:to="lab_vtl_GovernmentAssistanceRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_39173aea-385f-41ad-a463-5acaec99cf22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_567d1bd1-47cf-4a9b-b807-c5b724f324c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c1d80a4d-b6aa-44bb-ac13-a7bc0bc4bb95_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e442c202-c839-4372-939b-f725205763a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_aebd0533-1ac3-43fe-b177-6db2a3fa39d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_40026abd-ee11-4795-bc3c-2f3223cd3e69_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f32eb346-78fe-47c3-82c9-626e046cdd45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_08325ca4-65b3-4901-ad0b-7f62c8cda24e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3dc1f541-ff43-4501-9b69-17812c9d577f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ffc2b050-2249-420e-88f5-216297945355_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_57599efd-b9b9-40e3-8b82-3feb06dd778c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_e3e47d5f-1f29-40e4-83de-704ae0758bda_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_065d19d7-e1dc-49a6-9874-233cf0f105e3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_46ea067a-eb6b-4e19-bd73-04280645e069_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_07f96741-bcf0-43cc-9ca8-0ff166430a37_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3acb72ff-3a14-443f-b32f-e14828bcff42_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_29064874-0e87-4c0e-97fd-eb681ada9975_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dcbab29e-c7a4-49a6-a388-513251dcf1e3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_1567627c-57e1-4e4e-b5ba-842341db7ddc_terseLabel_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments- other</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments [Policy Text Block]</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:href="vtl-20230930.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:to="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_5727c3da-c25e-485b-9124-c1d2c4fe12ee_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20230930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_75e6a2cf-53df-4fe5-9108-abda77239122_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20230930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_80bf3a33-fb3f-4576-ac63-f640aca3c4a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_05a1a62e-322b-45ed-ba63-919dda754d12_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_1276115f-a92e-4638-b75f-ecdafa44ecb2_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20230930.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_96196ccf-14a3-48d6-9dd1-10bc0aa3cd05_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20230930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0d991144-575d-4f5a-b683-301550c3f80e_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_db3b52d3-584e-4d0c-94fc-530dbfdc5101_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3930dbfe-cb15-4ef3-9b3c-336e44d92f27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_95b0b374-627b-437e-9c53-e7942dd27826_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_8ae2c76f-48ed-4573-b668-322eca30391f_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20230930.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_def7a732-1e5e-470b-b4bc-e8a4bb3c37f1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d40461f2-357f-4678-b475-07c53c3dc35c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_a248f614-8c1b-4562-881e-d5a05605f680_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (as a percent)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20230930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2db95fa7-283d-463e-9206-290d66cd6c92_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_e71c566b-b973-4f41-b7c6-bdb46645669d_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9d622cf5-d043-4254-baf1-a8eeff4b8b76_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_67be0f79-53f9-40f5-89ed-25a2d9a0c882_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_eda2c59d-a503-4ec7-a17e-466d7a9ca3b1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_14d65e22-fcb3-43ef-9a64-824453da306b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f57cd71f-99d4-49cd-a12b-56e85fe04a6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_09b42224-a466-4d48-ac28-30e8a49cc7a9_terseLabel_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in USD per share)</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="vtl-20230930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5c04d21f-02c1-4a3c-933b-dd2af94fe705_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_a3e84105-6ab1-47ca-8bb9-3756e709debd_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, extended rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_3f37645e-b432-4157-a640-08d22d69c35c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_50a1aea4-ae38-4032-846d-b2f245323169_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_0dc91765-d797-4dee-9e9a-0211afaa22ff_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20230930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dc09b6b6-8911-4e3e-b939-6c1c6ae51d61_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1379c688-6134-4f85-804f-58c939ed0dd9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_0dcb69dd-6a18-49bf-bd3d-8751fa143bba_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20230930.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8ae124d4-3b40-45dc-bb97-b8e2bb3bb79c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7febb7c2-377b-440d-97ca-4c0caaa9479b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock ( in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3ddf0b8e-1c23-4f34-ad6b-221b7606f12f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_004375a3-c2ed-4dbe-bd62-04380502b71b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_91ec4f06-3c27-451f-aace-d742b17a43ce_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_90cc8a49-1c46-4537-80ae-c58dd6aa6038_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0869be05-727e-42a1-a60a-5d2edfb08d67_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_66188c02-af36-401f-9f44-ec44b6049fa5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_770e88c6-3ba5-4aae-a3d2-28ea8d3a435c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_9e3546fd-7882-4a06-b561-0848416898ab_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_366246b5-05cb-4345-8eba-d491c33b0099_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b2668a38-5aae-4d9f-8899-989aa5f8f3c9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_416e574a-46a1-472f-991f-db9eab6f9956_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0c56227b-7042-4df6-82b0-de9748e41018_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8e68232f-fc74-4645-858e-a27a6ca1bae7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_cd3f80cf-2495-43bc-8ab2-62570345a557_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a278e723-186f-4c07-987f-c61ab099b632_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33d7dbea-36db-4746-a456-fab423cbcaa4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_525e586b-f649-4586-9f19-85b12e4d9a1f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1be15f4b-9c08-4ff4-bda8-d2453aa04875_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fe54f32f-64c3-4a6f-9ec9-b74c44c02413_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_aab7db31-3d6c-446f-bf82-5accae252449_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_dabdc113-22ad-48b4-9d1e-d846a8da3fb4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_642306ac-ea89-4133-9bc8-62f36ef40ff5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_44d7f858-9a93-4c87-a4e8-fd72d852ae9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d1c8b598-3669-4ffe-9b61-c930d1e68d89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c559bd0f-e539-4bb2-afd1-75581c42fd30_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_71091596-f67c-45d8-a86d-c9f8ad206b33_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e9198aa7-a013-4ce8-8d76-1ee7d9545d1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d2e1de6f-0e67-4af8-a907-7d54f07d2561_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9290bea1-a3c3-4ddd-b6cd-8577691a9c06_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cbe40eff-df29-4f7d-9870-dadf574f8811_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_89219f54-6756-49fc-a767-5b8452221686_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c0aab4a3-a87f-455d-974a-df7127872add_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_08bf4608-473a-46df-8095-ba094563b9e3_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_dc67aa2f-15e8-4ce7-8525-654322766cf2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_dd3e5e13-f02f-4532-9e3b-b3531f3f02ab_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_661fd889-6d0f-41c0-9cb4-12129810e7af_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e8517be-14ed-47aa-9e17-56d1b5ff416b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b66cbac5-b959-4912-9746-344863b27944_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_353107b8-4f64-408d-a009-611b479a6c97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_188a6fe2-ca0d-4fc6-8f4e-4c00b66f2df3_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_fa734e39-d848-458e-bdfe-416e509d4d16_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_cf8faa13-6c16-4819-b23a-55e714e89048_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease costs</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20230930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2a17901e-a09c-46dd-b073-5cbc9eb0d23c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_86de64cb-fcf2-46c6-952c-9508ba1677e0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_6981197b-d14e-4e02-b98d-fc13188f9fef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_f5f656ea-bff4-4fac-bc8c-b4af754737f8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_02ce6d59-2d3e-466e-9668-45eb39bbf78f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ff3d8920-af35-4ac5-8d8e-e25361c7113b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6860cd3e-0150-4549-a778-0b836067e8fe_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b4ddc23a-12e3-4c65-a527-82936b8dbec1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ee8fe1b2-010d-41a6-b033-0cffc2b6878a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e1240f6c-a361-42a0-ba73-da240f30c9d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c73b6309-acaf-4d3a-9cd8-2b2754eef1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fa4c4f50-a6f1-4d90-a97e-5c24e38796d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_ab4244ac-f431-4218-9635-1d37bf37ef2f_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="vtl-20230930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_4dbb52d4-b1e1-4c27-8116-611813556ddc_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement, amount remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_474bed00-4149-41d6-b2ff-292d3c3ab0ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_07966b12-9f38-493f-82ef-3ad46bd8bb42_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20230930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ad862434-a040-467a-b323-9686194666c5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_e848c692-f92f-462f-961f-9414b904e2b4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4d23c278-8e38-4324-9640-a33a35d7d6e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e07373e6-c62d-41d2-8481-43e639d3dbf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0ba5da67-0277-431e-a8cf-bcc665b8f313_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_26e96233-aa93-4fac-83ce-30d101915655_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_fca395ff-1329-480a-a67b-0d9243b8a6ed_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_8a93ea19-0780-4b98-b136-64b9186d15ff_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20230930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bbb6065b-78c3-4928-ae13-4afd57aa3bbb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8a80db4d-46ff-42d1-ab6f-75598d99b2b8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_93316312-ce22-4041-9e1d-15fc9129d635_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_ad8a2675-55ca-49b2-b7fd-3b57c1489fa4_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9bcdeac2-aee6-4a34-a48f-00c1cf0752ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d2e8def1-c3ef-4f5c-b124-deea28f35b29_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_3315c148-1124-4396-b556-d18e58f9bd70_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_335e47cf-0549-4823-a03e-590d58251b79_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8315a74f-305e-48da-988c-e23b5b79658d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_229278f2-5747-44d8-82e0-e14fe957477b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6f172920-47ea-498a-a8fd-776d39ef3b43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d1c6c113-a08d-4311-a337-2c99b03d6dec_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_4e8c41ec-fb19-4cd5-89dd-b272886d1e23_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_4a2e8298-3b08-4bbe-b63d-0b8727e57462_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6154256c-3c3f-4776-940d-f463094f264e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eff26bf7-ea79-4862-bf81-19d9e7ab186f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7e54ffd0-3a30-4091-98f0-f4504ac6873d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c747ecce-1c29-463b-ae0a-0ace4dac3050_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_847560ca-97cc-469d-b356-b1faf26c216a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_329cf5f4-44fb-44a0-8c15-babd1fc87dcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted-average exercise price, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_649d4e58-1610-48b6-8a05-ea3ba7319818_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms" xlink:href="vtl-20230930.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentPrograms" xlink:to="lab_vtl_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6be07a94-4c86-4326-b524-6824e64f1627_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c7f1dd3b-4e04-4c0b-9a58-df9464eab0d6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_811ac140-91d6-465d-b8a6-2000fbbd97b1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3981c67d-1aec-4ae9-82cf-ea9bbec557d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_395cfb0b-eb99-46b6-8d1a-1d7dfd3b4b38_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0460ad22-df52-4615-96f3-374420600f66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ff0a2736-164c-4422-a387-300dd52469c0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's stock option plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dfae2bf1-863c-441c-a279-2aa71562700e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_3cd4041a-ecd3-45da-9557-0f062b5be201_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_004f808a-36c2-4edb-9dfd-87e446a4ec32_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_7f3b1ea5-5f3b-4f9b-92c2-2987d2cc86a2_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20230930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3e19b11a-50b0-4131-aa2b-89ef57e63f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2329e152-efcd-4210-a9ad-2cd1b6853ee3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_b72bbf04-8dc5-4764-8ce8-affb70880b31_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_50e622d5-3474-41a7-80dd-324d55799f26_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's stock option plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_059935f0-3242-46af-9875-a4ed355d1809_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f27ddaf8-a529-4d3c-b029-3d1888bb1ea4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0b2df6ad-e037-4762-a27e-2a655d695b36_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_abe0c219-4331-4e20-84f6-89c1ef4c7cbc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_7dc7b37e-a0d8-434b-b8d7-dcd0efa2345c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e4326e00-59ea-48cc-9a71-df9a6233b49d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_985b5c57-91e7-48f7-8dac-c5feb45db7f7_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance, amount (up to)</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b435f4de-b6ec-44d5-88ae-f7ec455d1318_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_3d2070ea-cde7-42ca-8f94-e620279873cc_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee stock Purchase Plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20230930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f204681-81a6-42c5-a252-728cb18093f5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_fdb1c582-bc2a-4b30-a96a-c3aa14b8ec87_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1dbf8cba-57b6-493a-a0d5-408dba64fdea_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_e59665ea-a715-440b-a847-7d91d22cb799_terseLabel_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_label_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany [Member]</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_documentation_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember" xlink:href="vtl-20230930.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AustraliaAndGermanyMember" xlink:to="lab_vtl_AustraliaAndGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_b8e269ba-5b25-49dc-950c-8381f18e20e1_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20230930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca5e55ca-3d10-4ee7-93cf-1f8e01597abc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_6f5eaf48-f269-4c4f-a5b2-6720927237e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_acbca081-02c6-447c-b6bc-5dd7ae79ca69_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_d687eb68-245f-4052-bf87-afffcd3bfda8_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20230930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_01323075-052c-4f0e-807b-b19aec6bc59e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6cb123c4-cd2c-4341-9761-8f5f6502760c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_a17b24c0-27f9-4a80-90e2-de34b729c861_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_06f226f9-5f1c-4805-b396-80a4df433ddc_verboseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ea012130-ffd8-4348-95ba-47adf2b053c2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_075a8c58-f815-4411-b665-41ffd0086a82_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_b4108595-0bbe-42e5-9b62-0c362beb70a1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm_3af48284-85d4-4d23-87b3-e717dabe18af_terseLabel_en-US" xlink:label="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of director, term (in years)</link:label>
    <link:label id="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm_label_en-US" xlink:label="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Board Of Director, Term</link:label>
    <link:label id="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm_documentation_en-US" xlink:label="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Board Of Director, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:href="vtl-20230930.xsd#vtl_RelatedPartyTransactionBoardOfDirectorTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:to="lab_vtl_RelatedPartyTransactionBoardOfDirectorTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7a741153-7411-4940-b47d-ac996ca8e73d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PreFundedWarrantsMember_08758e3c-da85-4753-8fc3-41d4a311a45e_terseLabel_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember" xlink:href="vtl-20230930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PreFundedWarrantsMember" xlink:to="lab_vtl_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e37af1ce-33f1-4c2e-a9e1-e7529f114407_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fe495007-df76-4bca-a62f-b3c8bc327e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5654a88e-08c2-4c4f-8366-4da21573c9be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_ef29a621-84fd-4c61-82de-1ac08341f391_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_56daa54d-51f2-4111-8876-c66eaa582788_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20230930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2c77bbde-b721-4659-a258-87dfec30f7e7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_048eabb7-0e10-42bb-9686-9745d46a26ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9d3c89a3-52dc-4a13-9764-40da0c622e25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c736192a-9822-440e-b448-3c3a08c5e9f3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d80bd911-13e1-4c65-9cee-01a8f6fb53bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a1ea9347-d069-4f51-84b5-6f52a56192fc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_26deb2ec-19b7-40c7-96d1-f8246acd2ecf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5b3ed4e2-9d65-4d4b-95b8-bad284143469_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bee63fb9-0ec6-4fb0-93a7-ec975a670077_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5061e232-d64a-4da8-8816-23874fb8a9ce_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f8adbf9e-3c0f-44e8-a3e4-90acc396ffba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d20e906e-e199-40ac-8e08-be1f2387ce3d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_131dc046-33e7-4838-8a56-f666de4d43c1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_664ad148-acc5-4ac0-ba48-83e5006c2da4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cb5c4ced-7ca4-4e67-85f1-ba1cea67636b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f2e749be-0d01-4fad-befe-c22233f36dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_44434c86-285f-4e2e-bb92-b2e5941576ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7ffa6d74-7aac-41a9-9950-932e4e2d8ef7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_948e3141-b420-4314-aafc-c4f216eae328_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_50fcc766-c8f9-4a34-9198-0d0da5f7bd5d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_aa603c58-9b43-4eb5-a4ff-b2e938be7369_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_51c17a31-995c-431f-b493-cacd4af53588_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4390c757-3262-4ddc-b906-1179e49e0074_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_19924dab-4dc6-4b57-9662-4115cb8c98a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_eb3bb5aa-3a65-468e-87b0-e6ee8a22a528_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_61e170c0-4931-48b4-944f-da20caf2111a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6d3bf3f2-27fb-49c1-adc8-6e3b452f8580_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ea3f00ea-51df-40e8-8d05-cad8ba40642e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ca179163-149b-45a3-96a6-19592dde05a9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_e6b201ec-5051-4b90-b97c-b3dfcc693ef0_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1aefb62a-22b2-4f67-b6bb-fd1e6514c629_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_3d9cbb12-755f-4491-8cbe-5e174d0e1474_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ee0efd54-f05c-4bf1-a0c8-967c5268d12a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2ebb59fb-270b-4e06-bd92-f555f278bd33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e13a077f-93a1-4b59-a398-bc9678039944_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option period (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f3f3e086-62c1-444a-b646-f308df1cf2e7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_bf35ee35-fb12-452b-88a3-3a8d53e16acb_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20230930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2400ced4-d694-4f8b-a8a1-7d220c233661_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_b6aaaa68-f043-42dc-87ef-35193d18e46e_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_160210e9-f3aa-478b-b751-7186ec0ce203_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_28230de9-8adf-4cfa-8ae3-e347d1677555_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_8b78a4ca-f2ab-4c05-b7c1-3b05ca63d765_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_2bc250e7-1744-4212-a06e-62049f9f6574_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5eedba19-4ae4-416a-930c-90987f7892e2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_49a21327-0e3f-467b-afd5-7d592c524624_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_443d5b59-802b-4539-902f-fdc51bfe26ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PV of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_80a147c2-6669-4fc1-ac33-5f2ae6f3fbca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a4258545-086b-4850-b402-b3d7abc2ad65_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8f25e1a6-855f-45d7-87d9-28a8f7c39ea1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e04c905e-9d5d-44ce-b6b8-ad89eaa495a1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f627908b-ace8-4bca-a155-970656d3649a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fddcfdb1-5ebd-4eba-a827-f01ff4187328_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fc650dcf-fde9-46c9-a5e4-65342e337af9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e9c8e478-1fb3-44b4-99b1-15f0c6645a4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_8f966c35-de71-460b-8dbb-dd016f1373b7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d515735c-c994-4eb3-81e6-7ac6608e72de_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_30d6eec0-26dd-4c05-bc06-3a13057cc4ff_terseLabel_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per each share of common stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_label_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_documentation_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:href="vtl-20230930.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:to="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ef19f833-88b6-47b1-8ca1-db1f54303d05_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8bfece98-8872-4385-ada3-cfc73887d633_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_bc8cdf3b-0cc5-458e-b354-53b40e825aa0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e0969b01-f946-48b0-ad5b-90b096155da7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_32e0a95c-547d-4b01-abb9-a94124ea08d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_450ee0c6-0777-4fcd-996a-4e6f592d2956_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_72f4a044-de1e-444c-8ee3-c38918febeee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_adf34e67-0f49-43cf-9da7-6a8bd0c73396_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_a3ce0cd6-140b-455b-90aa-b70e7b93a90a_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20230930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_dbf92fa7-1507-4751-8ee0-68370972723e_terseLabel_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:href="vtl-20230930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:to="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_cfcf11e2-53bb-4340-9af4-8b5e0626790d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_848e0086-22a5-4932-963c-efaf3ff8abf2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76582564-bb17-463e-b37e-45436ab34891_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_b29e9b82-db11-44a3-b363-69d6918316d8_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_7d12c420-bc38-44e0-b32f-e413772469a5_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of securities under shelf registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20230930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_71e0ea88-69a4-4629-af97-f1b683a433f4_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_6d9ee7c4-6c0b-4704-9652-b0496bd82a0c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_64d35d50-3590-4346-8b47-13753df4ae7a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,595,383 and 39,307,286 shares issued and outstanding as of September 30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ce3e40a7-736f-49fe-9d08-0f5db41ebe3e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9234dcc-fbe8-41c2-88d3-d116c4b0347f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtl-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:af8f48d2-cdab-45cf-9478-c11711513ff4,g:24bb404c-2b44-4991-8563-39da17607051-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20230930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aeb37bea-91a4-45c2-a9d7-3f18a8c88d34" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentType_aeb37bea-91a4-45c2-a9d7-3f18a8c88d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_64680af5-a38f-4ece-a984-c684d08fff8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentQuarterlyReport_64680af5-a38f-4ece-a984-c684d08fff8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_12db0796-16f5-43ac-821e-ff829a0c047c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentPeriodEndDate_12db0796-16f5-43ac-821e-ff829a0c047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ac1b9a7a-2ebb-43c7-a22f-dd7cd331f931" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentTransitionReport_ac1b9a7a-2ebb-43c7-a22f-dd7cd331f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_51e568c0-6d8b-46f0-a29c-510923ffd92b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityFileNumber_51e568c0-6d8b-46f0-a29c-510923ffd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d77ac6fb-6218-4096-b4fd-1f44ebe0b960" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityRegistrantName_d77ac6fb-6218-4096-b4fd-1f44ebe0b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7426ded0-79a1-480e-b817-efab4ea754f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7426ded0-79a1-480e-b817-efab4ea754f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4781548c-7f5f-4b98-89c0-0abba03ec4d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityTaxIdentificationNumber_4781548c-7f5f-4b98-89c0-0abba03ec4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ea03f4db-80bd-445c-8f3c-53ee2b44c7be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityAddressAddressLine1_ea03f4db-80bd-445c-8f3c-53ee2b44c7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4d5a6380-b5da-4264-bbc0-780f1c7d1fbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityAddressAddressLine2_4d5a6380-b5da-4264-bbc0-780f1c7d1fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_452728a8-f355-4523-97c6-79f60068d916" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityAddressCityOrTown_452728a8-f355-4523-97c6-79f60068d916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f58938f2-db7f-4f84-a4de-88742b4886cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityAddressStateOrProvince_f58938f2-db7f-4f84-a4de-88742b4886cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1436f33c-b2e9-48a4-8a34-ba060f1543f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityAddressPostalZipCode_1436f33c-b2e9-48a4-8a34-ba060f1543f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_87649379-6215-49bc-ae9b-d2884fe779e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_CityAreaCode_87649379-6215-49bc-ae9b-d2884fe779e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_88c76cc5-c5de-4b3f-96f4-719f30a5887a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_LocalPhoneNumber_88c76cc5-c5de-4b3f-96f4-719f30a5887a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_948d3330-4cc0-4915-92ae-b0f8c8c19bc0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_Security12bTitle_948d3330-4cc0-4915-92ae-b0f8c8c19bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3b719e10-1e9a-4350-8fa4-9f59aedc9d0d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_TradingSymbol_3b719e10-1e9a-4350-8fa4-9f59aedc9d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4ec44efb-8872-42f9-9279-69e62fa69fbe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_SecurityExchangeName_4ec44efb-8872-42f9-9279-69e62fa69fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e54d95c6-fff7-4c24-9206-e266b2089c70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityCurrentReportingStatus_e54d95c6-fff7-4c24-9206-e266b2089c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5ddab8cc-c213-4ef4-9a6f-45aef311fb4d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityInteractiveDataCurrent_5ddab8cc-c213-4ef4-9a6f-45aef311fb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d011495d-2cf6-4c0b-b428-e59616807acf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityFilerCategory_d011495d-2cf6-4c0b-b428-e59616807acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f15c413b-5b94-4a2b-8d6b-ad8a89c637a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntitySmallBusiness_f15c413b-5b94-4a2b-8d6b-ad8a89c637a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6cd7bc8e-65ca-48b8-a911-ceee736b52f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityEmergingGrowthCompany_6cd7bc8e-65ca-48b8-a911-ceee736b52f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a9815062-4742-4d64-9d2e-56b7fd2bbdf8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityShellCompany_a9815062-4742-4d64-9d2e-56b7fd2bbdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_801673ed-0702-439a-8644-9a50412ff1d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_801673ed-0702-439a-8644-9a50412ff1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ce8a47e6-de6b-40c7-85ff-9edb9a48bbd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentFiscalYearFocus_ce8a47e6-de6b-40c7-85ff-9edb9a48bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bdcf6177-835e-4570-af0d-d2dd251c62dc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bdcf6177-835e-4570-af0d-d2dd251c62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_669213c8-fe6a-4df4-8ecc-d1d5df815dc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_AmendmentFlag_669213c8-fe6a-4df4-8ecc-d1d5df815dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4d8218e3-63d1-40df-aeb9-cc808c22cbe8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_CurrentFiscalYearEndDate_4d8218e3-63d1-40df-aeb9-cc808c22cbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6cbfee7b-97bc-467a-95cd-97e022a1f946" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_39a81228-593d-4f4c-929f-19e91b717442" xlink:to="loc_dei_EntityCentralIndexKey_6cbfee7b-97bc-467a-95cd-97e022a1f946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f1420b3e-b7be-49ee-9d3c-e26393f77e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1420b3e-b7be-49ee-9d3c-e26393f77e85" xlink:to="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7dc08fa-33a8-4277-9b52-30b20f7ade0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7dc08fa-33a8-4277-9b52-30b20f7ade0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_bc645fd5-e17d-4c01-a821-8b51d2855532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:to="loc_us-gaap_OtherShortTermInvestments_bc645fd5-e17d-4c01-a821-8b51d2855532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1b884a6-fc89-4763-96f3-401b214f113b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1b884a6-fc89-4763-96f3-401b214f113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c646f3f4-9a9b-4c70-8910-75e309e8be53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_49ce2330-b8b6-4be8-a87c-5ead56ca6ba4" xlink:to="loc_us-gaap_AssetsCurrent_c646f3f4-9a9b-4c70-8910-75e309e8be53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db946ee3-883a-4310-ba23-e291f62d5860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_db946ee3-883a-4310-ba23-e291f62d5860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_55b2539c-ebba-459d-a946-beb8ed1fedc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_55b2539c-ebba-459d-a946-beb8ed1fedc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6bf9ae11-9cc5-4c55-9e1e-5dd44a364cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6bf9ae11-9cc5-4c55-9e1e-5dd44a364cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0610c55e-c112-484a-8a83-9fb35cb9485f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_956f31dd-8e46-4839-8947-7f5efcde7fc6" xlink:to="loc_us-gaap_Assets_0610c55e-c112-484a-8a83-9fb35cb9485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f1420b3e-b7be-49ee-9d3c-e26393f77e85" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3c5016b2-c60a-42f7-a5eb-288abbd8d230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:to="loc_us-gaap_AccountsPayableCurrent_3c5016b2-c60a-42f7-a5eb-288abbd8d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_90972f84-2a26-4f0f-8d2b-5ff8163946a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_90972f84-2a26-4f0f-8d2b-5ff8163946a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1ea7d320-4e3d-4320-be71-9a2a2a5f5a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1ea7d320-4e3d-4320-be71-9a2a2a5f5a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2212bd48-12b3-4a8f-b601-8dd4291e779f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4469d8f1-29de-498c-a15a-71057b57ac83" xlink:to="loc_us-gaap_LiabilitiesCurrent_2212bd48-12b3-4a8f-b601-8dd4291e779f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_0ee85a03-3efd-4bb1-80e0-8352ee433a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_0ee85a03-3efd-4bb1-80e0-8352ee433a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5f0fe85-1c4c-45c7-ac24-e58f517c552b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0ee85a03-3efd-4bb1-80e0-8352ee433a2a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e5f0fe85-1c4c-45c7-ac24-e58f517c552b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_af204d44-36d1-4b5d-bf4a-21e2938a5376" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_0ee85a03-3efd-4bb1-80e0-8352ee433a2a" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_af204d44-36d1-4b5d-bf4a-21e2938a5376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3b60c78f-a4b7-4649-84ce-5aa95c703b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_Liabilities_3b60c78f-a4b7-4649-84ce-5aa95c703b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_84d15d22-ee02-4855-b307-7c5cfb1f45cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_84d15d22-ee02-4855-b307-7c5cfb1f45cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ec7c9d71-d09f-46ef-8ea6-9326cea6dac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_PreferredStockValue_ec7c9d71-d09f-46ef-8ea6-9326cea6dac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4445d4b4-afcb-41f0-80e6-c6d095dd1d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_CommonStockValue_4445d4b4-afcb-41f0-80e6-c6d095dd1d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_42878b7a-4c2a-416f-87d6-b82bdeb5c20a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_42878b7a-4c2a-416f-87d6-b82bdeb5c20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21f48d57-ada9-40e2-8a0e-646e8d59c451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21f48d57-ada9-40e2-8a0e-646e8d59c451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ed5bcc6-f032-4c5c-974d-4c0051620a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ed5bcc6-f032-4c5c-974d-4c0051620a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_36464715-eaf2-499d-b12e-ef6f8b0b7f98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1adecdb0-f472-4586-867f-2e707a06e54f" xlink:to="loc_us-gaap_StockholdersEquity_36464715-eaf2-499d-b12e-ef6f8b0b7f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8cefd576-e67d-4a1f-a714-e6bd5cb8cedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7243c369-4f47-4c3d-b114-c546d76293a9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8cefd576-e67d-4a1f-a714-e6bd5cb8cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4a9f5224-96bd-43ed-921c-1287cebe817c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4a9f5224-96bd-43ed-921c-1287cebe817c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6baf575c-3f99-40e3-9538-4d91d55e1224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6baf575c-3f99-40e3-9538-4d91d55e1224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dd2bd55a-cf2f-4b1e-b8cf-f7ea49505278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dd2bd55a-cf2f-4b1e-b8cf-f7ea49505278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_b651c950-24ff-4032-a293-301113850360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_b651c950-24ff-4032-a293-301113850360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c11c94d-edc3-432b-8ec6-2fbcd1cda158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c11c94d-edc3-432b-8ec6-2fbcd1cda158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b57a58e9-210a-41b0-8c5f-26fec1bb9af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b57a58e9-210a-41b0-8c5f-26fec1bb9af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f7e3dbaf-2de9-445f-857b-21dc91803ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_CommonStockSharesIssued_f7e3dbaf-2de9-445f-857b-21dc91803ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_622607a4-2f27-4934-8cca-5dd9c6c67c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_885c398d-0067-4d75-b88b-788f040f482e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_622607a4-2f27-4934-8cca-5dd9c6c67c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_54da22ad-01a3-4f31-8f41-ab2a01362529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_OperatingExpensesAbstract_54da22ad-01a3-4f31-8f41-ab2a01362529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_23d4cb34-d606-4fcb-a8be-312e52042442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54da22ad-01a3-4f31-8f41-ab2a01362529" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_23d4cb34-d606-4fcb-a8be-312e52042442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9b4ac006-9345-43d9-81dd-fdae2f25c046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54da22ad-01a3-4f31-8f41-ab2a01362529" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9b4ac006-9345-43d9-81dd-fdae2f25c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dacd58e6-c4c6-4e1a-831e-d8d59b9129a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54da22ad-01a3-4f31-8f41-ab2a01362529" xlink:to="loc_us-gaap_OperatingExpenses_dacd58e6-c4c6-4e1a-831e-d8d59b9129a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_06be9a02-3d88-4ec0-ad62-2f9e4c32826b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_OperatingIncomeLoss_06be9a02-3d88-4ec0-ad62-2f9e4c32826b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fa767ae2-1e8c-4cfa-883d-1aa0e2ab3d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fa767ae2-1e8c-4cfa-883d-1aa0e2ab3d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_53e51194-6a06-4a42-8d6e-d502e021473d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fa767ae2-1e8c-4cfa-883d-1aa0e2ab3d9f" xlink:to="loc_us-gaap_InvestmentIncomeInterest_53e51194-6a06-4a42-8d6e-d502e021473d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c4cedf92-29ee-421d-8246-390dafa19e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fa767ae2-1e8c-4cfa-883d-1aa0e2ab3d9f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c4cedf92-29ee-421d-8246-390dafa19e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13d062d2-a322-4e76-8710-664b299d3fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_fa767ae2-1e8c-4cfa-883d-1aa0e2ab3d9f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13d062d2-a322-4e76-8710-664b299d3fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18521278-b9d6-400e-b0fb-3312eb1a2f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_NetIncomeLoss_18521278-b9d6-400e-b0fb-3312eb1a2f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ef8c5a6b-e98f-4174-a3fa-09a28a6ce5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_EarningsPerShareBasic_ef8c5a6b-e98f-4174-a3fa-09a28a6ce5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1b9edb16-2866-4b71-921d-ecac60dce4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1b9edb16-2866-4b71-921d-ecac60dce4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90cb845c-94fa-4543-ba2e-3e99608ffc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_90cb845c-94fa-4543-ba2e-3e99608ffc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_007e68de-ee49-4f70-8739-547b95a1a1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_053f1061-caee-4ac5-bbfe-49c802d47a09" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_007e68de-ee49-4f70-8739-547b95a1a1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_67acc540-d5aa-427a-8714-3731baaae94f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3f5dabce-aa5d-46bf-9659-b1d3f595989f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_67acc540-d5aa-427a-8714-3731baaae94f" xlink:to="loc_us-gaap_NetIncomeLoss_3f5dabce-aa5d-46bf-9659-b1d3f595989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edb19fd5-d508-4155-a906-afac0bcae359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_67acc540-d5aa-427a-8714-3731baaae94f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edb19fd5-d508-4155-a906-afac0bcae359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_76b7d606-604b-47b4-839e-f217d48d674e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_edb19fd5-d508-4155-a906-afac0bcae359" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_76b7d606-604b-47b4-839e-f217d48d674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6bb8b651-620d-4c78-a737-ba10907ae025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_67acc540-d5aa-427a-8714-3731baaae94f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6bb8b651-620d-4c78-a737-ba10907ae025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1174ec92-c180-4b08-966d-463e3ca05e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1174ec92-c180-4b08-966d-463e3ca05e77" xlink:to="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_81165421-bc26-4adb-b8ae-551650cf6ed8" xlink:to="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b8e8376-7766-44f7-bf14-899dcf8a90bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_CommonStockMember_8b8e8376-7766-44f7-bf14-899dcf8a90bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4616ce83-8719-45e5-b722-afe4922e3e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4616ce83-8719-45e5-b722-afe4922e3e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7751e2b6-6763-4e53-bd65-50ffe4e19256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7751e2b6-6763-4e53-bd65-50ffe4e19256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1201af95-e2d2-4e22-bf5a-16c27ed072cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73eeb7be-79ce-4abc-a6ab-ff9ed54ee046" xlink:to="loc_us-gaap_RetainedEarningsMember_1201af95-e2d2-4e22-bf5a-16c27ed072cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c7fef5cf-5f0b-4c6c-b01c-257421a05167" xlink:to="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f05909d-0ff9-4fe1-ab25-c384da7a64ca" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6b2e1a1-65e8-4d75-897d-9c993eeaea48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6b2e1a1-65e8-4d75-897d-9c993eeaea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_182eabfb-398d-4c38-bcd4-08bb332f7f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockholdersEquity_182eabfb-398d-4c38-bcd4-08bb332f7f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adce9e39-fede-4bb0-a1b5-85aa744a3795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_NetIncomeLoss_adce9e39-fede-4bb0-a1b5-85aa744a3795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_09a592a6-7e70-4e60-8747-585061037c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_09a592a6-7e70-4e60-8747-585061037c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66382c5a-88f4-4466-b5e1-f8f2d6c842de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66382c5a-88f4-4466-b5e1-f8f2d6c842de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb57d3ee-6e2a-4eb9-88cd-54fb5f4b650a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cb57d3ee-6e2a-4eb9-88cd-54fb5f4b650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b32b53f2-716a-4713-afae-a9d6e2d74475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b32b53f2-716a-4713-afae-a9d6e2d74475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b33bd17-42a8-4b92-8d57-68c8af2af1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b33bd17-42a8-4b92-8d57-68c8af2af1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_92512e9b-3301-4b04-ba6b-c481623f5fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_92512e9b-3301-4b04-ba6b-c481623f5fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_beea34ee-aedc-41ab-934d-df295fe63b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_beea34ee-aedc-41ab-934d-df295fe63b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c042660-7a9b-45d4-8d01-e031c7e32081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5c042660-7a9b-45d4-8d01-e031c7e32081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0be0652d-11a7-4f4a-a13f-f262c020d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0be0652d-11a7-4f4a-a13f-f262c020d9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_43be24e4-0e12-48e8-b866-3f3050390962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_04bdc748-366f-4d7d-bda5-1d0f957d57ba" xlink:to="loc_us-gaap_StockholdersEquity_43be24e4-0e12-48e8-b866-3f3050390962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dcb48408-719a-43fb-afb1-6bbebac4c2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_329b9d30-91c5-4427-a494-8612c359cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dcb48408-719a-43fb-afb1-6bbebac4c2a3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_329b9d30-91c5-4427-a494-8612c359cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_07571b27-119c-414a-a115-5cc75ccacea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_07571b27-119c-414a-a115-5cc75ccacea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_991b98e7-37b2-4099-823c-db9baa5561a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_07571b27-119c-414a-a115-5cc75ccacea1" xlink:to="loc_us-gaap_NetIncomeLoss_991b98e7-37b2-4099-823c-db9baa5561a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_07571b27-119c-414a-a115-5cc75ccacea1" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b2e573b6-28ad-41b7-beff-0bf5a8c37c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b2e573b6-28ad-41b7-beff-0bf5a8c37c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_645800e4-969c-468f-8a07-2fabc0180aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_645800e4-969c-468f-8a07-2fabc0180aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e7cb2b00-293c-4704-b7f0-e82efbd57ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:to="loc_us-gaap_ShareBasedCompensation_e7cb2b00-293c-4704-b7f0-e82efbd57ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_497fedc9-a32e-4bab-8c98-d2b22974d86b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a8a7002-d166-4874-88e7-1e46785e7c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a8a7002-d166-4874-88e7-1e46785e7c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_87c3e1ca-09e7-40c7-9e57-2c2d99e221ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_87c3e1ca-09e7-40c7-9e57-2c2d99e221ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fd17120b-c0e6-4a97-b5e2-88de9ab05771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_fd17120b-c0e6-4a97-b5e2-88de9ab05771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b9e173a-917d-4e78-a00c-ca2848ae6931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32b104dd-24e7-405b-b55a-98fbc5115ff3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b9e173a-917d-4e78-a00c-ca2848ae6931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f325b77-2a89-445f-972b-be0c8e532499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_07571b27-119c-414a-a115-5cc75ccacea1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4f325b77-2a89-445f-972b-be0c8e532499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cbc4242-31ba-4dd7-8313-a79789afdca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cbc4242-31ba-4dd7-8313-a79789afdca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c933fdcb-e860-4111-848c-357a226b9afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cbc4242-31ba-4dd7-8313-a79789afdca0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c933fdcb-e860-4111-848c-357a226b9afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ad21998-13b1-4784-af90-e87cfaa01858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cbc4242-31ba-4dd7-8313-a79789afdca0" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4ad21998-13b1-4784-af90-e87cfaa01858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6bc952b8-1f87-4b52-a0b9-4e74ee295804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6cbc4242-31ba-4dd7-8313-a79789afdca0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6bc952b8-1f87-4b52-a0b9-4e74ee295804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21ac3353-79d1-481b-bc43-928ea0d82c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21ac3353-79d1-481b-bc43-928ea0d82c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3aebce8d-b7d2-4eb4-aa7f-babf06c87697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3aebce8d-b7d2-4eb4-aa7f-babf06c87697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_daf8e669-c850-45b2-8a4d-fbfb9d228ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_daf8e669-c850-45b2-8a4d-fbfb9d228ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_374179cd-9a96-4774-9ca8-04b7f27ce19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_374179cd-9a96-4774-9ca8-04b7f27ce19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47bc96fa-82ae-41ce-a65a-286242568b00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_28011eaf-5159-46fb-af57-f2e3805db7a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47bc96fa-82ae-41ce-a65a-286242568b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03c4ad72-742a-40b4-9e68-0f2e6de9f76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03c4ad72-742a-40b4-9e68-0f2e6de9f76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5a8e7fd-43e5-4f59-a16a-7b1e19c2d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5a8e7fd-43e5-4f59-a16a-7b1e19c2d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_738d1c19-e2ca-4dd3-ad4b-b997ec285d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_738d1c19-e2ca-4dd3-ad4b-b997ec285d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35bc5769-1bee-469a-9c43-f03b915c28e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35bc5769-1bee-469a-9c43-f03b915c28e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_10f7189f-8a73-42d7-88e1-0c3127848ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2b9b591c-ccee-42c5-ae16-1acd41f9fc58" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_10f7189f-8a73-42d7-88e1-0c3127848ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb412ac8-cccb-48dc-b0bb-d9db275e603e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_10f7189f-8a73-42d7-88e1-0c3127848ac2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bb412ac8-cccb-48dc-b0bb-d9db275e603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="vtl-20230930.xsd#CondensedConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9272499b-064c-4baf-8fcb-d031b32583c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5564ee60-1d31-4d5a-b48b-40560bc0720f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9272499b-064c-4baf-8fcb-d031b32583c5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5564ee60-1d31-4d5a-b48b-40560bc0720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20230930.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aec7086e-db23-40ce-a811-1680365e70cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_22b59b0d-173d-4d13-9813-1205fea0a94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aec7086e-db23-40ce-a811-1680365e70cb" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_22b59b0d-173d-4d13-9813-1205fea0a94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59fc4438-837e-4dd8-9fb7-dce77590e46c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f0ba9e6-de8a-43ef-9c93-040f5adcfe73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59fc4438-837e-4dd8-9fb7-dce77590e46c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3f0ba9e6-de8a-43ef-9c93-040f5adcfe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbc6a601-9b47-435b-bbfd-6792cb492523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_759da2c8-5f51-4036-9e67-a966b615ae1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbc6a601-9b47-435b-bbfd-6792cb492523" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_759da2c8-5f51-4036-9e67-a966b615ae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b15f913-7fcf-4556-937c-f5950437e23c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a63c7be0-140f-4074-b014-3308d1a7e86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b15f913-7fcf-4556-937c-f5950437e23c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a63c7be0-140f-4074-b014-3308d1a7e86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1bc34dab-f089-4b83-a377-d9be9dab48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2ed8e089-a29a-4120-aa4b-89ab2ee6298b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1bc34dab-f089-4b83-a377-d9be9dab48f2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2ed8e089-a29a-4120-aa4b-89ab2ee6298b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7797385-f0ab-4f3e-849e-04ad84ad206f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67c2e31b-4944-4692-8705-974c26558cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7797385-f0ab-4f3e-849e-04ad84ad206f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_67c2e31b-4944-4692-8705-974c26558cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0935741-bbc3-4894-961f-68d8433a05e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ace71d3e-4664-4ab3-988f-89c889ef6e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0935741-bbc3-4894-961f-68d8433a05e6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ace71d3e-4664-4ab3-988f-89c889ef6e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectors" xlink:type="simple" xlink:href="vtl-20230930.xsd#ChangesinBoardofDirectors"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35ed5c71-5121-4383-a4b3-19a4b98eee16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_2992baa5-bdf2-438e-aeab-98fec8495263" xlink:href="vtl-20230930.xsd#vtl_ChangesInBoardOfDirectorsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35ed5c71-5121-4383-a4b3-19a4b98eee16" xlink:to="loc_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock_2992baa5-bdf2-438e-aeab-98fec8495263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20230930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_159e2aa5-cc0f-48bf-b95b-94f9ce5087d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c32289b9-4dc7-429f-8768-e36f02f247c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_159e2aa5-cc0f-48bf-b95b-94f9ce5087d7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c32289b9-4dc7-429f-8768-e36f02f247c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtl-20230930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_75a9ac79-4a01-45e2-9090-3cce5be1e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_991880a3-992c-4302-8ae7-57ef4152f3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_75a9ac79-4a01-45e2-9090-3cce5be1e93b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_991880a3-992c-4302-8ae7-57ef4152f3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7c771f9a-7c46-4db1-90a2-8619bb25c2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7c771f9a-7c46-4db1-90a2-8619bb25c2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_cdba8cd5-71f8-4845-b170-4b2626109976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_UseOfEstimates_cdba8cd5-71f8-4845-b170-4b2626109976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_95862b4d-7113-4114-9cdf-0ec5d8a6b089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_95862b4d-7113-4114-9cdf-0ec5d8a6b089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_8f710a01-f89a-4e67-8eaf-a6cf38d8ddc3" xlink:href="vtl-20230930.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_8f710a01-f89a-4e67-8eaf-a6cf38d8ddc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5b2a549c-8010-459a-b570-cb60bf3c1b76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5b2a549c-8010-459a-b570-cb60bf3c1b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1eabac96-e147-4ac3-9445-ead5b2d9ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1eabac96-e147-4ac3-9445-ead5b2d9ce36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4389a233-25c1-48a7-b483-3d0826ed4861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4389a233-25c1-48a7-b483-3d0826ed4861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b9689825-1f05-4a4e-9bb8-3ec8e783110e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_b9689825-1f05-4a4e-9bb8-3ec8e783110e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_81683ab2-d799-4048-b71b-7248f3532cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_81683ab2-d799-4048-b71b-7248f3532cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_568c5d68-7f58-4512-8349-52a9691845c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_568c5d68-7f58-4512-8349-52a9691845c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_5e341e6d-d2ec-4985-b10e-92e7dad33b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_5e341e6d-d2ec-4985-b10e-92e7dad33b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0acb15db-318a-445c-9f9a-25a9a68b33c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0acb15db-318a-445c-9f9a-25a9a68b33c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60e582e3-dc66-4f9e-8026-ff22bb982854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_60e582e3-dc66-4f9e-8026-ff22bb982854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9604047b-83b9-455b-93f3-65f3134c8be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9604047b-83b9-455b-93f3-65f3134c8be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_671e74e4-d7bd-4bf0-9571-8767bef6ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_671e74e4-d7bd-4bf0-9571-8767bef6ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ff5ccc62-03de-4f38-83a1-232ab8fb362d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ff5ccc62-03de-4f38-83a1-232ab8fb362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_7a2d4546-e618-420d-81c4-ffacaf87cc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_7a2d4546-e618-420d-81c4-ffacaf87cc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_dfa5e315-1a37-4d62-94f0-aef29388888f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_dfa5e315-1a37-4d62-94f0-aef29388888f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92cbbe2c-2de4-4d20-a31f-bbc182425805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62a9ae4c-73b0-4348-ab3d-8914e435872a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92cbbe2c-2de4-4d20-a31f-bbc182425805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_583a0478-8c8a-4fae-94b8-43aee446cf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_52dd0efd-0099-43a4-9fd6-39829e095b60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583a0478-8c8a-4fae-94b8-43aee446cf3c" xlink:to="loc_us-gaap_InvestmentTableTextBlock_52dd0efd-0099-43a4-9fd6-39829e095b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_193c33f1-2477-4914-a16e-0772a90fd210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_583a0478-8c8a-4fae-94b8-43aee446cf3c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_193c33f1-2477-4914-a16e-0772a90fd210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25030183-bb37-4953-8fcd-3880013de0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1f6f73f8-1308-4c1f-a63f-63282a8b2405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25030183-bb37-4953-8fcd-3880013de0ce" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1f6f73f8-1308-4c1f-a63f-63282a8b2405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_818abfdf-44cb-4889-a8d1-8befe2d5de36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25030183-bb37-4953-8fcd-3880013de0ce" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_818abfdf-44cb-4889-a8d1-8befe2d5de36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_89d328fd-d15c-4430-8f2e-ff95c754c16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_25030183-bb37-4953-8fcd-3880013de0ce" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_89d328fd-d15c-4430-8f2e-ff95c754c16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_217a567f-f521-47ef-af92-b0f97de13420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f8fc67b-7345-4b90-9799-6cb40028719c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_217a567f-f521-47ef-af92-b0f97de13420" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f8fc67b-7345-4b90-9799-6cb40028719c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_49925e8e-648d-43b0-b69a-318e139500ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7c412c36-7320-40da-bc60-8d4dd539f641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_49925e8e-648d-43b0-b69a-318e139500ad" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7c412c36-7320-40da-bc60-8d4dd539f641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3c7c0691-de15-403d-97e7-270dcc1fa0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_b611f046-e1ed-45ba-9499-b5dbe40083c0" xlink:href="vtl-20230930.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3c7c0691-de15-403d-97e7-270dcc1fa0d4" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_b611f046-e1ed-45ba-9499-b5dbe40083c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d0b9c6e-c7ec-4018-b2ee-d3f1f9d35d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d05f5c3d-47ad-400c-968d-37c818a3b55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d0b9c6e-c7ec-4018-b2ee-d3f1f9d35d7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d05f5c3d-47ad-400c-968d-37c818a3b55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1b118198-e371-4442-a73e-e4300b0e229c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d0b9c6e-c7ec-4018-b2ee-d3f1f9d35d7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1b118198-e371-4442-a73e-e4300b0e229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0c077f35-e5bf-4262-860a-28b659982ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d0b9c6e-c7ec-4018-b2ee-d3f1f9d35d7d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0c077f35-e5bf-4262-860a-28b659982ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6ec6901d-d62f-4788-a6cb-7fc8cdd9b019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6ec6901d-d62f-4788-a6cb-7fc8cdd9b019" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4464166d-010a-4d10-a60f-a6d3f379604a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c7d1a130-eb73-4507-92f9-993daa038129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4acedb4d-6db0-495b-bbbe-115092efc1f7" xlink:to="loc_us-gaap_SubsequentEventMember_c7d1a130-eb73-4507-92f9-993daa038129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0031c84-9fef-4bce-b775-d25f16e0e949" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_a5b5bd3a-592b-4376-863e-5407fc03a56a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_dei_EntityNumberOfEmployees_a5b5bd3a-592b-4376-863e-5407fc03a56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_1f60693d-179d-4ffe-923d-fcba9dea005c" xlink:href="vtl-20230930.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_1f60693d-179d-4ffe-923d-fcba9dea005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f20ee4d-ceef-4094-b18c-435b6cda3de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8f20ee4d-ceef-4094-b18c-435b6cda3de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a730cf3c-0720-45ba-a455-f1449f7729cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_a730cf3c-0720-45ba-a455-f1449f7729cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9b9f3f0-6368-4211-bd91-386c1452fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8d1823b4-d03e-40a3-a066-93eb7b7fcaa0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a9b9f3f0-6368-4211-bd91-386c1452fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c341503-ef2a-4d62-a8e2-ffed4ae40df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c341503-ef2a-4d62-a8e2-ffed4ae40df8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_49db0569-95fb-4062-8668-b17ea19cf974" xlink:to="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4cc2394a-2a6a-4772-a566-a4a232f5ff2e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_US_4cc2394a-2a6a-4772-a566-a4a232f5ff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1b31505a-d89c-472a-a19a-5a3b34f0fc19" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_DE_1b31505a-d89c-472a-a19a-5a3b34f0fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_0f68179a-0d85-46a9-8865-6d22ce22317b" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_country_AU_0f68179a-0d85-46a9-8865-6d22ce22317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_5cbe6659-2dac-48ff-853f-035edbb00968" xlink:href="vtl-20230930.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_200adf7c-3525-4014-aa62-274a76ffe94e" xlink:to="loc_vtl_AustraliaAndGermanyMember_5cbe6659-2dac-48ff-853f-035edbb00968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2f760cc-4d10-40e5-86f7-15c670959a79" xlink:to="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d943b8a9-86aa-4472-864d-b6f0725c275a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:to="loc_srt_MinimumMember_d943b8a9-86aa-4472-864d-b6f0725c275a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6aee9afe-d365-49fc-b0c4-73a4781d8ac4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_afde4198-ad12-44e8-82f2-b18baf78d0ae" xlink:to="loc_srt_MaximumMember_6aee9afe-d365-49fc-b0c4-73a4781d8ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_80dde5b1-cdff-4fc8-8249-a842b14ec226" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0a35c9ca-a9d2-45b1-8b85-7a6601d22b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0a35c9ca-a9d2-45b1-8b85-7a6601d22b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_32b0f0e1-c792-44da-b86e-a3feef303a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e9441531-dbe2-4518-baec-8cbc7b626de4" xlink:to="loc_us-gaap_BankTimeDepositsMember_32b0f0e1-c792-44da-b86e-a3feef303a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5a3fb74f-b1a2-4ab9-a97d-3d393b1c6be7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_a614308c-d9ab-4fb2-9391-dc545493a0a8" xlink:href="vtl-20230930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_473cf48e-aecb-43e1-8090-1f8bf7d25fd6" xlink:to="loc_vtl_PreFundedWarrantsMember_a614308c-d9ab-4fb2-9391-dc545493a0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_91fd3cab-f903-419a-bac6-0a0c204754d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7a22670-7818-4d78-976f-c6f964d84975" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b7a22670-7818-4d78-976f-c6f964d84975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_c1ad408b-b617-46b9-b5ab-01f201c521e2" xlink:href="vtl-20230930.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_c1ad408b-b617-46b9-b5ab-01f201c521e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_44337701-1efc-42ff-be61-0aa868c50418" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_InvestmentInterestRate_44337701-1efc-42ff-be61-0aa868c50418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8cbf559-20d6-4fc7-93c1-337e77d06c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8cbf559-20d6-4fc7-93c1-337e77d06c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_547817e0-3a65-461f-b289-e602640a3360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_Depreciation_547817e0-3a65-461f-b289-e602640a3360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_3c249d47-64dd-453a-be78-bb00d0dbaef0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_3c249d47-64dd-453a-be78-bb00d0dbaef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_79027644-a737-40d9-8fbd-900b0fe2f205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_79027644-a737-40d9-8fbd-900b0fe2f205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_57c7fb48-511e-4236-8cec-fc8eff8d74a0" xlink:href="vtl-20230930.xsd#vtl_GovernmentAssistanceRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_GovernmentAssistanceRate_57c7fb48-511e-4236-8cec-fc8eff8d74a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_e856ab2a-a92b-46f5-a8a0-cf2135894751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_e856ab2a-a92b-46f5-a8a0-cf2135894751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1f36f909-eac3-45e1-a76d-59489cc4cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_1f36f909-eac3-45e1-a76d-59489cc4cf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_24d0b7c6-49f0-410e-81cb-c105d51c0c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_24d0b7c6-49f0-410e-81cb-c105d51c0c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_8d8c7941-75fa-40aa-8f79-90fced4bf737" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_8d8c7941-75fa-40aa-8f79-90fced4bf737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1eb002bd-7395-4588-aec2-341d5b5785a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_89569265-bfde-459e-b85d-1a2a7f046f95" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1eb002bd-7395-4588-aec2-341d5b5785a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_431bd772-3bb1-4169-9bbd-14981bb850a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_431bd772-3bb1-4169-9bbd-14981bb850a2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_94b31d08-6723-49b1-9e99-f7cc933677bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_60538a1d-741f-42b6-950a-ccb5648e7dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_93cfd82d-674e-4545-a1cb-e7889badc449" xlink:to="loc_us-gaap_BankTimeDepositsMember_60538a1d-741f-42b6-950a-ccb5648e7dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_e23c3e95-b062-44c1-992c-ac0acaef263c" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_b1454610-4128-41f8-8768-876d1aab8c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_19c50443-badb-4e45-b9b2-c0277deb6452" xlink:to="loc_us-gaap_OtherShortTermInvestments_b1454610-4128-41f8-8768-876d1aab8c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ee89712f-09ad-44e2-a792-c811b403db8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ee89712f-09ad-44e2-a792-c811b403db8b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d68d0d0b-6d4b-4574-b77a-4e382279c2ef" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_10dc39f9-3db3-4c56-b7c7-3e3ef1d57690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_146cfb3d-94c0-4b42-b668-832d2740fa8c" xlink:to="loc_us-gaap_StockOptionMember_10dc39f9-3db3-4c56-b7c7-3e3ef1d57690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_170af301-c6e9-4c29-a65d-482ad045fefe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e30961d-f360-478e-9080-dfc3ee2d6c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f5404d5-b7cd-4eb6-b4e0-c85add1dcf57" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0e30961d-f360-478e-9080-dfc3ee2d6c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_782a6277-fb9e-4f55-ad38-f7d899cff89a" xlink:href="vtl-20230930.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_782a6277-fb9e-4f55-ad38-f7d899cff89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_77233ddd-7bdb-43f9-b4ad-1190d25c9316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_77233ddd-7bdb-43f9-b4ad-1190d25c9316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_baa743c8-8173-4840-a7ee-ad26af9cd14d" xlink:href="vtl-20230930.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_baa743c8-8173-4840-a7ee-ad26af9cd14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_40fa6098-b93d-42df-b314-afbd63d68634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:to="loc_us-gaap_OtherAssetsCurrent_40fa6098-b93d-42df-b314-afbd63d68634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_60f450d8-8000-4762-bed0-66555beb2024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bff7e2f6-1398-4d48-bba4-5460ca7dc5c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_60f450d8-8000-4762-bed0-66555beb2024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb254847-c8a3-4d58-a05c-844b79a682ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_80126550-db94-48b8-94fc-4487051c1c59" xlink:href="vtl-20230930.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb254847-c8a3-4d58-a05c-844b79a682ba" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_80126550-db94-48b8-94fc-4487051c1c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_f286962d-a473-442a-98d8-36b95717539c" xlink:href="vtl-20230930.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb254847-c8a3-4d58-a05c-844b79a682ba" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_f286962d-a473-442a-98d8-36b95717539c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_2f927fd1-b1dd-48dc-8b75-bd66edf72a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb254847-c8a3-4d58-a05c-844b79a682ba" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_2f927fd1-b1dd-48dc-8b75-bd66edf72a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e2ad591b-3a9d-436d-bd8d-eaccdb5693f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb254847-c8a3-4d58-a05c-844b79a682ba" xlink:to="loc_us-gaap_AccountsPayableCurrent_e2ad591b-3a9d-436d-bd8d-eaccdb5693f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_18da987c-6e93-4496-aeb4-3bdf5ba2b0ed" xlink:href="vtl-20230930.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_18da987c-6e93-4496-aeb4-3bdf5ba2b0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_2a7bfdb4-305b-4e69-9447-683346039706" xlink:href="vtl-20230930.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_2a7bfdb4-305b-4e69-9447-683346039706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_5ec24d8c-734f-408c-9c3e-0ce1b1ab106b" xlink:href="vtl-20230930.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:to="loc_vtl_AccruedCompensationCurrent_5ec24d8c-734f-408c-9c3e-0ce1b1ab106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3163b155-7e0f-4b8e-a61c-3130b10e8cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3163b155-7e0f-4b8e-a61c-3130b10e8cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8ed6301a-c436-4462-94d5-80be357de428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3678f49d-efd2-4d7c-9d9d-c8369d42a68f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8ed6301a-c436-4462-94d5-80be357de428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831b8732-430a-41f5-8344-24d6a2e8a290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad236205-2b37-4859-b915-0e39ad511e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831b8732-430a-41f5-8344-24d6a2e8a290" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad236205-2b37-4859-b915-0e39ad511e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_a1b4494f-dfec-444e-b2c2-dd1c22318f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831b8732-430a-41f5-8344-24d6a2e8a290" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_a1b4494f-dfec-444e-b2c2-dd1c22318f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f8e0b8b6-93fa-47b7-b33e-a73d1e758de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_831b8732-430a-41f5-8344-24d6a2e8a290" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f8e0b8b6-93fa-47b7-b33e-a73d1e758de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31a459de-ca6e-47d4-a2ff-6b66f68abcda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_31a459de-ca6e-47d4-a2ff-6b66f68abcda" xlink:to="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:to="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b10bce13-8b48-44bf-acd9-47bbfd2b4620" xlink:to="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_677cc038-e09b-4492-8c97-597faeddcc7d" xlink:href="vtl-20230930.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_NewYorkCityMember_677cc038-e09b-4492-8c97-597faeddcc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_786949bc-3678-4fed-b423-b39b088cc796" xlink:href="vtl-20230930.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_GrafelfingGermanyMember_786949bc-3678-4fed-b423-b39b088cc796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_6cc2d4a6-1f38-4263-87b5-1b641d168e32" xlink:href="vtl-20230930.xsd#vtl_PlaneggGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca74ce5b-4432-4607-a097-c1244319a88e" xlink:to="loc_vtl_PlaneggGermanyMember_6cc2d4a6-1f38-4263-87b5-1b641d168e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4f13da6f-aad0-4c2c-8d59-933a83bd06f2" xlink:to="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ea7ab4e6-7843-4243-8a1d-c1a8679f4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ea7ab4e6-7843-4243-8a1d-c1a8679f4c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0cd83ec1-14c9-4bf1-88fa-bd3d85332807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0cd83ec1-14c9-4bf1-88fa-bd3d85332807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_7c3bff73-8fbc-40e3-aade-d531754d7985" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_7c3bff73-8fbc-40e3-aade-d531754d7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_44d37540-9a10-411e-a883-cca95bd01a1e" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_44d37540-9a10-411e-a883-cca95bd01a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d7cba373-8d53-40ae-b67b-ed77e4272265" xlink:href="vtl-20230930.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_d7cba373-8d53-40ae-b67b-ed77e4272265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_ba4673a5-e29a-49cf-88d7-559f071b2b77" xlink:href="vtl-20230930.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_ba4673a5-e29a-49cf-88d7-559f071b2b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_8bb2020f-3302-4c07-ac44-269967eac1af" xlink:href="vtl-20230930.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_8bb2020f-3302-4c07-ac44-269967eac1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_759c2baf-3176-4b42-abb0-63485bb24be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_444da045-8fc6-4181-aabe-c5a11ff67e64" xlink:to="loc_us-gaap_ContractualObligation_759c2baf-3176-4b42-abb0-63485bb24be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c2fcce40-0fb2-4fd4-8a09-e354cf51dd5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c2fcce40-0fb2-4fd4-8a09-e354cf51dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_009b7540-cdd6-4959-b38e-f2a13050ea28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_009b7540-cdd6-4959-b38e-f2a13050ea28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3066f63-0653-42e6-85d9-2ed0b2a7b212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d3066f63-0653-42e6-85d9-2ed0b2a7b212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2396e5ae-57c2-4c7d-808a-5f705fb60734" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2396e5ae-57c2-4c7d-808a-5f705fb60734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_21e0a214-c127-41b4-a8a6-6fc26f25f7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_21e0a214-c127-41b4-a8a6-6fc26f25f7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_27072d2d-a2ec-4468-9d7a-7cea1198fa5a" xlink:href="vtl-20230930.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_27072d2d-a2ec-4468-9d7a-7cea1198fa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2025a60-5eee-4411-b254-462dcecf57a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2025a60-5eee-4411-b254-462dcecf57a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ce7a0eb-5471-441e-afde-8dec20df3783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6ce7a0eb-5471-441e-afde-8dec20df3783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fe2d01e7-c019-4a41-ae2c-5b368c3d2b59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41bda890-795e-48a4-807d-14c0d8521caa" xlink:to="loc_us-gaap_OperatingLeaseLiability_fe2d01e7-c019-4a41-ae2c-5b368c3d2b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38248780-e26e-4c2f-bbbf-b672f0f67575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38248780-e26e-4c2f-bbbf-b672f0f67575" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ec1ed5-14ad-46b8-b53c-e3dd3b683949" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_510f177e-8558-4b30-acb1-af1b74f3df02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bd17f4ef-cd55-4468-8198-ab7a7ed1506b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_510f177e-8558-4b30-acb1-af1b74f3df02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0a2ff8ec-ba5e-4535-9f33-3a5270f57fcb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_33a84aad-8e06-4656-a3f5-76a93476de8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cfcbaa04-6050-43f8-a45d-c6cd7a746a25" xlink:to="loc_us-gaap_MoneyMarketFundsMember_33a84aad-8e06-4656-a3f5-76a93476de8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7e937ead-54e7-49a2-b0ed-55c65dd085df" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bdd7ba2e-8e0b-4633-a98c-e432178dc4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bdd7ba2e-8e0b-4633-a98c-e432178dc4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5fd9e7d5-ad21-448c-bf53-db24388ffa01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5fd9e7d5-ad21-448c-bf53-db24388ffa01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6129855a-a522-4a8c-8452-2ffa1dad9e55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daff3825-d38f-4709-9448-309ebab83524" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6129855a-a522-4a8c-8452-2ffa1dad9e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7cfd878b-f09c-4750-82e4-e68396001a51" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_522d8ca1-4b13-4e63-be7f-6dd3d1092280" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b18b00d1-88dd-44f0-847a-efbd7651c872" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_fdea606e-8b5d-4c5b-b4bd-ca80ee039de9" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b18b00d1-88dd-44f0-847a-efbd7651c872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#FairValueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d44ac169-8bac-42fe-85c4-189dca0dbefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d44ac169-8bac-42fe-85c4-189dca0dbefc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:to="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7afd28a3-a674-420d-b05d-160d645f5680" xlink:to="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ac6d1d4e-f453-4c7e-9823-c84447e9f497" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3505651-f0a7-4075-839e-bbe775427ad7" xlink:to="loc_country_US_ac6d1d4e-f453-4c7e-9823-c84447e9f497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:to="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_255983ef-e4a2-4413-bd62-3ea678026915" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05ea3a58-a3d8-42ec-a07c-d092479da005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7df03417-4e6f-4f6c-8deb-97d68359b82d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05ea3a58-a3d8-42ec-a07c-d092479da005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc1cd6f9-b7a6-4125-adf7-1ba8b7d95c11" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_8b45b053-1e16-4c56-98d5-ff501b9570b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff3f9b85-e9bb-4518-be0d-f44844497c1b" xlink:to="loc_us-gaap_InvestmentInterestRate_8b45b053-1e16-4c56-98d5-ff501b9570b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_93d57f53-b67e-4d42-9b42-be5e7dd4f9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_93d57f53-b67e-4d42-9b42-be5e7dd4f9a9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_52099669-d5dc-4f51-9169-434857a5051c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_40cbba2a-3953-4378-b705-02d680bce5d5" xlink:href="vtl-20230930.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:to="loc_vtl_December2020ATMMember_40cbba2a-3953-4378-b705-02d680bce5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_a63c8ddb-f1d6-4ad9-9114-4433bb45a7f8" xlink:href="vtl-20230930.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b4f0541-58de-4305-a6da-f4fa2f75cb6e" xlink:to="loc_vtl_May2022ATMMember_a63c8ddb-f1d6-4ad9-9114-4433bb45a7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_73e0d400-fb3f-43ec-9b78-370759b2b375" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_58296295-7c9b-499a-b63c-01b25550cc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_088a2b8b-abab-4890-bd5c-b7979a6c44b4" xlink:to="loc_us-gaap_SubsequentEventMember_58296295-7c9b-499a-b63c-01b25550cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b747907b-3032-4819-8028-3afa17348d7f" xlink:to="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_53a8ed8f-066f-41af-97ed-fe8b45488068" xlink:href="vtl-20230930.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_53a8ed8f-066f-41af-97ed-fe8b45488068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_79320fb3-8264-4fb0-92ec-fe2ed78bb84e" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_79320fb3-8264-4fb0-92ec-fe2ed78bb84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_fe3ebe44-48f6-47ec-b2cb-d7bc1f03be47" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_fe3ebe44-48f6-47ec-b2cb-d7bc1f03be47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_6068dd7a-690a-4f9e-bfaf-b53aa2d2986d" xlink:href="vtl-20230930.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_6068dd7a-690a-4f9e-bfaf-b53aa2d2986d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_ca8e5ff4-f590-4d59-abb4-e104b359fa9e" xlink:href="vtl-20230930.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_ca8e5ff4-f590-4d59-abb4-e104b359fa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_643edf7b-5c44-4d76-b1f0-0ad08f209aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_643edf7b-5c44-4d76-b1f0-0ad08f209aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1a5049-3858-4553-97b1-a1a4b4797a74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fa1a5049-3858-4553-97b1-a1a4b4797a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_21386ea2-2a7b-470f-b786-4befccc2506c" xlink:href="vtl-20230930.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_21386ea2-2a7b-470f-b786-4befccc2506c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7bbd7f6b-9663-400d-a78f-3e1dae0833f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7bbd7f6b-9663-400d-a78f-3e1dae0833f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_8e380462-fe46-4555-a7b7-aece4ac5faf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2884eaa4-97ea-45ef-a24b-583811e71c8e" xlink:to="loc_us-gaap_PaymentsForCommissions_8e380462-fe46-4555-a7b7-aece4ac5faf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_30de824f-f042-4203-96f9-824bba420713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30de824f-f042-4203-96f9-824bba420713" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b04e6e-18a8-4f05-906c-04bd427edc58" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6267ca47-e0c9-47e0-b098-3608be105f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:to="loc_us-gaap_CommonStockMember_6267ca47-e0c9-47e0-b098-3608be105f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_5f349c3e-184f-43a1-a40d-eb0b7990cd85" xlink:href="vtl-20230930.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0fd9e8f5-3a4d-440e-ba30-24b0f8945aea" xlink:to="loc_vtl_PreFundedWarrantsMember_5f349c3e-184f-43a1-a40d-eb0b7990cd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3549811e-1ef1-431d-a414-076c33868daf" xlink:to="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_057cdcf3-5fc0-40a8-b316-614c166b15a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_057cdcf3-5fc0-40a8-b316-614c166b15a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_06efea59-894e-4b5e-b446-282664ddd050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_06efea59-894e-4b5e-b446-282664ddd050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_314947e3-a646-4780-835c-4c6e5f0578f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0b67dcc9-a43e-4dba-a251-05820652ce26" xlink:to="loc_us-gaap_SharePrice_314947e3-a646-4780-835c-4c6e5f0578f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_500db65f-7489-4a1b-add5-aae0814f6d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_500db65f-7489-4a1b-add5-aae0814f6d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b87288fb-f220-40f2-b819-25a8fe374916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b87288fb-f220-40f2-b819-25a8fe374916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_4892ede8-3ceb-447a-ae0c-3d67903ef19d" xlink:href="vtl-20230930.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:to="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_4892ede8-3ceb-447a-ae0c-3d67903ef19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_fcfad770-2852-49ed-8b28-a9ccd502627d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_fcfad770-2852-49ed-8b28-a9ccd502627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_039c406f-1ca2-4a67-a56a-58072f9d8861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c1e5566f-44d4-460f-b97b-d66dbe4ed406" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_039c406f-1ca2-4a67-a56a-58072f9d8861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d98e24f2-ca06-4570-84ef-ede64a7e59d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8f6dfa13-67e9-44c7-8a08-621d5cc6d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d98e24f2-ca06-4570-84ef-ede64a7e59d3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8f6dfa13-67e9-44c7-8a08-621d5cc6d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_64ab6f60-69d8-4d2a-8991-5e65d5ccd227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d98e24f2-ca06-4570-84ef-ede64a7e59d3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_64ab6f60-69d8-4d2a-8991-5e65d5ccd227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_189b9571-7243-425c-9504-394eec905a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d98e24f2-ca06-4570-84ef-ede64a7e59d3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_189b9571-7243-425c-9504-394eec905a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_85e56ccf-4bf6-461b-a2e6-0e16eb7b3019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85e56ccf-4bf6-461b-a2e6-0e16eb7b3019" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:to="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d1bbd660-6e87-45da-bdd1-06971dc0f0a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d305b9cb-7a50-45ef-affd-c39afb613c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d305b9cb-7a50-45ef-affd-c39afb613c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_b3502b17-1546-4a19-85aa-361587fac490" xlink:href="vtl-20230930.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58900f88-fcf6-4180-a756-6f9c9c2fa7e1" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_b3502b17-1546-4a19-85aa-361587fac490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:to="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2fd11683-8050-4791-9ebc-d440f331c061" xlink:to="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_447975ab-3b73-4faf-aedd-0dc5804a45a4" xlink:href="vtl-20230930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_447975ab-3b73-4faf-aedd-0dc5804a45a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_55e3ef16-dcc4-42ed-b950-75f13d1c5edc" xlink:href="vtl-20230930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_55e3ef16-dcc4-42ed-b950-75f13d1c5edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_9b2a8cb8-243b-4d8a-a991-5c7cccf77773" xlink:href="vtl-20230930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_9b2a8cb8-243b-4d8a-a991-5c7cccf77773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_e0126b52-0558-4f82-bd87-58e60452b26f" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_179f4d47-240e-4687-89d1-0063509f9aa5" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_e0126b52-0558-4f82-bd87-58e60452b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6eab5a9c-5adf-4746-aaaa-1f164396467e" xlink:to="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18ec550e-7074-4a95-88b7-9c30dd6b7953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_90a8f55d-c5d3-47eb-b9ce-ed5feff04846" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_18ec550e-7074-4a95-88b7-9c30dd6b7953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55d8c40a-960b-4704-a562-9a78e69e02f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_55d8c40a-960b-4704-a562-9a78e69e02f0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_438797d0-0d2b-4622-ae8d-3a85635f4da7" xlink:to="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_c4bf62e4-ed4a-4fb8-83f1-6c54506d66ff" xlink:href="vtl-20230930.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_c4bf62e4-ed4a-4fb8-83f1-6c54506d66ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:href="vtl-20230930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_b9e95078-c249-471b-ab31-bdb9d5be3125" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_566faf44-6a8d-4183-b14a-0a246f26d347" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_b9e95078-c249-471b-ab31-bdb9d5be3125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_812e55a2-3b1b-4168-82cc-1416291faa2e" xlink:href="vtl-20230930.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_812e55a2-3b1b-4168-82cc-1416291faa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_966fc097-195f-4583-ac1f-e2882bceae81" xlink:href="vtl-20230930.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d3badde0-9865-480b-86aa-8b4fec27a2bf" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_966fc097-195f-4583-ac1f-e2882bceae81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_77e365bb-9937-4fa3-8559-a2ea9517065a" xlink:to="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_870eedd9-c1e6-4c88-96f1-f441eb255d9c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:to="loc_srt_MinimumMember_870eedd9-c1e6-4c88-96f1-f441eb255d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_31e2b508-a848-4a88-8241-07d11c0a1a8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab825770-744f-43e6-930a-afb089ff0319" xlink:to="loc_srt_MaximumMember_31e2b508-a848-4a88-8241-07d11c0a1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6d3d4504-8e9d-4e06-9adc-2b33fd24d61e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_e62977d7-9219-45b8-9771-c8c3dc45f6ec" xlink:href="vtl-20230930.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_e62977d7-9219-45b8-9771-c8c3dc45f6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_dff2aee1-f319-46b1-95ca-4203d0312cf0" xlink:href="vtl-20230930.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7354449d-948b-4d6c-a8a5-0e75149d70e0" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_dff2aee1-f319-46b1-95ca-4203d0312cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59e7af48-b08c-44b5-932c-0637849e489f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f6a07abf-022b-4775-a28e-217e595fb89a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f6a07abf-022b-4775-a28e-217e595fb89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb5f0ea9-59de-4033-8838-ccc729f9f93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bb5f0ea9-59de-4033-8838-ccc729f9f93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2a8da2c-85df-4095-a20d-a755dd672eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e2a8da2c-85df-4095-a20d-a755dd672eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_85c69c4a-17aa-45f1-9dc8-6fd478b06abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_85c69c4a-17aa-45f1-9dc8-6fd478b06abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_759ecfee-822c-49eb-87e3-e049c85209ec" xlink:href="vtl-20230930.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_759ecfee-822c-49eb-87e3-e049c85209ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a08774f3-6d31-4023-b93c-ce5daaf22523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a08774f3-6d31-4023-b93c-ce5daaf22523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_8123fa07-0bdb-44ff-8711-084cc547ba36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_8123fa07-0bdb-44ff-8711-084cc547ba36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e7703aa-4016-4a85-b37c-8f8f6ef991ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e7703aa-4016-4a85-b37c-8f8f6ef991ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_974b98a5-b6e7-4b77-bb99-190aab62356e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_974b98a5-b6e7-4b77-bb99-190aab62356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22510dfd-7f71-4b14-bbe0-75d2e6b1bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_22510dfd-7f71-4b14-bbe0-75d2e6b1bca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4c0057f-895b-418f-a0c8-4a6feda1e261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e4c0057f-895b-418f-a0c8-4a6feda1e261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_112fbbe2-74f4-47ac-83bb-48b44c2dca05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_112fbbe2-74f4-47ac-83bb-48b44c2dca05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_af3df2db-6d17-405d-9bc1-bc486a411b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_af3df2db-6d17-405d-9bc1-bc486a411b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8c90f997-7e69-448e-94d6-bc945548589f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_20521a60-1db1-48dc-937c-ca714b2e741a" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8c90f997-7e69-448e-94d6-bc945548589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d569f220-233a-4e1e-8f49-5ed931ea3cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d569f220-233a-4e1e-8f49-5ed931ea3cd8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:to="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b9f762d-6c76-488c-b9a7-5dc306211733" xlink:to="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_3950469c-d891-4e37-b363-f1b254c9f041" xlink:href="vtl-20230930.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d14650b3-26ac-48f2-8483-dd7b0b7e01c8" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_3950469c-d891-4e37-b363-f1b254c9f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:to="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_442f5b4e-fb0c-4154-ba06-7c9fe4873126" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_65f40fcb-ba7e-4c9d-ba0c-8a2e163786d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d27813f-c6f9-4e2b-b7b1-1248f2aa3058" xlink:to="loc_us-gaap_EmployeeStockOptionMember_65f40fcb-ba7e-4c9d-ba0c-8a2e163786d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e66bb193-6812-4487-9927-08cebf06adf5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_060ac493-d567-4da0-ab31-2c752fc36cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_060ac493-d567-4da0-ab31-2c752fc36cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_54718896-673c-4fb3-b17c-5cc9f01bf289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_54718896-673c-4fb3-b17c-5cc9f01bf289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d09a8dfd-2565-47f0-8731-865beb2de5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d09a8dfd-2565-47f0-8731-865beb2de5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_488ac2fd-a1fd-47ce-8b5b-da1f2ede149f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_488ac2fd-a1fd-47ce-8b5b-da1f2ede149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5a876844-f818-4cdc-8e18-880bad71dbae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c696906f-9b1f-4ebd-88fc-8afbd2a77b3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5a876844-f818-4cdc-8e18-880bad71dbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a6e5f70-b231-49d5-b6a6-50ad84ddea97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4a6e5f70-b231-49d5-b6a6-50ad84ddea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ef11d89e-5015-4543-a97f-298b9083f657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_ef11d89e-5015-4543-a97f-298b9083f657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a7a7064-57c4-42e5-972c-ea11e1449b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a7a7064-57c4-42e5-972c-ea11e1449b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb8dc5a6-22bd-4146-81e5-2d71cb3a6cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb8dc5a6-22bd-4146-81e5-2d71cb3a6cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761d2556-9605-46cf-85e9-81a3a7c60234" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761d2556-9605-46cf-85e9-81a3a7c60234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e5b80a2a-18fb-4ed2-bcd9-1457725550f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e5b80a2a-18fb-4ed2-bcd9-1457725550f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eeff2ba-2378-4ab3-bdab-7bdcfdf6acc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_eea1e71c-4bc8-46cf-bb48-d3131b46d43c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eeff2ba-2378-4ab3-bdab-7bdcfdf6acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4467fb28-b676-4aef-a324-5034b7c98553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4467fb28-b676-4aef-a324-5034b7c98553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_43595a6b-3746-4442-9244-054a70f48e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_43595a6b-3746-4442-9244-054a70f48e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29cf5a4e-b87f-4766-ad98-24a4ef2b67d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e5fc1f-0458-4e4c-a310-e3f8475379c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e5fc1f-0458-4e4c-a310-e3f8475379c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8253f992-77dc-4c86-b2f2-f155c8f95fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8253f992-77dc-4c86-b2f2-f155c8f95fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_007a5aae-be6a-43ea-8fca-d63a5e5a592c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_007a5aae-be6a-43ea-8fca-d63a5e5a592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_203f031c-34a1-401c-aeb6-6a6a55ded52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_203f031c-34a1-401c-aeb6-6a6a55ded52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05f0a76c-1166-4001-b027-f56b9912ddeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_05f0a76c-1166-4001-b027-f56b9912ddeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2447a27c-4c67-445f-8b1d-85a6b17708fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9c868202-c59a-4db4-8b9a-03239b30bf16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2447a27c-4c67-445f-8b1d-85a6b17708fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b56d1cab-0163-4af4-9277-933359c17fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b56d1cab-0163-4af4-9277-933359c17fc5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:to="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_660bf230-d1bd-4c33-9a79-297803798814" xlink:to="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_bba71310-1eb7-43eb-b633-9ad8346192bd" xlink:href="vtl-20230930.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cfc78f57-8add-4270-b24d-03d3deb68e4c" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_bba71310-1eb7-43eb-b633-9ad8346192bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6541dae2-c911-4fd9-a102-9b6cec04952c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_485e03cb-e98d-44c3-a683-b978d4720714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_485e03cb-e98d-44c3-a683-b978d4720714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352f20cf-251c-4d51-95c5-f6bcbaed8774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_352f20cf-251c-4d51-95c5-f6bcbaed8774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7f43603c-b743-4bfd-aea4-b6cf60734c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7f43603c-b743-4bfd-aea4-b6cf60734c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89d821f7-337d-4e3f-9aab-0b8130c2d22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7c760794-ad2b-40c2-b6c4-c0afbf320682" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89d821f7-337d-4e3f-9aab-0b8130c2d22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98b82bb4-8e7c-498d-aea9-d1e58972d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98b82bb4-8e7c-498d-aea9-d1e58972d38b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:to="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1cc0df2c-6347-4e21-97b6-aec61ffe8926" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_73c7c35c-93bc-486e-a2ac-9dc61ea7f8fd" xlink:href="vtl-20230930.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_15a63f2e-f068-46c0-acf8-c6c708b7eee0" xlink:to="loc_vtl_EmployeeMember_73c7c35c-93bc-486e-a2ac-9dc61ea7f8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ea1c19c-b2aa-4d88-bae4-f7407861908e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e02e363a-441e-4746-85be-fba20aafb8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e02e363a-441e-4746-85be-fba20aafb8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a9b90dc-197c-461d-ad1d-65219c4deb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d13b1637-01a1-4f8b-b9d3-14d5d4bad74a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4a9b90dc-197c-461d-ad1d-65219c4deb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7b083c65-1a11-48b0-975d-ceb69740f5a3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2c814749-063b-40d3-8d42-83040133f18c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0f2b3b2f-59db-43ea-8098-0be07e3f53f9" xlink:to="loc_us-gaap_ShareBasedCompensation_2c814749-063b-40d3-8d42-83040133f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#ChangesinBoardofDirectorsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0bee4c8e-973f-41e7-98a6-0b6ca46d9ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0bee4c8e-973f-41e7-98a6-0b6ca46d9ae5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:to="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a7161601-e366-485a-927a-2820db0470a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_08f5b46c-5cb9-414e-bfc8-8053f39b1e6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f205d8d1-3122-4d22-9919-18de0b6819c7" xlink:to="loc_srt_DirectorMember_08f5b46c-5cb9-414e-bfc8-8053f39b1e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c21608a2-01a8-4cd7-96a6-3bf1e04b700f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm_d54235ce-02ab-49d1-bc25-065f35d3d96e" xlink:href="vtl-20230930.xsd#vtl_RelatedPartyTransactionBoardOfDirectorTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9517eac2-bf01-415e-ac6b-48fd53fcc599" xlink:to="loc_vtl_RelatedPartyTransactionBoardOfDirectorTerm_d54235ce-02ab-49d1-bc25-065f35d3d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_30d19dfe-e0ad-4a9d-bb0a-dfabf3bf05be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_30d19dfe-e0ad-4a9d-bb0a-dfabf3bf05be" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ebea2128-a280-4d2e-98bc-940f51a4c721" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_ec004adb-f80a-4f9b-ada7-01f84f0a93af" xlink:href="vtl-20230930.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd53fab-d483-450e-a7fb-bd26fb1ab303" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_ec004adb-f80a-4f9b-ada7-01f84f0a93af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a493ce56-d15d-41dc-a672-a7d7743d7ff2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_423dc5a6-2e68-4376-a331-450b3dda98ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_22a71a9e-7225-4cb7-887f-fee0561fbd5c" xlink:to="loc_srt_ScenarioForecastMember_423dc5a6-2e68-4376-a331-450b3dda98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4a187a3c-4725-4603-af73-d20793bc7334" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_baff2855-a590-4869-8a0e-bbd92f0d735d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ae34544-4f28-4dd2-a38b-e4d39fc68b1d" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_baff2855-a590-4869-8a0e-bbd92f0d735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_97ea3a8d-f230-4339-bc3f-5f2075602fe9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_eb800197-8526-46a8-a05f-29890daaca6c" xlink:href="vtl-20230930.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d09cf0e1-7697-4307-ab8d-6f5fe650f57f" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_eb800197-8526-46a8-a05f-29890daaca6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_02d07cdd-475e-43fd-b8a0-b238dc3d1303" xlink:to="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_9ff665f3-49a1-4ae5-b002-cd4035812ace" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ae2351c6-891d-4fa0-9fa2-0c2e75771498" xlink:to="loc_srt_AffiliatedEntityMember_9ff665f3-49a1-4ae5-b002-cd4035812ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1c583791-1354-45b9-978b-f815a2930838" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_9ca547b4-2b17-4fe4-ba57-6c2cf446b66d" xlink:href="vtl-20230930.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_33668309-56c2-41a2-93f9-ae89d6146861" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_9ca547b4-2b17-4fe4-ba57-6c2cf446b66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtl-20230930_g1.jpg
<TEXT>
begin 644 vtl-20230930_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
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MPM)S@)!#4X,DXO+#!?_:  P# 0$"$0,1    ]UC@D@           /[/X
M                !_9_                   /[/X
M !^GX                   ?V?P                               =
M=AQ_UYDEO3_H           *P>,EG_>,                   5H\9++^\8
M                  K-XR69]XP                 !6CQDLC[Q_8
M             %8?&2SWO&                              !S6MM)+B
MR3&WI_U(           JWXR6D]XP                  !6/Q[LY[\
M             "L7CW9WWX                  %9/&2RGO']P
M         5<\9+1^\8                              '*JVSD>+),;>
MG_4@#%F,28VOGT        *M^,EI/>,    #7>O/TB<V)  _2#9\.\Q^MYXR
M#2>_&[\>P!!<^"=8,X    %8_'NSGOP     ,.8^,QH,F*48LV3$@  ##F,J
M'])     %8O'NSOOP     /C,:OU&Z\3",^&;X,X   UOKS^FQ\^@    !63
MQDLI[Q_<     &C]^=SXF%9\,XP9P  !CS&K]>=YX]@     5<\9+1^\8
M     P/4$9_GT !A3&5#^TX'J,.?.@R8IU@V               !RJMLY'BR
M3&WI_P!2 *2WE#D^9VGG+),6>=8,L1S8>EZNUPC?T>Q:6]$\V",9<7;=+;YG
ML8OXGQK??BSU7:  5;\9+2>\8    'GUT7.:+WBN327\6S8?JB1XLOPF,.8X
MYNZ<^U]C,\^\V/.L].F:V?ENU@S/,R7'[X1OU]V*2\     K'X]V<]^
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MT]59U[L:[MFCOUSL:_F>UJ3S!E_(R_9XC&7Q8VML>C:^Q0R]IN_5UAW33V0
M   !6+Q[L[[\     #C>YIRS%EF>#-7.RK_Y1SS8U\B/71=;9UWO'S[8U^SZ
M._W32W*"7U'UK3WK15N]^     %9/&2RGO']P    #ZPJO:U=HZNTK995N-Z
M\_%')=O6L]5VG#][0W7CUO,>>S-;8<"W]'A>_H7GHKS)B0    !5SQDM'[Q@
M       "L5G6:#)CS(;3'F[+J;5)+R@]$N<Z:L=G5R[%ETWO'@^GY$I\PC-B
MZ;J[>/,:KWBYSLX9Q@]PS-Y[AH[DOQ9.3;>MS?9U>ZU]C#LV+/>+&UMF
M    .55MG(\628V]/^I    ' ]^OA.?#:VIM?JD    "K?C):3WC
M           %8_'NSGOP                  *Q>/=G??@
M     5D\9+*>\?W                  !5SQDM'[Q@         "&YL.-/F
M=X-@                  #E5;9R/%DF-O3_ *D           5=\>[1>_
M                  K)X]V;]^                  !6+Q[L[[\
M           "LOCW93WX^P                  *N^,EHO>,
M                   #E=;9[;!GQ_?@           "NZ;$(
M        $41*T@                 ")HEB0                 !$42Y(
M                  U_KQ5^YH[84E^
M !J?/K>1-LD            5%3;I                    A,IM
M           0>4X@                  (3*;0                  &ER
M8J1=%R]]^9ZT                              "JR<8MD@
M "HJ;=(                   $)E-H                  "#RG$
M            !"93:                   TN3%2+HN7OOS/6@
M                     563C%LD            45V=?;V]"
M        (R28                  $6)2                  ",$G
M              !A^O&J]X[Z<UUH          PC-    (Z2(CI(@
M    81F@%5DXQ;)            'DE?\_P"17U'XR
M                                                          !M
M?&3W?^;?5[W<WU?FCUW$>1O<?//]1_QO[OL?/NF:9:3(X:=>.H(XFF0GW,4D
MR.LE5TV#1P=/?T5L3K"QZ/Z./)V1,$9)T@JBGII2)-\'GS">KVHE1&#EA:]%
M:D[4Y(FX3S3=ZE:)X6Z14A->$]P1Q%-XD:,YZ28RC8DP1P!-QD 563C%LD
M          >25_S_ )%?4?C/4M*RR//ODN_5#K5?<\EL*8 #HVG9<YW*T #J
M.E9\NW:SIVE9\QW:P=:K[GE>]4S_ %=_G6Y6CJ>C:\LWJH"Q=3?\&LZ76^\7
M4]&UY9O50  _N/70=7>YWMUXZUH6_P IQ_J=;[QP?9TY;@V==Z\]CT+2%Y]?
ME&_4 #LM?;_L-!EPZ7)A^,QT_3L.<[>E%L^K,-?;Z[HV/ +.GL/57/"K.HF6
MOM]#U=S@]E3R/#L\YW*_\1UFON>36%,
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MCO7P]X,)[L!57O&K&IQSDUC1\#M*,
M      #:^,GN_P#-OJ][N;ZL        8QD@ B9*3^P#X'W -6;0
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M<6QU'2L.+V-1&\VM+M?<_D_F8VGCW(L.W"]C3ZGI6'#[*FP/>,
M                           #:^,GN_\ -OJ][N;ZL ?(KRGXEAT5\37M
M,[1CG9#@)'4WW><8XZF$G;3ZHQ$YB-,F2HT*90B!IX,7J16-.24@3<-$R.IH
MY>FP"*RI[VCAJ>W(XBGKR.>)^1+T2,XPGJ"(>GYDK1J$U)3=9YB*>4%F$?R2
M\ JLG&+9(            \H+VB\M/I?R    ?A^@ 'Y!+]    /R'[(
M ?.)^DP                  /E$_68                  'SB?I,
M             #8^/?M7\^^G7NYOJP!\3S1>K,HB1(BH*;4(X\GJ"-:?0[:<
M+.C%?TV$1P!,G1(2.&Z.$)[LCYD=+MHH2]2]'43\*GIFIW9%GD4C3#$]B1Q5
M/8D573<]'/C5E44W+1%C"-\=4*Q)Z:B IV!TA$3)L6X0!59.,6R0
M   !4=-N$                   "$S$VB0                 !!I3F
M                A$IO                   :;)BI#T7+WWYGK0!_!4U/
M?$0%.X)FBL*>OFK- 0<L.BM"?[.S$+,(Z8#\/D<X.L'%"0'>45&3V@Z CD"8
M6=?.@HFI1E,U.%ILHBLJ;!HL(BI:9L81OB3GS,8CQ$3=&W/H2DJHGT3><@ J
MLG&+9(            J*FW2                   !"93:
M      @\IQ                   0F4V@                  -+DQ4BZ+
ME[[\SUH       AQ,0          :XP38FK)$       0HFH *K)QBV2
M        *BIMT@                   0F4V@                  (/*<
M0                  $)E-H                  #2Y,5(NBY>^_,]: /D
M453>9'/R')K<=^+%(YT<,3)3^CKB*EIO*B '1@<Z)B?IHS<&A-@5S3WI$M/N
M<Z.B$$-B;,V)@$?/N9QA&R*;/5Z'D       "JR<8MD@           "HJ;=
M(                   $)E-H                  "#RG$
M      !"93:                   TN3%2+HN7OOS/6@#XGFT]=31QY.>:P
M]$WFJR=@5R3Z2/-+TV^11-ZT9BEL$<].$IZ<B;%:D]K1'DS%$13_  7>>:V)
MV)P]-Q$5V.P$B*M)ER(.F/F>=(1 $^EKR       !59/Q+7H
MJ0FVZ                   !"93:                   @\IQ
M           0F4V@                  -+DQ4FZ'F+Y\UU@ ^97=,=.8$C
M-L7$17=/'R<%L$<'3FFA(.:(MBCFZ>9G72$D".XD:!S(EY,#7G(#H!\B)G92
MOQ+CN!!S1&\(F0([&660       *L)Q"V2            *BIMT@
M           0F4V@                  (/*<0                  $)E
M-H                  #2Y,5(NBY>^_,]:                      (J2
MH       %5DXQ;)%;[:EL?4W50;WG.IZ6_T_3W^!V=19FHO!YJ];Q/6=*PNC
MS_3 5,N^?R(FU=+?@   5%3;I                    A,IM
M        0>4X@                  (3*;0                  &ER8J1
M=%R]]^9ZT #Y'U/D<G3M$=)/F#^C\.2)Z\CY']%5$VN11M-U$9P/TK FS:/J
M<@3UQ'Z?R4Y3T<X\=4.2%QT4M3>Y&0          "JR<8MDCSLZKC9+ASP/9
MU)5AV*]VE-N\>7ZQ/5=*PK!<474M/?Z[HV/\(X?8U?RF.[5MK7"VI<B/7:ZZ
MSW'C+G>?7*]S0OIS76=7TK 5%3;I                    A,IM
M           0>4X@                  (3*;0                  &ER
M8J1=%R]]^9ZT 1<\B7JR1%S0FW)P0$D)WE%64ZDF)!#LI%3TN>?+!ZZ4?=$'
M3Z(O-9D\^,1/-S$)L>E;SP]-/$^BSS45.Y.HE"T^J;SG           JLG&+
M9(A^?6_SS_4OCWN!\[^HT"Z;D?Z3"]C5ZCI;\_UMN,YL&#Z\\4L*N>ZVY%<V
MOT/5W-KXR9_CWC>O(Y=N:&U\9)5@V.[UMK?#F^L%%]C!(K:B
M       $83)T                  "*S,JB                  !K\6Q=
M:FO                  !I<F*D71<O??F>M &F*.IL:563T=&62HPC$(L:H
MS#:D^.6&F+_(K GEI("4EJ$5C3PU/4$0TV)VX[,CS(>K<(XP30X<FY"*9IO0
M\]*          !59.,6R0-+DQ;3QD^,QJ/>/:>/>ARXI;@V-;[\#7^O&R\>]
M9[\;/Q[_ )D ,'UXS_/O4>\<DQ9OI$CR2O\ G_(KZC\9
M                                          '7:F__ -0OR7[.
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MV.6;M;!=K3MG1]+RG=K^!VE#UG0M^3[]1U'2LH5L:NCRZX
M   Z[4W_ /J%^2_9P                 !I<F*D71<O??F>M
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M:F__ -0OR7[.                  -+DQ4BZ+E[[\SUH
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M:EWG+V(JKV08\E!^HX>]G,=QH,VM2[H>2](>/^B=<T;+F._34*Z;CX3LZ
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M )><#WBD&';&N]X?Z3KO>'8^,W\(P?>+/\9M[BSZC)AUWO#\Y@
M       ==J;_ /U"_)?LX                  TN3%2+HN7OOS/6^6G9<'X
MT]]\U_UG_$OT'LO'ORB>O21Y\JGJS1)D=6.4G]$*(HF<H[&38GJ*CINJCRT>
MNHHZ*;XINFQB+IH\UGJ3HB2?B;0F2(>G<%DT473*3K:*[I[8C@Z?6QY\R'KL
M2-,6>1U        JLG&+9(            \GKVB\K?IGQX
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M.8                  "$RFT                  !I<F*D71<O??F>M
M                             JLG&+9(\YNKXSI^GO4ZON;XSOUMX.=Z
MGD>]7;'Q[F&#9] .8Z[A-E5>6O9<'Z2<GVM#.EY.RE1=T]ON;] >8Z^2X<]Q
MZ'I   *BIMT@                   0F4V@                  (/*<0
M                 $)E-H                  #2Y,5(NBY>^_,]:    !
MP!/?T ?A%B5   X GOZ!'#@*>ZHJ\FV**BIL(CAR>RG)RVR!7)."?0ZLC1IY
M<=<.I(Y&FMI;)%4$VW1OBH:;?(V@   !59.,6R1Y:=EP=JZ6_HCTG)_J<;UY
MZ1J;O.=K3W6/)<>AZ2N-M3<1L*NVU)T-9[>CQYC5>\=O:/HL:?-^N9ZX  "H
MJ;=(                   $)E-H                  "#RG$
M         !"93:                   TN3%2+HN7OOS/6@#YGFH]=;1E$P
M(^<\3K3<HZH9YSDXZGT[>:%IG1QM/=4<K3]T6H17%/-$]N1;E%0DP ODBFZ<
M<E)K"XB!Y[/5F44Q3(CHZ)<1PN4BBZ:_)MVBKZ?31YV!PU.X.R(    JLG&+
M9(J[<T6+/GIFIO2?#GU'O%^&JR8X]EPV'JKG2Y,56;FAL15W-?+.GLA575;+
M:DTN3'WRLMNN:-B  !45-ND                   "$RFT
M     !!Y3B                   A,IM                   :7)BI%T7
M+WWYGK0!\2G*:XIL.BNR=F=%1&4RM$E.9)ER-4GT.>?')ZNDC,.,)W2/N=D(
M><63<=&]1Y_O7?$?<B! 4W*15@M>=>10!-BCC)7A-RT5A3V1&X-B1,QSE";E
M(QBC:?2IYE@   !59.,6R0           !45-ND                   "$
MRFT                  !!Y3B                   A,IM
M        :7)BI#T7+WXYGK0 /@?$^9\38FN-@:PW1J3/,,V9J#//Z/PUYL#[
MFE-L?I_!JC;&I-F:PV)@G(D]U1A&.9Q^GZ:PW!HS=GR/Y-8;0_LU!LS(
M*JI^1:]            %2$VW0                   (3*;0
M       $'E.(                  "$RFT                  !I<F*DO
M0\Q?3FNL      C)S%/=$   #@B=H=G0                  *L)Q"V2
M         *BIMT@                   0F4V@                  (/*
M<0                  $)E-H                  #2Y,5(NBY>^_,]: -
M*4J3T@Y@=1.5DS(P7M1Y;O4T-D=X1P\WQ(B)'7CD) TP(MBCGAL3N9VY
M             JLG&+9(            J*FW2                   !"93
M:                   @\IQ                   0F4V@
M      -+DQ4BZ+E[[\SUH T)Y:O7=D1Q,E1'$]"1]RY2*')$U.7)CIUE&Y*_
M)EQPHN&C2D<((GJ2+T(                 JLG&+9(            J*FW2
M                   !"93:                   @\IQ
M      0F4V@                  -+DQ4BZ+E[[\SUH $4)":8W1I#< S#5
M'\&:9)$"2F80TDIJ3< Q31$F,P                 JLG&+9(
M  \OKBGH7WWS                    82<U                   PGK->
M0                 !.JZX]^_G7T\                  :7)BI%T7+WWY
MGK0                              *K)QBV2            /)*_Y_R*
M^H_&0/[CU^GSGR       /T^WG)\/6, #,\Y</UB _#)\^_G,?.?('X?H !^
M'Z#\/T_#]/P_0 ?@/T _N)_I/RGR                          !UVIO_
M /4+\E^S@                 #2Y,5(NBY>^_,]:
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M:^',Y\37VUH                           .NU-__ *A?DOV<
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M#5W:GWO*WJYGMJ*]/PUJ*3I,=FS_ "DN#;_F,O<ZZSIYT/(U]M:
M                  #KM3?_ .H7Y+]G                  &ER8J1=%R]
M]^9ZWRT[+@_&GOOFO^L_XE^@_P"?'NA2;+G"SH)!"QZ($GFA&32)^Q;5%/TR
M(O<\^:;U91&B.TD (P7!14I,](T5W3*T=>(<2XF)HBIB;F(C9LBH*?39Y\S7
MJX:(V6?14=,G,$E1AFH*T)LDB3DD1A%(7KTY>?H 563C%LD            >
M25_S_D5]1^,]XJ[OL5?=5_M**>ZV[,-;=ANSI8TL#WCVV/W.=;>BV?4PY<^W
M*R6Z^WT+4L>+V-3R.PIKO\UV?)MZNZOHV/%[&JG>KNP;9TI!BVMGX][O'EIS
MT/'7<YOM>-V%+V*ONJIWG+VZH>IX;8U76=+>IAT7(#ZQ[O!S790'9U^26%+T
M#4L.C:EC$<^K+M?;XM9T?5-&TWF+-PZRI^VUUO#L^OI??FNMSR_4="XLU3=)
M13J.#[!7VOR9-+EUYQJ[_8]"TCN7%P^SH^:[E8
M    !UVIO_\ 4+\E^S@                 #2Y,5(NBY>^_,];7RTIZO7%%
MZ.\IVD3B:]IM:CS*>I$3Y%CT0)/-"&)L$BM*;AHHLGL2+QHI(D;HDI7-/9T6
MC1YJ/5C$10SSXFR/H8A)#CJ9\CEZ>L(UQB%Z$4B3]S%+P(I:GG29XB4G'$S]
M&M,L^AM#2F6740 *K)QBV2            /)*_Y_R*^H_&0            !
M)L&U&<^J -MCS?Q,:SWB
M Z[4W_\ J%^2_9P                 !I<F*D71<O??F>M  JPG9'7T:(Y*
MF<G'SMQN4=-*UIV9-4?$ZD5I3TI'V(LF$G7T=&*G)FA$">'Q):C^SX$*3@'X
M2,T!GD9+2HK0F0FK+%(YJ:Q,"-F? _D&"3DAQLS +&H^H!59.,6R0
M    !Y\;VES_ *3D0                  !HD[U                   C
MZ9 @                  9>KN^GG+]<                  -+DQ4BZ+E[
M[\SUH      &*90                      !59.,6R0           !45-
MND                   "$RFT                  !!Y3B
M        A,IM                   :7)BI%T7+WWYGK0!\BNR<8L8C+/+1
MZ],7FOZ>YHY(G/.7EAD49>K'HY,=0*_IZ8B6EI$                   56
M3C%LD            5%3;I                    A,IM
M     0>4X@                  (3*;0                  &ER8J1=%R
M]]^9ZT ?$\T7JSJ(:=O/.-/:BPB*@)MHB( N$BBB=H6]159,4+(E.$^DCR
M                !59.,6R0           !45-ND
M"$RFT                  !!Y3B                   A,IM
M          :7)BI%T7+WWYGK0!_!5!/>40-/P.^(H0]:0[^CK2(4D?IPX[@<
M/)\0X[ <C+FH                   JLG&+9(            J*FW2
M              !"93:                   @\IQ
M 0F4V@                  -+DQ4BZ+E[[\SUH    T1D&U
M             *K)Q3^P           "NB;%H                   $=F)
M%$@                 "-S$DB0                 !&IB2Q(
M         P/?B$]%RM]>:ZP                              "JR<8MD
M@           "HJ;=(                   $)F)M$@
M "#RG$                  !"93:                   TN3%2+HN7OOS
M/6@                              563C%LD            5%3;I
M                 A,IM                   0>4X@
M   (3*;0                  &ER8J1=%R]]^9ZT
M           "JR<8MD@           "HJ;=(                   $)E-H
M                  "#RG$                  !"93:
M     TN3%2+HN7OOS/6@                              563C%LD
M         5%3;I                    A,IM                   0>4
MX@                  (3*;0                  &ER8J1=%R]]^9ZT
M                            "JR<8MD@           "HJ;=(
M            $)E-H                  "#RG$                  !"
M93:                   TN3%2+HN7OOS/6@
M       563C%LD            5%3;I                    A,IM
M              0>4X@                  (3*;0
M&ER8J1=%R]]^9ZT                              "JR<8MD@
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M5_#+.DR(?*8U?O%*L&W!-K0F^MO1O-JYWG)&\VJ
M      +U<YU_L-Q??                  #18\ECZJU
M  &ER8J1=%R]]^9ZT                              "JR<8MDCS/Z[B
M--DQ<NW-#INIO:3)CD&++I<F.Q]3=<PW-"D'1<OZ3\EVM5;J@Q/7G*\^O7CA
MOHN;Y]    >25_S_ )%?4?C-]N6[NA/4\)Z2\?\ 1,N)Y=MZ1,GP[,IPYN:;
MM93CH.3MA1]-36_Y3V8^?_5JC7G/0G9T+7TG2<@WJV2X=K&]8?U.W\3@>GF]
MU_ST                           7JYSK_8;B^^
M&BQY+'U5J                  -+DQ4BZ+E[[\SUH
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M*^H_&0                                      +U<YU_L-Q??
M             #18\ECZJU                  &ER8J1=%R]]^9ZT
M                         "JR<8MD@           #S.M:JGG;_.0
M              !K4[)                   L54=!Z.<WU0
M       C7GUW/0WP                 !I<F*D71<O??F>M
M                   JLG&+9(            J*FW2
M  !"93:                   @\IQ                   0F4V@
M            -+DQ4BZ+E[[\SUH                              %5D
MXQ;)            %14VZ0                   (3*;0
M    $'E.(                  "$RFT                  !I<F*D71<O
M??F>M                               JLG&+9(            J*FW2
M                   !"93:                   @\IQ
M      0F4V@                  -+DQ4BZ+E[[\SUH
M              %5DXQ;)            %14VZ0                   (3
M*;0                  $'E.(                  "$RFT
M       !I<F*D71<O??F>M                               JLG&+9(
M            J*FW2                   !"93:
M@\IQ                   0F4V@                  -+DQ4BZ+E[[\SU
MH                              %5DXQ;)            %14VZ0
M               (3*;0                  $'E.(
M "$RFT                  !I<F*D71<O??F>M
M          JLG&+9(            J.FW"                   !#93*
M                 A4IK                   0R4S@
M   --DQTAZ+EK[\SUH                              %5DXI\
M      "NR;$H                   $;F))$@                 "-3$E
MB0                 !&92:                   P_?B(]%RM].:ZP
M                           "JZ<4MD@           "HJ;=(
M           $)E-H                  "#RG$                  !"9
M3:                   TN3%2+HN7OOS/6@
M      563C%LD            5%3;I                    A,IM
M             0>4X@                  (3*;0                  &
MER8J1=%R]]^9ZT                              "JR<8MD@
M   "HJ;=(                   $)E-H                  "#RG$
M              !"93:                   TN3%2+HN7OOS/6@
M                       563C%LD            5%3;I
M       A,IM                   0>4X@                  (3*;0
M                &ER8J1=%R]]^9ZT
M "JR<8MD@           "HJ;=(                   $)E-H
M        "#RG$                  !"93:                   TN3%2
M+HN7OOS/6@                              563C%LD            5
M"E:CUC                   $8CW//,@                 "#RG$
M             !"93:                   TN3%2+HN7OOS/6@
M                      563C%LD            >25_P _Y%?4?C(
M              ]]/E?VB]U'?                  "#RG$
M      !"93:                   TN3%2+HN7OOS/6@
M               563C%LD<MW- ?Q,;C'EC^7#]8GXS'7M&QA&QJ\'LZGO-9
M;<"LZBSM/>\PW-'LNA9    #R2O^?\BOJ/QG;8\UG:;HZRW/.:;)A S?&7"]
MX@.G:5IS#=J_TS?&7"]X@/TR_.7HNGO\NWJL"5X-S+\^MUCR]+T[#@=G2[/S
M[ANQI@   #WT^5_:+W4=\                  (/*<0
M  $)E-H                  #2Y,5(NBY>^_,]:
M          !59.,6R1YG]=Q&FR8N:;>EU/3WXUEP2+%FT67%ZP\3] XG85?D
MGW'SVT5-?5OMJ3T]X_NJ/]%RWK3Q'T(    >25_S_D5]1^,WZY;NJU6]']HB
MP=7=\@WZS4>\5Y.;Z^O%K2:[WXD^'/S#<T]MXF5X-CLU?;58N^;G.KO0/:T<
M9ZN90]%4B\YWKNC:<&M**<:EC^SYYSN5W8*^WK'<<]<*@ZF [6G -K2D^'/@
M>L>TQ[&MR:TDP[</V-*2X=O-\^JQ77,^YGS+Z[>ZCO@
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M.^                  $'E.(                  "$RFT
M      !I<F*D71<O??F>M                               JLG&+9(A
MVQK?-&Q\^_V)UGO'HLN+9^/?0-7<BN;7@&UJ=#U=SF^WI377VH'LZG=:VU
M  'DE?\ /^17U'XSD>??;:VZY%OU73=.RB6?43&TQY8MFU\+WBZ'J6$*V=1
M9L>ODCH&KO17/JZ;)BD>'9BV?5_ 3O5WH?L:NFR:^[QYY#AV.=;E;*]?<VOC
M)K_>/ZQ.[QYX?GU9IK[<%VM&9:VWEQ[Y/O57O5\M^RWNH[X
M     0>4X@                  (3*;0                  &ER8J1=%R
M]]^9ZT                              "JR<8MD@           #R2O^
M?\BOJ/QD                   >^GRO[1>ZCO@                 !!Y3
MB                   A,IM                   :7)BI%T7+WWYGK0
M                            *K)QBV2            *4YL?4]ZK
M               $LT;+J^',                  (/*<0
M     $)E-H                  #2Y,5(NBY>^_,]:
M             !59.,6R0           !45-ND                   "$R
MFT                  !!Y3B                   A,IM
M       :7)BI%T7+WWYGK0                              *K)QBV2
M           *BIMT@                   0F4V@                  (
M/*<0                  $)E-H                  #2Y,5(NBY>^_,]:
M                              !59.,6R0           !45-ND
M              "$RFT                  !!Y3B
M A,IM                   :7)BI%T7+WWYGK0
M         *K)QBV2            *BIMT@                   0F4V@
M                (/*<0                  $)E-H
M  #2Y,5(NBY>^_,]:                              !59.,6R0
M      !45-ND                   "$RFT                  !!Y3B
M                  A,IM                   :7)BI%T7+WWYGK0
M                          *K)QBV2            *BIMT@
M          0F4V@                  (/*<0                  $)E-
MH                  #2Y,5(NBY>^_,]:
M    !59.[(X?@           .-I[(@                   :8W(
M           -*;H                  &D-V                  ##]>>
M"V=38:JN                               /N6K0      ,,S   8IE
M                           &&9@   ,4R@
M                                                         #@5
MG4>.O>?.![Z?,_K6S\9//UZ[:C:'3$<K3LB;H@R9>BOR9D?AB&T.[(X$GG1=
MQ%5$]V1!$]Q16-/>D<'3W]%<$]?1R!,Q.BHY*GIR.*IM4@  ?*8YG8UPZ!H[
MVQQY*=)ZD2M'2"N:>IHXXGH1DHB*9NCF:>XHX,G:$I*=IL*C='4$<63WQ$A*
ML)L(CC";%(KHGJ**N)FIWM'&T]C1QQ/>4<"3VM'FV]>ISR
M
M     !5"[Y__ #F?5?C(_P!8_P 3_0.7CRTW3<Q%-4XQJ3YDE-29!S5.S,8L
MBBK*=V631QXE!91'DD]>MSSS].,5Z).<V3S Z$7L>?+]ZLDC8$33GHOR@  ?
M"8XI<4XZS5VFYQ9:/IQ#<ETD423DFN.=IZNC$,DWQ$S^"<$/-R:DWAICX&Y)
MH=?10]ZLBBT**')VA%"(IWQWM%;TV;139/3C<HQDW]>0
M
M   .,[]9Y?=CPH]E^!^E;#S[IJF:G/#K)EGV,<IRFUR,TY,=\($<_+"%=CK!
MU!%7T[XMTC5%-4]L-H5S-:;$V)T(D9]"LQ]ST$0  /G,0'=T1--3<SO'O@2=
M@?,[BCRP>KEHV1!R:E,4VX1RDZD;TXX=&(H="..G6C./X.FHJ2GK1T1'0#RM
M>KGH@1##K)UU'#T]W1P].L)X5Z/0)
M                                                       $3)8
M       8Y6%-ET9X .7)T9VU       $2): ")$M        (B2X
M
M
M
M                      '_V@ ( 0(  04 & P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& PY)/G\3/\^:(?
M5S--\^9C/ES.7\N?U/U2?/XF?Y\T0^KF:;Y\S&?+F<OY<_J?JD^?LPEC$1DF
ME^#G^?NY9(S":6,OMFIIRH3E32<L"YHP]CAI^K]W#ZO>2RQF$TD90G3S'S1A
MA'W$LL9H^]F^?O(0Q$2YH"'^0H33IYO<221G$TD9(^\,^7O>JF$?\"*:>!?N
M(0C&,Y4TGOB_E\%&6,(2RQF]J66,W+-+&43%32PG33R2<P*?JD^?LV_' XBM
MG=.H(<%,*2;T4J$Q2%%*-)E3)9U,W<IL8%(YS9S*8867)1C8A4EG3324LV<'
MTHTJ)M'-+D]F?Y^[IY\Q*6FKYULY2.8V<VF&%%IZ:8=*J0SI@E0&*0JIYB>%
M5_U5")V$E+-G"NFF)H$1.ZA,EG4S'THPJ5/3##I5:$Q,/_L/=P^KWE FC+,A
MK!QAB,B!"Z%'--B<5,3,72#9H*DDZ:8FE&&2GD3$S2T8V,#B9B9A1U4G6F?5
M[R;Y^\H_:%5:/)-K1$LD]50SJ#E:$Q+%/33#I5=/,302T^=1!4DF3Q34TP^5
M4AG3<A53,)D,.BL1^\,^7O)OE55YJ8*3.,2RD3GHSZ4:3(F23J8FT<V25,GG
M43'TR<J5*BG4A13#"90F73IH4Q5.KDA[TOY?!*BXF)E9LJ$M*BG4A13#"9>$
MGZI,FF43S2]&-"GC(*R7",U)3P--K*CB"5<3HE+.R):>8H@JIYB>"6GSJ(&4
MXR29;2(QE3))U$T]&-A DJ)TQ='-G"A/,GF3TPPZ54BG3!/33#I5":9/-\$I
M^J3Y^S;_ /ND4)")D*B90KJ9TQIU1_\ 336_-&!M,+ZPI(EB@DM[_P 333)C
M9C*9"45N$.C4S)NH2'S%HJ!' R'LS_/W=.ZOA9%Y"6% FP-,,B;-5DY,TQLY
M):9=_P""2$T80JO^JM_*IF303H8XI$?9$\8EHI)HR"2G1FD4%RR(O_L/=P^K
MWEOX=(E6E31HYL352DV:<VO_ .39Z9T16)80),B54I:<CF*5*DI!L]74%G1%
M [09]7O)OG[RC]H4F))#5JR969<!D9C#(])"6@C/(85*6B3G%'DK*?.EC5DY
M4T39R2DP3)IE,]24R22^\,^7O)OE5(IPL7RF23&S2(:"$:2=1"CIRRC*8KD3
MS'TOJY(DEQ2(XITL(!.= J9,HEJ,LTL98^\+^7P1"R"4BHHHI3($EQ1HHIT@
MHL8&PIW_ +8F HGR20XI+V9(O[+4>S+>QU!.5&2$Q!!"8XH\E:@G2BJP_P#3
M*CU2&E31+/Z,)5]6GB8?6/\ U!5TY,YB@PF1-).2M*5HYTLWP2GZI/G[-)52
M)C @.@2:IG@882L*.)+5$HI4'1D3)BDJJ>GG2HSI)^A%6:F5SU)9(HE7*I#B
MRE4DJ:EJI$\_LS_/W9"N21.*6JD3SX Q42MD42D22D*RC25'422+E4IQ=25R
M*(+54AI:57*60G52R)Z>MD+E,E3%RF*25A:A83%/Q4O"^[A]7O*6KD3Q@*6I
ME3G&1Z4U35RGF*SDRR:HK2SR^J23A34^D>?PJB93U6(0'IDLZF!/O9OG[RGG
MRD&JC(&&0%552J#(JI8I8J"511JLF"<DM.9(O523R3JB5DBB4B24)5A!1$TB
M6$/>&?+WD155<BF(G52Q34M7(GC3E9<A:)0F1SIH$S#B"4I:987.3.6F+@$W
M#S2IU*="(QC&/O"_E\$I5R&)R%LAA*587,5,6E+@E.B29<!L)8BFJY$\*8KX
M4VJ+(*C%2J4PA6JE-)4*Y#$\%92DHZ1/)*26G,E7*Y)RYE!"DI"MDDD(,3))
MDRK ]8; TVH*I3Y351"V"B4B664I*;+4EDJB/P2GZI/G[M+4(DRPJD"A&./O
M)_GS1#ZN9IOGS,9\N9R_E\,G-ZJ=4HBHGYG4_5)\_B9OGS1#ZN9IOGS,9\N9
MR_ES^I^H=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AU
MDPZR8=9,.LF'63#K)AUDPZR8=9,.LB.LF'63#K)AUDPZR8=9,.LF'63#K)AU
MDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZ
MR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR(ZR8=9,.LF'63#K)AUDPZ
MR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=
M9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.G$=9,.LF'63#K)AUDPZ
MR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=
M9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF$#(Q'63#K)AUDPZR8
M=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,
M.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)A)/&:-?32HSNL
MF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'6
M3#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K
M)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AUDPZR8=9,.LF'63#K)AU
MDPZR8=9,.LF'63#K)A&./\KAS/#F<KZKK[3_ %5#F>',Y7U77VG^-)4DZF;+
M"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H98
M5#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"
MH985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985
M#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H
M985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#
M+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H9
M85#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985#+"H985"%L*AEA4,
ML*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AE
MA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L*AEA4,L
M*AEA4,L*A);2J2-U]I_C5M]I_ITSZ;I[0+2)E,GX$D3_ #_BUM]I"NHDI0FJ
M9"F/)&H2]?[*I>6FC[)51)-G$*B3$SDA4)8G]*&)J\LHSD,70D.Y3:ZF*F+,
ME,E!BZ$AWM1C@$:XM7+R+%\$\RNI$I8IJF2IBK7%)1)/">"I86EE@IDC(574
MQLRA? @WV%-5(33)JJ0IF+J!4YBE5(GE/4R$2I:PG4S&*Y"YYIH2P)6%G20K
MZ6(@=+&7,"4)U$BB574B4L<P)00?*?*M7%HY81QY(U"6!_\ #S/INGM H=6E
MI\V<"A-'&/\ %K;[2*Q/+(KJ4Q2DY?49BIRJB<2;'[DH4*YIJ949E(3U@]4*
M;4YCXD5)2KA4UG4QJ56F2&RU,\@Q=4)Y#":DIZ\1EB5,I62DDHD\2E$M0FBJ
M55"8E1_^1(,4\9!<=*H7U6=.=+5#TYBGMZFHF3&HJB9$U1+&>2AJR"9#9RT)
M1=063RGQQ7*:B9,:BJ)D39ZP=.<?5#2AWH>EGJ-0G*G1&'Q"&IPX9*J5F<A4
M>OJ%4GDD6+HE*5%>*@:9;YT825B;BS%)$YM.1*DJ^6Y"\4Y)G621GA =9+R*
MCRR5Z)2G/B<1-UM:52J4E?DFEBE-3K14NVJ?]=%[!35261+129RT='J"4M.3
M&6,LY4LXI!,LR@VK&2'+EAA)"X\Z0$U(XHZ;[C-4#SS$T\\\G\-,^FZ>T?QJ
MV^TBKERF+%I,M+/J)4..[K*Z<?N19QBXVWL.NMU7)*$1DIRU6GE1R54Z)T%_
M;KB^=6.B6KI<DIQPI),#PGGG4A=#!=$R!516*9#ETOW(DR!=0J$<5JY1(0OK
MYLI\RCMY:?%6EIY19QQTI,M0@E5E=$PVF)ZB3U)\T)EY:?%6EIY19U*[8?/!
M/4+B.E-DJ*0E5&E*C.MH<2^$.A-2HA!#H+JD5*:M5%0I:BL_[JH;W:I*31*0
M4U660FN(LF66NF1E1HI>B4HH"<^?+"8$E0*E,Z'>!,2H1I$,3ZG)%")U99<:
MD462HK4W4*%]0***IA$Q*%!2"E2.FK9E*6A]3PQ<TL8"C=H0]NN7_3559D#C
MRH%*YON*I$7/&C+9E9'\-,^FZ>T?QJV^T@Q+(9.H32*)3T19\J:CITT>%DZQ
M32"%$Q*,LB-*I<A\A"4LB6%"30F.2%G"=+)/.>ED/"Z28I3(3Q9X(2R$QD2%
MR3SI9)YUE/*5P+II)<>%DZQ53"548HBXS*TW6K4M*(2QF3233JZ>4K"2F$I8
MS2PFAW"EQZ,,):&FEFBEDC.KIY2H)*82EB6ED+F4I"U,$E*(2Q64XE6$J(M+
M"1 5)(GHR=/,%J><M3.EDGG4I9%,IB0LR*E(6IE,)E,EF0E3%IZ.G3S5=/.J
MG]A32R%$R>E$)YBDTA4RE$6I"I"4I@DI9*6)I,ILI5#3%S3R0G@01*3+(B+D
MCW"E"=/(GE!260J:1+)).H32*(*T1:J!-*()$4LD3#J(G.F++@7#^&F?3=/:
M/XU;L\)%'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<
M84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.
M,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'
M&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#
MC"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"A
MQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0
MXPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH
M<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84.,*'&%#C"AQA0XPH<84
M.,*'&%#C"AQA0XPH<84.,*'&% Q67&%U=H_JJ',\.9ROJNOM/]50YGAS.5]5
MU]I_JJ',\.9ROJNOM/\ 54.9X<SE?5=?:?ZJAS/#F<KZKK[3_54.9X<SE?5=
M?:?X$BHYBLL&4 PJ>IH.!,)+ZR:LTR" SDRZ41)6*-*ADY5U)@G3KJ/%*3_&
M8<SPYG*^JZ^T_P "M-5U9Q-+P7U,V5:O64B29:82@*.KZ.*M8=)3TAE0II-.
M471.1"2X88IKDIQ2.-3II9290A14V2XI)9$E4IQ1*9=3T*"*ZEHDHKE-)D)J
ME.*)2=WE< GIQ"9,OF)FG_B4.9X<SE?5=?:?X$E/B08=*65&E3QG5*%$I%36
M4&>95454J>H5*W35"BZE<IAEX?.X8X)JU39JG+7<"$];I4U3C<)<"TE;['>'
MU7'V:H_;3D<U20KDO#4^D%+4\MTR%RG\B5+.IFRTJ&6E0RTJ&6E0RTJ&6E0R
MTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6
ME0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RT
MJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E
M0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ
M&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0
MRTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&
M6E0RTJ&6E0RTJ&6E0RTJ&6E0RTJ&6E0/H*@B7F8KZKK[3_ XFS1A",8":>,T
M9CYYH3SQG$JDR6 G,FG$QDTT)3YY81GC&$I\\L(SQC")DTT)S)IQ,9--")DT
M8%GSECK(X%J)RX1CCRVWVG^;5SLW,Q7U77VG^-6WVD+ZL6CF2ULE1/[M>O@C
MA[*:M$J#0562C3N22H1F4IE\#S.2EU"*R'(I4R)Y)+A*C'DI=0BLA[50701R
M2QQAR(E\5)D;B)A,B7EK)4]:)/-!=9),.6U<M-,AJ4BL4U?%3[)]?)+F0U(M
M9!=5RD<P1KY%05JI4I9<\#)>/DZY76BTQB*K%*XJZT6F,1U:15,;7RBYT-2*
M60/.@3+-<I,H1U:15,$"^"N J*N*4D@SK).9*YV;F8KZKK[3_ J33(KS#Y*:
MFF6II(''(#B86N3(9*45,;$Y*81&L3%3P-)F*B:1.4((S8S12&0G.3SD1]W;
M?:159X2+*T=(K-JE0.)/4+#T!:B*U+(LK$8$K#E:2-5J!R6;KSD)48K>K4UJ
M:)",I07,G4J5\:JL-2EKUIB8^K+9RIC59RHY$L-+.$DD9)5]0E)3H4D4R@E9
M/,K4K)Y%1/W"GK)SCD:M6NA2EYD\]!.@2408L624E?%877D<ZHA#6RE J:\R
M2=*6J*GH)T"2B#%BR0FJ3'):<>K60XP]<8B7'%GE*E"XRJ*SDJ>J+S"IT11Y
M<5)G5EVZ7T$U"4EDBB8&J(%QEE6U&4I.C2Q3*%$\],4HU92J!,>JJ!ALI<.]
M4X)7E'1K)\2$]#22IT\"I99HI>\YJ(KXE/;WSN#LJ/\ U?\ Y*!TI=0G,E5K
ME"R5*O15&16$E4)1GTF2*A0+C^=;6SI"D,%4TU)6FJ2SY%Q<E05<4@1?ZN9*
MYV;F8KZKK[3_  *SL,#<>E0HJ.G3"SII;3^FE3<$A5U@Y677/]EW=HNOZ;@J
MIB*%8JDZ<BM&\4A]W;?:15RI35:=&6G"WM]Q232PJ%;(F)7D13I$R@B<VKQ_
M]S<":8],F+IQDDTZ.0BFSP*4KS$AL*F;.8EKJ7KT]'.C4#YDQ!:JG$HY310B
MH&RH)9U!BKMYBF5(NF6R*EQ/W"D=IH=3*3PI4_%*J81$]-3BD,Q=*D(E+6KY
M$<*\J3JRUL\4:@JK$G3TPB)Z:G%(9BXR$2HZ)V:E*I$!A1L%RU?,C/A4#IS4
M%1,33BB&1@<M+ZPJW3>FEHB$I1&22$D*&5 V"&2<\Q9VZ:M)X34B$IBN2'65
M$XF4Z7N9,"*:21-4DL5)-)K191:JO%S%(*(:65298H5-'J)*::KJRU*--6TT
MI<(XU&=,6H7D)Y"(&JI$Z]/4B5$U(DA.=3H\"J%Q_.Y?] I)LQ:>7AC$\?M:
M+_5S)7.S<S%?5=?:12:3&H1R=.)H81Y^I%3B@,4*::HFI];()-IU114^-!J9
M2.%'JY1952G22EUFKEJ LJB%6*_5"UT+AJ12T5>IEJ2%53*,1>[MOM(F+EFB
M(ERQC&&(D1E%QJZ(TV99*IJ4DI$L("9"5--.3+/ DB0F$4949IRY9QAB"RI2
MX&D2&P*3R%<DA<L@E+EEC$N6,3D\AT($R0$"Y81E+EEC2*=&4N22$D)"Y9 8
MC*,C++"6$TL)H%)"RHSR0G@2GD)$A<L@,1E&1ZN7"66$L#DTAPD+E+A.C*GF
MG+EG@:1(; LJ4J IB.=)/(7+)R2%RR"!<L(Q+EC$U*6:)9(20I2*<J;V#$Q9
MD8D21@(E2QC%(7-&!$D(<&4.JEQ@7+"(G32&1D3R%QE+EEC$J6,1.5+.)RY9
MX"0N602I"Y9NIEZ,(8<RUSLW,Q7U77VD6=]8,^K^+6[/"51Q18XHL<46.*+'
M%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%C
MBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQ
MQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18
MXHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL
M<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46
M.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+'%%CBBQQ18XHL<46.*+
M%:423)N9BOJNOM(EGC*.NG_@"9/,HG5TV8@Z=$;(8I0&I@67,9%2@-30.1&$
MRIDABF,TL98PA&,>XU.$"YHQFHBF6662,T9J(IEA3*9,NGGDC)'^+PYGAS.5
M]5U]I_@5HD0G/0'1.7*?NE1AQQ=KD0EFN(Z)R2X>R6?_ +57^R@'2%*8$JI5
M:RHX+*+,KEGIBLGCTY2HE2F6RQJ%RD0*4_Q>',\.9ROJNOM/\"LZ;_SI$O15
MJ?NA*OJ:E6Y):<FK?8:DFF7(K70F)HHJH6FGI\Y-44EKU<5=6I\>+H9ZR<U/
M3R#%Z)>K-5'II"JA=DV*G^+PYGAS.5]5U]I_@5!6P2**I-PJJ:IG3&FJS##%
MB\U9$ZH&G2(JH<C"NM*%4 4;,5-&Y%48%JS"YS+C53P)4SDSSW(JFA;L)8J*
MDKXH[^+PYGAS.5]5U]I_JJ',\.9ROJNOM/\ 54.9X<SE?5=<,%/]50YGAS.5
M]5U]I_JJ',\.9ROJNOM/]50YGAS.5]5U]I_C5#32*#\O)1EY*,O)1EY*,O)1
MEY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,
MO)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1E
MY*,NI1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O
M)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY
M*,O)1EY*,O)1EY*,O)1EU*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)
M1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY*
M,O)1EY*,O)1EY*,O)1EY*,O)1EY*,O)1EY**M1$Y!',Q7U77VG^-6WVGEC'
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M\*J_RH5H.UT[M2#MB!4=*9"4]0H4E'$G(JA(KA2_]ALO6+ZO+ Q/THS(*1)
MM/1I>K%&5'RE)9#C%,\AR,Y&LD52_!)_HF^7LU5),I+"XB)Y2:2)99J,TD\]
M(:MG7](Q0K.4I)%Y$RPJ:7I00D*49=.13IXHTLQ4YJ6:914DLRB3V9/E[L])
M-.H%22S*)04D.13DS'33'(C"CB>NGG1I9BIZ:CF3A&EF*,5))C3U"28P^HH9
MS9I)E!DQ*8U'.0B-@IX2;BO=S?3[RI(YE/)54DRHF6&$*:DF3R(B%"*6GH3"
M#>M4R!-3.B0E@I3RI^LP%22GJBR8F^]E^7O%Y$3RDI<2RXBEI9DQ<$DW%03G
M)3BD1L5!QA\DR%)/(86D.1SDS'33!2B.-/EBHQ]X5]7O("F(YDT!(EF@IJ:.
M93"H)###%R90LD4=; 13G*35"(R0Z4Q09$*('PG6)#UXA##WIOS^"3(YBSSD
M,\AZI$9 Z4Q09%23 Z2W"9II14D<RD5)'Q95*0Q2%I4<Q1Z5),4<F1S%GP1F
MIC2ISYYCC#RYD22>0PM,<G-7(9YYU12A7*>EA$E&5$DI EF(F(2G(IB9CIIH
MFJ"YJ:CF3P^"3_1-\O=J:?*=/-3(F^]D^7-$WT\S2_+F8KZN9S?G\,>5ULB5
M/*GDYG3_ $3?+XF3Y<T3?3S-+\N9BOJYG-^?/Z?Z(0Q'0E'0E'0E'0E'0E'0
ME'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E$)
M(#H2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH
M2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH
M2CH0'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0
ME'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0E'0
M@.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A
M*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A*.A ="
M4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="
M4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4="4&0A++;:V
M9<1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1
MT)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1
MT)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1T)1
MT)1T)1T)1T)1A@(?%0_IX_Z++[)S_$0^*A_3Q_T67V3G^(A\4J5R)9,WHQF]
M&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WH
MQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&
M,WHQF]&,WHQF]&,W(QF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQ
MF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,
MWHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQFY&,WHQF]&,WHQF]&,WHQF]&,WHQF
M]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,W
MHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&(7<CB,WHQF]&,
MWHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF
M]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,WHQF]&,W
MHQF]&)[L23PLR&"7G^(A\5<_8_Z=*^JSNRB]CYRI.\3P7](B,!@(P&')AR8#
M 8<F')AR8"'+@(# 8<F A 1$!&$1$8# 0AR0&(@(B,/\XB')$1B(CY",1" C
M 8<F P$?8B(?%7/V,(:.>M@LHBE)+R0H\T4OLH*4:NA[)]&4$E"-'40*Y(T>
M:"6)4T)4])-/)Y":7$Q-RE6PK-E/(F(F!-*B8E]J22,\:C3#$$_)3:3%7(AH
MRA;*LHJA)*AI9RX&E3%3(:<:MFB@-@:;;"LJ5'28JB/824)2KD5T)2DD-I!Y
M12) :LF2HC%4ZRWE224FG&G%EEQ,F/IIQ!L;76P$4L\)\K+0K1F))T-&4+9<
MK+0J2SI9Z;2S:A-&$81$M'FBE_AY7U6=V47%19ZG+D4X20P@(B(B(B(B)A_Q
M$?\ '_ P$?G$1Y8#_CYB @(P$.2(CR1'_(^8AR0&(@/F)OGCB(<D1&(B(\D!
M$1'_ !@(B/L1$/BKG[&+=EGF0TB!Z4BE4:11(?1TZ@B7[0E1H))*U1Y485V\
MD0QK%#E3P4T9$AC1*= ^%'H!:XB>B)515*HY9A2BC(^&@(S2FR(Z;,<IJ*B!
MJ4RD22H4%'D4),(1I*DE'%#-32(I*30BE:<RAIE9*/[4BHY)9%2HY4"4)DI9
MMPHE1TY19U44&4FGES$20DIB*CDED5*CE0)DMY,60FH1!T8T1*NDI%(+/+J)
M*6 JM%C.L6H4!4 ?+PM*HDAD]/ILIR5+:IT22KL30C/;Y? DIE,A-5J*9=3)
M[/.P4K">I-E3SS0X4P1A@$)!QU,J218GE(4R0)MQ%,B6VR=),%Q:VGBC?;J;
M_OKWW*J)%QBRNG2&5"MTU<:H4PGA.2K,)A7E1DB4FA$F$4I 2>KI:1.:%-%3
M'IR_M!=(2IB5Q999G\-*^JSNR^S&(B(Q$8C'DB,1CR8\F(C$1&(Q&(@(C$8\
MD8\F(Q$>2(QY,1"/)"/+"(Q&(Q'^!&(C$8C'EB(C$8B,1&/L1$/BKG[&* ;,
M4@IJF:M)J2='N_OA1U4O^:3,F*II%UX]1=R TX5 B8FGHE$ZZ>AIH)IJ7]MM
M#Z*$G@:BKT\R=/ 5Y5%*%4A:04N:,U-E+F44JG)#$]-G^T'D3G4NE2QEIU+2
MSJ:9:R>=)*DCC2S5,>"7U,\U,F33J9Z1!<B.Z91-57T=1.I3EQ+IAJF/!+ZF
M>:FKW8$Q<5=+M)+.G,HZU2DA7$)74W)*;%:1T:S+&& JLW6TRCG3$TY"HFK:
M6W>S44N%62'+8'U.M4\U4KM<Q5&:W299JA59NDH376I3R9S5!2HF43INL[K6
M2*HPN":,J>CGRU"66G'FBD&'');=AQ"2E4D^915E,I]3J5=.1KZI394BZX.,
MXH^2>287#V2J?;+,[10:>5$A.=$Y$7]H0+#Y(7#3Y$*C^&E?59W9>?XB'Q5S
M]C!-1-)+1KC$<Z>J'IYU=PJE4L*B;U26X%2:114CE,+@K4Z4Q4O-4SQN=9&5
M-434T"JB:46DJ!J2%,-E/13J. 3!54#54#:B<8454#2BZ?5ST(-KBDV$:B;$
MI%6E".6%5.A)3EO#TY;75"R61<9(4@JYZ$+JTH6PDGC)'-*SH];-TIKF5S22
MU V4I!5ST(75I0M@?433Y$50-13+JXH6P05@]"%M2.6S&U8\PU5<*I3(*8LD
M.1EKS2RD2XQ',54C2H(J@:CF)53DSR58^0U5<*I3+;RDM$7&./L(ZZI22*Z\
MI52*%QBB5#4SD0154]'%=6U"V"=3.GF-N969*4;,5,J53J9S*J=/#-*P*UAB
MN<**@:HD-J!IA2-<8CF05(Y#,?7U1PA438%$7(K)D..F.F_AI7U6=V7V8C#D
M@,1A_F(@(B,<.7 0& P& P& P&')@(\F A 1A$1@,.3#DPY,.3#DP& P]C 8
M# 8##DP'_'LQ$/BKD+F,2<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<
M"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.
M!.' G#@3AP)PX$X<"<.!.' G#@3A&GG0' G#@3AP)PX$X<"<.!.' G#@3AP)
MPX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$
MX<"<.!.' G#@3AP)PX$X<"<.!.' G#@3A"GG1' G#@3AP)PX$X<"<.!.' G#
M@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3A
MP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3A"GG1' G#@3AP)PX$X<"<.!
M.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.' G#@3AP)PX$X<"<.!.'
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M=,2@65(Y6*;#_P",M V6:-*MM06II2F14MJ"4^0FWX8([55RIU2PZJ%FRE5
MQ16"XJ$=,*7)XT8@LE;;*WAE5P%RTQ+(K4&HZNHJ$Q$!<RB9//4C2DA2/[44
MCG7TR2G3HJ:H^TW!V2YZ*<LFK4D$:.LJI4RRJG5"0VOF*9C*;2C%XMM"J03H
M9)5Z4VWU"<NLJ94RRJG5"0V4Q3,ON6."VNHIZJ4:1&F4ZF%KTT:60634J42L
M+C<I4)D]*-ZI1=A,2UERU,Y'*8;,;-<Q\R>-1-*3%4[_ #3)+<51EKT9BD)D
MT"J2F4SII\R+ IK:E3)1ED$:BN6Z:H.06P86=4KE)B=79H5)'<-*/6R4- :C
M7K[<5FG3R1DI,BPQ+3%2TU5$A&8JIBNB*4TM>.G*3U:7O)$+.^FS>TP^==(+
M/5QF5EJ?_P S5.T<R6OVSF8_Z++[(*U6Y:9+GLL2QZ4!AR1A@,!ARP$(# 0A
MRX",/;A\!#X6(AR5ND2U(I,DJR66IV^I/)JE*J%3EN2D'+HUVAG&G4F1=,90
M:(:F"&CU%$+:HYM.C;%)-0"B4@U(I1T@TJH>[N?L8D43R2B51/+++-&6)M3/
M-EMVI$D2((I*1,8M,FF$M642RE*C"IE*PQ3&6J'RRDJ)R8PC&$3U,Y\4ZLQ/
M%0L-4<AJB<X3J)YY8'SPE3+#$T9UAL\(GSQEG43SPN"L8G&FS&Q.43G FIGD
MRF&3&1+-F+B?43CX%'3%14KC5(.43G FIGDRQ43QG,-F,BF7&I@<?.=$NJ'E
MRDJ)R8IU9B>)ZB<^,!6ZB4O*-43G<AJB<T3*)YI93YY92*@<1 PV8Z:O5(LZ
M7V"5YQ,(+383"51/+++4SY83+39I^]5 BI,C+$^>,H)7G$P.7G'0,/G,A*IG
MEE!*F<D$GSDQ!RB<Z,]2/GEXHSIS31FCS):_;.9C_HLOL@OO_6"OI$8<O_ C
M 1$! ?(0& PY(\F/^(#''DA_D0Y8\D(B$1 0_P B')\Q 0_SR8"$>2$1#_(Q
M$?@(B'Q5R21G2<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!F
MC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S
M1P9HX,T<&:.#-'!FC@S1%"="'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.
M#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'
M!FC@S1P9HX,T<&:.#-'!FC@S1!"=$<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S
M1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9HX,T<&:.#-'!FC@S1P9
MHX,T<&:.#-'!FC@S1P9HX,T<&:.#-%M)C)%?,Q_T67V0320F'#R<L8<D1B,.
M3YCY" @(##EC#D@(" _Y@(<GS$1" _Y@(" @/^8" A_@8" A##D@(# 1^ B(
M<BM5*E+15:101)4"9RTE2)5@TV4J5)4B5<2%Y1\ZM:4DA+-":$TT)89A2=*)
MLL)9;@2333SPDA+<*2::K5:6G2%F0,E]N'\WCS.?]%E]DY_B(<E[J(R)ZB1
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M4K8D6FFG)Z45<YR,P7$<;+)<,$4LD:G(D*M6I$I3/=7/V,4;"I(J>D7)SEB
MM;4J,<;.H(,5)SZTF+/25I,8H13_ &BW/_<([8I9TBFBGP/GI?VVT/HHDD3:
M?:W3*D)JB^$]*6+"!6DI4LEXI3##Z_V:].TU<F!Q:J29(?5?NES]LM"$8R(+
M<4J9ZJNE/7U'B):@H+A4DIJHV"-8N5GDKB8T^>YRC3%:.::K0I2F:-/GJ:Z<
MJG*E:>6Y4):-1;/8_P":'_19?9.?XB'(I1EJH'HBCY)TTD\B=-(GE2HBDL%=
M+(5124\E+R*4I:F5/1DR>90FD42IZ(F(F5(2E0A0TL/=W/V,%F3%QS*LPE5F
M2SSW$KGBFJAZ:=;4CED4M94)9(KS8E)U$Z>9575*F5,N-30+7&EEI5QJ:"*H
MFHXSU V<TVXE9DJ*JGHPL7&JYIZTIG+/6F'RJUIBN8]:8?+&OJHR&5(XPQ0H
MG43HJB:CBHKBD^!1LQ<TM4.E-65A0L@BJAR,+:J>L$E>522&5$XR917E2B5(
MM-23*JXI52IZ^J(D,,F,C;/8_P":'_19?9.?XB'Q5S]CYHMGL?\ -#_HLOLG
M/\1#XHXB0^7N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!(.X
M$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2
M#N!(.X$@[@2#N!(.X$@[@2#N!(.X$@[@2#N!("")")?YH?\ 19?9.?XB'Q4/
MZ>/^BR^R<_Q$/BH?T\?]%E]DY_B(?%0_IX_Z++[)S_$0^*A_3Q_T67V3G^(A
M\5#^GC_HLOLG/\1#XJ']/'_19?9.?XB P& P& P& P& P& P& P& P& P& P
M& P& P& PY,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@(P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P$\G2A0Z7&G$X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8"/]]UU7.D
M39P6#."P%3=*4?(8C#DP&')@(P$1@(0$88##DP$>3#DPY,.3#DP& P$.3#DP
M]N:.$.)F'$S J;I2B/RP&')AR8# 8# 8##DP& P$91$8<F'+AR8<F')$8<F'
M)AR8<D(?U%=/8N0CZ!-R1'_$1$1^41_P(C_G_F/)$1$.3_D0$1$1$1@(<G_,
M! 0'R]N;Y<A'TB/RB/\ @1Y)N6(_XP$1,,!$1$1'DF$1#DB(\D1_Q$0$/G 0
M^<.2'^! 2_U%6$,5I&13AD4X%R]&48\F(C$1$1B(B,1&(QY(C'DQ$8X\G^!C
MRXB,1$?,8CY#$0B(" @/G[<88CA(CA(@N7HP&(B,>2(C$1CB,>2(C$8B,1$8
MB,1B,1B(Q$1&/+B(\D1&(Q&(A'DQY,1_@0B,</[!Q]K$8_\ UG?_V@ ( 0$
M 04 O&\J(W]'WJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C
M>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:
M)=:#'SPWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHW
MJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C
M>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:
M(ZT6/EEWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHW
MJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C
M>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&B76@Q\T-Z
MC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHW
MJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C
M>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:
M-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQ
MHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC
M&C>HQHWJ,:-ZC&C>HQHWJ,:-ZC&C>HQHWJ,:#-:#'E3;U&-&]1C1O48T;U&-
M&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48
MT;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1
MC1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U
M&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O48T;U&-&]1C1O
M48T;U&-&]1C1O48T-R[5GNXEUH>3\*:DP[M2#NU(.[4@[M2#NU(.[4@[M2#N
MU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4
M@?E(G*O/NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[
MM2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU
M(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(&_1IYGJ[M2#NU(.[4@[M2#NU(.
M[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M
M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(
M'?1IRW-[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[
M4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2
M#NU(.[4@[M2#NU(.[4@[M2#NU(-8Z),2RR>G))BN[4@[M2#NU(.[4@[M2#NU
M(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@
M[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#NU(.[4@[M2#1
M^C3GMIW:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI
M!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'
M=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=V
MI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!W:D'=J0=VI!IBD
ME+O76AY/P^7Q#^?FO-#>^=O,SQ>9_,VLOR43?Z>9M'7EES_ID_-]:'D_#Y>P
ML7):<6CKU*J)L81A'X%_/S7W:ZL4ZES(*FAJT/9A",T;3<>W[YJ-&N>C7'-R
M*[EH]/J/L>)-NYN]VWOG;[Q;44=,D0UJF50V_;_H38T5$K*J";W%0J*.D)Y)
MY3)?>/%YG^\4*"4A9-S451.;B1!OW&M]T:7[BK5FG4 BEU>GUU/[S67Y*)O]
M/N_F#+HH94Q1DAY25R+>6W;[A6K3T\BC7/1+CF][HZ\LO@B*HA5**A54%(EC
M",(^PNJ2*ER23R&R_,(:L@JD:=<U'JZVCN5;M?N7V(PC#XS3)^;ZT/)^'R]C
M7S) QN[\T;MM"UF&?,SP34:MV_DKCJ/K:+.&V!JFLAP*RY+I6VTE,.UJ6,@.
MNEZ+;LVV;<U.63=UY576-8B0]M'-MUW:/5]5#?4.>R]53>7FEM+5W8-W5V,(
MPC[#^?FONW]LZCW^_P#J/8^@,!0;H>2B6+;=K:F[*O6\7!U)6@WM7:U[K5>"
M#IOM:+/3-7J&M)UZGI5Z7B#I[3MO*MK&J1OJ":U6H^SW=J-^$-U%V')=*V6D
MI5DZJ[)O6L7UJ<LZQJNU+ZVF\L8?]K/=M[YV^\UXHR:A3GKTCM_;5I.M>M2<
M72S'5ZW]FTZTKII-]TFMZO[%IJML'5MMXJ3>&J2T+3K-CW_0W%H*_638A!UF
MWG1'!H\N&.K-K;IEL>UOL/O'B\S_ 'FKOR?;C1^V%\V'HSO*MUZT],+[6HTK
M=M,]]J/2F<#4I9[>U9J]0-HO J<U_;6:M<U[OT%VR7#U(6BW=7:U[[5=_DNC
M3/9M^W11+/2L/J0]YK+\E$W^GW:3_?I88JQG7(;>BFL(_-4OR@MMJ.L+559#
M@5]S'<M=H4=MZN;(KM8<5Q: U%'L;4Q;%\UIT'JM5H96_P!2UH.#60Y#'6\[
MM3U)-I;[&W0HEA*;[S1UY9?!-E7Z;:;X-=:]0U+78Z+T6LT95A:FK0ORM>+=
MO2WRY+CT1IZ!3%\E61:X:0GN&;1W<*Q'1=5U_'V18.CVRI&V<IJ2&Y*<)I?^
MQ3EZ@K2:VH-@_P#:3L+'.?RUFJ6V_J.M&O4!H-75.HM<<%V+6:RBTC678"Y=
M>EW4ZP:#<.L1O*')8#@4%T*+?FIBT+$K#7/3:KPDN#J1M1O:RV[F4-UJ5\%I
MD_-]:'D_#Y>QKYZ7AW6&_P!0KD4I\+$I;8:?--EH4BU&XT]%%W6].OFEIC;!
MU(W(7;=]NFY"#4S<VOV$JYO[<MRCV/0K=U)*JO)HJ..-N+3';U,5.JZ%F42X
M]3.O-.6?9QLT9YO8?S\U]WJ'A<TS]51AW/>A7KR2E'V'0:#3;'HVE2^;^HM)
MM>WW&NEZV8DDN34'/2T2RI:4O,/1C]TTW6[3%CP/<1(AU .Y_P!BG!3$7=J:
MJM-25^:JZ@DM+N5N*[5Z_J6A_P!K/=M[YV^\UY\3W;=35OT[B35K:].L9AVW
MM&CT6Q=!YL2F]HNI(RIQTA+E)KC44J_=(M5U!._2KY85L7#="SK3TF6%=5A$
MC7AY16M]A]X\7F?[S5UY0-[0]0U?L=GF?IC)6EH&H%.06;;J8NC:J+C?M#;U
MUVW<=;N74PXEH7^V[FL^_%OO*GTL7S?M'06]07'NQZ@Y3DT)I:!IQ;RO7#7O
M>:R_)1-_I]VD_P!^F<MW)RF?8:JVK<J*VZ7<.JG7&5"21Z'9MEJ56K9PKQO.
MTM2345]TZ'8FIW,EQ);KNHG4([Z)W7H6'S0G,<:S%E^4ER&]K^E2L4FID5M!
M[S1UY9?!7JTE2>%S-.[Q('@M15=%SR:BWJ2.Z]TNL9&?9]1U!'D/*X4\W3FU
ME?<G7,@R;]1C%Y=0+%?Y??3]YU,[+"?4@P-]WRENA71W/<-V'(L^_F[<YEWW
MH#TC2B;-)>ETIB;SU0ZH*,DNEK9JHKK&DS2U;]-MQLM(\\;5CI.O>_[;M:P+
M=<.M/;5J,X.GJ_6G=RW7GI'P6F3\WUH>3\/E[&JUL+A=JT"I>@4_UFU1PF[;
M6B++8L^\6DOVP7!J[8N?J#J[[EU:Y'H<"XWW9&@Z@;/K;_MQ6J457J6UMLOJ
MR5%TUM+=C6UAC6QN"P[MN=LK@JCW:IVRN!U[4FC"/LOY^:^[O5K+BKCU#5,V
M-PNM;4#.A/2&O<[3_76^J3N5RM7^TU^6:X;;S.]7KC89M*^W]X:;VNN%LES)
MMC<-C7LZK7W!=KGN"V-P7$\+^LS<EU5JW*@_%W5NAM\Z+$W6WS2N0G=[PON#
MQX]VWOG;[S4^U%QNJ2?/ PS4\WE;=-O;92&4NDZ9VDKC=6:UUH/:PU-T\-#>
M+=7?&Y=1=!E;K3051FJLN&H!JZ4V<;Y,ITO1C%\;0?5Y[>:A<ZD#O>/%YG^\
MU!V75G%;QL:"LM6SCY(F%:5VTN!J+,2-E<!#\RMZYK-W[:;4N:J=Z\*X]-L5
M]B&MNFW+GIC7N8P-P-_4W<KM:#K-.[MVN=3;DU$GKI^C";W>LOR43?Z?=IYX
M%FZ6VHN-J$(HK97 A?75 UEQ.K3M0K677<EUO'8#X/W0',,<BF%P;]S'FO9R
M&EO6@N!1;A?:Y*C-A&+FR.]2J[>S</)J/G1HR*<F]YHZ\LO@FR:RXK6=N_&:
MNJUW'=)HKQIE^TNXWZN1:Z%IHK\M'05:RZI$#48UEPN6MU)M<:\EDZ9&C7-!
M:#6MC<%INFTK87!9[E-^V-PVV\2]JW#9^];)K#RW!7;QKCTVS7V,:RZJ%=*9
MOG;9^^'K9BZ*]7KQH#ZOK3W+;&96T[/V\MLRRM/C77 W5:MUM73T[U-MJ@ZU
M8K-2N5_+4JFG)HJRV"+X+3)^;ZT/)^'R]TZ# 4]Q*VITP5&\)B22DQ7NW\_-
M>:&]\[>9GB\S^9M9?DHF_P!/,VCKRR^&<.U3[YMEL; 0-9:W,^F3\WUH>4$/
ME\0_<L8WIS0WL(^-G,SPPC,Y_,VLK_+*)X1E*YFT=RQ@V7/^F6$9;WUP31@R
M\=$[;Q&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R
M=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW#SZ8+(M2[-
MD[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VX
MV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;
MC9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;BBZ+VT/J
M^R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;
M<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=
MMQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<5G1@VA5:V3MN-D[
M;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3
MMN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;C9
M.VXV3MN-D[;C9.VXV3MN-D[;C9.VXV3MN-D[;B_-%C9D6_#1.V^&R=MQLG;<
M;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=M
MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)V
MW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQ5]&+=($&C/3S:+O-]LG;<;)VW&R=
MMQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)
MVW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQL
MG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&
MR=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<;)VW&R=MQLG;<
M;)VW&R=MQLG;<;)VW&R=MQI8M.GV%=FN'R8^)U&_GG-%O?>^9K@_(.9G&_&X
M<S7)]H_7#Y2\_L7YDZX?)CXG4;^><T6]][YFN#\@YF<;\;AS-<GVC]</E+S^
MQ?F3KA\F/B=9%^T1M;C]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU
M67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67
M'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J
M LN/4!9<>H"RX]0%EQZ@++CU 67'J LN*/KN9])5/4!9<>H"RX]0%EQZ@++C
MU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU
M67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67
M'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RXJ^NYH%=8]0%EQZ@+
M+CU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++C
MU 67'J LN/4!9<>H"RX]0%EQZ@++CU 67'J LN/4!9<>H"RX]0%EQZ@++CU
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M6VY8%JV 7';51+&K#OZ;4K5UQK=.=Q23;6]2$DTK2ZMV%O%P3]1=.BU+-/\
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MVP_^GU<UK<ZC+XN^BL0^S?WFQECN T-]I;#I=3J[X-8[%2H>G@K6FU,E<O\
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M*&T4L(TBMGJ:U34*F\N&U&A56\Z;0V+?ZJ]V=96KVG<#,,EX=6Q:S-O6SR%
MW58KEA,.W#F-XBMECG<9,JT+(KZBU;68YZK#HVFAC#=/MMN4WE&=BUT+6ZB*
M52[XTJHEC&BNT1#<U-MIF'Q:JFM6QZ1JK18)M%+.M[<E@E:>F?;O3]?M-LAO
MD!^LQF*NTC_WW27BT[I[W:9ZVC5NHLU)-,K?-MW@H!K@Z@+P7N)IVN;VCI(F
M29./&3CQ3$DR%,+'9Q7:;I-.U2INJY3&G5H':&E^PW-245E&15-O'38TRMC&
MWOYCKK17HVEONP15V3L=PE-VLTRM4LZMVTPKMM/'3DQU18^@Z;&F5L8VZ!B7
M0:VLZ>F.JC+3M.RSB,[66J:!4WEUT1AG198UF61.;8:;&F5L8V[*M&K:Q;>U
MG4IPJ!0FDU!632+=T_T^R&L:>S#6YL@:8K$<Q/3V-9-6VBBCZ52CVVNYAWT<
MZSW58>H.(U3J6><X5EN%IWJ-Z,DY=JG7U:%;TTEW*U:>TM1]0#[LJ<ZQ+KZ:
M7;U 4/\ JVV+&H5F'? JTA%0(FT4,G,;2Z4BH:/V'+96QWB);S3BV[5U'W]F
M6+0F]0^Q:MBT*R)_@;,L.@MZD_\ JF__V@ ( 0("!C\ _7H?XH>J3U>IQZG/
MYI'^*'JD]7J<>IS^:1_%0G(-A_P8_$H!/4J01_&)2%$J0A>!#U/I])D 6%9T
M#^'ZK>Z[/T[/Q#U?BT4IR".I7(!S8F/X+"G9^,/Q:%4;#Z+LPQK_  6B"=@=
M,01MH_%/XU1L*9?5;W26?I_!8+W@1M!'J%R%0"=G\5 ?TT@A D$ U'6AF$42
MJ]1#^(_M* F;P)8AA42R^EEZ:0-5#HS+!GK-):MD\10*R: K]$@*S$NKL!MU
M#:G!B0-(*,(LX=^K4OJ28='Q6+WC&/032KLPQ[=B! #$.[T =*%%Z]48TCP1
MG06K +D?Q#\2<H%B#P1R<YI @Z!0RE"'PO8"OJ28=#^]2K]$8ZY%@A>J-1%(
M*)C4*R: KQ8BIP7"ROV\%#ZI%3Q;517TU($"@AWT =*O%B#I%(4[I%SXM?4K
ML Y[$94$"MB[(3HB#49%D+[,:B*0OG[_ ,0]7XLR/Y5&&81(2+$,-*,(U4MU
MA$T!R2 2Q-.I&,PQ">1C%ZG-*NS#=A0F2(@U7BSJY*NBJFNI4F(.HFE&$PQ'
MH&5E18,7)Q2/!':>T_BC\6/7V*0!< F@@5:E&<0UX.1TIXL!=%)H"%_34145
M>H .F19"4F(-1!<*\& J<E@A>8@U$%P5?HC'7(L$#*HU$4@^@0RVCK+4G:I3
MS,430;.+'\4_C0&66!CJ"^M,"]$LXTJ,(!S?XJ_01I8NR: JKT (R!C("NZ7
M978!RKSQD!7=+LC=J%9- "OT2CI,2[>@B# G3IV!9D,WWH@.YT&G3O\ 4.3&
M-)- 7]OEEY''+N'M0.DHW!0*R: %?HD!68EV7U?A=NE7(5\$1J69(5B+V.HY
MT:IA^M.:H^\>JK>LN>LD\-RA]0B[\.NK2LK:>]7@PCK)8*])B#I!<*\& %#D
ML$(T>\[$&@MTJ%P1!;WJ:SWJY .17J'6GC=DU8!I0A&LJEA20'-;:E<F&*OT
M1!J,BSH7ZC412"K]$1H,BS[%=EM#5$?X0?Q']I5^$92(JO5.HSE63W5*1D:B
M0.@!94!4:3TGIM1AHD"XT+-RXT/4:AL=3EG,'BPBX+E;(GN1E*DDK^OF")(=
MB\CUK+8O[M>NI947H,:1KJ4[I9I,-A9U(:#$O_$/Q)_4>Z]+5Z$?[>)O$->E
MH1/^DHRD:2:5&,\R[=%$6)&U'*C.\7<4$,LN(J+D].E70:#HT+*_;P65^S@L
MJ+T$4C6LV.@,0LWJ[E.4:#*3'90O=H>@H3S9"(.%Z3U#0@(RO 3KMHZE\_?^
M(>K\6;U7:5?RHRE(57JATJ_*LWB;$9R+EZ]AH9 ZXA Y\Q$D5%Y'K64QO4&G
M74H@RN3B+K'"=GMT(0S*PYW4*4I9M))^$T?Y*%PWB Q+,_H&PH[3VG\4?BQZ
M^Q2)$S($N/A?@KYHT :@A$U "A1)T28;T)YLA&/PO38$1"5X7J]5(H7T,TW2
M"X.CK0$F(-1%2C&>9=$8T18D;4<J,[Q=Q00WH$(5]@UE#RV53&.(ZY>WM1^*
M?QH?6O/=HNZD,G*%V M)Z4 "SR8[*5F1T&"-TM$#WB31UZT3#,$GB7 !4A/#
M(,2*POJ94A.(K:L;1[;%",IW :30]XJ0^I>$@S72*=?HO&(ET&I'(:Y0XNX3
MM"(.@MZ@R3(4%P3I#Z1W]":L&D'6./\ FH1E.X)%S0[G4I?U+PD&:Z0I^7-4
M@XVCV%BS,XUX!MT[^ST9O[.*EE:8>]'9[.O]6:?]H]MZRNM9/6LK:>]9<)SN
M 1<!B7Z5/*$[UZD!B&/0OH9IND%Q+1UH7F(-1%165^W@C*-!E)CLJ4+NDL=A
M3#^;M"G>+L2!T :EE$Z8A]R$9YEVZ !&Z2R^C&=X@N*"&Z%'*G*Y*- ?"5=G
MU$5$='^$'\1E.IB-?HC.50X*4A422$,G/<7<,AWH_1)E,AKQH &Y3EFAX$AO
MYC)?3 E$FHNZE?T QHVH2&@NOJRE(&AXMJU%0$ UT$-JJ99<8UQ#'<I91Q&0
M(W>*,IU$$?Q#\2>4:R:-WH,IZ8D:_1$9Q,91#7@'!";+,I2>LT!E]#/<-AD-
M"NY;RD^(T,.C:LN,:XACN4!'X8L=M"RXQKB&*S,LURJ69EFN3-N4LK-!,):J
MP4;I,R10] '3H41F$QE$-0'!7T<MZ)/3IZ?!?2^*\_5^(>K\6=_3%AZ!.=3'
M>B1I)[5&<- %>L%?5E*42P>+/8H1RP1=>@Z-5*O7I1_TL]A0S8"B+  Z1T[4
M<R]*!-)#/3T(?2=FK.D^@9EZ1+-5KZD^7*1)+TAA3^*/Q8SE4."E(5$DCT7H
M5,!J7T?BO/U*,,TF)AI <$(Y.6]8+GXJG/1L0OR,9::'!V*.3EO=CI-941G$
MQE$-> <$)LLRE)ZR&#>CZ;RC(XB!3L=>[*3Z*/#\4_C1N:(L?0,KXA)^U2,]
M,6&U3R<UP):1H*<&4G!%YF ZM*(S7#U$:-H4H91,C.LD, %]#.=A3&0T(M*4
MBU%#!^GT7<UP7HD.PA&663.3,'# )SI]09>6*XUHY.=HPRK(]NRA'(SG9WC(
M:"BTI2+44-3TJ,Q6"/\ )#*C1\1VGV/HG>^*+#;2A(U5'8GCA 8++RQ7%W67
M 5Q=U#+%<27WJ.7G.#&@2%-'2B(&4I:"S ("<C&6FAP5')RGNQTG2H1S"8F%
M% K&]2R<T$PEJK"^I$F<AA#,!MH0S9ZW*E.-1)(4!'X8L=M"!S28S 9P'!";
M+,I2>LT!MB#RE$M2&=ST*(@]V(8/6?\ "#\0Y9 E$Z"GRH1B30]9ZE3^(/5)
MZO4X]3GU^)D.Q=D9RT^J1_BAZI/5ZG'J<_FJM5JM5JM5JM5JM5JM5JM5JM5J
MM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5J
MM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5J
MM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5J
MM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5JM5J
MM5JM5JM5JM .KF6X# U[56JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU
M6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6J?TY&
MT+Y1W_KR-H7RCO\ RW<A22L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"P
MBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+
M0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT<5A%H6$6
MA81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%
MA%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$
M6A81:%A%H6$6A81:.*PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(
MM"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT
M+"+0L(M"PBT+"+0L(M"PBT+"+0L(M"PBT+"+0L(M'%81:%A%H6$6A81:%A%H
M6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A8
M1:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%H6$6A81:%A%
MH0)B*.D+Y1W_ );C[:#^CQV(?M'?Z)W@#0*P#I6"/*."/Y7C[:#Z ,R3/57W
M*[ER!.K3O]/]NQ>[>?1_%$3+7BP_B.5&0,AHV5^CZ-X7M7M1Z?[=B]V\^A,H
MY4C[TJAZ8Y#%Y E]%'\%V4P_6=X#(2B7!J(]$<AB\@2^BC^-RK^67#MZ809S
M,L!T:3U(#,DSU5]R;+D"=6E YA9ZD)"D&I7LPL%]1Q=9WT,KD9A^L;R&4,N0
MQT Z'U=?\-W,D =5/<%<RY.:]/!'*$A>%85[,+"I7YD :RKL) G52.U#+D6E
M*H:TY7U(EXTT[*UC&_@KX-#.^AEC%AX(3@7!TH#,DQ.WN"QBP\$)P+@U%"68
M6!+>G^W8O=O/H_*!V(?M'?Z)&0)<"I8);D_Y7C[:#Z,DS8#WG>I98\LQD)4F
M.B/210ADY0O3E2SL -94<KS$0+V&426?470_]?>B,J$0!ID:]@"E"8NR@6(=
MQM",<J <$@DDB(U=)*EEYHNSA6-!&L(YF3&-UR "3>/<.M9;Q!O2 I^'9TJ.
M7&-Z\#0*WT=6M1AYB( F6!B:CJ*CD9(!F0])8 :SI0R)QB]9()IB])'#T3\Q
M&O+S:?VF@HYVAG'3JM63*6*=Z4OF\$<A@PC>?2H9( :;N=(9%O\ [?>ID1C>
MNAPY9J*BH9>="#R=B*2&"&5&-YXN-=Y[ -948>9B )E@8FHZBLO]DN]'(\N
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MV^AH@#8&33 .T.F@ -@;T>Z 'U(R #FLJ\P?7I33 .T.@P%%5%6Q7F#Z]*)
M >OI4HYT13,D L:]*8!@O= &Q7I1!.L@)A0F-*>$0-@ 32#CI30 &P,O= &Q
M7I1!.L@*ZP;5H3"@+WX@[0Z:( '10KQC$G6P=-( [4TP#M#IH@ =%'HG'X";
MT2^NL,O= #ZO1[H >ME> #FLZ5>(#C3I7OQ!V@%-$-L4\W-HE.3ZVB*@_P#"
M\H@[0"KK!M3!O1>(#C3I3F(L"N@!M346+#&P*\P?6U*O,'UZ?0\H@GI 3QB!
ML 1( #U]*O$!Q46I]'O %M::0!V^CW0!L5X1 .M@ZNL&U-18F'J6>SU.-H7R
MCO\ 1/8.WT';^5XDEO8K$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"
MQ"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$
M+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L4;0L0M"Q"T+$+
M0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"
MQ"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$
M+0L0M"Q"T+%&T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+
M0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"
MQ"T+$+0L0M"Q"T+$+0L0M"Q"T+$+0L0M"F!(&C6/4XVA?*._T4%E6;?R ,N-
M9++Z ]Z5%6LZ%](Q-XZ-*?,B0^M",0Y-0"!S(D/K0G.) -1UILL$D4T)BF">
MX>^RM70"]3:;%>,"WMHK3 .=2O&!]NBM&$2 0'ITHQ-8H/Z3#:%\H[_R&9GX
M8[S1V.A,Z9D]JAL_ZE9N3\4""++P[PI>8G5 &W3N[5ES-9(-L2LG8/\ BI?M
M[PI;3VJ,LR@4TFH%J%?,OZ5=?NLU3:^GK='.\OK845EKK]>A2EYDD0;XF%/1
MJT]"E.@ O=.ASIZZ;5*>;+^G2:3[K:*-#:?%?4A5*3<U&^M2;XFE;7O'Z3#:
M%\H[_P ASCK [3Q40=$N*AL_ZE2B:I,.M@1PZT<J'QR)ZG<V4163\O\ Q67+
M*#W0*!74QL*EFYH,0S4T=).P,IF4!.\7#M12=8.M!X"(C$FZ*I%]- 7TS$W'
M9FHN_P S[]R,/+BEA)AH-=':RNYPD8L7O!MC4*88-$ W=%ZAZ.C5K1R\R)N%
MP011$"HOI[T(9=5^-&JHD=2V1'?^DPVA?*._\AB4JC0=AX%D9Y1%=X$,:]U:
M&<9>\-+#L9E]61]YP7Z14@<TNU50[%'+F7C&H4;.Q?TY,-58L*NSE1J#"UJ_
M0)0+$:0FO=;!^Q?4C(WM>E->;8 #V*_$D'6FO6 /V+ZF9("Z":3631IKUJ69
MK-&P4#=^DPVA?*._]>1M"^4=_P"O(VA?*._]>1M"^4=_Z\C:%\H[_P!>1M"^
M4=_Y;$)AP?%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YX
MK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8
M-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O
M/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YX
MK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8
M-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O
M/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YX
MK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8
M-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O/%8-YXK!O
M/%2G"+$"BD\?4XVA?*._\MQ]M!_@<IQ_@G'\3$UU=/\ "YH"<?XQQZXGL]3C
M:%\H[_RW'VT'T9402 7<:"B1J/8I2F22TJ3UJ!/\JN"8?=;4KV80 FRY.=51
ML*D)2 NL_75MZD,TR B:CKZJU=RY.=51WH0O"XQ<TXJ:% 0S6(E4']ZJCVUH
MY3^\ [=" F6,BPZ2FS),=59L"O99!'0C(U"E',,S"#M$1H);22B)3OP:A\0.
MW4RN2D'ZRVUD90(((-(1>5T>][PT4UH&,[Q(]TGXO9T+\P)$4L]!9.)WXAS>
M/CJ5R$G.BNG9Z&-65'_=+P[%E0!(!=QH*)&H]B^KF$EKQ)-=!7ULR<H X8QH
MHZ5++S97XD4/BZ04<J5>7(QZM'I,Y5 .>I?5G.4(G#&-%&LE&,YWXZ'Q#;K4
M<C)+%C(L= J'65&>EJ=HH*S8DD@"+#0%.42Q K0G'.F"0#32*E+(S\<=(JD-
M:E#+D89<"Q(Q2.U?6RIRF!BC(NX4)91;ZA O?R@H3AFR-(<2+@C3L67E1D8B
M3NQ0D<V<FT$T'T".0 YKD:HC9I.I9@G(R:1#GVH]$LT9LR1H?65'/GFS8 2(
M)HJ=1@)!Y,W75L?I4R)DE@\-$:O;K5V4@_12UBG*!<&)I&Q0V>N)[/4XVA?*
M._T>X"=@)[%@ERGA^6(^V@^C)^92V'L4MD^]9<06O&(.RG@A Q#"JC4F$+]V
M-$7  >LT^UBR\WZ=RZ?>-X%XG8LPS#W0&>JD!1!A>DYN1 #].Q9,I9=PWB'<
M%^BCVI40PP'O62P _J#N67YD5/<EL-7>NC*'^Z7MN69F1R[Y,B\KP#?Z:0IY
MDH7(R H<'WNKK4P*[I[%!M#CK<J<XUB)(L42P)D')UDZUGY4<(I U._MU*6R
M2!/\@42PP#1T(Y<2Q)+=4G4<GS&7<E5$T&)/0=#^C/)KO"RE9/S*6P]BDW3_
M ,E Q_E&ZO?Z,\:+PMI1EEQO'4[)LS+N!J[P*FVI0;5V5^C,SIB1O&[%@XNC
MBLS)#@$WH@ACTT6+.V14]BA^T=BD8_#!CMH69'2)E_;J4W_E(MH"AEYHH8;1
MJ*$A*_EN 0:X[/9NA948DQ<2I%:O2S)2HJ-2(&2X>@WA3Z,W]Y]$^KM"/_K_
M .JA( .0Y.E_:I9NR/<I#R^5? )<T $Z:ZUGAF8RHU45*&SUQ/9ZG&T+Y1W^
MB>P=OH.W\KQ]M!] 8W91+QD-!7T\S,B(FNZ/>(1R,N@73$(>7F:A6-8TH0GF
M"Z&I ]X@(9V3*[,!J0X(U% YLXL-$17UE3SB0TFHU,HYN46E%V>H@J&;FS!,
M2[ >ZW1I?:HY^3("0#4B@A91E(/"0E*BO8CEG34=1T(B9O2D7)4I^6D )4F,
MA0^L,B<Z0+U !@._T$^5F(Q-)C(.!L1EGSO.+K"B(&S7TKZ>1.-S1>%,40[R
ME3*1TG@CY<D.0:=%*_MY'X6<=JN9DHF(BP84]#]2^E"0$@7=J*W8A1EYB46@
M7 B#2>E_1(&K,BXVBOO08W91+QD-!7T\S,B(FNZ/>(0R@/= 9NA$>7F!$TM(
M.VQ2S,Z=XD;(Q >H*6<?_J2)ZM'?Z6*(\M,")INR#ML4S/,><@PH:,=@[U'+
MU"GI.G>H9\" 8T'IC[.IYN3.(O-6'J4\O-F"9!@0&;6Z$!F1   HC2P1 <DT
MF1K)1SO+RNDX@0\2A_<S!B*;L0P)Z4#DSN&.AO=/00A_<S!B"]V(K/2H9N5(
M Q>L/6@9SB1I 'H'T9".MPZ)C.+2+FBWT2RP6):O:"CDO3=NOHJ91RS2P93S
MB0T@ VFA&&3.(@232'E%]6@]:S,N\]\ECM#4J.6:2 WKB>SU.-H7RCO]!, "
M^M^XA88[^*?\KQ]M!_QHE(.8TCH_A,94@UH1B& H _*D]GJ<;0OE'?\ EL9@
M#LL M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M
M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK
M +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L M*P"TK +2L
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M5>,:!6Q!5S+#E7C%P-1!W*[$.3H"!S0SU4@]GX<?;0?092+ :2FO':Q;L0E
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M'RXG]2-UW-)CT$K.$R!2*RVM'_U]X65G2P@D$ZG1A$@F3  %WI"\O UB418
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M5>A  ZT#, L7#Z"A,@.*CJ0O@%BX?04V8 1TKZ8 NZM"O" ?8OZD06UJ[E@
M="^H(B]K9&40 94GI5V  %=")B #*D])5^X'K=D<L 72[C136A&(8"H)LP M
MK3PA$'8C$U&A?2,1=U-0GRX@%?U(@[5_3B!L5\P#UNR,1$-(DD-02:U>A  Z
MU=F 1TJ]" !UM2KTH G6R84!2ZNP?G4;0OE'?^6X^V@^J9=78/SJ-H7RCO\
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M(%9V=Z EED-(-(D44]!>E1.61>C(2#U%M'MXKZ6;$PF=!I!V'VU.LR4(7S$
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MVE?6G"X#%C[PDYUT:5+-A&_"3.!BBVK7L[%?AL(-8.H_X,(_Q78,[@T]'HE
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M4C*$PX)%.BNW4$)YV9(1(#"@R)TZ*(]76H9N0;T)U/6^K1V:*4,OS$YWB')
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MM_\ Y*=\LX8$ZRWMNTHYAE(@_$"X+T4^/4KAJG$C;I[E*&HD6%DX!/4L)L]
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M,V=X]!G Q !;WB1W%',+2 KNEVW#\20$A%@]/\7UI,8T5&D/4] V4/Z/[B3
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M=0/2L^0J$XQ&R)CVUK+SP/>E(@ES5[VBK0%F9TA[T9  N>C15I4/WG_LLF<
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M9?\ -0_=W%1_:.Q2CE.310*R :1[5H98A_6H%7O7GK?5T=3:5'(\RX#/*FH
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MC=(->T?YJ4?*0D)3#$R-0Z*3Z(R%>5)CLT=L401>A*B4>CV?:OJY67*\*G-
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MZ$)$:V*NR#$:"K\82(UL?1FYF=&]<B"S[7[%],1EEDU%Z'M(IV=:^EG0.8-
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MC3L=$3:](N6U:!VGK4QFM[Q#,7UJ4_)D&,M!:PO11H(+H>8\X1[K-$=%(JH
M>G2_HC++($HNSU%^^A#)S;D8N'-%+;"=P"RX>3(: 8B3>]T]ND5J)\V1&,=
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M%>0Z67-O$7E)H=A_L/L'U8NFI]PBL7><DJBPW'DI?> X2A!-3_X[:5I_)_\
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MM.I8$QW:RP_;J..)_P 24YP2/ZL6G>)?1,1:+T[&9BA+'YY*I*2I'.H4H9*
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M>TEP* ]I2<2+78RHZ@U(\BRVY"#Q\S^QU2:>P@Y?QK&->Z&CKSJM4.#&6O\
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M:*@^ZRT548T]=W$_][#U!'1'=&Q3:5H.9*?822E)H-E0,9U&JE *)]DD5/\
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MI&Q<=Y68?U9N<1^)8QH#<I:'.=LKQ3J6XE!V=ZE.=K-^-I)(_2#!4  .P!L
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M/4K+34#4-S3)MRVWD.%QL..*JI*35&Q0V*H:U'8QIK>M"9:5INV6>1#E/%]
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M+KX1CNNI/.2Z^$8[KJ3SDNOA&.ZZD\Y+KX1B5-9=U&7&6'7$UU)=:52DD?\
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ME5=N+*[;+C)9G_[FTW&>E1UEA;J5SFTN \V11+FW,D<4@TX/4WNV^ZS9$F+
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MY)1YA*0D\PI2%$BI(J2:[+[O,N#0<U'JG4MZDW20X IU7,RW&&F5*.WFVFT
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M4YDH2$A-30=DZ.9T]#;:5<K-;KO,=4D*<>ERHR'EN+6=JB"K*BON$)2A-$I
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M=9H[RBEIRX2VHR5J'"$EQ2<Q%=H&!J:UW"))LY;4\)K+[:XY;2"5+YU)*,H
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M#CN7.4MH2" #FWL;F+; C#0TJ)9+K]3*90J$V].9=1*2A@@H"'N;25(IEV4
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MF+DXG>N3BY\U:YMG!V*^H5,J2L E)*2#0CA&SLX4EI:5%!HH @T/L'V,%:R
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MTH230%1 %?Z_4U.W;(;T0Z8U'.TX]SRD*YYV&EM2G492:(5S@H#MV8+CJ@E
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MCQLI(+V1-.>403V!MK33VJ-]MNN&H]6:FC"XQK-%E=YQXL)7N%NN)!45KJ*
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M2E2R,H4HY034[,1+)J3=?=;%;'U+#URD76VO-L!*%*!4VRZIQ68@)HD':JO
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MU9/M>)^%;GOO9(^S)/K3?OT\;]G3ZSV#_-,_4^L]P_1I^&GUGG_17_U9PO\
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M2 DJ/'J-M3[0QN<WG:B47=3W",]#ER%]T?:C.MAM:SV3M*JGA*R<6']YZ>^
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M%JE3LNWPKDD2H5JMRG"(T:,PY5L50 M:\N=2E;37,52-=;MX2[$Y-B*B2[=
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MC7#&ZK>3I6Z:,U1/BNS+8Q<'8\AF<TQW8,OQEK07&QQE(-"$\;&\G[OZ8_\
MKKU+A;]S>A[UK2V6B4Y"G76$]$BQ.^&C1UJ.N2Z@R"V>*HH&7-L"CPXN.^;G
MWX-ELHE)N[$QE3<N!(B=WC/LBJ@\@T&05S53EKF&+6B[;M]26K3UZ6E,.Z.J
MB/<VE:2I"Y<=EU3L9"@.%05E) 7EQI^Q6C2>HY%JCVN\MIMD>9#2U=0A:0F8
MA"GPC*C8?SI0X,PHGA!T3:M^.ZF]6Y,G4L*/8[A<'X+K<:Z.5+*Z1Y"E5&4J
MV@CBUH2!B-NHN=KNEQOUQM(N5L8MS27G)KRI/,"*TC,"'*!3JEK*6D-(4I2Q
M2F).E=\^G+QI+5"8S<JW6M:6I[MU2ZYS2&X*HBEI=?+A"2UL(KF)RA2DV_=I
MO-TE==&W:^M/O6-4]V,^S-$='..M<Y'6L-OH0<Q:7V*\:N7-%TMI32=[U7?I
M;"I26;:VVW&::2K+F?ER%MLMDD42C,I9X<M-N+ANVU7IZY:6UQ;X2;E]47!;
M#AD0U*R!^.^RM33B0OB*VC*HT]FF\)EW0FJ;C&1&L'-6+OZ ?JO,PY59"Y :
M'?-,XYM2CQ3GILI:M.1;5/OVL;X%JMUAMB6U25I: +KKBUJ2VTRW4!3BU4KL
M3FVT8W6[R=,W/1>K)\=V7;8UQ7'?9G-,[71'D1UK;4XT.,MLT4E)"MHQ#W9Z
M2LEPU9KF;%7/3:+8IE!9B(5E,B2\^M#;+97Q$U)*E; ,;IK1<[+<M.:GL<?5
M'UG:;FVD+:1)@#F'6GFRIE]ISFU@+;4:%)"@#A^9%87*>::6XAALI"W5)22$
M)*B$@J.P5(%3M(&-Y,69HC5%UCBXVA+5L5-@D6=*HG&20Y("!SNQRC14*>Z(
M5PV_0-FM5PU-K>ZLN28=DM2$%WO=LY52'W75(:89"N*%K5QE<5(40:1=UF\_
M3%TT3JBY,NOVMFY+COQYZ615Q$>3'6MM3J$\939H0D@BOJ7K<O8-.W:_:VMG
M>)BVZ"&O^\1*8+ZW@XM00RRP,J7''2D9UH2D*KLT_<M1Z?N[>L=3..1[9I-E
M#3MR=?:)YP<5?-!MM(YQ;JEA"6R"=IRXM^[O>KI*ZZ*O-Y#OU0J>[&DQ9BV4
MYW&D2(RUI2\$\8-KH5#W))H"SH[1VD+YJR^O11,4BWMM,Q&6BLH'/3)*VV4K
M44G*V"I=!4I":'%TW?:BLEPTMK6SM-2I5HN1:6I49[8B0P\RI;;K>;BDI/%5
ML(X,2-UF[735SUIJR!':EW.-;5QV&8+3VUH2)$A:&TN.#C(;%5*3QM@Q'N,6
M!<+1<[7H*7;KI:[HP69,24FY-N9%<*%I4A:5MN-J4A:""#V,3]W>ZG2MUUO?
M;.&_K;ZN<CQXD)3@S(:=DR7$(+Q3QN;1F('NJ$$8N>D9]LN&G-960-JN-DNJ
M$)?;;=[F\TMM2FWF5\ <0H[>$"J:ZIT[;HS\=[2MU^J9"W2G*ZYS"'L[>4DY
M:+ XU#48NVY:/"D&Z6FS1[RM^J.:<0^XIM+:=N;-4=D >WC>&R]H35-QC-QK
M!S5C[^@'ZKS,.540N0&AWS3..;4H\4Y^Q1+BTE"E)!*#2J21P&FS9[7\C?!]
MX;5]BQ,7_P"E63[7B?A6[S[RO?L+OJ3E2+>S>=-WJ-WE=[5(.5$A@UVA5"$K
M2"H D$4401V0UKK=YHF\2=21E%Z$Q=YZ508KX-4+ 22M>3A36OXP=HA;Y]9Y
MY\U%X9NTQ+65!<+;@64(KQ4B@RI' D #$[^(#2$3(F9.??5 E*!SQWTY7&5J
M345(VA0KE50[:8F:KTIH.Y.7^8E]2(5QFH5;(KSM>.EM-5+"224I-$CL 4%+
MGN?WIV=S4&A[F^B8&F'N9E1)20!SS"SLJ0!4&FT<-"H*FVK=CIN^.7B4A"&;
ME>IS9$6BTJ46V6 $J40"BJ^P2>&F-';I(T)]F9IE^:Z]*6M);>$E:E (2.,*
M5%:XU'NRWDVE^[:/U.E@R1#=#4IAY@U0XV5<4]@T--J4G@J#JO=CNOTQ/8@:
MCM_>YNEQE(=G+?"ZHYP) ;2RE)-$(&8J)).+WN9WM6>==--768S<6G+=(2S(
MCR&@D$C/Q2%!*=OXP0:[-X-ML%HFHM&K+0_:K8RI]"W(H6#E4\M7N]IJ<OM@
M>SBT;Q8;:GT0'CWPPA027H[B2AUL$U )232O9IB#.TU;56?3EI@-P+?;U%)Y
MI(45K/$V<91_L Q9-&_Q$6*Y39NGF.\X%ZLTE#<HQ1[EIY#O%5EH #[5: E1
M5!MFZ33\ZU-1EO+DS;E,[XDRLX2$)*4@-MI10D9=I*C7@& I!(4#4$&A!'9&
M+=:OXE-+2KQ?;4TF.Q?+3)$>4ZTG\EX$@*)X2:D9JJ2E))K;-/;E-+C3<>V3
MD7+ZRDO=\W)^0V"$%3IV)0FM<@)3F -!V6];[Y=)7=O6/,M(FN6.8VU%GK;&
M4*<2NBD$I !R[:;,QH,6R<U :M&F["RU#L]ICJS(C1FE T*C3,XJ@S*H. #L
M;;=_$!&MLEFWPI5MD*@K<07E"&$A0"AQ>-EV?\</;^[!#*2;VJ[-0Y"]N52J
MEI:D^RDD5'L]G!UEN_L%VMFH9UU%RN+DR6VXQ11*G&V6T\!4LA68D4H0!0[)
M.]+5.G)$[3,V$U#>MCDD-2$E$<-!UMUO8%H4,R:[.P<7ZQ[A;'>6;QJ: ;;,
MGWR4TX(\9=><0RVT**)["E<'#V*&F+'<8YYR=N_O3T"6VD$J1$G<9MQ7L)S%
M" ?^DXG&1;V;SIN]1N\KO:I!RHD,FNT&A"5I!4 2"**(([(:UUN[T3>).I(Q
M+T)B[STK@Q7P>(L!)*UY.%-:_C!VB3O%NLM1U!*F=_JDM\0H>"@I)0![D((&
M4#@  Q$NV_\ T;+?U;&90P[=;%*3&[Z2@4!=0J@!]]3@20FB1:-%;H]),Z?M
MD1U2&/SBI$^:_)R-YI#QX=J1D0*A)4JAVT&G-T5L4A3.BM/PK8^6U I,I: M
MVE.S3)7LYJ^JB5&6IMYI25H6DT4E234$'L$':,0G_P"(K2$J;JF"RB/]<V24
MF,Y);0-@=0:"M23^4*^YRCBXTPQIC1(MNC[!<$W"4V7^>N-P<2$T#SRM@15(
MXE2-JJ4KB\[Q9J%-BY22MEEQ06IIA "&FR1L.5"0-FRN-6[E=5P'YT*^J:EV
MUQE:$B',;'="%#:%%+=<NVB2/RJC36ZO>MI2ZW5S39E*:?ASTQT*5(<4LFFQ
M7 0*'LBO9QI7>#NMTS=+;%LDM<FX1Y<Y,A<G@YL-$U""GC5J:*J."FV;K.9H
M"]7"YS9+TMQF9> F,IUU16JJ6Q7+F/N=HILQ$F7IF/ M-L8[UMEJA)R1HC.S
MBH'94:"JO8   2 ,0]SN_P"T\[J&QVE1-IG0G^8GPTJ.U 4=BD@;!4CBT20H
M)3EG?_<W:8F0]236EQOKZ^2$OR([2_=!AM-4I.S8=G_5FX,72%O9TT-36RZH
M15U+Y9FQG4E1YUEWV59N."1F(%=E0;G_ /<[::N474MUBJA*O%\E(><BLN#C
MAAM%1F)I11(V@$U&S&J=V>\6S3[M:]3.PUN&#)0PM(C$JH5*VU*J'9V*@\.)
M<70^EK_!OJVZ1),NZ(>9;74;5M@54*5V>I,.]NSW.[LN(;$1-MF)BEM0*LY7
MF!S5&6FW90[#79;V+OI*_HFV6T)M-L<3<FDI;0TDAHN #CD&A4?RL;>'%HWC
M72*[-BVU;REL,*2A:^<96V*%6S85 FO8Q$WLN177(4:_?6YBA2>=*.?+O-YO
M<YJ&E>"N+[KR$PN-'N\]Z8AEP@K0'%5RJ(V$CVL:3W0QX3[,W3LJ;(>E+6DM
M/"2I1 0D<84!%:^P?9Q;M7[X-+7B3K.WPF(;PMLYMF%< Q7*7BH%Q /Y609J
M&@)H,:$WB-61=OCZ3BV^/(@L.)R+[T?+I3')KE13BHSU([-<7S7\".Y%CW:8
MN4AAU04M 4 ***=A.SL>O%A^ECX)]9Y_T5_]6<+_ 'U-^ UZENM6K)LZ$U;'
MG7FC!4TDJ4XD)(5SB%[ !LI3'CR__&1?D,-Q4$E+2$H!/"0D4VXOVE(AH_<[
M7-A-DFE%/L+;&WL;58TU;F3DN5@C?4=SBK 2[&E026E-N)X4J*0E8!VY5 G;
MA$!UYM,IU"W&VBL!:D(("E)36I"<R:D;!45X1C6W\0F['2=LU#9-03_JBT39
M]Y,$BW6A2F$\RV([WYMUWG'%*S"J]E.*#B\6?>G9HFG6=YT 7*!%AW#OYA5R
MM*$HD95EMK*MUE7.+3EVE -379OQ/8S:2^S#C5_W?NO[(YC07W>@?JAC<U]"
MU=^QLXW>V&TWRXZ=D+T[?5B=:BR) "5-$H!>;<1E5V>+7V*8.\>_7:\ZLU>E
MA4:/=-02DR'(K*_=MQFT(;:9"ORBA 4=HS44H%&FMY5J:N]L8W;MRFF7E.)2
MAX79Q 6.;4DURJ(VFFW$US=?8X]G5<0T)194XHN!G-DKSBE>YSJI2G#C?)(W
MFVI4^3"O-L:BO-RY4=;27+>@JR\PX@$U -5 _P!F-5?PH7/FJ:6=:N=BD)90
MTY,M$^I0MW($AQUAP%IUV@*CEKP5]3?>% @_7UI.WV# V8F2'VT+=C[M8ZF5
M* )05W9:5%)/ 2-A([&S@QIC[\Z7_;T8T[N4W21(#NL=2,RY@F78N=XPH<0#
MG'5H:(<=<43E;;24BNU:@,;H3O=U#:KV'5ZH5":MMM5",<BU$.*45.NJ6E0*
M0."A'9KLWD_=_3'_ -=8N2+-7ZP,.0(^7AYWFSDI[>:F-+R]W>N[+;;,&'T"
M$[IT2'6'4R7 \AQSOI!4OG,Q42A))-:=G&O=-[V[TB_'>#)[XN*H,,6]MI7,
M)9*FD!QT!PY4K*CPK *@K;C3^G]ZLR%K+0-TN<.PQ+TRT8EWB/2CS<;OMFI:
MD(J E3C>5SA6H$\4[O54.4Z7OX![%0IO&YW_ .V39_U;V([CJ$J4UNR>4V5
M$I4;RA)*?8)!(J.P:8W3./-H6M%KU8I"E)!*5!B, 0>P0"?[3[.-S3K5 O\
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M<BJ45&.\EQ#C;K042H)4G8K:#A&]*#-O%SU:N!(M\RY76:93TQ#[K;F9XJ2
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MSM0D1D*6U'6TM#3Z&U*)9#Z>(G*V<R$"MS_A^T?+4%W"T7*$NXS 5K=ESVW
M[)>H:DJ<65$ [$T2#0#&GM#37D29%EM$"W.O-I*4.+BQT-*6E))("BFH!-0,
M:WU).EM26M5WL75AMM"DEE C-LY%DFA-45J-F'])W26U->>N]TN0=90I"0F;
M*6^E-%$FJ0JA.)NB-V5^1IRZ3U(:=G+;6M0C&O.MH*"E2%+%$YP:A.:E"0H0
M=&:.O.@;?9K<PF/%C,V:X!*$)'MRB2HFJE*)*E*)4HDDG W>:_EAF[+:BO\
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M8L3%_P#I5D^UXGX5N>^]DC[,D^M-^_3QOV=/K/8/\TS]3ZSW#]&GX:?6>?\
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M.S_$0?R5"2SH*^WO4.I5K:$9UV"B%":1FJX5A14XM13L2!05V]CUYN/[E?\
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M' CWV.!'OL<"/?8X$>^QP(]]C@1[[' CWV.!'OL<"/?8X$>^QP(]]C@1[['
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M[#C)6S&N#905%]IA="BA%*I'Y*JE6RFYZ9I:W2[BRS;YC#JHC"WLC@*!E4$
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MX1J:-.DHO#;H?1-2\OGPZ-H7SE<V;VZXA3+MJR[//6YP/15&2H<VX$E.<!-
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M?)UI1(*5/-QG2EMPI% 5H-4D@; 2*X-\UO<Y5UGY0@/2W5.*"1^2FNQ*?:
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M;0IP*"U!*DE&9)]T!A$[?)J2/$U(9LY"FH]MG9.]T2%B.?S;3B:EK*3QJ^R
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MF@&(]@AZJ9YV4^(T>0Y&E-0W'2:!*92VDL&IX#SE#V#@ZGUK-1;[6EYB.7W
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752860032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,145,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592753448416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,689<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">9,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">65,234<span></span>
</td>
<td class="nump">125,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">1,412<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,977<span></span>
</td>
<td class="nump">127,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,199<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,659<span></span>
</td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,781<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,570<span></span>
</td>
<td class="nump">14,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,595,383 and 39,307,286 shares issued and outstanding as of September 30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">433,818<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,905<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(389,320)<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">48,407<span></span>
</td>
<td class="nump">113,684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 66,977<span></span>
</td>
<td class="nump">$ 127,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592750012800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,595,383<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,595,383<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752627008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 19,796<span></span>
</td>
<td class="nump">$ 16,537<span></span>
</td>
<td class="nump">$ 63,931<span></span>
</td>
<td class="nump">$ 50,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
<td class="nump">11,911<span></span>
</td>
<td class="nump">11,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,570<span></span>
</td>
<td class="nump">20,116<span></span>
</td>
<td class="nump">75,842<span></span>
</td>
<td class="nump">62,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,570)<span></span>
</td>
<td class="num">(20,116)<span></span>
</td>
<td class="num">(75,842)<span></span>
</td>
<td class="num">(62,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="num">(2,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">801<span></span>
</td>
<td class="num">(1,108)<span></span>
</td>
<td class="nump">3,802<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,769)<span></span>
</td>
<td class="num">$ (21,224)<span></span>
</td>
<td class="num">$ (72,040)<span></span>
</td>
<td class="num">$ (63,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (1.63)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">44,574,377<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">44,227,264<span></span>
</td>
<td class="nump">29,655,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">44,574,377<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="nump">44,227,264<span></span>
</td>
<td class="nump">29,655,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752807376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,769)<span></span>
</td>
<td class="num">$ (21,224)<span></span>
</td>
<td class="num">$ (72,040)<span></span>
</td>
<td class="num">$ (63,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">870<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (22,846)<span></span>
</td>
<td class="num">$ (20,950)<span></span>
</td>
<td class="num">$ (71,170)<span></span>
</td>
<td class="num">$ (64,067)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592748829200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 324,237<span></span>
</td>
<td class="num">$ (252)<span></span>
</td>
<td class="num">$ (196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with the Company's stock option plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with the Company's stock option plan</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">127,115<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(63,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">108,810<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">369,999<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="num">(260,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's Employee stock purchase plan</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">127,848<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">368,087<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(239,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 108,810<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">369,999<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="num">(260,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 91,218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">429,955<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="num">(342,552)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (72,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">44,595,383<span></span>
</td>
<td class="nump">44,595,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 48,407<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">433,818<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
<td class="num">(389,320)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">91,218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">429,955<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="num">(342,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's Employee stock purchase plan</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,488,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">69,284<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">431,849<span></span>
</td>
<td class="nump">3,982<span></span>
</td>
<td class="num">(366,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">44,595,383<span></span>
</td>
<td class="nump">44,595,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 48,407<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 433,818<span></span>
</td>
<td class="nump">$ 3,905<span></span>
</td>
<td class="num">$ (389,320)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757546416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592750033936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (72,040)<span></span>
</td>
<td class="num">$ (63,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">4,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,464<span></span>
</td>
<td class="nump">6,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">3,881<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(951)<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5,961<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other liabilities</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(56,801)<span></span>
</td>
<td class="num">(50,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Sale of investments - Other</a></td>
<td class="nump">9,796<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">9,627<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $9 and $1,226, respectively</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">39,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of pre-funded warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">39,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(311)<span></span>
</td>
<td class="num">(3,658)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(47,056)<span></span>
</td>
<td class="num">(14,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">86,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">59,689<span></span>
</td>
<td class="nump">72,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752900032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1,226<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757752160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately 80 employees.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $389.3 million as of September 30, 2023 and $317.3 million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through October 31, 2023, Immunic has raised net cash of approximately $355.9 million from private and public offerings of preferred and common stock. As of September 30, 2023, the Company had cash and cash equivalents of approximately $59.7 million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital and such actions are not solely within the control of the Company.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="margin-top:12pt;padding-left:24.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div>Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757863040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $35.4&#160;million, Germany of approximately $22.4&#160;million and Australia of approximately $1.9&#160;million as of September 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of September 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany were earning interest at a rate of 2.00% to 3.25% during the period ended September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:56.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-333">three</span> to thirteen years. Depreciation expense was $34,000 and $17,000 for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense was $88,000 and $58,000 for the nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and nine months ended September 30, 2023 and 2022.</span></div><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.2&#160;million and $2.3&#160;million of <span style="-sec-ix-hidden:f-353"><span style="-sec-ix-hidden:f-354">other income</span></span> related to research activities performed during the three and nine months ended September 30, 2023, respectively and  $0.6&#160;million and $2.0&#160;million  related to research activities performed during the three and nine months ended September 30, 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752584688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592843260384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $209,000 and $232,000 for the three months ended September 30, 2023 and 2022, respectively and $642,000 and $498,000 for the nine months ended September 30, 2023 and 2022, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:84.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $5.1&#160;million, all of which is expected to be paid in the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757752160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.0% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of September 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592843263904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2023, there is $75.0&#160;million remaining on this shelf registration statement. This 2020 Shelf Registration Statement will expire on November 24, 2023. The Company plans to file prior to that expiration date, a new shelf registration statement to replace the expiring Form S-3, which would permit the Company to: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expiring Form S-3; and (ii) offer and sell additional securities to be registered on the new Form S-3.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners LLC) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Prtners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October 31, 2023, $8.1&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC (now Leerink </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Partners</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> LLC)  as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of October 31, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three and nine months ended September 30, 2023, the Company raised gross proceeds of $0.3&#160;million pursuant to the December 2020 ATM through the sale of 107,012 shares of common stock at a weighted average price of $2.72 per share. The net proceeds from the December 2020 ATM were $0.3&#160;million after deducting underwriter commissions of $9,000.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $4.34 per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through September 30, 2023, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of September 30, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,471,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592843260384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This maximum number was increased by 1&#160;million shares in September 2023, subject to approval by stockholders of the Company at the Company's Annual Stockholders meeting to be held in 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 167,642 shares life-to-date under the ESPP.  The Company recognized $19,000 and $102,000 of expense related to the plan during the three and nine months ended September 30, 2023, respectively.  The Company recognized $21,000 and $74,000 of expense related to the plan during the three and nine months ended September 30, 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-515">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:51.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2023 and 2022 was $1.32 and $6.94, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there was $12.7 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.90 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757781616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Changes in Board of Directors<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock', window );">Changes in Board of Directors</a></td>
<td class="text">Changes in Board of Directors<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s initial term lasted until the 2023 Annual Meeting of Stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held on June 28, 2023, at which meeting he was elected to a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three year term expiring at the 2026 Annual Meeting of Stockholders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for MS. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#8216;s extensive leadership in clinical research and development of MS treatments provides valuable clinical, strategy and management skills to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Director Resignation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Vincent Ossipow retired from the Board of Directors on June 28, 2023. Dr. Ossipow&#8217;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ChangesInBoardOfDirectorsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Board of Directors Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ChangesInBoardOfDirectorsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592843234624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#8217;s monthly base salary to $32,368 from $30,250 (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757778096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592750038496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">Basis of Presentation and ConsolidationThe accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock', window );">Cash and Cash Equivalents and Investments- other</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $35.4&#160;million, Germany of approximately $22.4&#160;million and Australia of approximately $1.9&#160;million as of September 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of September 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany were earning interest at a rate of 2.00% to 3.25% during the period ended September 30, 2023.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:56.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-333">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div>Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div>On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.2&#160;million and $2.3&#160;million of <span style="-sec-ix-hidden:f-353"><span style="-sec-ix-hidden:f-354">other income</span></span> related to research activities performed during the three and nine months ended September 30, 2023, respectively and  $0.6&#160;million and $2.0&#160;million  related to research activities performed during the three and nine months ended September 30, 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity, Policy</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592758820512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:56.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.713%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752718432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592758804400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of September 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:84.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592758821344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592758759168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at September 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,471,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752179728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,263,910&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.27</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:51.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,548)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,799,573&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine  Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months<br/>&#160;Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,607,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,464,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752194352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">114 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>employee </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfDevelopmentPrograms', window );">Number of development programs | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (389,320)<span></span>
</td>
<td class="num">$ (317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,689<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 355,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592748603584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,689,000<span></span>
</td>
<td class="nump">$ 106,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,689,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceRate', window );">Government assistance rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount (up to)</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount (up to) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember', window );">Australia and Germany | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember', window );">Australia and Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfFinancialInstitutionsUsedForCashDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592750023904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752779488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock ( in shares)</a></td>
<td class="nump">6,263,910<span></span>
</td>
<td class="nump">3,799,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592749873264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 2,304<span></span>
</td>
<td class="nump">$ 5,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 5,545<span></span>
</td>
<td class="nump">$ 9,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592757488384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 2,846<span></span>
</td>
<td class="nump">$ 3,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 3,199<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752797920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 12,415<span></span>
</td>
<td class="nump">$ 6,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 13,659<span></span>
</td>
<td class="nump">$ 7,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752859568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 923<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592754697792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod', window );">Lessee, operating lease, extended rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember', window );">Planegg, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Additions to right-of-use assets</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752191376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PV of obligation</a></td>
<td class="nump">$ 1,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752288624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 35,031<span></span>
</td>
<td class="nump">$ 85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,031<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,031<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,031<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752546528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional Information (Detail) - United States<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592748294352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationStatementAmountRemaining', window );">Shelf registration statement, amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock at premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 39,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares) | shares</a></td>
<td class="nump">107,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,012<span></span>
</td>
<td class="nump">4,204,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SharesIssuedWeightedAverageSharePricePerShare', window );">Issuance of stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock at premium</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of securities under shelf registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592753419008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Equity Offering (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares) | shares</a></td>
<td class="nump">8,696,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in private placement transaction (in shares)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued in private placement transaction (in shares) | shares</a></td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592755242400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfVotesPerEachShareOfCommonStock', window );">Number of votes per each share of common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfVotesPerEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Per Each Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfVotesPerEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592752770704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592748574096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">10,471,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,263,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2021 Employee stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">32,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">4,085,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592747251648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">45 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increase in other share (in shares)</a></td>
<td class="nump">4,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592754709072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) - 2019 Omnibus Equity Incentive Plan - Outstanding stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,740,564<span></span>
</td>
<td class="nump">1,837,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(268,342)<span></span>
</td>
<td class="num">(194,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">6,263,910<span></span>
</td>
<td class="nump">3,799,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">6,263,910<span></span>
</td>
<td class="nump">3,799,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending balance (in shares)</a></td>
<td class="nump">2,393,294<span></span>
</td>
<td class="nump">1,248,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 11.33<span></span>
</td>
<td class="nump">$ 13.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">1.71<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">7.80<span></span>
</td>
<td class="nump">11.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">7.27<span></span>
</td>
<td class="nump">11.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)</a></td>
<td class="nump">7.27<span></span>
</td>
<td class="nump">11.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted-average exercise price, ending balance (usd per share)</a></td>
<td class="nump">$ 11.67<span></span>
</td>
<td class="nump">$ 13.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">8 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">7 years 1 month 13 days<span></span>
</td>
<td class="text">7 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 119,691<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">119,691<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 6,160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592755042512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.04%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as percent)</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">97.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592749990608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,464<span></span>
</td>
<td class="nump">$ 6,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,687,000<span></span>
</td>
<td class="nump">$ 1,912,000<span></span>
</td>
<td class="nump">5,464,000<span></span>
</td>
<td class="nump">6,043,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">815,000<span></span>
</td>
<td class="nump">831,000<span></span>
</td>
<td class="nump">2,607,000<span></span>
</td>
<td class="nump">2,392,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 872,000<span></span>
</td>
<td class="nump">$ 1,081,000<span></span>
</td>
<td class="nump">$ 2,857,000<span></span>
</td>
<td class="nump">$ 3,651,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592753468704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Changes in Board of Directors (Details)<br></strong></div></th>
<th class="th"><div>Apr. 27, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_RelatedPartyTransactionBoardOfDirectorTerm', window );">Board of director, term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_RelatedPartyTransactionBoardOfDirectorTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Board Of Director, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_RelatedPartyTransactionBoardOfDirectorTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140592750012720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember', window );">Duane Nash, MD, JD, MBA | Forecast | Board of Directors Chairman | Executive Chairman Agreement | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="nump">$ 32,368<span></span>
</td>
<td class="nump">$ 30,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>vtl-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20230930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-04-17</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-27</startDate>
            <endDate>2023-04-27</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>vtl:financialInstitution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="vote">
        <measure>vtl:vote</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-82" id="f-333">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-353">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-5" id="f-354">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-143" id="f-515">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-597" xsi:nil="true"/>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">45145383</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">59689000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">106745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">5545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">65234000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">125864000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">288000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">294000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">1412000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">1552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">66977000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">127753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">3199000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">13659000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">923000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">17781000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">13077000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">789000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">992000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">789000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">18570000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">14069000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-61" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-62" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-63"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-64"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-65" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-66" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-67" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-68" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-69" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">44595383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">44595383</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">39307286</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">433818000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">427925000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">3905000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">3035000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">-389320000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-317280000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">48407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">66977000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">127753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">19796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">16537000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">63931000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-96" unitRef="usd">50520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">3774000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">3579000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">11911000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">11641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">23570000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">20116000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">75842000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">62161000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">-23570000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">-20116000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-75842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">-62161000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">766000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">230000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">2534000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">343000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">35000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">-1338000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">1268000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">-2115000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">801000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">-1108000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">3802000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">-1772000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-22769000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-72040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">-1.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">-1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-133" unitRef="shares">44574377</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-134" unitRef="shares">44574377</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-135" unitRef="shares">30564995</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-136" unitRef="shares">30564995</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-137" unitRef="shares">44227264</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-138" unitRef="shares">44227264</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-139" unitRef="shares">29655946</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-140" unitRef="shares">29655946</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">-22769000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-72040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">870000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">-134000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">-22846000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">-20950000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-71170000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">-64067000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-153" unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-154" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-155" unitRef="usd">427925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-156" unitRef="usd">3035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">-317280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-158" unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-159" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-160" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-161" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-3" id="f-163" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-16"
      decimals="INF"
      id="f-165"
      unitRef="shares">5096552</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-14" decimals="-3" id="f-166" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-168"
      unitRef="shares">44403838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-169" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-170" unitRef="usd">429955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-171" unitRef="usd">3811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">-342552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-173" unitRef="usd">91218000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-174" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-175" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-176" unitRef="usd">1798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-177" unitRef="usd">1798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-25" decimals="-3" id="f-178" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-23" decimals="-3" id="f-179" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-26"
      decimals="INF"
      id="f-180"
      unitRef="shares">84533</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-24" decimals="-3" id="f-181" unitRef="usd">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-182" unitRef="usd">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-183"
      unitRef="shares">44488371</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-184" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-185" unitRef="usd">431849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-186" unitRef="usd">3982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-187" unitRef="usd">-366551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-188" unitRef="usd">69284000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-189" unitRef="usd">-22769000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">-22769000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-191" unitRef="usd">1687000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">1687000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-34"
      decimals="INF"
      id="f-194"
      unitRef="shares">107012</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-33" decimals="-3" id="f-195" unitRef="usd">282000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">282000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-35" decimals="-3" id="f-197" unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-199"
      unitRef="shares">44595383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-200" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-201" unitRef="usd">433818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-202" unitRef="usd">3905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-203" unitRef="usd">-389320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-204" unitRef="usd">48407000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-205"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-206" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-207" unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-208" unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-209" unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-210" unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-211" unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-212" unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-47" decimals="-3" id="f-213" unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="-3" id="f-214" unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-48" decimals="-3" id="f-215" unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-46" decimals="-3" id="f-216" unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-49"
      decimals="INF"
      id="f-217"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-47" decimals="-3" id="f-218" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-46" decimals="-3" id="f-219" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-46" decimals="-3" id="f-220" unitRef="usd">918000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-49"
      decimals="INF"
      id="f-221"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-47" decimals="-3" id="f-222" unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-46" decimals="-3" id="f-223" unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-50"
      decimals="INF"
      id="f-224"
      unitRef="shares">29240383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-225" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-226" unitRef="usd">355949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-227" unitRef="usd">-310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-228" unitRef="usd">-217681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-229" unitRef="usd">137961000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-55" decimals="-3" id="f-230" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-3" id="f-231" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-57" decimals="-3" id="f-232" unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-56" decimals="-3" id="f-233" unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-58" decimals="-3" id="f-234" unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-56" decimals="-3" id="f-235" unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-59"
      decimals="INF"
      id="f-236"
      unitRef="shares">24612</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-57" decimals="-3" id="f-237" unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-56" decimals="-3" id="f-238" unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-56" decimals="-3" id="f-239" unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-59"
      decimals="INF"
      id="f-240"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-57" decimals="-3" id="f-241" unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-56" decimals="-3" id="f-242" unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-60"
      decimals="INF"
      id="f-243"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-244" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-245" unitRef="usd">368087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-62" decimals="-3" id="f-246" unitRef="usd">-660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-63" decimals="-3" id="f-247" unitRef="usd">-239582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-3" id="f-248" unitRef="usd">127848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-65" decimals="-3" id="f-249" unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-250" unitRef="usd">-21224000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-251" unitRef="usd">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-252" unitRef="usd">1912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-67" decimals="-3" id="f-253" unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-254" unitRef="usd">274000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-68"
      decimals="INF"
      id="f-255"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-68" decimals="-3" id="f-256" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-69" decimals="-3" id="f-257" unitRef="usd">369999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-70" decimals="-3" id="f-258" unitRef="usd">-386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-71" decimals="-3" id="f-259" unitRef="usd">-260806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-72" decimals="-3" id="f-260" unitRef="usd">108810000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">-72040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">-63933000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">88000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">58000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">-712000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">-4217000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">5464000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">6043000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">-3881000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-270" unitRef="usd">-2061000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">-951000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-272" unitRef="usd">1151000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">5961000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c-7" decimals="-3" id="f-274" unitRef="usd">465000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">84000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">-102000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">-56801000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-278" unitRef="usd">-50040000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">169000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-280" unitRef="usd">113000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">9796000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">0</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">9627000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">-113000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">9000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">1226000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">282000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">39584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">51000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">96000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">130000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">429000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">39719000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-311000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">-3658000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">-47056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">-14092000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-301" unitRef="usd">106745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-302" unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-303" unitRef="usd">59689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-72" decimals="-3" id="f-304" unitRef="usd">72771000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">544000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-307">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany. The Company currently has approximately 80 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#x201c;MS&#x201d;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#x201c;UC&#x201d;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#x2019;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $389.3 million as of September 30, 2023 and $317.3 million as of December 31, 2022.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through October 31, 2023, Immunic has raised net cash of approximately $355.9 million from private and public offerings of preferred and common stock. As of September 30, 2023, the Company had cash and cash equivalents of approximately $59.7 million.  With these funds, the Company does not have adequate liquidity to fund its operations for at least twelve months from the issuance of these financial statements without raising additional capital and such actions are not solely within the control of the Company.  If the Company is unable to obtain additional capital, it would have a material adverse effect on the operations of the Company, its clinical development program, and the Company may have to cease operations altogether. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:24.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="c-3"
      decimals="INF"
      id="f-308"
      unitRef="employee">80</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentPrograms contextRef="c-3" decimals="INF" id="f-309" unitRef="lease">3</vtl:NumberOfDevelopmentPrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-310" unitRef="usd">-389300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-311" unitRef="usd">-317300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-73" decimals="-5" id="f-312" unitRef="usd">355900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-313" unitRef="usd">59700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-314">Basis of Presentation and ConsolidationThe accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-315">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments - other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $35.4&#160;million, Germany of approximately $22.4&#160;million and Australia of approximately $1.9&#160;million as of September 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of September 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany were earning interest at a rate of 2.00% to 3.25% during the period ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-333"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $34,000 and $17,000 for the three months ended September 30, 2023 and 2022, respectively. Depreciation expense was $88,000 and $58,000 for the nine months ended September 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and nine months ended September 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 20, 2022, the Company announced the outcome of a significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.2&#160;million and $2.3&#160;million of &lt;span style="-sec-ix-hidden:f-353"&gt;&lt;span style="-sec-ix-hidden:f-354"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three and nine months ended September 30, 2023, respectively and  $0.6&#160;million and $2.0&#160;million  related to research activities performed during the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-316">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-317">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock contextRef="c-1" id="f-318">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments - other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $35.4&#160;million, Germany of approximately $22.4&#160;million and Australia of approximately $1.9&#160;million as of September 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of September 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany were earning interest at a rate of 2.00% to 3.25% during the period ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-74" decimals="-5" id="f-319" unitRef="usd">35400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-75" decimals="-5" id="f-320" unitRef="usd">22400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-76" decimals="-5" id="f-321" unitRef="usd">1900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtl:NumberOfFinancialInstitutionsUsedForCashDeposit
      contextRef="c-3"
      decimals="INF"
      id="f-322"
      unitRef="financialinstitution">2</vtl:NumberOfFinancialInstitutionsUsedForCashDeposit>
    <us-gaap:InvestmentInterestRate contextRef="c-77" decimals="3" id="f-323" unitRef="number">0.050</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-78" decimals="4" id="f-324" unitRef="number">0.0200</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-79" decimals="4" id="f-325" unitRef="number">0.0325</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentTableTextBlock contextRef="c-1" id="f-326">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.489%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.713%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:OtherShortTermInvestments contextRef="c-80" decimals="-3" id="f-327" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-81" decimals="-3" id="f-328" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-331">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-332">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-333"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-83" id="f-334">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-335" unitRef="usd">34000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-336" unitRef="usd">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">88000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-338" unitRef="usd">58000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-339">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-340" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-7" decimals="INF" id="f-341" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-6" decimals="INF" id="f-342" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-5" decimals="INF" id="f-343" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-344">&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-84" decimals="-5" id="f-345" unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-346">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-347">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.2&#160;million and $2.3&#160;million of &lt;span style="-sec-ix-hidden:f-353"&gt;&lt;span style="-sec-ix-hidden:f-354"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three and nine months ended September 30, 2023, respectively and  $0.6&#160;million and $2.0&#160;million  related to research activities performed during the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <vtl:GovernmentAssistanceRate contextRef="c-1" decimals="3" id="f-349" unitRef="number">0.435</vtl:GovernmentAssistanceRate>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-85" decimals="INF" id="f-350" unitRef="eur">1000000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-5" decimals="-5" id="f-351" unitRef="usd">200000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-1" decimals="-5" id="f-352" unitRef="usd">2300000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-6" decimals="-5" id="f-355" unitRef="usd">600000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-7" decimals="-5" id="f-356" unitRef="usd">2000000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-357">General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-358">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-359">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-82" id="f-360">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-83" id="f-361">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases contextRef="c-3" decimals="INF" id="f-362" unitRef="lease">3</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-363">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-364">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of September 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-365">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-86"
      decimals="INF"
      id="f-366"
      unitRef="shares">5096552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-367">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-368">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-87" decimals="0" id="f-369" unitRef="shares">6263910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-88" decimals="0" id="f-370" unitRef="shares">3799573</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-371">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-372">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-373">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-3" decimals="-3" id="f-374" unitRef="usd">2304000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-4" decimals="-3" id="f-375" unitRef="usd">5608000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-3" decimals="-3" id="f-376" unitRef="usd">1187000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-4" decimals="-3" id="f-377" unitRef="usd">296000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent contextRef="c-3" decimals="-3" id="f-378" unitRef="usd">607000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">2361000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-380" unitRef="usd">1447000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">1225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-382" unitRef="usd">5545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-384">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-385" unitRef="usd">2846000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-386" unitRef="usd">3749000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-387" unitRef="usd">71000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-388" unitRef="usd">288000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-3" decimals="-3" id="f-389" unitRef="usd">282000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-4" decimals="-3" id="f-390" unitRef="usd">244000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-391" unitRef="usd">3199000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-392" unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-3" decimals="-3" id="f-393" unitRef="usd">12415000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">6807000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-3" decimals="-3" id="f-395" unitRef="usd">78000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">169000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">1049000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-4" decimals="-3" id="f-398" unitRef="usd">890000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">117000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-400" unitRef="usd">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-401" unitRef="usd">13659000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-402" unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-403">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-404" unitRef="usd">662000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-405" unitRef="usd">571000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-406" unitRef="usd">261000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-407" unitRef="usd">239000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-408" unitRef="usd">923000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-409" unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-410">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#xe4;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $209,000 and $232,000 for the three months ended September 30, 2023 and 2022, respectively and $642,000 and $498,000 for the nine months ended September 30, 2023 and 2022, respectively.  Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of September 30, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $5.1&#160;million, all of which is expected to be paid in the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-89" id="f-411">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-90" id="f-412">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod contextRef="c-91" id="f-413">P6M</vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod>
    <vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod contextRef="c-1" id="f-414">P3M</vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-89" id="f-415">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-92" decimals="-3" id="f-416" unitRef="usd">544000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-3" decimals="2" id="f-417" unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-89" decimals="2" id="f-418" unitRef="number">0.08</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-5" decimals="-3" id="f-419" unitRef="usd">209000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-6" decimals="-3" id="f-420" unitRef="usd">232000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-1" decimals="-3" id="f-421" unitRef="usd">642000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-7" decimals="-3" id="f-422" unitRef="usd">498000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-423">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of September 30, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.079%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-424" unitRef="usd">189000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-425" unitRef="usd">758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-426" unitRef="usd">433000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-427" unitRef="usd">78000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-428" unitRef="usd">82000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour contextRef="c-3" decimals="-3" id="f-429" unitRef="usd">55000</vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-430" unitRef="usd">1595000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-431" unitRef="usd">144000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-432" unitRef="usd">1451000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation contextRef="c-3" decimals="-5" id="f-433" unitRef="usd">5100000</us-gaap:ContractualObligation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-434">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.0% in a U.S. Government money market fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of September 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-436" unitRef="usd">35031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-437" unitRef="usd">35031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-440" unitRef="usd">35031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-441" unitRef="usd">35031000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-99" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-100" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-101" decimals="-3" id="f-444" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-102" decimals="-3" id="f-445" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-103" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-104" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-105" decimals="-3" id="f-448" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-106" decimals="-3" id="f-449" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-107" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-108" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentInterestRate contextRef="c-74" decimals="3" id="f-452" unitRef="number">0.050</us-gaap:InvestmentInterestRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-453">Common Stock&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of October 31, 2023, there is $75.0&#160;million remaining on this shelf registration statement. This 2020 Shelf Registration Statement will expire on November 24, 2023. The Company plans to file prior to that expiration date, a new shelf registration statement to replace the expiring Form S-3, which would permit the Company to: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expiring Form S-3; and (ii) offer and sell additional securities to be registered on the new Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners LLC) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by Leerink Prtners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of October 31, 2023, $8.1&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC (now Leerink &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;Partners&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; LLC)  as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of October 31, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three and nine months ended September 30, 2023, the Company raised gross proceeds of $0.3&#160;million pursuant to the December 2020 ATM through the sale of 107,012 shares of common stock at a weighted average price of $2.72 per share. The net proceeds from the December 2020 ATM were $0.3&#160;million after deducting underwriter commissions of $9,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended September 30, 2022, the Company did not raise any proceeds under its ATM facilities.  In the nine months ended September 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;$60 Million Private Placement Equity Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) for a private placement (the &#x201c;Private Placement&#x201d;) with select accredited investors and certain existing investors (each, a &#x201c;Purchaser&#x201d; and collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase Common Stock (the &#x201c;Warrant Shares&#x201d; and together with the Shares and the Pre-Funded Warrants, the &#x201c;Securities&#x201d;), at a purchase price of $4.34 per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. Through September 30, 2023, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at September 30, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,471,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-109" decimals="-5" id="f-454" unitRef="usd">250000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationStatementAmountRemaining contextRef="c-110" decimals="-5" id="f-455" unitRef="usd">75000000</vtl:ShelfRegistrationStatementAmountRemaining>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-111" decimals="-5" id="f-456" unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice contextRef="c-112" decimals="INF" id="f-457" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-113" decimals="-5" id="f-458" unitRef="usd">8100000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-114" decimals="-5" id="f-459" unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice contextRef="c-115" decimals="INF" id="f-460" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-116" decimals="-5" id="f-461" unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock contextRef="c-1" decimals="3" id="f-462" unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-117" decimals="-5" id="f-463" unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-118" decimals="-5" id="f-464" unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-117"
      decimals="INF"
      id="f-465"
      unitRef="shares">107012</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-118"
      decimals="INF"
      id="f-466"
      unitRef="shares">107012</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="c-117"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">2.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="c-118"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">2.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-117" decimals="-5" id="f-469" unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-118" decimals="-5" id="f-470" unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions contextRef="c-118" decimals="-3" id="f-471" unitRef="usd">9000</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsForCommissions contextRef="c-117" decimals="-3" id="f-472" unitRef="usd">9000</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-119" decimals="-5" id="f-473" unitRef="usd">40900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-119"
      decimals="INF"
      id="f-474"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="c-119"
      decimals="2"
      id="f-475"
      unitRef="usdPerShare">9.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-119" decimals="-5" id="f-476" unitRef="usd">39600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions contextRef="c-119" decimals="-5" id="f-477" unitRef="usd">1200000</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-120"
      decimals="INF"
      id="f-478"
      unitRef="shares">8696552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-121"
      decimals="INF"
      id="f-479"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="c-121"
      decimals="INF"
      id="f-480"
      unitRef="usdPerShare">4.35</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-122"
      decimals="INF"
      id="f-481"
      unitRef="shares">5096552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="c-123"
      decimals="INF"
      id="f-482"
      unitRef="usdPerShare">4.34</us-gaap:SharePrice>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-483" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-484"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vtl:NumberOfVotesPerEachShareOfCommonStock contextRef="c-3" decimals="INF" id="f-485" unitRef="vote">1</vtl:NumberOfVotesPerEachShareOfCommonStock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-486"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-487"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-488" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-489"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-490" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-491">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at September 30, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,085,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,471,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-124"
      decimals="INF"
      id="f-492"
      unitRef="shares">32358</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-125"
      decimals="INF"
      id="f-493"
      unitRef="shares">6263910</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-126"
      decimals="INF"
      id="f-494"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-127"
      decimals="INF"
      id="f-495"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-128"
      decimals="INF"
      id="f-496"
      unitRef="shares">4085919</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-497" unitRef="shares">10471748</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-498">Stock-Based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This maximum number was increased by 1&#160;million shares in September 2023, subject to approval by stockholders of the Company at the Company's Annual Stockholders meeting to be held in 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 167,642 shares life-to-date under the ESPP.  The Company recognized $19,000 and $102,000 of expense related to the plan during the three and nine months ended September 30, 2023, respectively.  The Company recognized $21,000 and $74,000 of expense related to the plan during the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:f-515"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,740,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the nine months ended September 30, 2023 and 2022 was $1.32 and $6.94, respectively. The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2023, there was $12.7 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.90 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital Therapies ("Vital") on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three and nine months ended September 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-129"
      decimals="INF"
      id="f-499"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-129"
      decimals="INF"
      id="f-500"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-130"
      decimals="INF"
      id="f-501"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-131"
      decimals="INF"
      id="f-502"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-132"
      decimals="INF"
      id="f-503"
      unitRef="shares">167642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-504" unitRef="usd">19000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-505" unitRef="usd">102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-506" unitRef="usd">21000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-507" unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-137"
      decimals="INF"
      id="f-508"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="c-138"
      decimals="INF"
      id="f-509"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-138"
      decimals="INF"
      id="f-510"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-139"
      decimals="INF"
      id="f-511"
      unitRef="shares">4408871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-140"
      decimals="INF"
      id="f-512"
      unitRef="shares">4440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-141" id="f-513">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-142" id="f-514">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-144" id="f-516">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,740,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,263,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.27&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.570%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,799,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.59&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-145"
      decimals="INF"
      id="f-518"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-145"
      decimals="2"
      id="f-519"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-146"
      decimals="INF"
      id="f-520"
      unitRef="shares">2740564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-146"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">1.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-146"
      decimals="INF"
      id="f-522"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-146"
      decimals="2"
      id="f-523"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-146"
      decimals="INF"
      id="f-524"
      unitRef="shares">268342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-146"
      decimals="2"
      id="f-525"
      unitRef="usdPerShare">7.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-147"
      decimals="INF"
      id="f-526"
      unitRef="shares">6263910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-147"
      decimals="2"
      id="f-527"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-146" id="f-528">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-147" decimals="0" id="f-529" unitRef="usd">119691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-147"
      decimals="INF"
      id="f-530"
      unitRef="shares">6263910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-147"
      decimals="2"
      id="f-531"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-146" id="f-532">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-147" decimals="0" id="f-533" unitRef="usd">119691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-147"
      decimals="INF"
      id="f-534"
      unitRef="shares">2393294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-147"
      decimals="2"
      id="f-535"
      unitRef="usdPerShare">11.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-146" id="f-536">P7Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-147" decimals="0" id="f-537" unitRef="usd">6160</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-148"
      decimals="INF"
      id="f-538"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-148"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-149"
      decimals="INF"
      id="f-540"
      unitRef="shares">1837513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-149"
      decimals="2"
      id="f-541"
      unitRef="usdPerShare">8.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-149"
      decimals="INF"
      id="f-542"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-149"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-149"
      decimals="INF"
      id="f-544"
      unitRef="shares">194548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-149"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">11.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-150"
      decimals="INF"
      id="f-546"
      unitRef="shares">3799573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-150"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">11.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-149" id="f-548">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-150" decimals="0" id="f-549" unitRef="usd">2400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-150"
      decimals="INF"
      id="f-550"
      unitRef="shares">3799573</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-150"
      decimals="2"
      id="f-551"
      unitRef="usdPerShare">11.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-149" id="f-552">P8Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-150" decimals="0" id="f-553" unitRef="usd">2400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-150"
      decimals="INF"
      id="f-554"
      unitRef="shares">1248875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-150"
      decimals="2"
      id="f-555"
      unitRef="usdPerShare">13.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-149" id="f-556">P7Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-150" decimals="0" id="f-557" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-558" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-151"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">1.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-152"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-561">The following are the underlying assumptions used in the Black-Scholes-Merton option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine  Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-151" decimals="4" id="f-562" unitRef="number">0.0400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-152" decimals="4" id="f-563" unitRef="number">0.0204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-151"
      decimals="INF"
      id="f-564"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-152"
      decimals="INF"
      id="f-565"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-151" decimals="3" id="f-566" unitRef="number">0.960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-152" decimals="3" id="f-567" unitRef="number">0.978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-151" id="f-568">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-152" id="f-569">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-570">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months&lt;br/&gt;&#160;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;815,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;831,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,607,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,857,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,464,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c-153" decimals="-3" id="f-571" unitRef="usd">815000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-154" decimals="-3" id="f-572" unitRef="usd">831000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-155" decimals="-3" id="f-573" unitRef="usd">2607000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-156" decimals="-3" id="f-574" unitRef="usd">2392000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-157" decimals="-3" id="f-575" unitRef="usd">872000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-158" decimals="-3" id="f-576" unitRef="usd">1081000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-159" decimals="-3" id="f-577" unitRef="usd">2857000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-160" decimals="-3" id="f-578" unitRef="usd">3651000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-161" decimals="-3" id="f-579" unitRef="usd">1687000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-162" decimals="-3" id="f-580" unitRef="usd">1912000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-163" decimals="-3" id="f-581" unitRef="usd">5464000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-164" decimals="-3" id="f-582" unitRef="usd">6043000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-583" unitRef="usd">12700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-584">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-165"
      decimals="INF"
      id="f-585"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-166"
      decimals="INF"
      id="f-586"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-167" decimals="INF" id="f-587" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-168" decimals="INF" id="f-588" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-169" decimals="INF" id="f-589" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="INF" id="f-590" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <vtl:ChangesInBoardOfDirectorsDisclosureTextBlock contextRef="c-1" id="f-591">Changes in Board of Directors&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Appointment of Richard Rudick, M.D. to Board of Directors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 27, 2023, the Company announced the appointment of Dr. Richard Rudick as a member of the Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#x2019;s initial term lasted until the 2023 Annual Meeting of Stockholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;held on June 28, 2023, at which meeting he was elected to a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three year term expiring at the 2026 Annual Meeting of Stockholders. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for MS. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#x2018;s extensive leadership in clinical research and development of MS treatments provides valuable clinical, strategy and management skills to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Director Resignation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dr. Vincent Ossipow retired from the Board of Directors on June 28, 2023. Dr. Ossipow&#x2019;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#x2019;s operations, policies or practices.&lt;/span&gt;&lt;/div&gt;</vtl:ChangesInBoardOfDirectorsDisclosureTextBlock>
    <vtl:RelatedPartyTransactionBoardOfDirectorTerm contextRef="c-171" id="f-592">P3Y</vtl:RelatedPartyTransactionBoardOfDirectorTerm>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-593">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#x2019;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#x2019;s monthly base salary to $32,368 from $30,250 (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <vtl:SalaryCostsMonthlyBaseSalary contextRef="c-172" decimals="0" id="f-594" unitRef="usd">30250</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary contextRef="c-173" decimals="0" id="f-595" unitRef="usd">32368</vtl:SalaryCostsMonthlyBaseSalary>
    <vtl:SalaryCostsMonthlyBaseSalary contextRef="c-172" decimals="0" id="f-596" unitRef="usd">30250</vtl:SalaryCostsMonthlyBaseSalary>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<"RW\- ^'G&QO><(QS Z;FETW /IG ^,FP3N7LH#<H]61CRH+F-I>ES<JPP
MT,\A0V[MD@<$]@Y"/*XN6.EU7-R9;$W.;O_$4N\'Y)I-RIJN-6V+1]8%W3G]
MJF1VA@"K '04^^*5_":L$^H!*;/U8#WG[,RZ4\:#_R]G:^=4U"QXV6%Q0CR3
M@<T/2(NGQ8'T(#N&;96?YZ?9=]RLEPD)Q0Q"G=,SF/!4?D"<WVBYS,Y8IU)K
M&667"\%]H<P'\'XFI=[>F!\HCNG[_P%02P,$%     @ 8#MN5QV;RPS&!0
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M*6M#IWLNQ%;ZV7Q($E'K0[>DC_0V8T:'R23B+H['O&"0\DB$9U:E)S!L9S
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M5'F7*3M&YL5U8"8-7BZ*9HKW/U V .?G4IJ7CKUAU#?*Z"]02P,$%     @
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MO-0 >+\20KW>Z ;:(\C9/U!+ P04    " !@.VY7 MPTP3 #  !C"P  &
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M_,P_[BOB* %A)Q+0?0(Z-@';)V!6 AJ?2,#W";B5@(L3":)]@LCV<*K08I]
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MC*FA2:SDBBCKC6QVXHKIT)@^$[;M4Z-PER'.)",I,FPB9 1G6G*648/&U."
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ML'1Z;K7).<<<?8J\95]WG'Z[DQ'+GZA\"[&Z9V76<VD[]4++K>XXN=Z7(DJ
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M%>!,=;#:E=UL=;-7G056_V)48=H.](LR84_=E$H[T"1;W!)GZ4[IY1)DG58
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M?>Z1D@GYTX9*1D3 VI(;,P==1RP$H:/I8#[U_RZ-J-QA*V[2\06_@N, >J4
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M@XWD(.5'N_DE7SJ^)80E9L8B<%H><8ME:8&(QI\#IC.YM(:7[R/ZJRYVBN7
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M_]VJ/*SIK72:/>G^P'/R<#IYPF-!8@^G9U/^TN2Y,YA(!>]+\.S0HT)G?)1
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M93QU3&&84XN*E@_0?F:,;R=LH&MZE_\!4$L#!!0    ( & [;E<.GQB/N H
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M^HR;BW.!M3']&8D'OX>\"L.O#]QN]X,I[2]K9V04VF@<@DI"S]<;L07KT9"
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M+W-H965T,3<N>&ULI5;;<MLV$/T5##.3)Y62Y6L26S.VG+3.C&J/U3@/G3Y
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M8@%\7QI,E.Z%#?0[_.1O4$L#!!0    ( & [;E=9Y.J#$@0  $8*   9
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M(6$/?416ETZOHZH'-\L>_$:_F\4<WGJ;-Z_&23*X.A6;8#*\>A=8EI6QA.>
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M;MLP$$5_A6"!K@I3EMVT<24!=IJB700P8K19%%W0TM@BPH="CJST[T-2LNH
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M4(+TX]#>KMT&#, I>M,B0Q+PBXC].Q)WDN$EZ(>^%=&/BP322^2V<K8FF>_
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M'Y"3DLTB!3 UJP!-W[7TCQF<B5W&?>#\78[1ZRSS"L19U)E?@F[9>LU0\#$
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M;^!E\$%5]F3@;55@\4_[@+@-!-F%X)J- NZPOH%)Z ,+V60$;S($/&GQ)M_
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M]D@#2H<&E!YO0/@TJ#?( BE\87SC;XR%QN[04_VL_]WS?1LZCOMMQ\'V[+K
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MXAH_9T#9#;B^E-+L!]; \($T_P=02P,$%     @ 8#MN5W?)O92G P  ,0X
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M6:/<[/\^WF9#"C\D6#@06$MXU_EQ271ZB_91\ @@EF0G>$:8E"7>!T%OZ87
M5:N %"G.GEVIYQK]?"GY03!S+C::=7\4MTHV%%JEF7UVQ\Y [,U;19*(E[FJ
MKMO-:/,>>C"O /N'>?68>D?%GN42S[T=NCIW$SQX1/4^J3J*%^;&ON4*[_^F
MF>";#H0VP.\[SM6IHR=H7HG+_P!02P,$%     @ 8#MN5[B3CA[R"0  (6T
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M:0+P_D((O=N8N=]^YI._4$L#!!0    ( & [;E?71INOLP(   L'   9
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M"FT2$Q6![6':@YO<-A:.G=E.R_;K=^V$K(50[6$OB3_N.3[WY/IFO)'J41<
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M=ZO:W4W3M!<&#A#=).;:IK3??G:2!D)3 ^K9FY($_W_'\?D3.Z<>;!C_+I8
MDKPD<2J&UE+*U76S*:9+2*AHL!6DZILYXPF5ZI0OFF+%@<XR41(W7=ON-A,:
MI=9HD%U[X*,!6\LX2N&!$[%.$LI?;R%FFZ'E6&\7'J/%4NH+S=%@11?P!/+;
MZH&KLV9)F44)I")B*>$P'UHWSG7H]+4@:_%G!!NQ<TSTK4P8^ZY/[F9#R]8]
M@ABF4B.H^GB&,<2Q)JE^_"B@5AE3"W>/W^A!=O/J9B94P)C%?T4SN1Q:?8O,
M8$[7L7QDFU^AN*&.YDU9++*_9%.TM2TR70O)DD*L>I!$:?Y)7XJ!V!$H3KW
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M&ZCOYXS)MQ,=H-R7-_H/4$L#!!0    ( & [;E>U3_C)L0(  ,D'   9
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MLN!RH"L7S;W1!(I7ME<ON-*=WPX+?=>", OT_(IS]1:8]M_>WMEO4$L#!!0
M   ( & [;E<D>PN]WP,  / 6   9    >&PO=V]R:W-H965T<R]S:&5E=#,W
M+GAM;+58:V^C.!3]*Q8[6LU(G?(*:=I-D*:MJEEI*E7-/#Z[<)-8!9RU33(C
M[8]?&RC@#7%+Y/F2\+CG<(]]$A\\WU/VS#<  OW,LX(OG(T0VRO7Y<D&<LS/
MZ18*>6=%68Z%/&5KEV\9X+0"Y9D;>-[4S3$IG'A>77M@\9R6(B,%/##$RSS'
M[-<U9'2_<'SGY<(C66^$NN#&\RU>PQ+$M^T#DV=NRY*2' I.:($8K!;.)__J
M)I@H0%7QG<">]XZ1DO)$Z;,Z^3M=.)[J"#)(A*+ \FL'-Y!EBDGV\4]#ZK3/
M5,#^\0O[725>BGG"'&YH]H.D8K-P9@Y*887+3#S2_6=H!$6*+Z$9KS[1OJGU
M')247-"\ <L.<E+4W_AG,Q ]@#\Y @@:0/!60-@ PDIHW5DEZQ8+',\9W2.F
MJB6;.JC&ID)+-:10T[@43-XE$B?B.TP8^HZS$M!'M)0F2<L,$%VA.U+@(B$X
M0Y\X!\$1+E+TA> GDA%!@*-[P+QDD"(L4(]%3LTC)"5CI%BC:\P)1^]O06"2
M\0_R$5WEV0N#-(7@9SW41_1M>8O>O_N WB%2H*\;6G+Y=#YWA52L^G:31MUU
MK2XXHFX)VW,4>F<H\()P 'YCAM]"(N%^!0]TN"O'N1WLH!WLH.(+C_#5(SDD
MH\9-AG'JIWS%MSB!A2-_JQS8#ISXSS_\J??7D"A+9)K$L)48FMCCKU1(R^#&
M,@*MU'SOU'P/R:ZYIA67^L/9Q6'DA?[<W?7U'%;-HBCHJK1&)VVC$V.C7V '
M&?*'NC("QTZ&)3)-8]1JC$[T6V13HB4R3>*TE3BUZ+>:*WK%;X=5!K]=M(U>
MO.ZW6G8PU)H1/79&+)%I0F>MT-F)IIO9E&B)3)-XV4J\M&BZRP,[>?\SG*E"
M:]#WNF7=>ZO=AA:^:S-\[&388M/%]C*,?Z+E&J MF9;8=)E=>O"-*_=(VS5D
M)M\92_0FN_7?-P> >UK +YE0V;-\!UF5QV*;D63TO%ABTR5W2<*?G&H_JU'"
M%ILNLPL3OG$A'VN_Z$UK[4"98;'UNUC@FW/!H0W1O\B0^<QTHV?*$ILNOHL:
M_L6IAK0:,VRQZ3*[H.$;%_FQAIR]S9"'929#=I'!-V>&XX8TA$(SY^CILL2F
MO_MVD23P3GW[M1I&;+'I,KLP$AA3P$A7-F2F5=I8HC?9VX@P1XG7W#B8&<V<
MHZ?I=VQ3!%U."<)3W6@UF]ABTV5VV20P;W.,=./D8*OEP(VFDKI)M[<=J?:"
M[S%;DX*C#%82XYU?2"NS>GNU/A%T6^U0/E$A:%X=;@"GP%2!O+^B5+R<J$W/
M=I,[_@]02P,$%     @ 8#MN5_DC>V%B @  =08  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S@N>&ULS55M:]LP$/XKPH.Q01<[SLM&YAB2EK) ,T)"NP]C
M'Q3[DHC(DB>=D_;?[R2[)H,T&V.#?;%UTMUSSR.=3LE1F[W= 2![+*2RXV"'
M6(["T&8[*+CMZ!(4K6RT*3B2:;:A+0WPW <5,HRC:!@67*@@3?S<PJ2)KE *
M!0O#;%44W#Q-0>KC..@&SQ-+L=VAFPC3I.1;6 '>EPM#5MBBY*( 9856S,!F
M'$RZH^G0^7N'!P%'>S)F3LE:Z[TS9ODXB!PAD)"A0^#T.\ U2.F B,;W!C-H
M4[K T_$S^JW73EK6W,*UEE]$CKMQ\"%@.6QX)7&ICY^@T3-P>)F6UG_9L?&-
M I95%G71!!.#0JCZSQ^;?3@)Z/9?"(B;@-CSKA-YEC<<>9H8?63&>1.:&WBI
M/IK(">4.986&5@7%87K+A6$/7%; WK%)G@NW5URRF:H/W.W<FQM +N1;\KA7
M B%G*^0(-@F1&#B<,&NR3>ML\0O95E!V6"^Z8G$4]WX.#XEXRSYNV<<>K_=+
M]E=L8BV@95SE[$[PM9 D!2R; [>5(<XD9 E998Q06^_U62O33DRY%99]O:,$
M;(90V&_GU-5L^N?9N/LSLB7/8!S0!;%@#A"DKU]UA]''"UI[K=;>)?1TI@Y@
MD>X#,J$0* $R0\=PCF>-U(T\E+N7AS3J1(,D/)PAT&\)]"\2F&L%3U1[9D^]
M8E.I_&P!7,3XPRT:M P'_U4Y#/Z!UF&K=?C7RF'X6^40GG01UY#GW&R%LDS"
MAL*BSGN2:^HF5QNH2]]8UAJI3?GACMX%,,Z!UC=:X[/A>E7[TJ0_ %!+ P04
M    " !@.VY7Q2*%U? '  !N4@  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6S%G%UOHT84AO_*R%U56RF- 7^GB:5-^%:W7:UWVXNJ%P2/;;0&O,PX
MV4C]\9T! L;&8[MZ5\U%8O"<YPS.>V!F7LSM<YI]82M*.?D6KQ-VUUEQOKGI
M=EFXHG' KM,-3<0[BS2+ RXVLV67;3(:S/.@>-TU-&W8C8,HZ4QO\WT?LNEM
MNN7K**$?,L*V<1QD+_=TG3[?=?3.ZXZ/T7+%Y8[N]'83+.F,\L^;#YG8ZE:4
M>133A$5I0C*ZN.N\TV]\8R0#\A9_1/29[;PF\E >T_2+W/#F=QU-]HBN:<@E
M(A!_GN@#7:\E2?3C:PGM5#EEX.[K5[J='[PXF,> T8=T_6<TYZN[SKA#YG01
M;-?\8_KLTO* !I(7IFN6_R;/95NM0\(MXVE<!HL>Q%%2_ V^E1_$3D#?.!)@
ME '&7H!Q+*!7!O3.S= O _K[ <>.85 &#,[MTK ,&)X;,"H#1OL!^I& <1DP
M/C?#I R8G!N@:Z__.2U74/$OS_5B!CR8WF;I,\ED>\&3+W+1Y?%")E$BZV/&
M,_%N).+X]"&-8R'3&4_#+^1G,EO1]8)\I,N(\2S(%3SC :>B(CAY:U(>1&OV
M$WE#NH2M@HPR$B7D<Q)Q=B5VBM>?5NF6!<F<W7:YZ)Y,T@W+KMP773&.=*5'
MWJ<)7S%B)7,Z;XDWU?$317Q7?"S59V.\?C;WAA(XHYMKTM.NB*$9/?)Y9I*W
M;WXB\]VC+_ZT]/5!C7X?9 *MYVCC%=UVR-^OA];YZ*J'9X%M-?CWD%>'WE,<
MNG,^1O4)NJ?^$2]$UTY2/#7%I&'5&4V!\=68W]*GZC,_@FD(N5<5>2_G]HX5
M^3I@C*2+LLS_^E6\3SQ1U>SOMC(M8/UVF+Q@W[!-$-*[CK@B,YH]T<[TQQ_T
MH?9+6QT@82829B%A-A+F(&$N$N8A83X(UBB)?E42?15=U/VW*-[&)%@N,[H4
M5SA1'@N:1<F2;+(HE)N$T7";13P2)[NMN*2(465^=<QVKHYMY:-,?&GY(&$F
M$F8A8382YB!A+A+F(6%^ 1OF,#D->IH: TW\W':?6@IC4!7&0%D8LP.-$_8Z
M KPB09QNQ4@PHW+J)8JE3?]*_J7Z1\),),Q"PFPDS!D<"&,TV-5%(6QD2@\)
M\T&PAOR'E?R'2OG+^5#$Y.S_BFQH%LIYC[@4++-4C* V61I2.F=DD:4Q8<$Z
MOTR$Q12*R;%56STH$UY:#TB86<#DE+)2BG:M]9I"L9 I;23,0<)<),Q#PGP0
MK%$/HZH>1B<N!\4LG[$MG9.W8H9?S/O:9C?W2M2E2A\=G,4&36&:R'06$F8C
M80X2YB)A'A+F@V -E8\KE8^5*O_0.+%+L0=)>'!R)P$7EP :1]NX3?W*%)>J
M'PDSQX<CQ;&Q=Y8_;-.;#,;]9BL;V2T'"7.1, \)\T&PAK GE; G2F&;-*3Q
MHYBZYBM*[SZ];Q.N$G&I<)$P$PFSD# ;"7.0,!<)\Y P'P1K%(*NU4:'AEP$
M+6F@JH#23"C-@M)L*,V!TEPHS8/2?!2M61T[-J#^?ZV'JC-?7$E(F@FE65":
M#:4Y4)H+I7DEK3'7TPY6K'Q4TF:)&'6)&!>NC%X13K,X2LH-42AI1IY%B7":
MD"3ELF[^(6U6]GV9:[!SR/K>\3ZH^W.QU$]GM* 9;2C-@=)<*,V#TGP4K:GS
MVBS6E<;;94L^):LQ;]POW =UPHN%?$9*JZ517YOL-[.A/7.@-!=*\Z T'T5K
M2K0V;W6U>UL,X0\5*LZV1V]+N2^9S1/@2-.-?;5"/=<SLUHM[?J&UM?UWKYD
MH5XIE.9":1Z4YJ-H3<G6MJJN]E6]G47%8C51ZE;>X[/)1])"M5*^]0U6K1(N
M<HQW5_*N1P<"AIJF9^6T6EI-1"MMYT??%S+4](327"C-@])\%*TIY-H@U=4.
M*62MO,QQ8M@ -3O/26FU-9H,#X<-4!L32G.A- ]*\U&TIG1K+U-7FYF?Y:J%
MG)^),VY8&?WM9]I#^W&R+T^D_66>3FBU--&-0VU"S4<HS872/"C-1]&:VJP=
M2%UM01XX-6(P,-L^,OIU*^]!L9[$[U:A0FU'*,V$TBPHS8;2'"C-A=(\*,U'
MT9IE4ON9^@3JXD"]32C-A-(L*,V&TAPHS872/"C-1]&:WU>J/4Y#Z1)-9^4M
MB?D0_*J^39>$@<@:\9>V&E$S+ZT1*,V$TBPHS2YIN\.QL;X_''.@.5THS8/2
M?!2MJ?W:P31..9@OQ;>XCMSEH@Z_6.90&Q)*LZ T&TISH#072O.@-!]%:Y9#
M[58:!G*@9" =K <HS832+"C-AM(<*,V%TCPHS4?1FM51>YR&VN/\CK>[J#-?
M7$E0ZQ1*LZ T&TISH#37.'23QX<WJ'C0I#Z*UBR1VF,U3GBLR-M=C#87=&\]
M5=V?BZ5^.J,%S6A#:0Z4YD)I'I3FHVA-G=?&K*$V9G?G#6>NN:J)%Y_BH78M
ME&9!:3:4YD!I+I3F06D^BM:LD-KQ-8;0J03T"Z]0F@FE65":#:4Y4)H+I7E0
MFH^B-:NC-I6-$]^0_4]KKM"ORD)I)I1F06FV<6B!MPS$'6A2%TKSH#0?12O$
MW]UYD%Q,LV7^X$)&0OG0C^)Q4]7>ZN&([_)' N[MO]=O'O26_:9^8Q6//JSQ
MQ9,8WP?9,DH86=.%2*5=C\0U+RL>;EAL\'23/\;N,>4\C?.7*QJ(>;EL(-Y?
MI"E_W9 )JD=,3O\%4$L#!!0    ( & [;E>_X)OQK@(  )P(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;,66;4_;,!#'OXJ531-(HW'3)FU9&FG
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MA2W3#!.\U(#0!OA^P;'&JXD.4%^3PC]02P,$%     @ 8#MN5]3AX5QK @
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M;JB51NT,Z/M**?LT<1M4S?GX+U!+ P04    " !@.VY7<2#^*0@$   3%@
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ML#_:-;HH&EDJ+D$9KA5!J'.ZF,Z7,Y\?$GYRZ,S!G/A*-EH_^^"ARFGL!8&
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M0NT2:'VFE-U.W ;-)S#]"U!+ P04    " !@.VY7GE@AC$$#  #N$P  #0
M 'AL+W-T>6QE<RYX;6S=6-%.VS 4_97(C FDB;3-",UH*VV5D"9M$Q(\[ VY
MC=-:<NS,<5G+X[YG7[4OF6^<)FWQ18R'K5TJ&MO'Y]QCWQMB&)1F)=C-G#$3
M+',ARR&9&U.\"\-R.F<Y+<]4P:1%,J5S:FQ7S\*RT(RF)9!R$?8ZG3C,*9=D
M-)"+_"HW93!5"VF&)&Z& G?[F Y)-WY+ B<W5BD;DKN3U]\6RER^"MS]Z,W1
M4>?N]')W_*0"3DGH%3U_ANA9QUZH<H5B\O'SY)\2QZ0OMJ77TX^M5L,]QLA]
M#[EEHK3$OYQ?/WXB26B1C32$=;Y'@TS)-NT1<0,V,LU9<$_%D(RIX!/-@971
MG(N5&^[!P%0)I0-CZ\U:Z<)(^>#@KNM!*=8Z.9=*5[%=!/<]J:?O .L>&.1"
M- 9[Q V,!@4UAFEY93O5Y&KP$134[=M581W.-%UU>^>D)50W&V2B=,IT$Z9+
MUD.C@6 9V-%\-H>[444(H#$JMXV4TYF2M/*P9M0-*SME0MS <_HUV])>9ALY
M[4!&9=.TANJFDW$=T-]4<]J;LM&+=(."WROS86&7(ZL^5 J[UBSCRZJ_S!H#
MF'H75Z=%(5;O!9_)G+G%/SO@:$#7O&"N-'^PT:!4IG: :1+<,VWX='/DNZ;%
M+5N:=3DM,]QS[P ]_]U]GC')-!6;IFWM[_,NO]AQ=/&O+%>_578->SW6+]]]
M-WE^"";C0S!Y$#79/P23R?Z;C/;38U@?,C9.,EOGF&8T@//BD'R!DZEH@P:3
M!1>&R[HWYVG*Y*/CC)4W=&+_F-G2M_-3EM&%,+<-."1M^S-+^2)/FEG7L!'U
MK+;]"9;7C9O#JHW%9<J6+!W773V;5,W -FS4^@+"+G)577X$XSC,CP"&Q<$<
M8!S'PN+\3^OIH^MQ&.:M[T7Z**>/<AS+AXRK#Q;'STGLY5]IDD11'&,[.AY[
M'8RQ?8MC^/&K8=Z @<6!2'^VUWBV\0IYN@ZPG#Y5(=A*\4K$5HKO-2#^?0-&
MDOBSC<4!!I8%K'8@OC\.U)2?$T605<P;]@3C2))@"-2BOT;C&-F=&#[^_&!/
M210EB1\!S.\@BC $GD8<P1R !PR)HNH]N/,^"M?OJ;#]#]_H-U!+ P04
M" !@.VY7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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MY+/N?^OT$U!+ 0(4 Q0    ( & [;E<'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 8#MN5TS-8=SO
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 8#MN5YE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !@.VY7NJ&%&.,%  "R'P
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 8#MN5QV;RPS&!0  V!<  !@              ("!)PX  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( & [;E=[$(]-_@(
M %T*   8              " @2,4  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !@.VY7B[;Y+] $  ".%   &               @(%7
M%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 8#MN5P+<
M-,$P P  8PL  !@              ("!71P  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( & [;E?_Q72@APP  +UY   8
M  " @<,?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !@
M.VY7Q!">)I,"  "Z!@  &               @(& +   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 8#MN5RR63.N&!@  B!H  !@
M         ("!22\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( & [;E=BP\5=8P(  , %   8              " @04V  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !@.VY7"ZT3CAX)  "$%0
M&0              @(&>.   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( & [;E>4=<XK/!T  *I7   9              " @?-!  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 8#MN5T$S0MZ"
M P  K0@  !D              ("!9E\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !@.VY7ZA>HR5@)  #;%@  &0
M@($?8P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( & [
M;E=WT[XVE 0    +   9              " @:YL  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 8#MN5PZ?&(^X"@  ("$  !D
M         ("!>7$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !@.VY7&Y:P2F -  "Q)   &0              @(%H?   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( & [;E?UN7S.204  ,\+
M   9              " @?^)  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 8#MN5UGDZH,2!   1@H  !D              ("!?X\
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !@.VY7Y12*
MJO<!  "B!   &0              @('(DP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( & [;E<,=K1S+AP  ']:   9
M  " @?:5  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M8#MN5Q7@<1<# P  ^08  !D              ("!6[(  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !@.VY7I4[]OZT#  #$"0  &0
M            @(&5M0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( & [;E?3"-.JE@(  +8%   9              " @7FY  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 8#MN5QCF3%OT @
M3@<  !D              ("!1KP  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !@.VY7B<H<T,P"  !>!@  &0              @(%Q
MOP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( & [;E>%
MN?O_1@4  "P-   9              " @73"  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 8#MN5W?)O92G P  ,0X  !D
M     ("!\<<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( & [;E?71INOLP(   L'   9              "
M@?/>  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 8#MN
M5X,#.9#8 @  T0<  !D              ("!W>$  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !@.VY7I^"$G94"  !T!@  &0
M        @('LY   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( & [;E>_S5M>004  *,G   9              " @;CG  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 8#MN5[5/^,FQ @  R0<
M !D              ("!,.T  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !@.VY7)'L+O=\#  #P%@  &0              @($8\
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( & [;E?Y(WMA
M8@(  '4&   9              " @2[T  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 8#MN5\4BA=7P!P  ;E(  !D
M ("!Q_8  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !@
M.VY7O^";\:X"  "<"   &0              @('N_@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( & [;E>FS<'9Z0(  #()   9
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M970T-2YX;6Q02P$"% ,4    " !@.VY7J#PUJ((#  "H"P  &0
M    @($W'@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M & [;E=Q(/XI" 0  !,6   9              " @? A 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 8#MN5^LI*G09 @  ^00  !D
M             ("!+R8! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !@.VY716&TD[4"   .!P  &0              @(%_* $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( & [;E>>6"&,00,
M .X3   -              "  6LK 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Y #D A@\  -TW 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>241</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Changes in Board of Directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/ChangesinBoardofDirectors</Role>
      <ShortName>Changes in Board of Directors</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueAdditionalInformationDetail</Role>
      <ShortName>Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Common Stock - Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockEquityOfferingDetails</Role>
      <ShortName>Common Stock - Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Changes in Board of Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails</Role>
      <ShortName>Changes in Board of Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/ChangesinBoardofDirectors</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="vtl-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vtl-20230930.htm">vtl-20230930.htm</File>
    <File>vtl-20230930.xsd</File>
    <File>vtl-20230930_cal.xml</File>
    <File>vtl-20230930_def.xml</File>
    <File>vtl-20230930_lab.xml</File>
    <File>vtl-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20230930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="517">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtl-20230930.htm": {
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "vtl-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "vtl-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vtl-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 30,
   "axisStandard": 18,
   "axisCustom": 0,
   "memberStandard": 24,
   "memberCustom": 19,
   "hidden": {
    "total": 10,
    "http://fasb.org/us-gaap/2023": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 173,
   "entityCount": 1,
   "segmentCount": 44,
   "elementCount": 376,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 31,
    "http://fasb.org/us-gaap/2023": 517
   },
   "report": {
    "R1": {
     "role": "http://vitaltherapies.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-45",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical",
     "longName": "0000009 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "longName": "0000010 - Disclosure - Description of Business and Basis of Financial Statements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "longName": "0000012 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://vitaltherapies.com/role/FairValue",
     "longName": "0000014 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://vitaltherapies.com/role/CommonStock",
     "longName": "0000015 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "longName": "0000016 - Disclosure - Stock-Based Compensation Plans",
     "shortName": "Stock-Based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://vitaltherapies.com/role/ChangesinBoardofDirectors",
     "longName": "0000017 - Disclosure - Changes in Board of Directors",
     "shortName": "Changes in Board of Directors",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ChangesInBoardOfDirectorsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ChangesInBoardOfDirectorsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "longName": "0000018 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://vitaltherapies.com/role/SubsequentEvents",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "longName": "9954473 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "longName": "9954474 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "longName": "9954475 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "longName": "9954476 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "longName": "9954477 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "longName": "9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "dei:EntityNumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "dei:EntityNumberOfEmployees",
      "unitRef": "employee",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)",
     "shortName": "Summary of Significant Accounting Policies - Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OtherShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-80",
      "name": "us-gaap:OtherShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "longName": "9954482 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "longName": "9954483 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "longName": "9954484 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "longName": "9954485 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9954486 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails",
     "longName": "9954487 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954488 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
     "longName": "9954489 - Disclosure - Fair Value - Additional Information (Detail)",
     "shortName": "Fair Value - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "longName": "9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-109",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
     "longName": "9954491 - Disclosure - Common Stock - Equity Offering (Details)",
     "shortName": "Common Stock - Equity Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-120",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "longName": "9954492 - Disclosure - Common Stock - Common Stock (Details)",
     "shortName": "Common Stock - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:NumberOfVotesPerEachShareOfCommonStock",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "longName": "9954493 - Disclosure - Common Stock - Preferred Stock (Details)",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "longName": "9954494 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "longName": "9954495 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
     "longName": "9954496 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-145",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "longName": "9954497 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "shortName": "Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "longName": "9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
     "longName": "9954499 - Disclosure - Changes in Board of Directors (Details)",
     "shortName": "Changes in Board of Directors (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "vtl:RelatedPartyTransactionBoardOfDirectorTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "vtl:RelatedPartyTransactionBoardOfDirectorTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "9954500 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-173",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-173",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20230930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r184",
      "r185",
      "r490",
      "r569"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r201",
      "r207",
      "r336",
      "r505",
      "r507"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r306",
      "r343",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r163",
      "r346",
      "r384",
      "r395",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r528"
     ]
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter commissions",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r523",
      "r626"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r93",
      "r369",
      "r381",
      "r383",
      "r390",
      "r415",
      "r523"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r234"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, impairment charge",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r179",
      "r180",
      "r181",
      "r512"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r72",
      "r118",
      "r368",
      "r382",
      "r383"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "vtl_NumberOfFinancialInstitutionsUsedForCashDeposit": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions used for cash deposits",
        "label": "Number of Financial Institutions Used For Cash Deposit",
        "documentation": "Number of Financial Institutions Used For Cash Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r88"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Operating Lease Obligation",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r414"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r66",
      "r414",
      "r432",
      "r628",
      "r629"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering of common stock through At The Market offering, net of issuance costs of $9 and $1,226, respectively",
        "verboseLabel": "Proceeds from issuance of common stock at premium",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r385"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r613"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r201",
      "r207",
      "r336",
      "r506",
      "r507"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r240",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r274",
      "r275",
      "r276",
      "r277"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r154",
      "r156",
      "r158",
      "r159",
      "r160",
      "r162",
      "r302",
      "r303",
      "r361",
      "r376",
      "r508"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r334",
      "r335",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433",
      "r465",
      "r613"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r91",
      "r92",
      "r93",
      "r115",
      "r116",
      "r117",
      "r164",
      "r205",
      "r206",
      "r207",
      "r209",
      "r212",
      "r217",
      "r219",
      "r386",
      "r387",
      "r388",
      "r389",
      "r515",
      "r542",
      "r556"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r164",
      "r205",
      "r206",
      "r207",
      "r209",
      "r212",
      "r217",
      "r219",
      "r386",
      "r387",
      "r388",
      "r389",
      "r515",
      "r542",
      "r556"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r236",
      "r267",
      "r268",
      "r270",
      "r521"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r166"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercised (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r136",
      "r204",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r221",
      "r300",
      "r460",
      "r463",
      "r488"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r114",
      "r137",
      "r165",
      "r169",
      "r171",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r290",
      "r292",
      "r311",
      "r364",
      "r426",
      "r523",
      "r535",
      "r572",
      "r573",
      "r614"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of investments - Other",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r559",
      "r560",
      "r604",
      "r624",
      "r628"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "AccruedCompensationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Compensation, Current",
        "documentation": "Accrued Compensation, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r112",
      "r504"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation adjustment",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r18",
      "r122",
      "r125",
      "r130",
      "r314",
      "r315",
      "r320",
      "r359",
      "r374",
      "r551",
      "r552"
     ]
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options available for future grant:",
        "label": "Employee Stock Options for Future Grant [Member]",
        "documentation": "Employee Stock Options for Future Grant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "OperatingAndVariableLeasesCost",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and variable lease costs",
        "label": "Operating And Variable Leases, Cost",
        "documentation": "Operating And Variable Leases, Cost"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ClinicalCostsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical costs",
        "label": "Clinical Costs Payable, Current",
        "documentation": "Clinical Costs Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_GovernmentAssistanceRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "GovernmentAssistanceRate",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance rate",
        "label": "Government Assistance Rate",
        "documentation": "Government Assistance Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r398",
      "r399",
      "r401",
      "r403",
      "r466",
      "r469",
      "r472",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r527"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of pre-funded warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ExecutiveChairmanAgreementMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "documentation": "Executive Chairman Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r111",
      "r137",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r291",
      "r292",
      "r293",
      "r311",
      "r523",
      "r572",
      "r614",
      "r615"
     ]
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "documentation": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "SaleOfStockRemainingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, remaining capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "documentation": "Sale Of Stock, Remaining Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Equity Incentive Plan",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r230",
      "r345",
      "r377",
      "r404",
      "r405",
      "r467",
      "r470",
      "r474",
      "r475",
      "r480",
      "r501",
      "r502",
      "r511",
      "r515",
      "r520",
      "r524",
      "r574",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ]
    },
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "A2017InducementEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Inducement Equity Incentive Plan",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "documentation": "2017 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate offering price of securities under shelf registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-statutory options",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "documentation": "Non-Statutory Employee Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r222",
      "r230",
      "r262",
      "r263",
      "r264",
      "r344",
      "r345",
      "r377",
      "r404",
      "r405",
      "r467",
      "r470",
      "r474",
      "r475",
      "r480",
      "r501",
      "r502",
      "r511",
      "r515",
      "r520",
      "r524",
      "r527",
      "r568",
      "r574",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ]
    },
    "vtl_May2022ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "May2022ATMMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "documentation": "May 2022 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian research and development tax incentive",
        "label": "Research And Development Tax Incentive, Current",
        "documentation": "Research And Development Tax Incentive, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "LegalAndAuditCostsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and audit costs",
        "label": "Legal And Audit Costs Payable, Current",
        "documentation": "Legal And Audit Costs Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r230",
      "r345",
      "r377",
      "r404",
      "r405",
      "r467",
      "r470",
      "r474",
      "r475",
      "r480",
      "r501",
      "r502",
      "r511",
      "r515",
      "r520",
      "r524",
      "r574",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ]
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r222",
      "r230",
      "r262",
      "r263",
      "r264",
      "r344",
      "r345",
      "r377",
      "r404",
      "r405",
      "r467",
      "r470",
      "r474",
      "r475",
      "r480",
      "r501",
      "r502",
      "r511",
      "r515",
      "r520",
      "r524",
      "r527",
      "r568",
      "r574",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNotice": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf registration, termination, prior written notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "documentation": "Shelf Registration, Termination, Prior Written Notice"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and audit costs",
        "label": "Accrued Legal And Audit Costs, Current",
        "documentation": "Accrued Legal And Audit Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r398",
      "r399",
      "r401",
      "r403",
      "r466",
      "r469",
      "r472",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r527"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r394",
      "r559",
      "r560",
      "r561",
      "r604",
      "r628"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r176",
      "r177",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r294",
      "r296",
      "r297",
      "r299",
      "r301",
      "r378",
      "r380",
      "r394",
      "r628"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r93"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r280",
      "r622"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r108",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r163",
      "r176",
      "r177",
      "r221",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r330",
      "r378",
      "r379",
      "r380",
      "r394",
      "r457"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r30",
      "r295",
      "r298",
      "r330",
      "r378",
      "r379",
      "r551",
      "r552",
      "r553",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Entity [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r135"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum annual contributions per employee (as a percent)",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Deposits",
        "verboseLabel": "Time Deposits",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions Used",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r167"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, amount (up to)",
        "label": "Government Assistance, Amount",
        "documentation": "Amount of government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r522"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in private placement transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in private placement transaction (in shares)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r168",
      "r170",
      "r172",
      "r510"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r61",
      "r62",
      "r63",
      "r64",
      "r137",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r291",
      "r292",
      "r293",
      "r311",
      "r572",
      "r614",
      "r615"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "AccruedClinicalCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical and related costs",
        "label": "Accrued Clinical Costs, Current",
        "documentation": "Accrued Clinical Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to right-of-use assets",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SharesIssuedWeightedAverageSharePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock (in USD per share)",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "documentation": "Shares Issued, Weighted Average Share Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NumberOfVotesPerEachShareOfCommonStock": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "NumberOfVotesPerEachShareOfCommonStock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per each share of common stock",
        "label": "Number of Votes Per Each Share of Common Stock",
        "documentation": "Number of Votes Per Each Share of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "EmployeeMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees",
        "label": "Employee [Member]",
        "documentation": "Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized foreign currency loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r434",
      "r533",
      "r606",
      "r607",
      "r627"
     ]
    },
    "vtl_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AustraliaAndGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "AustraliaAndGermanyMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia and Germany",
        "label": "Australia and Germany [Member]",
        "documentation": "Australia and Germany"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "vtl_NumberOfDevelopmentPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "NumberOfDevelopmentPrograms",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of development programs",
        "label": "Number Of Development Programs",
        "documentation": "Number Of Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r612"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_GrafelfingGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "GrafelfingGermanyMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "documentation": "Grafelfing, Germany"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r523"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at September 30, 2023 and December 31, 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r366",
      "r523"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate on operating leases",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "documentation": "Operating Lease, Incremental Borrowing Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r40"
     ]
    },
    "vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Investments- other",
        "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]",
        "documentation": "Cash And Cash Equivalents And Other Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SalaryCostsMonthlyBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "SalaryCostsMonthlyBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly base salary",
        "label": "Salary Costs, Monthly Base Salary",
        "documentation": "Salary Costs, Monthly Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r309"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r101",
      "r102",
      "r105",
      "r106"
     ]
    },
    "vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent holiday period",
        "label": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "documentation": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of existing leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "vtl_December2020ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "December2020ATMMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "documentation": "December 2020 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r309"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical and related costs",
        "label": "Prepaid Clinical And Related Costs, Current",
        "documentation": "Prepaid Clinical And Related Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "vtl_ChangesInBoardOfDirectorsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ChangesInBoardOfDirectorsDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectors"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Board of Directors",
        "label": "Changes In Board of Directors Disclosure [Text Block]",
        "documentation": "Changes In Board of Directors Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized (as a percent)",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShelfRegistrationStatementAmountRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf registration statement, amount remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "documentation": "Shelf Registration Statement, Amount Remaining"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "vtl_PlaneggGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "PlaneggGermanyMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planegg, Germany",
        "label": "Planegg, Germany [Member]",
        "documentation": "Planegg, Germany"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r83",
      "r99",
      "r109",
      "r121",
      "r124",
      "r129",
      "r137",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r151",
      "r152",
      "r157",
      "r165",
      "r168",
      "r170",
      "r172",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r303",
      "r311",
      "r373",
      "r435",
      "r455",
      "r456",
      "r510",
      "r533",
      "r572"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r163",
      "r346",
      "r384",
      "r395",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r436",
      "r437",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r528"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "NewYorkCityMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York City",
        "label": "New York City [Member]",
        "documentation": "New York City"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "DuaneNashMDJDMBAMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "documentation": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r278"
     ]
    },
    "vtl_RelatedPartyTransactionBoardOfDirectorTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "RelatedPartyTransactionBoardOfDirectorTerm",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of director, term (in years)",
        "label": "Related Party Transaction, Board Of Director, Term",
        "documentation": "Related Party Transaction, Board Of Director, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, weighted-average exercise price, ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, extended rent holiday period",
        "label": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "documentation": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20230930",
     "localname": "IncentiveEmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive stock options",
        "label": "Incentive Employee Stock Option [Member]",
        "documentation": "Incentive Employee Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r231",
      "r562"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r437"
     ]
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia",
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r123",
      "r125",
      "r131",
      "r360",
      "r375"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r442"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r397",
      "r400",
      "r402",
      "r469",
      "r472",
      "r477",
      "r482",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r516",
      "r527",
      "r575",
      "r623"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r231",
      "r543",
      "r544",
      "r562"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r86",
      "r416",
      "r432",
      "r458",
      "r459",
      "r523",
      "r535",
      "r557",
      "r567",
      "r605",
      "r628"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r362",
      "r372",
      "r523"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario, Unspecified [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r231",
      "r543",
      "r562"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r87"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r104",
      "r107",
      "r371"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in connection with the Company's stock option plan",
        "terseLabel": "Shares issued (in shares)",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r93",
      "r394",
      "r457",
      "r487",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in connection with the Company's Employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r93"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease term (in years)",
        "terseLabel": "Lease term (in months)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, cash dividends declared (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r397",
      "r400",
      "r402",
      "r469",
      "r472",
      "r477",
      "r482",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r503",
      "r516",
      "r527",
      "r575",
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal option period (in months)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r81"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "totalLabel": "Total",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r523"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r81",
      "r134"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other share (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PV of obligation",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r93"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued in connection with the Company's stock option plan (in shares)",
        "terseLabel": "Stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r93",
      "r386",
      "r457",
      "r487"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r512"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation and Presentation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r228",
      "r306",
      "r341",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r137",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r291",
      "r292",
      "r293",
      "r311",
      "r412",
      "r509",
      "r535",
      "r572",
      "r614",
      "r615"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock ( in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r228",
      "r306",
      "r342",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r108",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r142",
      "r144",
      "r150",
      "r152",
      "r163",
      "r176",
      "r177",
      "r221",
      "r271",
      "r272",
      "r273",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r330",
      "r378",
      "r379",
      "r380",
      "r394",
      "r457"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual obligation",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity, Policy",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r461"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, cash dividends paid (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r414",
      "r432",
      "r628",
      "r629"
     ]
    },
    "srt_AffiliatedEntityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AffiliatedEntityMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Affiliated Entity",
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "auth_ref": [
      "r433",
      "r500",
      "r528",
      "r577",
      "r610",
      "r611",
      "r613"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,595,383 and 39,307,286 shares issued and outstanding as of September 30, 2023 and December\u00a031, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r367",
      "r523"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r414"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r205"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in connection with the Company's Employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r93"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r65",
      "r66",
      "r93",
      "r246"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27",
      "r44",
      "r93",
      "r203"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors Chairman",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://vitaltherapies.com/role/ChangesinBoardofDirectorsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r625"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r205"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which compensation cost will be recognized, in years",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r120",
      "r137",
      "r175",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r290",
      "r292",
      "r311",
      "r523",
      "r572",
      "r573",
      "r614"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r310"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Line Items]",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment",
        "label": "Investment [Table Text Block]",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546",
      "r564"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r156",
      "r158",
      "r159",
      "r160",
      "r162",
      "r302",
      "r303",
      "r361",
      "r376",
      "r508"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r306",
      "r341",
      "r342",
      "r343",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r334",
      "r335",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r431",
      "r433",
      "r465"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r98",
      "r370",
      "r523",
      "r557",
      "r567",
      "r605"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of options (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in USD per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments - other",
        "label": "Other Short-Term Investments",
        "documentation": "Amount of short-term investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r363",
      "r549"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 4)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r56",
      "r365",
      "r413"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Financial Statements",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r84",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (usd per share)",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r191",
      "r570",
      "r571"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r341",
      "r342",
      "r343",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted-average exercise price, ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r470",
      "r471",
      "r473",
      "r474",
      "r480",
      "r481",
      "r527",
      "r565",
      "r566"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r191",
      "r570",
      "r571"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r438",
      "r439",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r337",
      "r391",
      "r392",
      "r393",
      "r440",
      "r441",
      "r442",
      "r462",
      "r464"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r523"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r442"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r235",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12",
      "r96"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "b.",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//321/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//325/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001280776-23-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-23-000018-xbrl.zip
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M*98\,M?$X_QJK27W ._&&Z;!<3S'M8P,INEXEE5W-^^>:^$[X5$AU^H(9=^
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MQ-J(B=4'%J$A.)+BKSN,$IY78:)9FI-7S\U$"$ WG!P%BH8$V4P+;8?/PL6
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M]#_KP4N3\EE<X33MU=$?4$L#!!0    ( & [;E=4+'5*2P<  ,0@   :
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M,M1>G0@0]+,0>"N\2)X*MNR]4+&V4(&%YH1890LD0L[?NVJ]?$*!T57O^S&
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M2CQSU2];^.ZA6CX<R!W6A T]G".PA8T]K'+4]U?W^\0-?>*8G]W0"RAU^$"
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M6++[N1!"1[+[F6,9CYOS:77B3Y3/MOLJM?G9(+XGV?O<L=S#%/P UA2X2H'
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MT.2A-$=>LU52TA91FY.2MHO7=FT 9HBVMQE2(C%=CN_!4S]&"SXEC[Y[=$;
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M/]@VKT5<N2 /PDLZ#+MS7H 0,*^3*_^8-+)T?!]LS<[>!P\R;4)@:MER?E6
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MT&\F.%V&3;2@MM;L&K#HF>M;2 I7'K79M->/KY893&).33T8H;LU?X0,81%
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MEC[U1I9/L3<5H+ Q#ED;CE?B@>4?[)9J='X>=7:=H=K94FC(#G7N&+0_A1[
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M<+JT^C(;]U2VHD36_4@L22R=((Q4L;X.?17[.G1Z78$*OR112M$AL22Q)*2
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M$:'NC%V?V>3"CB.*5O;T]YF>"4MFE^;3EN9E/&JW-NAEI"#+"(W0]"/C:%7
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M"MA(>6VA?J,VZ(G4FU::K"=+E]V5A#K8=V,UJZ'*<Q/9MSMJLVN(+#[O\^3
MEM#L>'M!V3FR38'B"RS>>O3<%\NDYA]O/P ;8('$N+A.4%'8ML4#X$Z]U]HG
MG% 4E14R>B^:/ L401R*/'M GJUR"H<.3IX75T!J.2_4EP6D^Q:05BX-02Y8
MJ-0_L1,]'D-O- %3GS4)FGEH/P9O[.@?YQS.=AZ 5]VHU'XFXJ+J?21O\8S)
M$8#3HX\1A!]MX@37CGD; SE+N_;!K>JL-M&N<DVNI)W<(<V]:*>'K3!56;AZ
M[$1J0 ,*4FYZ\0+6AL*"G#*PN;,0]5P @^E_!J,6 ?PPAK^8(=JT=+=$E1X>
MT=>[_=7&QS+L>3YDM4V^%B2KL?6+FHU_4L_-HB@M&0<H$$U=9BQT%@4ZE.&;
M\BX*C+[/](8/$AD]=[;:(JW71)ON8O#O'FWJZ2BU.]K>16V%,%@A@_FL2/*8
MH=!,XEREOW9)-O41^L9?4IPS:MLNXYP7%N<L:THMI^14$^GH^0;>?*7V3C'E
M@,?F(@N5D_DL'-K6"+S+,;P-B!W<S!$;J K+<D<_E6 "L'B>*->!@N,1OA+O
M)PV2V^NL7Q*ZIKX?LL&X(]?GK<'_Y0 !KX<QJRF^BSYV@]_*$JD&J/05@<K"
MCX56E3.4DKVJ@E8()CO4-6W5=ZPK'O5GE#D0]MM2Z_O+B'\=R.N/$?8P3HT0
MSL)-MS8 5TR@3#X9-CVA5[^&; KR.P[!Z]>-_7/D9$1U;QU(?U%O9/DLQLJU
MGCM#5,BTT7*BJPC2!P[1VPC49I$H6%_$*)B,K)XRLII-4BNDTV_5!GNGX L:
M.JV2A W =4A+V9E'&^.0C:AX)9Y'P(J^L'R  \G:_^;0C'DBRSOJJ\ 3LJSI
MG FF@"1=)9C<>KE?WNF4-&+W%K$^-G3R62"&)^T#23B4T\JK%4R8#+[ALRW_
MW5?H=&:[;Y1&!N\L2MA29C;9K4';9=@H.X476*\M_P>H.^_.P:$X>!;LF-DM
MN# /)U-LXSF53"TX9^+:*0A1#G'A(92^]WQCV=?SDK,BLD[,9"[$T7(A/L?@
MWWC<W#=J@[:V>CHBDQTNF^:VZ)XB-%<L$M[OL$AX5ZT&39Y1'D0VT=R.Q^ U
M8)"&_AJQ?IV*1P*JC*+>G4!'3/+C:2K[ 2LZ7@"IN\9PMF4>5)'S#E(0S#'S
M,+Z-\/(-T/+@(%OB_]_.T?"-^H%GC0*P_> "&(.+?TC=F<6/7>!'M81&8V+H
MAA*]C\NET+R)< >AT(+J! ]6ZYV,63&"$?!1TY!.YB-P!6*5K3.*5G>?(U/F
M51M[L=\C;,0U5SNXC.P0@9MF=,[\A?FU#_Y(M]XR5D-;XA7[2X=$0*4C-'WK
M+2R9;-=;_7T:&4G/II3I ^M44%T9TF?+<:+\UQFC"7D(LI8SVYMC!<>T]_26
MBEW".O5N6Z0\#WDV4CK-"45T6FW0Z]1[G;WGWHB76U1)^4WAKVLE]V&]B.J/
M<\^___,1)[I(T@1;3??KG=[!(^""^4&2,25CKGA]FDB<V:X-NEJ]VRTK7?+4
M[0@KES91N057R4W.+H1^"F<SFV)E([$5@,#(=OW08VG;  =F>Z6Z7H#A=<A*
M:1WXP'3#H4U%+I7.N\IS(_;*+?B,"BR21KN*C2%+A2F'!C!I"+^P68N*.PP(
M/,>R@9/#?-" T1/N$+:0.9$YIQKCJF>9^B_(,LL#@/,QS;:DI7W#USZ,?_B\
MS]5#1'QW3AQ$_^QZ"=%^00J,^_^_99E>!CA%[;*J8_/CJQHND>2\B^*\+<EY
M>W%>WG(?O=4IN]SG\%QY;O:+7+!<<#46_"' L92#J%%-J@W2E'C/EL/<ILZB
M<L+B%>H=7QQK*(ZQN1$9C7A]'%K5CAO VPDXOK 8"U;V[($_/",>RXT-)A0L
MZ- AH6D%%$'CF#C*D?W$PCH$_QRYQO"@'\ ?6+N@YF(/GQ1HH@5IW::.H)FY
MOH72]<JC-L&RGH^OEAE,8OV1>C"2H*WY(V0(BPB#]8^( O?>4D>CU+^X6M0]
MEFGHACX<4V+HX[9I='O][KAC$J-%>CU*].'_:KU:_-#$BW<P(\^T,?0H^=D@
M8]C@%;%?R9M?^[!(CD"+T8+:&J^Z6089!\S@MZ$'CV:L]J1078GA,*C>??WZ
MX_[NIJ[<W=^LI[<4*ZK:27@Q>_7WC/4"5[E)N.HFS56?$ZYZ2KAJ[29%V=2[
M'[&P>+^ZUGQDKJNU+5@\1E>Y[.VI326R:._#*;QBM.H\+AJM?X0^O,3W/U%_
MY%FLE<>U8_Y!?,O'GLD@7IV !2>^PTO^L%F/I=@2[7(#V7)":EX'T=_P$_ N
M,D.D>R&HH]2K46;'7V1!2_8A_&LV,2UL98GKX5KT=;:^^:IP!1GKTFK;N<Y"
M0@?1KS6-0Z*0O?'*"H ?1CF0N@: NPB4OX=^8(W?CKK;C?[7W70*+M<(1*0S
M:BKO:M'O-<7U6*E\+:J5K[U7@%"(,K1 *HTF#BSO^4V)# 5PRUZH[<Y8\%L9
MP5?0%5%FUHSB%UE#*6KSYGWP8KADX6?X.[!_/YE9L*6Q.V(=I0', 2@L%M4;
M33P7W@:FQ]@F4W#17(]/4"%AX+*W4(S.HS?G-UEOQFC!N-P))>8_0K!5J,?#
M?PBTO[G>3^4&G#[>#\ *?&5*YM/]0,+BG7]Z__873>M]'%-[S.P@2CSE*X)F
M4E?^I. L.F^+WQOQ<;CVFS(A *G9S'-_@:\:4/C+6B\W[C^P\6#^[OYS+#9,
M:EW= FL%;\"40^H]C&^C-\R+6%IS"0$&06^UG#GI>K#!"%M+H%D&0+:>$8G6
M56U.ZT@9L]#S0T9?,;%&)(R"#^D5J1001TRPC"R?$5!=\0$?MC)U@91#\,\!
MPV -3S'QAHPF^-3K!.B#X1\^](^0*J#&@I UI #LLD8_H,]-RP->8&\W/93$
MR&BA,Z4!D!EVLL <'B!%-N&"$2ENV W]XMS@8]4!9O%2]I$7RW3'F-,[Q9<1
M>V2%4^7=W=<?C9[>>Q]OJ![MPV*<\,@:8NC9D,(P^N)2IZ$=6#. CC^RJ>>B
M>GF'\1*M]?'K$_M!_?B>K7D.+'_BOCJ1(*!A !N,CM#>Y@O0Y@L(/-!3;&W)
MI_TP[MS*NH"@JS#SL<VL1Z=6P"3)UZ<ZWR! '.70UR>VBJEK(M]3$-= 5R^
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M191'6/:7P 2Q=0U6%@8WO?B\+?DDDQ8>8"(6BG- @&T+]A0#&0?%G*::R=<
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M[8=/QZ']Q1K3U20%,_26^^)B^6HPL;P ?0:LC5TIP<PJEET ;B1C6$EUH4"
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M8WY V8P-L_%0.8A;]@3L]7MUJQ64NMF\AP<G&4"@<6M'6VP0#R3JXB0O[N"
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M^U-@%P,_?D^;0ICQ U@+%/CT<_DL?#*'KQW@MO0L);Y;<X!^+'R$,U=6OF?
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MK@-RA/7E%(4.ZNFE4+\'#1NP+H4[R)$I*'?6 U!P ?P,)T0/%]!XZHS)VXZ
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M);E+=!2LX;\+R;R<!AZH%!'^$WY30A([4>@T&C3Z_4?5.0V[C>;@<75.RRN
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M538E&7S# K,*"_@(L>(9L/K(EEF8]*AZN05" _%-55R<_IJ6?T;XENP5Z=*
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M@4,RTVP=OJRD4!>/5C9OA^G6J)RHBR:7%TT.JXLF7Z'^L;IR+U>C]YJ&Q%*
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M=^Q!)AWXQ^IK:Y*6L)WBT N79O4HF_(1'4L[*YNN[XIG80A\S.ZM[JFPLI$
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M.9C#4>^@3@\\%R#3[I]94-40\\[VAB1T"3U?"1\N?>-LR%3S//LF@.M!$$R
MB8WC( 30+18A:$L\=R+'5H&=SMSQC-130 VJOT7NC?T[J04&H-U7^+%^7\/Z
M74,]M];F^-G?%_SL W[V[7:O:(DI_ 2(9R\"Q/L\4"-Q[IF*X=+OA!J'1<WX
MQ<^QET0T>( 0&UOD_Y4 ]DUQ<(^< H*3NGQJ$@K?1'!C 2^(P[P6H;AS@R2"
MWZ>M]6$AX_JQ_SXNH.X*)YJ$KD.-_1TI)L4_<"1&3"/D=.M^>AH5$=D\92X<
MG!:,9_V6 "7V^IW>N_'[=]WW2H/YZD03YR_K-Y>GH^!344&0[BOM;>8E&*S
M;=G41TS*D5PV&2K:"8"M]V"F1\(O0]3!IML<OLHVAYMN<_0JVQQMN,U!\S6V
M.6H>G7PMCIY[Q ?:#D=Q@+9VB/) #<]BY=DIF&3FB)V8FE_0!-I-ANWD1K!L
MH'B;'&30Z*_!0P::@93IDK@TPM6=]#J]SLU4.+W.M#OI#8:CP;0_<7I-9S@4
M3N?F?WKMHQ.SY=.2%9^;7Y6;U\-U1]G<Q=Z'LQG*U.C<_P45B,OI)R4_/KD1
M#E-+PI(A-:.2(36CDB$U<G%4)GY1^HE^P?*)+Q7C6D8\KF5WM?H-72&GBT4
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M9P3G!&W_(TXLCL%<0:![PD'&,7,7>+=C.C+<4%C108>V>6W%H7!B[N^*+C+
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MJ2CEG#:I(.*G@T5>6+0$+_XAEBQE6\X\0-:)#"7"A,A;>!"?T3BN I'N6(U
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M<)?L5-5*,W#N"%WH'HHSH 09 2.N[M\&=-K41T H%ECH^Z1?I^FPY SPV=6
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M#:,X]V/%(O@)3%;66]4NN,Q.,V6$REAB%]9M0+I\)(,I" &;@XV(N_2L+G]
M6UIKMSH(0DPQDX. OC,.?Z!49'-+>T])E@*D;CBXX(XQN(*>-HY7DSF\D U/
MN96IU#RY\H*]74X$RF6DO<ZR=E&ZL C6NL?36+;><&0?,+A:^&H_RQ27^VRF
MNAZ%$#5SZ>5!$1(#0"4WKE]&XC9]=.>&2(.ZUM>@9,T"9DY>H9)4I0QQ76@J
M [<9^TQ5Z7CB)Q+P+%C,@&38H4-UJ@WKFQ@S*B\2KAF99$(RQ#Z0'U+M1L5Y
MF><Y,D6O<)@8B\7&H<O[8_0&= ?^[B!/0U]F(.L&X2TMS>^_ IFUC.Z<VLB*
MHF#LTL/20",Z*'##$'U&.K,.@VS"GSG,Q4V(WH"U-G6S-G\#*P+("D(2J5!!
MR.!C#[CKS]P;UZB=%O[_/LR1$F</8$L&L"WD1A-!?X)]B#)2'?33?U]^^N^R
M@UH_,#>!5])Y4*!P@_$>D=I VHN,IK"7! Q?&=@"]$HB1#L9Y,$O4 V!A><"
MB1?7* $G-3\I""45*B.D5?A9)=2)UV3(1&(BTX-^?>4"Q.TDALN#@U(%Q#_F
M0FZED'%CJ-2] A=.B6=XR>Q\D:%;I91\OKB:G5Z?2VTPHV%E7"H:$6QVQZ &
MGWA.B)C@,%6XGI?PL%S9H2I#H\!TDS'&=&]]@3O#\!Z7I+OP&?[$$Y&L@@W)
M_R]W(BA#@WY,,AG1AIHN1DHWT^H2>D_8S4*/4UU^Q&[<$&!(!#$%X4OLP4..
MADP;SJ,I;/I;BG8H9'4\+U5] MDG@+P/P&MF6+I<<F.IO\LLDY<2E>6X]!+B
MB1Q*_$4')$9PN?4$AF@05DHM+6JE"SH/HP"^S_%0I#]PIPG0&H*(7S%'IQ/@
MG6^U;.#IUBS!4@R9_R>S6)0^@R%);MBK@DA@?6AM#K$I\:H25?9?M$DWGTN5
M@LHWK#4V(K4'N*2Y<E)Q=4S.7SP'N]Q#-B%I71KWUVX8)P#>OL:WZ_-OW_L&
MQEG$KN$1&=-#C5@FAV2$!@6#;^4[2#.M]"=*@C \</!\WCG9L'Z1$<Z"L,M)
M>)>571QY0!)$I]&426#2$AP,04BIG?)9C-2/#?D<J;K[.$BW&<^6NDKI:'R4
M>X0_%MZY*.T2<K%6.HTKG8B5WM(,Y^<WIM^MY2SE- (BJZ4G2F5/)CQDR@X;
M_N*T.X6MNKF,YC?F+7+@649B*<SJW 4NRPS)-@F'#'D)IXKI>LGBFB+WH'!1
M@:OK+ ;YZR@!C 5!0(P]XPA(.Q>"<'K0S7!5O42&V9+C(\:6/=*\YKB;WC":
MQ4*[T;0VXZ +KB1/A^6LD]9@I 1MM"6!0S!BD.-6=YZI=C#7!6-5WN?N3GN?
M=U3T?,HX)J;$'\B%)',@I<K6RND2I%UDV%6!YMBXY?@)(I!_/*4$.%>P4<L?
MHBJ$[8UN42N? UU1:I?A*U(Z+I*4XCR4H22=7[B3*>J6J*2#+H3]@I \,?6L
ML$'3]/I@*2LE9?NWE-67\G,;V0.:G,H9HPXI-1-@NW,PFS!&FZIJV.D4=B!8
M*Y3&CEK 3V+L^06O ;H*2:PV]+FH23<VB=)N*38S41&3N2Z>=\RZ6&Q4$L6<
MKRB#SZE?!/@6Z,R9.+32P%D84(:>UCY\[:>5QDQ>( 'W1'4$=TAZXT2*-^D8
M2_E?FDO(H4.=,<"RJ$P4DI?W()4[SBUAS5SU,U2Q2U*RS(B+]K<_-3*I7[$\
M'DJ222+Y1+OA4Z/=5D8>9S<YE"O +JCQC!52"]'@CHLK,J]-$3&G&TCD.\#+
M3MT5J9E^S)X1D6U0)AW4"$M9DJZ(+YZ%Y.(T(:;[G&'!@>N7VKJD56#6$6B_
MH&<)SNDF1X$1_N,;]^&XJ1]!84.:% 16' ",C P5PEEH10YX<^3>> _:_E<,
M()_D@OFK^B7XY#3PW,#,*S=#.=$"I&XPG<HF,[1'*K&0S>;'1N.3]%? 7I#E
M(T",;D@:M5ZX62@A@572$'_O,?M/800$5,D8_AL[\VDGN2S)*>_)9Z \:1SX
M<"Z%3*>-6=1'76:F8-;,A%5OH*(("UQBY(MV:H\^&&%MTLSI<60UF&"/A<X)
M9^2ZH;$/[.,BI(N6"L+@X7^0)F%VXY$T@SOR9.4"I4Q+0H]XH)CRTF/,X-ZL
MQ%"N-U=6=LB""XQ-DH,$;DFFZ(\!BL=I9K;@/A:LGE"HH23?GBJ45/TGOQF=
M=I'*=M?5NL2%+X1W Y_Z(,Q/R6T& EY&(M#'LM;=24^@_+T3N9AM?$N*S)^I
M=D#P-EG8/:84PF__&_6]?UX[#D9BU&TKGH<.*;#C;I0YKEVA7T(G\6<!EKN<
M@Y+HQLE!!CDP"G^#EP>2WE;9EG"3LNK'KNP,<!L&]S'*C(#:[!=*;;&-(ZD2
MZ.&L*K<UZWT$9JU[Z--0A60Y9R+:X4(HFA+^A!IUXQ;E[[ 8X8;K>S65IO%Z
M3F3//XF*#89J4C&*I6JR:XPSQB %6]!8NDF%@RCR/,]FKL3QT!65&ZKP(Y/5
M4DI:^]^'HI#+35CVF_M7 CQ!^G9+6G/L>Y(W.03^E.XC/U Y2\:H).FA4<4\
MD:/]V7<<X%4IE1.J[:'8 ";<HMQ2&5#X(U:9^%=4ODH>,?*0Q]IY2U\#<:$^
M/#&HV@LPSDN^;PQ$8R\+(%0JP4C08X?H+@=LMINM?OHJAX@A(9\XZ958]<F=
M0S.IU7_K#$>-CA[4634[BS;YMTYK4'BVT%(#J^UOL#!"IH>BM2 )J7 N9EJJ
MF:H</1*E@'"+3<"6Z@^9>CGVJ=(E,3-1N=0ZM3:*BU&U=6M>]PS/4\V,@)OA
M]AKNK+E0*S6C."R]+E7EAX[72 CNV\45>X ,]T*./8B%Y*=*!>2,FHKRP:)%
M4%(FQ]<W,4K: "E  LIN;C(C+2N%S'J)XI(-RS+ 0GT<RC"4]+&IEV!I+=8&
MI6!3U>.R,@+3M^4_:;=(JO@9D>Q$ZI!IS6/9\;<O55ZU:P ")^502G]3"6"J
M3:3NGTCNC]!Q,=[CBYB+'4OX5:_7&&D>)+DM=Z/G5I\W'A;'R\ *ES)0NYI0
MMBPUI[)1*5SUT&;=7W#FR.)+SMW!EHX@'T%)X7*PPB9[H\9 [1$13>JH6# '
MRDJ477P2".[PS(Q[ DOC:3PM@E4Y/J5!IN4UU 4O1NL*+*OX7F#G!#EM2;MK
MW0@;GXY5L]=(E+=N0LZ'^58(?C*Z4^U*=0?@:#[RW+&,;L@\IRCP\,Q&"QA=
M)IJI;<6>CKF^LEBEPLJ:5N^*;Z:8#\=C&$!I9A.0/? #Y0%6;0,-$&5W8!,$
MEY%>FB>I]HCQ&PXQ83,:JD,P2F:].+@5Z-A0M2ZJ\)+PF"PK*0AISCKZ=%5:
M6[[(URCCU8R3?'_L\H'/0!'W]X8U;*AO7JMZ[8,RV)3P15(QJ_%RQ@=E;MRG
M/C861W,'^ FV.,GGSL@TJ"@;Q\327HISIXY@F1HK(X:40.@)C&"F]8)FDC\I
MCU0CF\8YI41..Q5/JI4OUY^&Z&Q..-!-@>5L,: TY:GSG^E;("^'D(U)4+#*
M9:NT =?/^"MADS, N%'!)LN[1*B4C\(2Y6%C@H\T#ZD;OVQ>.^8;9.U'I:$9
MP9Z&]2MHE"KQRTR:<M*, %D>[!B& RY9?D9;9>!PRJWA36.?CZK!7J5(L3I,
MC6B,.S2A1YH;9BE$TJ<K3":<\0L30#7&E56"R00])7YDYH5,!^*9-FC'%,Y;
M1['7CV+WZBCVH\MNTX"3P8\EIRV&3)8X5;4^&V>*K-+V3-(4PI!7L?II+>3.
M- _NK#'7\K@UW 2^IZA#/6WH&:6(]3^^WNBS;(?E5J=!$)#MG>5]JJA9KJ@'
M67*A!":7PZ!O>TE1S,5UM5)67^%VKE E()2J[*E/FK,9M._6J:C<MC-)>.SU
M69;64-_O]N_WC#4:>6O%*+9VUM-=4Z*^CO)J/Y*..-FK5!=4@*2GRL AV] 3
MC=(86VMHYG*I>EZ^6(TEV\>2+\X8K6(5X7(F%/9BPR=-)4J=])Z3^%S;56$Y
M:*FMBF_(K8&FSK&! (B2Q\:R1CBXON3ML_JTX+6LSV4FW"M-F5(;(E,);# /
M,F 5\ZBT7L?.@ETPJ@X)O6X*_40INAEA0O:ME2 <=J=R?K!/S3"J95*Y[+?)
M7D7C_5@:4@( [B^8'K*\3(IJB@"D8A-S:[=:27&QF_69VFUMR^6%1+D+#B\Z
MX=< 9^C1?%6T'71>^N\^-8JD!N21=>50W<V53$.5VM#WM)1P:GW3A><7JB+[
M6E=DDVZ3J0*B[H]8\^%X)9#=%>@4W8!E?3J>]T)735K[BDF_-#NIM)2=?'CW
M,AJ+Q9,N%9%;I1>O_"6EMX]7]CW$P;Y.^,.Z1#>9L-[]?GWU_?*]\@'*JA:5
M26NU!O_LC%IVMPN;0[80>U@3*ZM[,OA3@C5G:6<"JGBTSE719-KA3 W.Q>14
MQT67';9_1:6;/-RMIC6GOJ;='OZCLGI0%Y]$@(^F*XHRP8']DH]LGH8>XPSN
M8V'L=W*".>X\4GF)NJI=544;:=R4.=AN=EMZJH(>>29S%+?F8M\I?G.ELN7/
M97U^FM9?,(*_JSX0&<YQEIJ\5V87JP+^[$N(8A6!/[I5!>F>FS?7R!BD5PJU
ML2N F%(YKGJ3[JC J;YR6I^<1T([P+Z@%/I&9._"QL6/B+NM8+WIU^EOLKZ"
M*I'<FQ KHT(B-ZS-E;5^[XY^_7)Z=?1>U:MR<_)LI#-MT#!SO&FF;YSP0U!<
MBC4(5DG-,7QK%K!OTL_C'SO2R>.MM[Z]UJBEJEN0F8?"J!\V[Z"J3S5<)C"1
M*-\H3U7H4!X(2(@HN5D$"UWPRSWXA:Y.N,+"</T]1LDU%;S[^G_;S<[[BDX!
M5%^3RPARK'YC\'<NWHYUTH$F,9.LN*N/$[+X<:Q6KS'\NYY.R%5)Y@]5A=*[
MQ?]M-IHM'+2,I!2,<71=;'6'Z:8'HZH]<U7YQ"!N0.!6L]']>W:G^<WU\0F]
MMW0WF02N]-CR.N6(>N&KFU+PABN)'Q;HBS'$N,G7B(21PC%G?Q)P\@#^:5SN
M/ZD34V4I_KNCBV_GP)$4Q6]"=?M/8KJU#5BPV.M"R0-DT\P_^7*8B5+1]IS5
M.!K1[GTH)P3Z>3I!$Y"G@_A>W4D>B;!+Z!6$*=*4X:LAEY"RJ MT>_GBFN1,
MY,R\Z"IMJX "A[:O> [FE,B4/Y).""[*>A,\680BS1'HW?0M7"$1K6P2G1%*
MCN6!N,,:: KN'"<+R@51@@',<^'?PC^E<&,(OP4IL*'B><8IU_*R/I-2H/3W
M6O.L&.+-G;K2$<,9S7.<@:C(0'1KJN>Y["EFYYJ*N51" /P8M*8K[&@K1[%2
M)VI@Z?ZQ_"L26'X@'V,KF!*?0R"V /-:2 K)CA[=WA(CT:1]ZQ1^979,0Z<P
M&IS2IS9-O%P;-+/16:&QV;X@S(8T5TH]IV.>YW)%*JM%39OP0\R=#$+;^F:H
MNE]S:NZ5T284U+'#2]("HKL [EY!<61(4&*I=OB6]MYB!]V2YENR9\K"O (G
MO0(W.Z</#0[N6H4]HLUL(ER$73.ZGU5#W:7<("\^3N=^DH!TU:CE.J7&3*GI
M[T]*S2N!J-!P"2T565Q2T11/]S^A?&#W)HE5(:5IE>N.4ZE]A0EW@3]UPSFW
MFU&IL?=!& FJ;)9S.(@9&4EXUT8UO%U.HE$I\>%;0>\M)]O8PO8ME(#KQT8Z
MHZI[QEIUV7U)MH^EMZ'"F_;JDZG1"R'"8^[CB Y92EMTP2@;Q]:_L.J2Y?0%
MEJ92L?X95M"#KOG S '.NA"AX=%]YEA>I=Q9$F!L?OR4S43,\[O; (MP !4"
M;H,#![MS[X),)XB&]#/ODZ1I/S78L1O*PY4Y?@ZN[\PLV[DR:.J3&ORE)XO%
MUB<7IQ(C$_@DC?H_P2!4A1XZ40<C4!><3X'S0*1T.QV75A;N\)5OI%STJW6+
M',@SE5(%-I8!.6H"=]B_#9L]'B-3%N&*BVC(BS!<LYD-D)L'$]+I;?"!?)EF
M_67:B"3QM,,<5M5@%[G7[!ZWEZCTV,#.-SGV\4L:TVG=I-2K36NCF<\9I[E)
M#-E+:*U#>-WE 1PU+U-'8:GM_)G9Y"KM3%IH<Y6%:-90SJ41IKI!W<CJ:8VL
M#@]5E\3$1*P"V9',*L].00BFQ_#_23]=<'-DV+Z@\7B@7_O4,=P8;"1[7R*\
MJ[MLH3:,[N- )DV5,5H3>PS<UGOEN*#>:3:4EY<I4L>W4WS(=822XQ%L[ME[
MK*M99"<JPF?L$0E?PI&)/.$Z/%DOA!EA:J7R^JE2@KW <(SN_XA&!469U!:S
M5&7 \0Y+/V4!.G>V<WT.T@!@J$**6K$@XNG.\E.9E$BA1NY::902R='8DVS'
MKT*//1OO5SAA),E)%N!PZ!8AQ9UW2_#!Z+Z='>B$M9F5/=FR[4FW,+QI/TE[
M0YE]NJ!.*#J-!;0B+#3[!A@^_F%;%XU/#03[+X$L/_M$[<' ^MU+X*ST=I-+
MMEWM>G.RX/H4-G(@8UURSNE84EP7@6<;(VVY=X5\LU3,Y5S4,\^)(NO\_%SV
MJT?''+V27J4Q6W%B[#-CP4]02"7 =#UZ._7,D&.H+X10C12OL>A\%GC$8E^I
M =F+V)Q+7P[:.=5=_0MY7'NH)V['TD"82X#-.&JH.B)BT/K-PHQ[$%$S"<(X
M\7/A<OX=5T< "/LK$*YQ@,7515X >'0KK$&;1W*0^MSI$>"X_/0G=ITE/42Z
MY$";E7WM22!RX0A6)\M9"F/,O 1!.6>G'&@%U]2 YU^.SR/C"7E3#I%VO<;5
MT9OB3E0:Y]GG2^([V$W<=:Q?9'$VV\C<Q&+E1%@?SN1)$>[*:A2,V%UIGVIF
M-RKGB=N"_H&YH^F>J']/ZJR['C-D *=@:Z#S\?A;NW)0+=.K\&^=6R[+!GFO
M,D-M8].V3+?W7)DUFMT^.9!5-;H>LS+16N==.E349JT*S;IVL]65+#?MWP&W
MT6R8YY?Y*@H(#E9[3*?I*R.^&<7KE7ET(;#G,%C(&)9(Q]M3*AS=)&F3O!F%
M":W1<" WI/:7V0K2(?7O)P%//SUCSPQZ;7RTX'&?F 6,?2W0Y7T]G@6!Z1.6
MFO;78$Z=PY$!X&[ O@JH8.E7A#XGS9P%<YR3(82N/F>9F+$S<I*M_U$FQ%*$
M'1LWPD9F[B(S*Z*RAH)&U9B]R[4M0"4>J/NI16Q5X/ @U4XUZ=R*?K@>-X_3
M6Z[3*HK"2*DUB#68>W*8KE-$SS]<BKQ8EU'D+H)[0+^81JEK?TU1U2MH%TR'
M<H74.@%3BM*(Y*Q[:OE Q(X6IJ?:CCG<GD?6[&!G3G1^(E=V(^<6Y#+AK6Y$
MJ5K'H,T#-&"@-ODML:=,' LY2(F885#:$29MGH%Y@1XVQZ#1\PN:)#1^VBCL
MO4%T[=],$]8O'!IF34R.O7+97*)/E]>?CUNKDXDNC,G+USQY^?>S707;>E94
MSS"B=&15.QBS,P;G!A@7"HS&#*8; Y8;IA"5S+3^_<SP$>D41:P:H6P>)\RD
MHAJR9NYRJI\<9ZCR5Y5/E*ILQ ^KUS3'%#J^K CF_&YL=84%@*Q?R.SY-,:,
MT.A0Q8JJ8BD]IO10IFMQ@VN<8A#*%-Y.;_B>(K4T2S!3K6R<1&]9ISMV*.52
M)4QD7+%UIH:9J3&H,S56@,B,&#2L4RMRX25 7FF3M!*4#+G+HD;,U#\_I9%*
M[$",9X$YQN-^%J25;6.,EHPI_ABX$W.N#ME3+$J)S32HGRRE:%0S .'#-V,P
M'L;63 !882G*():N5SL5MVL0+@\=+N;U=P:8GE]*=9FX"U<= #!2LC8Y2MH4
MDJW*=9@/LXMV;_1^KZ3X'GA*RB8:%D4=Q[:GAHB3XB!:664D_0: -D)V5AS/
MPL"G2FV3!N#/8[/E+(:_SM)A>BJ5%HLA9)S'&( BB<RH8L'"BLQJR\1QI7Q/
M@V@9>EH>?=LK%'VLHOE)T&6 0/S_V_ORYK:1)-^O@O!Z]LGO033!F^XW$Z&6
M[6[-^%K+/;/_38 $*&(, AR D,S]])M7%0HD2)&T)!["1.RV;0*%.O*NS%_F
M9?U7_T/-?F\0,X_ZF/>;[5>%D,D71J$YR@U:RT97!LX 864IP#F,VW@$,HB8
MNR@+5Y;VJLM>!:-D*UQ@W1B(2GHQSUQZF><=T'2J2Y"?@8GUH[H:!Y%1\@L;
MP-W?L)>["6>LT^9_R(>,3FPEK4G4;3.^ ]XF&<^CP ^]A=N)>,'N-C:+8:IS
M@ <[[UF'D3%-:ZIZ4U_H%K,.C-67H1^1Z9UB,#$-%(Z$D@_G&.:C.BX"_2<8
M"])1927.@??G%X'7;K:;@Y'OMINCEM?N]OK=4<=SVW6WU_/=YN"?G>Z+@\6,
M0/<YCA0@K\J&@3]^SD$H?R+??V](& 0K?RR%"FLQ^+X9B)9;H^ASL)&K!G,P
M\QRH:?%E@O!$S/X<_5LW)EG&+Z\A-O$BUA]8S,",Z1J43NFA,40H\E$62E::
M:MY2TM2"UHYW['KB:M)J:HPKM:*+P!!%STQUBK>"$?6^B:@*!W;CCKK;_V#S
MPF?L\J4/Z=U9!K(A,"39L_(%TRQP_MS*@);.N1J,WRS9(DN]/#@K9;X&F8GJ
MB)1UK00XM_.(A@I0/N_&P'NNQU4#DL5'@-KBF)3-YF?*?O8F!HR0NVE_O!/L
M_F,7$,NK+'"BZE @Q>1<(K"J?4-^/V$ Q.66@TF ZKYJKIE=(_5NTI>@9GU>
MUX[";&B!";=O[L&UV:%>^;%AQQ[T? \-@*S%M(X2,XG676P5.F1,$,IX!J8&
M.&ESU:-7&I9D$9K,;I*@<9ICZZ,UF7C<GIX[)G+"U.77SZG-]3%8 @*KRQ!!
MGD,G<0)6GXAF>JJ @\;N(PP843\Q9 Q0.R[U5R)8'6SRH?N@H;6.N7WI+_CC
M3U%319=/19?21"XTNIXH0CR:RM5-^M)@W?YJ7#X1\YK':M8G\FVP)0;W3Y+F
M+YH;T2BXB6./V56:[PG^!-E$F!B9LMDB]M8F7>T(/YI[4I#;YJ8,.!MX1?D@
M?R%@43;J5/\_G1DBS?30@TSRQWC.1JFTQ%9/X["OR]M6?:1MQ^95N5^03FGK
M.3)0TEZET>W5>KH'#%G:]PEN!?RYW.FE)"WJR+:7G2M"H&1NX0+]@!*$R?"P
MM(I;J=76")L<?&UE([QR:!J[$+XP(D)YGS(^:@Y7_@LC(MI'6'FF>5@ECE9\
M%M^GKJ.E@-'4V6VA5R&5DMK6'Y><3_/Y[U=OSYU^K:1/ZY$1APKF":8$,%H_
M;[ET\9L)30B[P\9N-J5DRR+3=1L=&V:9^X_<SL-Z[WM4!ON10]-T?N_ 3LY=
M2F764PVKZ@@L>597X-!^S#X%E[];9_CG6S%O%+]^Q'F.SS\%\%9D7<8Z*8(:
MA?IN.!MC<XY7>+K8R1).#&^9>2G4;,D0J"3T53<EE\F9&W1I8I-A"LD9;C:+
M)2-?I[QCNY54&UK,&.I=997!7%CH\268$GJJ ">AB*8!$8GQ5B_?:"HI&&*&
M?!#EHI!3[EYVNO0,M>5SZG7Z"Q7NZ7$DH! A5(:TA6*<PQ7=_;!WGTT5/9PC
M3?=S=!60$,!BFH(AR>-^IH#I53XYO X92E*@="M*XY!\)()7GNFB(*.U'AV4
M;MXI5Q-\< %FW-SI=IW'KP%UZ]8-7(P%$$OS5G1M\SVS28QJKZMP[3>P;^R\
M>Q_6#*ULV"<"$_]MD 4A,\"]O?8V=)0QM$0WK1NLVM.-F55;#XM _:B4-"EI
M)?6L$R=ZAYHX<0 QMW)V]:/;((DC9I,<T@X5&.C#X1C;U:5C+ V[0>YAP9Q'
M?\V;IW1F9-\_\8T\-YS?DV^K3%,4"A2P96P/R@<QDZ,,H5)2]%=L]KFF931=
MV:4S:99.UX$4&,&VFZM#UWG<>:?0]=$K)W;/\EN,A=!G60.VE*!+PGG>'UQ7
M#^(%1<X%NIVRNH.I608B7-[<U0 U8Q\&OF;=XHDOM%Q=#?]/63JH%P*$R,;O
M$P0T795PXWG0C\-@R@W>W/R*9((][SP?ZVJ"*.^*1A<J 7]*>C[!>%F29M*S
M&2R4"0;RE V#'=LH YF0S=S\34[\U<IX0)>U[+8R:J&HL<6.Y 8YJ@N/E9#^
M$O53?6RP>6W*X1!>2OE;.MG8N%O9 -/V &1V^3W);T:[YXMBN^>3NBGY;75;
MZZ6[DCP:@,R\Y-W;U)Z/\311W/GB\(?^#=Y7HEV/-2U8Q#-S?XC=EW(C%HDZ
M4T*<A-G0C$RSA"-RF&"823MN:KA[/M"Y&/!Q28HZ/C(K.$!G0EFO;!A^=BSD
MM65V%,'&(] 5+_I85GE/5$36)&ZV,$RJBOGI-W!8(L[T0>T/CK0_5]?3'%X@
MAG"C[XI34M$:J(K<Q72>U4VD!VZ(/,,WBL'"S'3@V.C.+A$2!+]$UUWY\$V4
M]S=A/*!"1ADFR7N>+@QS-,;+EO1Z ARZON*#UB?D<2:R_%5.P@6A[Z[VO%&D
M<WT5)TLPHI\)ER&F>7YE@2BJJGLOIG!+') K#U6$MOQK'-V1(BM83B2>^W#.
M<!V"*'4#]B0S5ABC(6/."U&9SZD$FJA;5:*&L1O)%8]+36KG%"I8D_#S;>PO
M#P'L,;M##I$(*1? <N@ZCYEBYFSJSQ""#P6#47W*Y68-';[$5'!@<LH:'F6I
M1H\O#@_+RD<__-Y,)9EUV_'488H,JK]+@C0/T7ZCL.Y'#IZ^NR]XNJ4=<PA2
MY%NA>2VCLX"WC)+C?WQ.8I6 +8)NEE\';1I;UEUPY3,JI(9)QN>4W#!-_3?J
M#[]X03H-W?F;(*)ITTN_R$9*' X#3R!SJ+)"Y#3M+/\L,:E^O]:M=S$L-4O@
M_SSU88E8U2AB]7KF+?_6:M8Z#6?ES_7:ZM_6#>LXM7ZKO].PZW_K-3K59(]J
MLNW61L.^)LIEZ@7^0"[Z\XOFBX54FS>-Z0_+*9HMF$ZRR"+,'0\M<'KWR9LZ
M)]HXG7H.ZBH+UVOJ;[(F#J/O9U5+BJ/.4G2]FEBYWN4SK.-J7YS.UEQ2E49A
M YX-->=K$B5'^G\ZL^AJU%+3.ZKS1(W^4 M>2>M+XXB^7Q[JI#:V\1!RXCGN
MW<N*(A]A5_]T]%*[?%UG'KH8B10#Q1D,Y:6O5I)0PSE!,7Z616[F8:_95]N<
M\L =?K])$!#@7":*=ZBCT;K%EQT_[.#3.[RT\,]+WNR;#:S1>]>]B>#8>8Q=
MY['U88[H?XN':=%_^X=\JJOJAA:/=IN5UZV]RK(-5[ZD^K9:HKFT!$<]J+4Y
M?;O;[Y0;V;O0\!;+W8J/%SZYR,<5T1T5T77L=K-;$5U%=$^XMJ;=:/>/GN9R
MDWD[&Z.4_@[OD!KUO9S0/I:ZE>NWJ5-P!';DZJRJU>[A=OMP)+3>M+O=UI;D
MON;4'TL@;>I!G>HAM;O;:HWJD)[<B6E71W381[2? SIXO:X2,*(X\M<35/5D
M\<F'#+PUNX=L,'WCJM2EH.I.YI+LPLHH^S'*E@8JZ1T=A\TVXHB<OM,ZV;KM
M.#M&)ZN3/>23;=JM]K;.SZD>[!$>G[.?Z.W!VW,/=7F[UQ5_B%-IU!LOYY[O
MX*YL?*5_),1_Q@;'4CK#@^W#$;FBIW>V9')49WN*9TM&1W6TS\3D>"8AI$UM
MK8,V.23&45IO^2AQCB,58;VZ\\!.TQ'[3:=VN&>.[=1[F^NGZFB/YF@=NU_?
M,?GD%(_W"$_PS.DVMF;-YV=['&&XXY,_(PB$'?T"J5)I3K$G1H95UQO+J8/;
MBLWS_W;:@\.F_+-&P^YV^KOZAYOMP9Y]Q(JFGQM-.W:CL7/,HZ+IBJ8/CZ8=
MN]UJGS1)GW@H[UE'\EX3RLY?5G2G*@,LVJ3!Z;ZAU]L;=1;+X9H'<^MEL];4
M_46,3M8;(1[9BZWJ-WVSH4#)!/H\\4>ACVT+SX)7EFN];!2:GAB]LLN:>S"*
MK@&<AK/X0FV FT:W4050N[J5, XQ)<3!"4)]3A&[:1CZ29P&J0U3X[DYM4;I
MW+PDN]&0V30E1(\J_1;,43>'0. I@;)E_#GZDOI4_4&VH;& <;=N$VB?$"/U
MUE^Q#;<TMWJM73JW)=C5M5UKC.FZQ7'&ONL1RB2]<Z8^VB_]J!I&6B@-$[P\
MCZ@A"ZUNYM_$2>"G1;)+N>,#]2K#+NVP+:,4_%!@"Z9#SY=/P'X!3>8+9M1G
M/#.ZH3>:W"K^,=O!_%0'6UZ^$$2]ULF9U=^=()P2@M -:W;K\/PL6PWT#[75
MP($">A)(_B:(SD4=53=$[M/JJ""?"F-A3A-LMK1&POQ$?_1#.)P"VFKQ%!Q#
M^.[-4KAS3<17=P;B:Y QSB*,>J;T9J]43"HH5O\']U17H*M%$5NNUQ:!BF$>
MKD+_!^F)30)\ \XXX6XPRW,O43;TU5;IC#=#LTU7-?K2Z+6+TU7?\*@M&?<E
MBM:/D.\Z?FRUMM "[; PAFG$C2!2R8Q>ADC]A$U_'@DA]? D]0. IF[5CZO"
M3#U29,]JLA5F:H696JY)^&9SO=ZH(%./'7RO@DRM(%,??6,KR-0*,O6 =K6"
M3)U6D*D59.K/W2M7D*E/<:H59.IN2SSL._U.T^XW=RS#.*!\[8KHCHGHVG6[
MO2=PQ(KHGBO1.4V[Y1R_I#OQRI1&A<518:8^D\Q1Q['[6TND"NSQZ4^ITZI.
MZ<!/J;$U9EYU1$]]1,\Y4;Y"3:U04Q\?-?6^E?\$ZN+Q^ZH;+OZP14NW;?=:
MVTK2K3;@P(,J%0D?.PEW&K;3>6CDGXJ$*Q)^TEABIW?*)'SJ4<8=->BI^R(G
M 8%3(?[> SG -F0%'7J*9\O&576VIWBV;'549_M,;(YG$O^L('^?$71HT^[5
M'SIZ=<2NTZD=[YEC=W= %JV.]O"/MFVWMV[P>L+'>X0G>-9TM@":JR(>QV-]
MK +]W<%;6HTH>&H"[:S;L.NMG1L?/<!&'3O4Z,]1Q,%QT</CD&Z^00?.*E0E
MTJQ8I6*5BE7N896>[=2[SY=33CR(YS2?<Q#O<=!^>:V'!-I%"'[; @ [31-[
M+L?UVP2^JQ36;X,7[\/_=>HUYV !@!LK0&CWB\JK)]=\='3BVR60Q9_9AC58
MM+;"_74,W-M'!1NVBV"C,)6[<0!#(72CEQ'&9!1'YT,W'0-?Q\/OUH 8"7D
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M$,)IU2QCT"*]C(&#D0^.9:5K6>0?OC4&TP>4/)KX7H9NN3N%/]Z"M"(Y%T_
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M\S#$3FH\/<(.%;JA(7Z?>@@S^J67U]^"93#U:4QI1*+'L'-$(/$#14?14U@
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MWV\R,59)C8.?2DN3!8(F#G]!DE\Y#C"R,L*3RDZ+JP9-!*SZ;ECE8O_F(HP
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M2X[50@F]D%),/[+Y=!>:>: <TMHAR5"DWTII9G5R"!1HJ0@B/76=)ZEI$RL
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M^K4T,60=LF\LZ;V@>NKLMN3';?*WM4FS!^'Y;$;IP=(1QU ,NA1!I/HL.AG
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M0^Z LW,0OM%#4*E0.46%?N%4'BE/R8#/A2HC%DPTSG@GFG=:UC</'S<0M>+
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M=:*<^U*GJ^?06JHUQ[9T)+MJY@DG<I,P!0)J )3%^?43"7 5 ?("R N I/Q
M@R"$&\N7F1$9V[__SZ^GHQ^^Y.EL.!G_[4?^%_;C#WD<)VDX_OBW'__X_36X
M'__G?_S;O_W[?P/XWS^__^6'EY-X=IK'\Q]>3#/.<_KAS^'\TP_S3_F'?TZF
M_QI^P1_>C7!>)M-3@/]8_+,7D\_GT^''3_,?!!/R\F.7?YW^%8LKRB4!,6$
MI6,!KZR#R+GE7'-9BOH?'_\J5 B*J0@B* 7*>PY.&PG2)^36,,LT7WSI:#C^
MUU_KCX"S_ .Q-YXM?OW;CY_F\\]__>FG/__\\R]?PW3TE\GTXT^",?G3Y:=_
MO/CXUSN?_U,N/LV]]S\M_GKUT=EPU0?I:_E/__O77S[$3_D483B>S7$<KQ]
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MB],\B6(-BW%9PZ!8UG2:%PM<1V.9UQYMI^S^!PR;JP<^69]F.Y$V7*971%S
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MBV02FR=QKJ;DR<&@@<![:I$Q3$.<GG_ :E<MQB\L=D%-% 2K"EG,*&I/;MH
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M]@N(#E;<_O"PB;C[Q\%ELQ$GO!%>@XUUSI[W"(%.-& \"*TUBU$UCURN(N0
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M#]J&[W-5+KV_:(U.K)[AJ(ZW$P.MLRZU#Q13FDS@K"(=A)Q!EL4IJZ7U_9C
M^V7S$:V3]D!M-2MQ3RCK*R"Q \MKC,WU1^HZ2?"!$UH6[P58FV+M)V,@B"*@
M<*VC*UZ7W,N0NJ/@_OLR?/28["NPL8,DMF&9,8L:D6R0;+#V%T)P)2(D(Y'V
M*M1>',VXW^W9_+[>'@_*CC"D<>.D?U,GZHQGP[B<""B8K"VX(DB%=<H]O<(<
M#!@TJ'7*2?>S?/I@YOLB.3;$'.&%V\/7C2<?/T[S1YSG;QAGNC"T)@+GY.@J
MQC@$)BP4;8+W7*24PY$ME:V9_;Z4'AOB^KK!:W/0WF:,#X12%H6M-FHMHE:Z
MD#YX E<O++FUS)5>UE(OW'Q?+$>'F3[N])IUO\S&A,"]!..XJ%,++9#/9H&Y
MF$-A!E/[%)'G..MOE]OI@RC[*&?]^>"+-2*!B37 ZEP$V@PLZ!0E,X)S*UO?
M*S^M67\;(>"^67^;:*+_\6]=J'DNL_XVTLS]<^"V$>L>9OUQ930+$H1!.H!=
M$>"4DY"2#2S83%Z@>X1*WF367T,=;R+-0XX%NVR^[C53QD=(SI/'GZ6%((V$
MPH/0JO: 45TF^&SQZ,,/\]E$4]O.]]I"S#TT4;O=>5@I470@XZD$1HQSK2 @
M,V")CJQJOQ71.K_BB?6XW^78WUX71U6N<D\OV2X\?>]QOU&/^XU@LH]FX=OH
M^*B*&._KA9R$=5P6B*9XVJQ%@& #!R[J(8$HF6YM$#T>W&[4X_[H8+N):GN
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M9S.JJH5"FI$JJKV[O[NS]7TM'!@JQY23?A^+%]GV/CG!BP4I;9W.1VZD1PS
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M%M'NRHJ+&ZFH*4O)*D@"(!  H,DH6#LXPF "@+V#FXN:M!C%71U="L0!  9
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MYF^$?>U;"HB3N=GXN+F9V)G9_N"H?_KP+])U;+]S!ZK?8@;"[_L=^YF<8Q8
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MU\=Z(!U!LZKTO8OKD2U<4?2EUB.B;+A.1VO)YV!/FF9FO'K,(U7$5]Q]:?R
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M<L]0S)$>Y#\B*,1[QD=#H=@JT;5IM;)1@512N&OUL?!3UR)XJVLMY 3[4&:
M-?U%L$^ 62E1T&CLG&5BJ/<="ZSSZ,\H):DF4Q2_:="#.LW"))RP#^$#R%\
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MA?COS,T58\4$*2]@I7LH[?M9'9Q,?"!2%-/WQY34+_]!#?_?(-#5-( $@@%
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MCE1(;'".5N3G0\H;A(DM9[M549C"%V);Z'-XZ)JM(FS6AE^4*L>GB$OYPJZ
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M3'Y+PU*_":>SC3;FL0Y2_2>C+)NM-% WG+MM2%,@![J@0SN"W\4/S2@8XX"
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M8!:'A <^/UN1/,L:4;_=I/=?B+I'Y'RO_O"_ML]_0#TKE\D#M_Q@)IZ8]C?
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M/46Y>@IFYZ+'G 6!>6ZOHI&.WGFYKQ$TQOS&B,L)70H\I["C ZR.7*=!US]
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MJH:[7T3G<MI_IG!&_6*%O+T[X8N(#VV@*$M/"<6U>7+V[<+@?M@VQBBO<Q,
M1>\3? N?[H,E5B-=ENRRG^0SJN)B<AY,"=%AV#J-.T26;GK"\$&U45O@1/%^
M>F@0?R)0G6*WVJK[ZP0<-5D\3LC+N@:8+A"6=%^NJ<2'=Y>$H7\/D_ST3KI^
M1/YS098:&HKA>"E(%UA:(*\ECO] K@(&ZY4.(.S9QQ2+BU_'T /C&H>>'#$Y
MF5D-EC(P$_1,6^&/JS^:X9BNJL"=DGO+@..RE)0F\4"6]3NY_&4T]6=JV7G[
M9QQR6O?-,TO<%K)O7GU,UH?6ZTO!BZ,!\K+#KS%6(CK2TR7F,3M#>7,SE]V
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M%"Q4WE8UQ)!M#:STUO\H%#SMEJ>J(X0B6D/*X:Y]IC2)0S;L\\BOY-ZK]H_
MAI22IX\_1]1S8/6./EYRV&7'$RM+7\D9IDTL-0[*"1'(5)9FG6_&=TKP*@ZP
MX&;CC5ZR $J'^^$80&[5W'M41->6U7,H']TA"T/DMR\7[2+(@@=##L*_QO:/
MR=,O_]7H;>W_V2X*3;A6Q(Z.4U)/!]TJWU\IB\LI[?>DFR'YA=X/JQU#5J=-
M5;2@'C8+'\C=,E5[ HPOS2[:-VD7!IBU*\5/52/ID"!\:4:MI2T_(;##)B@.
M#YO=H*1[/^8P=FK\4WG>PGZ9\K.K!J40F)7]%KC;?@S9U$.G^$/M>1,4DYA#
M%4&YE =@#T;AM_;M^!I6NX^)>C.+CG63*P*3HY+=)K:]W)?)<X;8"@KOSSNT
M)\JV&C8]_JM>X=6FB\H;.CEAFC5UA6N.JY .OY;!6M1&,W_X-_)UZ\7.T1HF
M)VM7RP.P)__/)_A/+\W>Z3AD<XIPW@+V[;S[QU^9V5&='!757!G9.&N:$8(*
M;.X@ETQ?S)7[M+T2'%MFU**A"IW] <@/J:QO3(+5?QNVGJ#KJL,5! :M'14*
M-],%$C M;CISTO*"%B&]\5W_N3<%8EH(?!?_,:=+\5UZ^3\Y%_K_,XE#JDGX
ME@X;=IX0  QI7*K<4HQV6()4+7HE<6>G_DUO]\B><7,M(,9=<34Y-TZ^IZPT
MS)FHI/T?!3271_!^L*D<(<\G7=F7JTN?>L,*A7\$P)LH &1G0'X@'U;#499/
M*G^@" 30\4(H$QY7!*_NCY*!^3#$0L]H;U'9-=LGTF4QP>%?O!GUE_+=_V8D
MR0I:OA7?2[E^Q(<#K&F(5_^'P]M_8XK4A_>VGG#Z_D/0[!CYY[CZR&@H0=DR
M-ZR5/RS8&^CKELFZZC=)AY44$>5+TCY9V<<2A\+.WWQ>CZ92=;[/0TP0<H.C
M'3IA-I6[0G0OK#*:9,_1BX566B&B.:T.7%OUPBKI*N,Z[%&6C6,=VALB^@T
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M0&#PH_PAZ3"!2/FFL2A.G-K*$B&=5 ?AL_>J.U:&'6M.Z\;?*+5:?9N=1ZB
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MWC]BEC])Q#]L6<362";QA#]=9U+>P?35/C :9]]PAK.81N<FQ8 1D8B/NWD
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MW'I^(!6<&.B5PYJJ6JTE\$O%:<GA@J=]D Y)(<*[@+?;/7]75>&&1C%EK"+
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M#OAF,['<Y%.2EFD^/!8YZ^VN**@@ZHJ;U[% 47TNF_JT2GIB'C^N;,*C*TY
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MD)H;6\@2PD\[ W\>GY?:FI%U@#M )8" .+]7>1FA,K8Z<D\=>UJUG+IDDD)
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M85^F9C+UV_:\6!ON;=/!7_D!55;B?W5"L&W\J:UM(^!!C;GH+8+F@IH%EL2
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M^B2D:WD^-,28%8%EM34G\WUM,>^%66X42NY;*=(%V!4$J6P?D7XB")1:IW@
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M^'B++,R2^^E>XIYI#NBV@K!WX*_$.M@D0X<7VXY6\2:U7J"#!_6?XO3^/QK
M/QD.ZF+KE*+HTK\5=O['E>&+G8B*5[.G=_[_2^7D]29Y7\*I5?DS<V>OEP*M
MDMU4:W2;>"=);AB7[\7#;ZQR^X,:)C_U+N]]_:\._Q,=$C4 +R[Z/"N@E7K<
MZ6 DY/_W I3[UQ?YMBV[J3M8^\W)&4,90]E?YG!'8IRS0<A*7D1PL2@7=39]
MB:^6M2#^789:EMQ70#R@1--$ 5?27V+/T*%D,*7'EFYV3Y0236&A06,ODS&Z
MD( >CYO:)A(F@GH>5C:-+PBL#XAN+'DC.2R?_,T"(0T5I\C,377-;@UU(IPO
M"M:Q(XJND2).,O2?:%8+_MJOZC411RB@&E^04U)5]O6/<*;<]&/<YEUOFDF@
MKB;>05Z'<HCPK)0FVU4)?F8Z6Q9$M>7.,.L$.X,HH+>^\70W:UQCI-B$L. P
M?5]1V<FR=D20!K?O$1#F'$3=D3W3X\G8=!(\=#YHDZ&ILA\(++,S_F4T+1DA
MC[(QA-&EFH3DW!V<8YYQ5/$6ES=?B$N:SN5G-T'MRL*6BK4)?I)"T46_^BN-
M!MM@%P>E)KXK S^ID%[,6L/WM>F'RZO7NJ__IL33/?7S, JT> "@=O?E4( %
M20\!CR_S1_9PK>"<\Q=$5Z0!&6X&%D:Y:I:C:P^ %TGFL_#L"@HJHO+R<2E6
M:EWL6T4EK<F S8D._WH;N!SM@C<]R[*$D1V[(G,<%@U-I2CGN)"EA^Q"?)XW
M<:.6D:6R!JB<C/E]@YJ045N_2(0>#6V9H?Q1V=>F/\B VUY9[FT/EC"_3F2I
M![ >3;?!*-O,3IK?6\;8 ('M59JF+AI[?_JUT?>;3EX32\8C$5"7ZK#THG;F
M(,9I!D?+(YNQ?1C ODJKV8MU2GT&\N-IO2\(A68SNL8&)H[W .BP&X9T<%%C
M3\0SF_ZDAQI 2*;2;]L\.'HTI9[U&$#&1T<GHG5CV"%/X##,"-"E#8G,R#,Q
MH<+!.%+"^!C5*+J)B1&;PT38Q\NPS:)L0254^P 'H@6%)<4"7RV[^?&T=HQ5
MD1G?%/FBSUHYQ!G0HDRND4WXY"H*4]B2FF.!>?;D^ 1S%@G/;'"K'/JOO9"V
M[C_^=_S7TN5GNE(/#D1K>%$:9@]MG2:Y<D2/&JOHS]C6,A28-#V)6 _S;HL]
M?5F-AFU;MY)@D*/N=^M'XPI.>#.JX7A%>S);#$<B:BK,E8  [[YBH7%&,/\'
MG>!?Q*.3'8_:O53XZO/?\K;["]&@Q*8%;LAVJCAR3*8\>B^_.7%QQ/[[L5+1
MM_0GR8\PD8]/3X<%IWFD#@.T>FA0+7X:_>;AQ4:2_=^_F"M4W+5H]Q8*Y;[B
M4WMQTO)L_$O$(V :;1_:[)I49S;PG5=>3N@$RJ(I^JNNFZO\W#+CL;$P?^59
M6L>D8&L$*^ EBHGD"\<REP0>:::[MW3T[8&92Q/P8G49X]9#EJ#8<<[G"=-2
ME*YF_HP:*/*K=U6'-IL3R0@T>2S5L,W5S"OJW2A9/B5 DUQ'LC\9-8&6/4O9
M2N9EKVEVAZ?Z3,.E<YUQDGF.4&*1?+(G]L>9#2-<TN][NLG)K#EH!'A'4[J^
M1)@BK3'EW@T'-:I>7GB%E(41FM5(WNPQS^07V(P^\YR7-2%.>WD ,R'RMJ9<
MG5\0^)Y1WA/R.4,:6:^G:YNR6O]-8KR+<[_Y[8__4/Z-)9A2CQ1=1GU=^]1+
M^XIJP"W\I\M7<X)>O*VV_E=B/P6B/V+\7];$I2Z8%5UXGO1:-^)O@_2O!*,Z
MCC\=^O]W(*;X(PZG!N#^ST?I7<L%PQ9]/KT$O7_WB\?Y6G_?QW&A(<8P=SW_
MU_=VL$D=U5#[F27U'!_IA.'L>3Q/!5D:A^,1N@]%B$A]50WU+A5J)[:33H:.
M+Z\]2XLJ=51B96$!C"'A&J$<J%>#K:JAJ85-676-C&DIEP?%5?2CSML( 2C2
M("RL/:O[S#U=3XG^V#N"+4^J%9H?<>A^*UZ"_U:!AN@K#I"80#G^,@0]R22P
M:#QC2:\@[0D.:N,\8=]6UQ.%>25.6\T<BP&&4(>VGRQP/#/>0R.M$R0)'(.B
MPR;@Z)CQM :_?%%=5U%2UX[  !@R$#VP&B+UWT6$$MR27.R45H7W-V'T3@)C
MN"5GZFWW+'?CTE7U%?=;RXV^#X#E +FR+*)'5,B1@$J*Q:+,G>W'(*<2)<?*
M@K=%6;+[_6=X7!M:94;^<OH$?&R1AHX'J+U#*#GJ2O*%P)GGN8OV]/2-MS)_
ME&<%A.F\> F+#,ALD1??!Q-NGVDB.DE^S I:@)@S4 9$W?3AGIX:GQDY4VS3
M:=IN>9Y\(65)C\6=?(6;V%CW?A-5Y^EXJ6*G;P$2+JQQVM8Y<8%[[EC50"28
MRT*,TS.+0:4&XJL!^T,$QQ(54D1[1/ >@R6-,'6R?+LGV2_W>:2$61\-1F-I
MBAY5/!,74A6W,0LC,3?ZA!3@M@GD=?C9&;!6@N"*2?^85$9:='K^](<]1-(S
M>2S44]WLLJ:5R^;::29/A:I^?*VRS7(LV&I"=IFRBT[Y)A!3&X[_EG\[)H[
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MQRZ+XG&.9X!>]](>1)K+6;84.1L4DJ2*BMJ1;7KM+23O5* M]&4N[CLA6P\
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MW#NJ#MX<$'9X0?PH)5\B#BE]"T-2HOX@8Z2V<7J/!A46/GJ$IZX,I@E*EDR
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M]9N$-3]W-]6?)K7QUQT<3DI[%0"!CE#3X D3YZR]=CF.YEWS#?U.DI4+1^2
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M+/AF?,.@[ER#"-/V][)\;J*. IOFG%$E>(I^O/*5J9..186*2<ONV@K6+,;
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M,Z1]<+(Y>#CBU*8EUYI#=79WW%A<0_M;ME15XXX[V..40>LX,6+)H^N^E_/
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M!@P..ZK[8Z$B<FSH<-U?SA^D3!GI^9M,!OTU*R69RROP9,]OU9$3*FH^?>-
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M?OC%>Y,M3MO:&@BF<7'_F(T\K9HU01NV":K=L?C=Y%"#MP'+)'^]R\9 +(=
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MQ@1PW@%B] *&FI$.OC_"6,Y/6!:G:+*WJD"'8Q:K-4YSK8#I+T(!(Q'CP-G
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M*-,Q'73VF])E5N:S%[*XEG8&F&M]3#&6F\]8-HX_ P1AC,HSY%]Y= <U5]V
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M,N%4/=DYM(OQ6,3+J]:-\W+J^4ER+/FU& ? &SFMI_PQ?Z^)[$61P&]+; L
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M\'GV9B\GZ<"H;0=&7;3(&4 4DYGNXQVSA+?ZT9S"BV"L*,@C#9KYRMHM?6B
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MTV=.#1):XT0?G)^[T"8&J6W2)Y$XSP\BY9P>[_)I!CZ*F)F:&7R_(.4D"9[
MQ*U=6U.%E$LT\EN +"#N.L3-2UI&!A+B5UB7GZ_NYWC.)H98NK;WO&J4F*M3
MHO5OO,!8XG(9JZ3+RPN3S-4Y%]'=ZY[#BQ$WO@5-!3<D;B<Y/E$DLIID7](7
M:@Z40XS,L\MY[IG;D'7SNB+VLY^X)+T,,#-E?NF0;B9DLC&U^];$757"/B.+
MA*M;RE"CYODD/]16!O=5Q8(WK7>^TC)$V4\T= Q!O8Z^.Z9;>?NZ4QWYUGLW
MM:\B(+^OKZ$?K17^!<0V+ 2<^A9U^D]=]#2UG-=SP+#QP1&9!H^U'S.?_>\L
M&L]/YZ5V!V^0EU_=$CD.^OG>^2] Y?W4S_?^OX4?"4?>?_'-[B_ ]I_3UNJ?
MT_8QC;?&E<UU-# Y_*D-Z?K47$R.DQ K$7;%M3I[_NSG<%NMFH>[H!0-H>-!
M*2W?\A)T50D_4VI<6^NGWTIO(U 8+"J>NW#H+G08Q*H7*(L7ECZ#A&EG)PHD
M9VG,9<UCXS-@0@58()B?3[(XLUG@MQ!A[L#;L$[94E*YR/3=)(Q-+_ J7OA,
M#^S&^P_<K27@BX'(WL?K%!4"Y'Y^VO8A"608P%#6T]6^U3^:>_]KZ/^?/QVT
M%]6X]:NQ3+YS<JIA!98O#S-('GU#60RK6)/0$OC9DXM#^.>S<YY7O4'?\>L/
M9\-6HA H@5CV6*!><30T&BH:U:(@7#'(<U2H1K^U> _Z)[!!FD*(9>9]#7+T
M)AZ?.+J::H9L4);0AN?TLL7<0&!S5O'/W,DP\K8 )']@ZUZ#HMBL>XER>#L\
M;221 PCG!)E@3.W4M=^L3?&MKODOCN[M]*&!%95R.V_E2:&]SEG-1;-(VC![
M]=?U$:4OGBQ\.]5L>KI@2Q4 )X\%9_ZD9L6@?R=[VK=$;,KAXAUA:"Q>."3$
MI__GG>==_2W;\XH+'@OX=YAV@YO "K'@&!X!@@HMZ8Y;FH10-2AQ5GML^VQ]
MR3>5_O[)R(#MA65#F[%:T"P7;9ADDRLN]42E;]3M*8/34?/EKCTD@1 O31B$
MD%<SBFH0&#DY#23:G'PQOYL[@K)T.MW\7B1HP.W0$*T1> BW18U3R20.=<62
M_8A_5KEXI.C2'>,#018:]FM>/4=2I(MI<?&*"M]%7Y\K7-]",W)%@EN8)3P1
MU=9X]FC6!=8Y?Y74 ZMYEV6^\F+=3/^TQ92A$ZE\9$]U! ->.QU9R4[MB+":
MOT_/LCXOV\JZ_\IZ#[$QWE2G<-]C;$QT<L\LK:8, CR1!$X)CE,'V5 %=<Y9
MNF<,$$7/T@KZVKZ<?SLA<"UR2NW]C8YU=%>?!ZK*$S=M5, B4E!W8+NC$HI#
M3N:R88S@4^IZIDD6KG+D\ZH/)ZWN.6+J4T9A"5\ON3L+V\CI@K0BGR8*UNS]
MG.5D@H%C)0T2:Z$T)!)<84N096H[0]35B&]\6KOBY-Q=V>L5MNB012V-F]S/
MN<,^B+-"C^K.#Y2U.-51M()J/"KS7%O(!67@@#6QXF5EB7(B3&XSZ9V%3GE6
MOG3AM9G.5PN[P]EW7-38:@?DK6+*-<NSSKJEG5?%4KH6$^K%U2=':B'GX)18
M($R:*X))%#1KS1,3;5WZ'PP-8JH5P>99*R%,_^X>/2\B8?J>_^)0 9@PE&>%
M %C$FC[M&7MV+ HQM5\Z?RRMF0'E02Q,%9]UF^08F[6K"<[7&@*AAV,H94 O
M40E@_Q5%_@46EHJ614E8<\[4Y_SAO3H-C#A>H0@F.P1052WN59.[-_HN_E\M
MUW_L:^5JM":RPR1@XE-<GL8L@A&46\F2BQ-!&L#<<0H2):V1AP9*23"!*Y/U
M458"M/-%NEZ^ZV'H5E(C7N/Q+F7QY)R+4+,Z_@],1\(I:=5GS_ A12<=XX Q
M#S ;0)D%=Q2.EE )YY-N+V14\W.4M@D/&<Z<"V%6R>WO#T!QFWJ=R%W@=QOR
M;K2O\M_M/AM!H>>YZ,K7+4'R))K"&(;AMDAT4Y>ZS<EMQY(%4I4$.%OC>(W,
M%W;&(19$W&6?6@M0)HOM\?H(@A92+\C3KFH)&*OY,0'="7P*$A]8VF\U1#'\
MMV'XB .W]'_1NS_Z?=UO?G)'^^FOR9M6.]J]W]#?T4?/HR;N_K;O^0N(-/_.
M$05\_[7FSVVRWUGK^57Z@5WY+?=_XEX&=3MI<7/\66/&9Z2]1XDIDHLE5*!%
MO@7@=RXD<Z9\:T^!5'>\XP"W_PN@Q)!5OKN 94HXB/WKJE5G!2%2G>:SBZJ^
M+P8EE5M-+Q4HY3F4*=F2%^^^:[6-Y=R-%] %$")8I!</ @3!*++A1,OUU20<
MDGH) \@FXTI %LOWA/V0BWO^;DMKNE3%N6??/ HS)BW>)8CJB2'A5'RT7A8K
M.]-3A(5HZR=OU8YA_O7#NF9,PH@U)(AMI)R,BZX&@ T]0:G+OL"3I727F=Q-
MX>Y >8%9R?.LVUD?D>2,XMQW<!O<4UV+P?Y/Z%%MG\8E'\J\X#G# 1I_59;+
M4-Q$<+Q(.([@S%SL(=36TT)KY5)[58O)*-^N) D(&FR6DBL7L#\RD3_<^Z6)
MY YO1/096$E5;P,9DD-S3_O9FZZ&B1NQ5F^0Y?O'F%@NJ/7J"=$7.A<@_]F1
MTLKCW4ASC./9Z]%T-+4@ CW/B?#Q&+DT3+D&! &39MUX"H!?,#%]=T(E;7)O
MJN VAJW@,WB5E?YT)Z\"%8>EC1,!TUM:P6A>1L5,R$>9JT'7^7)NBU@C'BN3
MX*AMM/EA'S4-=/63MFG57G[85?Q)&1_:1]R#A!RB([-1IV<])+;.;7QLP7R9
M;\CH+!JS?9$H:;9UH1BT!<YJO_X%.0.G%I<3193<BPF4MUT)LZS->U]E#!*2
MJQA<'M.VN34^L%<5CUG[%R6*7E>?[-!<+(A>W=ZSQ#0N%K0\_#''N1F@K]@V
M^&MGT*] U)D5F67.*8.&+/I:V=YND3;YM?^BK6_RBZ0V3P2CRGVME<H?4VE8
MT";_ !AF$RCJF_T]<]KL!-^SPPE-FV%E8Y1H)^?>EJOH*TDLCN5%*$O;"6C+
ME+R_W8KVMOD9X'7.8R^@!H$@_P4D5B#7/FE'&ZD]Z7):WS]![-248TRU;M$N
M)7NE8Y_ZM=*2'/2O$DZ0(L%>8.PJ[DNS]*Q78S7P4[?8@XG3YJX%*7-'N5KH
M2E/RY*U ;T5[3'\)6W T7Q=YA(P1X4W]Y"=B1\OO6)3T8SEEX>5%7DKF<W?Q
M[1H^5X,.WQWDU,K5,/4T$6<LB!!Y1GF=HJ)2E6-:/S7DSAY#F\P+YLF*8Y5E
MC2B (4&Y[@!&#S5\$+["I\Z,[ ?^.MI^Y'!/4!+:(T4LOU::1,Z9;F'3-=$E
MFIP5?A]V>CJQO^T$K(HQ?#U%<I@,-FR2X^[U[<V\#%Y*&T?(C2WPQ2O;/'3I
MIXA-A.:>ZF) PU'3'R\NTI*1TZ.3SFMX&RVE_(IHW,!!*,_I_MN&'=/#U#OM
MN>>\,UF8@F&._]7_#WZW5Y)RM%IR:)(KGFTTUQ8>,PW$@GS#FI\2KA9 /M^K
M=M&V,V0M0%C!JF,-<9(,YLU/42F=P/69>)CNVDCSM4KT):V+K\]Q+MK7V^XI
M8"B+/CPHO&^VC\NU(C3&_\IU_VC*%!32LJ'W1@*F3C<Z#GWAE_CP!:/U"'6F
MPI=#TNJ:,XUKP7/8EQG8<KV%Z,L%KK^?4GW 1EIV<&CIZUSPS9;N2[-^5K+_
M!<6>[]I%T]654G* (RT6[H4N!_N\:E1-1126*6C4GN&;MWB@,Y ^,^OMZ#U6
M\<*7XC0ZLS$D#7?O:XHUQL2+LEM!!BQL%TS=Q9DV3N"V:BW$X(_63F7S^P)!
M!A13DQ"NR!TO99C#N6K1<%DA$616> ,!]P5OZ;;$,6GLV,)Y\"TNUYS.F=^@
MX_Y]]6$>W%WAII IFJ RK$,@9^@Y.NDL8$N"*1]/W*N^Q<R=2)U%F&2BTWUC
M)=]+-.4RKL1;BSJ8LCK89UMGA.R:#%2V^G$JVSE GS2A'%IH'N):W$IU)6^+
M</9.B$H]+A%VA(8A:,!$*NA!L@Z-1BY8'#YYU)O B)C:$5C#?WQKSA5OS8_W
M,A%Z;8$IK?PL]I]-X0^K35=>UA9XWOH+F%X-.;OB4 RV89T.D 6A_@+^WU/3
M/V=ZJ N'E3MYG9[&'U5W_P* )K?88(P_!U2.]X,[+OH>^?(:Q+P-+?()G+P3
M+F1G,)M GO7HM9P;.+KZLQ$SD$IJX9AQNU*F,091E#'$Q-0FG:\1@@W/'6/]
M%H$5O15E%;,7':2VIQUMVU;!9^!W?I)5Q*Q^W 1:L$P="!F#I"[X,GA;9M?8
M5?K:OHYYE9?V2#>BX-<>2V\A#[KY:6/RG4^UGBG!HD9!VV*FZ>YN8/JWX%?&
M2GL :&VE_/*]*;+3-]$-3/ZRJ>-"USP0#L>+=LV!''@8PA:'WP'EA@=$.,=9
ME=1L(B<IYOQ>G2HN2P>I=SCZ)[G?X+_UIN0X#*TE5B.=[-G@Z>N(5=O5$XM>
MUO!GQ\]"-MPZ1Z$YSH,NUE9Y%N,T8PSTQ=OMNR?WO"/;9L\]A8"EZNT*3+_0
M]?<VBZ6!<!_I#(XS) Y0XMY!H+G#MQU2$\TR1JLR*H^3KTISI<R$0\VQG<>Z
M!:.1]L9)K3/2,\?R04NS1#M;VJ;FG#P\N&\BB'^UUNZ?-6V-%YF9<!C"E'C-
M/B@]TDX[#M4\'0B$0&.S=3/'D3;F[2:BZHF=H4&$]-MJWNY<)7<S'_[L+'(I
MYAHJ'\#&"XBR,A:^*^4K:8Z'2M2'PUK+D$1V96XO^6>)EI9#.<.+@0;K3%7L
MU>4 V6O3^1/JJ"-@Q8K T;TVD-"D\ J;?1YJ<EZW.J/>&5S,(VOE+GS.S+!C
M5V__P$M0M'6#KR9:#GNZ!J(9!.;%?V^,6"*,FE=@QLZ8RB<1.$9]TZY]6$&P
MAH/LFG63*97TKVO:76*6 4X]^Q_U\\KC"LS"1DJL^>%"F"L+R-G>5,.J$RET
MJU?1Y9K*@KYAE?:_ #M8;$"PA)*8RSITS1N]6P*'/T8@SJCP@XNP]*6<4>=6
M'%E<]XG&_%=J=]=JN?8H>0(F%, R>3?XV>=[3O76);BH-M46^NG9O-#"6@T3
M%PC_KI!M>(N-%GJWT-OITRU3R?[(EGE)/:1C#>$=.DBKB&\UJ18Q-2O\?+K\
M*K1S)GGZ9Q$JULZXSD-NG*F/G&A>IZ;2],7$E^2&U/U%8)]0,W4J,$;_DZ"&
MZ%=,^OM^[0SWT'R_,:D8CPHB>=:+F8- MT488/,7].ENC>!/;F9%BO[C#DFY
M&S<J<Q(^B?.14^81LE#V<=OHB;!QJSR*=R0DT.N+&QX$M@XX=";XF+"M!2J(
MX^H5+OIH>>IF=M3L%S5]JK&9+^,\>.CUV5?^6=KY^@I1MR:ZG:@Y,FO['=PZ
M"APO[#K<_H-[3S-=9S!6S5S^-K)L1L3Q7;J4PD7RH:,A[DN-883XPLK=;^M/
MC>=+!]$T\JO:T>FME.)HBFM37/[YW)"4?9 AFRJ@"C/541\0DNQ;3<WO<>XT
M(YNV13I(\K\K@73MW *U(BC+;.Q(>" S@%<'7+/W*NJF[8#-D8*1QZPG&,OE
MTC'H26F78U/0K,:#=-ETM+A "2*)Y(5O/WRGAC -+=F34Q1:]#)_)4=SP::@
M!*4*5]PAC'P]4HLGK07E/QEP6UZ/:F.4/RPFT/]@5X=FBF6S&AIL :M3IQ>I
M^8*6+)-!S?/.NCAAVZ"SMUUD[]CX5%6IJ-/OM'83< M'9J?6R6C,XK!L,JO2
MIGK^^2YL,[H.$M4G\S%BP*CZJ6_ <$"+8Z&5XK[M=.=[(-L_WJER:/$EHS0K
M&R7G/%3E.=VA]Y;P;3)\Y*@]W&;H7I=^IB)U& )]^CPO.>:+MR[*Q>'W8J&Z
M7<L2J7;![UBHZ?3=RV?#X'3P]6@\0;Y8M@2&"L#Y8U.-GBY;?"D@TR#"#\R'
M<BXBSVW'C#Q+\BX*@,$C5D[L\-(2K!@*%60#NB\0.?YI1>SW3<YAF:UJ@0J<
M8^I[GD4FX$(,P1<"=%QB3W8Q_4#[SGGR3O4* K4->O,7T%CZ?W0R3NB#ESU@
M1Q6_?X8M-U?.1)S]4?'H'XC_]!_MB[^ TE<_FV/__"SX+'ST<N=A0X^O=L\/
MH+(\\@RR,&-;Q!0-1B:JP'EX<$D2DNU(L/?W?Q= .+IZ^G*&N^[,Z1#*05D8
MS:+$F);3MBW'OIII8RF3*/Z!:/08([UVVVOILG>'17JYL&G:=+D$3R )IH.&
M(=^=!5F"34#&PD4I:O7YE)OH<QG? L76#_$0[@&]KV5*YF$!:=<0NW:"8GHY
M/]9UXB41ONV!.0YRPTYD$LC1=$90R]OV;>FB:.RHTA86S(9I9:@N9CT)JFRY
M\YYHE5Q4YO^3>U3_/KG#(019>"<X90AN9W">%+L.9 /"0?S%"RPEU/RXUTN9
M.Y)<<,9M[.N76'-2*T-6/@BHG=Y_ZZ/7TMA@BRH/M'#S!]$SW-2A:WC+;0-F
MP@CUZ8F_ST(7]>*8;J[<H*4FW(@X6M\P+>Q=R1)(>5H KG,[/U1U-OK%Z/]-
M2062#4;#<SPS3)A>>,\?\?789JT:6F<8ZMQXUX?IKQ89>%AT8[^85_E*/D>K
MM#'$_<0^4:/FC1FZM]C&6X!;\?T):Z&HPK-V]:*=[.07JMX%]\^ZOBRQ L-?
M Z7+G^JI&XV-\>7DX/F$91DX+C1$IO#7/LX P^8 %SF5BLF7F*6G+N]<?.GK
M4N6G!GV+>1H0@,(]1_<-@]G@2/77E?+4J-,C]<V+*-OG[.71-U>B=X98=5:0
MJ8 _S:F")<[OL<(/UBK]> CZ%G<PL_8.#Q?&AJ95Y_5W3V]45"WAQ)S"J*A
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M&WU:^);R=YMKA]4H&B<E  +X6$?OT0NM]YREKL,F;/O1K6YS6:>IC5#4WE_
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M2%M60*X0$J;W1#(6=BR+K?1KRK&1,_,*MYWQGG-%FL8\$H=[7AO-OM7_('A
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M+Y/&7D A''*"%^/4)-5JJ HD.E OJ07T$]F573FB^NQ4.6O M";UF>N(C+\
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MF!VN?-6W<QANH0HL"P^6P4-K9S\'UML,Q+-53V>R+O/+HNIEHE<"FPO,_P+
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M)ABSYII"X-TAT_?S9'[!(-ECKKTZN7Z)D5ZMDFB%QY9H46>?1[SVU../<L'
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M%NE_N^1/6HCC?U<SE?$0:(KOQ=A]2+EN]']@$]_%WHE*F0T$(M_J8;>, ?L
M]U0+X$3=WXET_W%-YY=^D;R14AF<\GNWY^YX:UA4J^B9U[E<G](<V]./^W1[
MRZB-3[;?@:+P&?9<)HG:,BKU5_K_$4WW9XGU)H6V+VYML'OH751^\/YF<\D#
M50)7@=>%?^Z'?#[Y+W8F'@FVO&FM>M2Q1S8UA]3BZ\M&03 R\! @)LMQ'RK
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MW!5^AFIX*5U<]I1V\]PPO8.VVN.N2D=7CZ5!#8>)$ZM6'9'TA>0O.^L,')4
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M\)^$(<RC[\\8)BK:1;@>*(2VX4E?U;?OIG4XJ)8[KH]!37Q[K"7693T&3K2
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M*'#S-T OUM(84_AK8PP/W$CH<$/*V)P="B_N0-"Y*O+[S7M^H$^-^1%,_RC
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M"T: $0< @>%+,X;T#4Y#4M."@JG+(#5D0J-V3:8?Z7CS#0&9"]D?\\V.C P
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MOMY)4AO#:@_?\D#,LO5X[_?6FAKAE)_H%TJWTP"*KBV[Q4C,3@,;3CWNHT+
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MQRFDT^'L0!F=4J4Y#!^^P.#JH8$A):<51!E^[N@M=?5U-$/ZJHE<U*D.9('
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M:\.AS]I5L:WLR9.K1!PMQ\R /P=%0YPUBO?E>GONE@7C,<;'GY!<H"JCTQ,
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M6 %U2B8HFG?#?[PRW18Q\U%P6QRS))NOAV #&<,P!#F2"7'5V.J>>JVG.:;
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MA&QGAH;-[2C^( QOD@_+G5=#JOZUY/[R"?Y%([1(L<5.:*#&?Z(K0H@4&)N
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MKE >-3T9(]#[I"GD^#F>0;W0J$S_=*K\ ^Q&-OBIU "XOW19@G.B?1\U!UI
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M.,XA$<;^I32+(HRI1-(KTU!+7U-;@DK90.Q9"KL%2[?5(1!" U.YE1*48MZ
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M@YR [04%:R.I1S+]2X"V3]I0, T\>1L('60$G\(@Y%%O( !28Q4<\$?,K^[
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MDS&5&*I8"H@HRR$E&,$D386.=!QERBL^L-GXU,B@*1M0WVS0D.,=R+/0N5%
M5T &GO)-L<)-[W/*!IK.SYH>=?J>4^IXNIY]IMOT?*\V92S(>F6/7^5/3[\6
M2KY;OITO#0$8$Z(.:S/VL4VP-E]NS>]J^\(&O>TVN"A7+,HQ@XKGO*H)S25.
M8802$N4H4Y%?C$<8L:9&":6G3)>>,COP0._4 6ROSY_]."+0^+FQR_BC,C O
MV1/8*G2M5LEF,/[!:@7FRS^"O6+@H-D-..@&#LH-XAP)BW<@:@PDU*BD&A;(
M8SH.W/K01#Z+L*8Y1C'DQNB"*!4"4L$(C+2.\QRE$4OQ;+/:L$5HLO8BY+T
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MF3H;].19I&[X07?CZTD-Y<#LW@QO>1:LU%#79N<Y&P9C=;X!5FM0J@T:>M\
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MT46U6S9#I^^,M@>Z*&YSZW/YH8ZW\&UZQB_FW=MO\\(6&HH3)!%,.8H@RJ2
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MCJ=%K7![GA*% G&\TR&S(.U%;MYXO0&5U."W^L]!8K2]@ M]7M3:Y\N<$[G
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M'".!D(@2%*<^O-+2U]08Y54CA?E-G2D2L+VXW?-'MN'M1C.!4!R88&H /U<
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MBEQXH4+0FLNI74 TQ87"2IBP5,H7.AH;\]>W#590'9H;^1*4?B0; Z">>?*
MS4 IC*] $BWO^H5N!LZ[WJ[L:=[U*\]WC:[1+G=NO>+=+:KKFBJX>><6EPB>
M*4YSF* \MXS@JC(P::"0DM),,(-3'!9?<[7/L=%$G>6O$FZ?J,!:!X^5+D!7
MR@3'V%Q''U%=4(0QY+S 5497AJ6&.%%IDA9I1K-LNG$)%%X'_7W/_:%?IH>(
MCZP?44?&JV?.KJ7=F;#E=[3Z\N[R1D1SZ^P 4+0XINL]#AS)Y W!:2R3_ZOA
MM^-?OB^_?%MNU_9K\&&VT!NM%_</BYG8KEUI]\WS4;QF??1O),=%9@Q,,2H@
M80F'EOP%3%2!"!:,4ZU\+\H[]#\VZD>69$$M-*BD/GA) R>W_VUNE^%H9ZD!
M0.Z9L:ST8"<^V,G?#GB'>_0NR/M?J?<\ @/=KG<8B3@7[#? UW+7WJ75P:[=
M;U"Y>0-_2S/AJ\F=E*NM5F_LQS/)Y^6IQ,Z88M8ZU3PM8)*S!!)1,"A23"&U
M/Z:,JM2N*+ZK1DL_8UL=:E&!K&4M#:Z5KMP; \M?ML%[?16(!%K/;+_#:R=F
M=4;>(:JK#2Q_XHX$VD $W16\(#+V@*2%=-O>'HQ</51HDJC/XS=Z+K4=_'Y8
MEB7UM"KSR*[+S6[S<R?/A^7FW_3FY;'PK\M5_2?W7#H50M"$9@+F3&)("L0@
MUZG]B1N5Y9QC^T G=ZA!Q!\;M=>7>,LGNWG^_FTFOY7! #NU2G('WV?S.1#:
M,OY.M8DKK_2L^:JK*]8P7Q6_LX_Q?@%>^XIPK_0NO[C3TOYU8\=^T[@*GNSN
M@IV/:D/9'OS.!AVCV,YLPPC_.AYR@P[,1;>[8:4(6R_7J\WT=_YC]K!]J/?>
MC+-$":(@H<9 @E0*N: &YEE6,%44 @FO.F8G+8]ME:F%\ULL3G%JY_&;M.^9
M8FNY(GKB7M2VC:SL2PVBLK\=2.JTO4'XXZ(:NZE]^8'.M01?!F?MHQ$+C%.*
M4P2E1@B2A*2PT*F"=CLOBQ05BN*@VZ>6OD9YZ_0B -15] HN(G@17#\C+!)D
M/4]G[XI;YRMM1:TW> VN>#4'+_8T=-W!:RJ?J3UX]94(64:^Z-7#;%'^^-&:
M"ZM_7<TV&VWMC8VU15SX#D<TSV"626[WJP)!D1L%L<ARF1)6&.[ED1_>]=BL
M@--\(Q.P.2@P 8].!?"]T@$L2B5N2(_1/B[7#QO[0[OWC=W+Q!@3\*4)="D]
MJ,4''_H%^H9D)-$ ?[6,)+< ?UMB$B_L0K*3M#?X>BE*O!1MS5/BU\+(3D>G
MA9!*<XD@UYI"PEV$*&$&)HE,I4GR#/FY,/0NZ=C6H<KFW2X.YYG'AYZUF]M(
MCC9?^Q1S5.M:M /+*L;A;W! ^7<YB_Q/<NPX^ ECQ^7%E6U[6QLUK@K+5"'-
ME#8IE%@;2$PFH4@1@4IKCIC!F4"%;W'$9L-C(^^=;&7E'_]:B$=8M3/J+0CT
M3(!^R@>5/#RG::=2AT<-#5;B\)SXS=*&9S^_H4J1M0_ME@;C-'-[=YBZ*49P
M0:'(,@I5RG3&3"%4'A1(=&AZ;-.ME,QMS*4&/\T6X(_/;\&C7H&U^_O/'2H+
M50#ZV33=8!G"" &E5)'K^QQI&K-L3]7P\-5XCA0Z6V3G^(EN\_)3Y8CVD:\V
MSU^L,;CFLLP2\\MS\Y.R#![&F2:YM'LD5SR8,(0A3["&69&HC*$L%;G7(AG>
M]=CF=2T?* 7L5&HP ':_V=X/F#VSP1&.DW[*$88#$XD\ CH>E%S" 7E)/AU:
MB%G:L+%I_>7Y?*GU.M-8(P?6^\5F-5NL9[*LQ3IEU@;A.3$0)YFV7*8X+!B3
M4",L,LMC-&-!QS^]23HVZFL(.@%W7[^N]%<[XF O=%5O> +>59G'!+=O^QZ/
M]S_L 9;3:P_F@*=!32V/JC**9W#VU*@Z'JJUM3\TOQ,OO@E]5W&,."J]UGJ,
M(><(*D)&A-NO;F3,#L,/B=XM-C.[DBEEI]ZZ_L]OLX5.IP@5*&<&P2PG.21$
M,9<K.($Z)487[H^YER-U:R]C(_]*4%"+.-G] )RPX'X1<*)T&=CKQTM1X.J9
M7CLC%73\=!6)3F=1EUL=[&#JJF+-4ZKK#\>;^&A*39K;N9] DFOGD<(XY,PH
MF.=4X4(;+(A7JHO67OY6$__+]^7M$Q_=,/&#X'K-B=^&5)2)CWJ9^.CU)SX*
MF?CHYHF_\V]8;#[8L9ZJ5%*9INZ\BRF7WB9UR1)SB&11B 0KJOQJH%SJ8*33
M_2 D<%*&3O(7(/K.[^[0##.U?5'I,*'/JW[#7'[1X,#3^+PZIS/XPG,=ZQO9
M)M5LOG4A[9^UW*YFFYE>NX;?+ET%I2G13))42VA$6D B5099H104*$?,A:%K
M%)2KZEJ'8YO<37G!0>!)^6T&?U5"!QYG7P7=[^ E)I0]D\&-*(87)/*$)E8%
MHFO=#5MRR%/YDQI#ON]U3I6YTGRMW^KJO^\7526C*C#\MQD7LWG9XY1PI!DJ
M&,0B89 (H:&@6,%$L!SE.LL)#4JY[-WSZ,BGSD_0+1F>/^!^?-,+C#T3STYF
M\--.ZI]=/'E=)ZU./]@0/6KRS3"TXF7C].QWZ/2<87"<R=<9V$ WFGH[6\OY
M<KU=Z7O3/%JM+^O*9!8G)ZOK0[9:FF8$951"++&!),\I+$BBH"$4)P4QB!(=
M0EXWRC,V2BNKE9R[27$)E0()[M:A\J.] 0=@P%NL,S[-X*]>LA!'PB\2/=XJ
MS:"D&0FZEU0:J]EN!&L;G:WOS<OB'R<)U(VE2F%RJ'GN_*<H@L*P%*:%*G3.
M1<JH5_ZSL&['1I>EU"[4]Z-M=1=45I516"[65G;%6[.?W#("?O08']>>67 /
MZ4'D8=*QAR$5B>\\.QV4UL* >,E>@6]WCW6H$K*\6ZBWEA6G=M])C%$)Q!PG
MD"1%"@MF$FO790GADK(<>_E 7>QA;-2S#P"H$RY9,8&3,SP0XAC(ZR?;-\/3
M,X,$(],I2N*L]C>%2QRW.'C<Q%F%S@50G'_PU9TB_U7/OGYS$5=/>L6_ZG<_
M]$K.UI5?^:?E?&Z6*_?B5.8DUU)JF$J7[YMB ;E..$SLMXDH+G&2A4=L#*K"
MV*AH)S8$M>!@)_F5X(BQ?"7\3*EQ#_2 F].H+I8[*"Y\=\!?=\)=I\E-S/)C
MKS:2XW/+]%7@[^JO&3A /3IRADIR:YG-7_EL5?J,5M4U[A:J<0S[N^;NA$'=
M+SZYNZ25E:^TW,NJ:X=-)B-Y1A/)89%+:1?+0D&!,PI%:KA!5**4\F[E-2-(
M-[9UL%E6\]?9@B_DC,_K0C3EH4!#0[!3$? -<%A4'N; '1^ O=*@U+IK*<T8
M7P#/I?&UAK7O5:\YHOM!FEP=4SN*+\:PKJ'9S]%%+_!'+Z,90[97*I\9$=;+
M93-C=O(ZN[%Z27,BM2UV4XP*:3)#("%&V']X IE,,RBX4*F1+%<RZ/!X(+G'
MMM[4T@-]$'\"ON\V8[RVI_7.GBY#]R= 'P6S@9^V:W5;'/\ 7YAA-F@]? W^
M1KNR=\UOT95=V7BV8H%C-I+]EZ_4?ZM-5^!0Q-YIA78?GN[UP]9EG[XW;_63
MGB\?R[/0U?+KBC^LIY04BNB,P92F"21,4,AXDD'-L> Y3@N6>B5PO]+/V):@
M2E1G'JN#L':EJ:3U3R3:!FT[^4<$K&>RKK&Z-Z A)_@8%2O_#*N1,!LHG6I'
M[(+RIGH@TI(DM>WMP3*B>JC03'_J\WC7J*,WMK$5G[]?*/WC?^OG*14ZR7EA
M;7[)*"08N419B$#*$-&4F)2B/"SLZ$4/8Z/&.L*FEA*48@(K9VCDT4L@KU_0
MW@Q/ST08C$R'Z*,+VM\0?O2RQ8'CCRXH=!J =.G!CD<"6['6_]S:-M\]V7_J
M,BPR-ZE2V.[==>)F=")@P:WQHTQ!*-%<)(H&;>#/]3*V"7T0$I12!FZ5SP+I
MN;&]%9Z^MZ$OD(E8Y,8+@EB[NK-]#+L':U/S9,?4^G#'B,-Y.19:G=^.U77;
MIRQ-N4Q) HM4V=6<9@JZ2ND6TR0Q0J@B%VE0W*%7MZ-CA/)8193'*K?G#?>$
MWH\RX@,ZX%'6V8S>[ZY@&AZ%& 11K%A$OTZ'C4@, N(D+C'L[6ZT5 83-:Y#
M=J6/<<%227,%4ZXE)%P7D"%IH.:%$%IF6:Z\CEVN]#,VXJD"Y&0=(#?W") +
M1#631EBC3HO"N<BYPRR5<IBJ7!EK]A&!64@5M!BH#E4!+0Z"?B0= 9>>6;GZ
MHC5$C%A]VQ.%2,1[J9=!F?:*JB^I]=KCG2.]EP_Z\\9R=GF&7OO731-"$ZX0
MLKNX#-E9GV:PH 9#G!."$FH-.QJTJ;O0S]BXM*[=MY?3Q^,P"%<_+HB 5L]<
MT 6H+G'9;3#$B\(^V\O0,==MJIZ)L&Y]O./YC@OX?;]>;[5ZNW5>)95W?VG+
MK3_H[^5'ZZDQ"4<YIC"EQ-I9Q+($QRR'.$F4RA"AA4RF3WHEEMY'/EX=AWS]
MF]WWO$]9@UDIN4M68$=[H<N<T>#[;/,-6,XN[^+YXOF_K<':J0F6Y14E>+0M
ME;432E^+=:BSA=]0*<,U$B:%C&(W5*F$=N@*B#C/TXRB/$F"(MSC#]1@@>R[
M4>H;<L]3O.A ]KTE+S&L) :5R'5,U:3R*'$9@O3WZHF(N3G"@(IU^.?7Z;"G
M@4% G!P/AKW=;?VH'!:5TNH+__%)2SU[<AX8^YVD5*Z(-H=:*@Q)YE+3VTTY
M3$Q"D<B$1DG0.6%[=V,CH3_OOH#57L@PZKD"K!_EQ(.K9ZJIG-]+25W9;'"0
MM8<-IQ\JD7CE2F>#\HF?XB]YQ/.M<$>!.HO9<XK$E]EFKJ=)0@Q+&(>82KL#
MU4K 0AD%6:X)H9QHB;TRBYUK?&S<4 KE'*=2])/X>9=U+\ [X 2]=DJX%9.>
M"2 4CB"7@$MZ=_(&.&EL,$> 2VHT?0 N/M/!W7&Y<+O-K<7U>5_TTMD4E<-E
M?8.=&RQ2S3.8&></8 H[9Y&=O:A@N4)2,LJ]YJQWCV.;R%9HN-Y)7>_T0KSY
MO%!NG]N]8-?SA'>P[04&.XE!M>>H9+[N1M 1S0 OR=BH#N4O&0/=,._)$*3:
M_"B]VAG.HS)$K2/?RJ 7NVV^]A%CAY1AC?QY6*>%2.W>*TM$ DF*4\@Y$I 5
MVF2YIMCD05%6K;V-C94/T9IAVZYV2/UV7=& ZIF"&V''#4E[RC/H!4JD/5=[
M7X-NN;S4?KGC\GOI]AJI=3YSA%&ATPQ!;:2"!*4)Y 57$$F5"LHRK'50$OG3
M+L;&#B]JGG9*$W\&2#]ZN V>GCGA;!73Z G@+T/00[W2UTCR?EG!MOJC41*Y
MET;&M^7<OK%^]\^MW0N^S!PI<B2$20AD2F:0Y-3^)#6#W!B1)XPE @<=RE[M
M<6S3ORGP?P.5R+LDDQTNB%K!#K@;B@7A$-="%]#K-T6G-THQ[X1:^QO^.LA'
M_;,W05XO1G4B*$V8PRUIEFB*D,H@)CFQ^Q&>0Y8H!3$B*LORHC"(1O$A..[W
M/Y\+090[[!>#DV1%@3.3N-%PSE_<P(+E&>1$*YQE*F5)$<%KH/O0#.;/O^[+
M:^ %X@$+0TP<AU@<+O@,U,F3!G09. ]3OQX#+_H<@\/ >1@\_04NO-QMI:A6
MG[UKI$&Y4MQ8TS-SN5@5EE D]B=L^88QX2X62 CK'#<_-GJII.OL7_H".S_^
MZ(Y(ST3A#T8P&9S7.=*L?]'XH-/[O&(OY_&%IVX(O*D2DNU<3Q*!E*%<09W@
MW&T?D7,PU!!Q:@T%6F0"!_F)GW8QMHE;2M@A,.08-[\)>QL:/4_:*ARDDJZO
M2)"SNL<, CGN8/CXC[,*G@W]./]DMXG\9L[7ZWM3+O*_S1;Z_48_K*?VT40B
M5SH4XQ02C1+(B*&0%3+5ALA<"J]BP*V]C&TZET(Z7Y/*6/W+"0I*20-7Y/.8
M^LWSFY'J>:IW 2EXPK>"$&G.G^]CT&G?JN;+F=_^<,?)S]??[A;*_<=9!T]\
M;@EE??C*YDKF MLUG">*62X@ @JF<JBD2K3A"),LC ;:^QL=(5@YJZI-[H>&
MQ+=PPQ7(/5DB'I!]\\5M&(93AQ\RL4CD2F_#THF?ZB?$XOE:N"/OW8->*.?5
M].N<?YUJE]Q+)PG,"LTA85+"@N>I2P[$*<)8D,*[%--1RV.CC;UPP$GG[[E[
M#%<[$=P$0L]3WE/_(%?=L[IV\M,];FDP)]VS"C0]=,\_T&U=_\?R2:\693CH
M>CUSA2:DOGMPA=>F!<M$)K,<%JFVNW1F<L@4EU!F1@N2*9$;KWQ[U[L:V[0\
M2 KX7M0)X*6PX*?M(]@L T_T6W#V6\?CH-?S?&X =]< KI(SWLI]'8M(BW9+
M1X.NU]<5?KE4>[S1C3!^7R[T\^]\]>]Z\^MVH=:U0[0@.#-$:2BH2Z-#5 89
MXQJ:7$OB;O^P7_;B]F[&1A2EE."A%!,8)V<8*UP TX\1;H>H9S:HT*DD!*6(
M/:3U:T<A$@]<Z&10#FA7].7\O_)T>"S/G04E/7)#_VB_)]_X6KO"[O47%RN4
MY(FUV:5R)@.2'#)3$*BI?3LO6(ZEURF ;X=CXP,G\B%6HG*[V$D-/GH[7GCC
MW4X4?:#8,V4< _CY%, .$3U>2/H'],1&=*!XGJO(Q@GB"4&G)8;'JYG!0GA"
ME&I&\ 2]U\T<._CWWYMFTL3:*?C-<KU9ETY)HE'T8KUW 4 &)82R%+*44T?8
M&>0H0S!'3 KGL85-%F*VW2;.V.C\H(V[QC@JC[/S<B\UJI.9U'E<=UIU=M.X
M<4S]K,?A1JKG)>-*VM=>_$/B@!?).+U1F$&-V#C O31V([4:\V;L[L=L/35*
MI#)C" J)."0"N[ H:JUCS'E*!-.2!9V@7>YJ;,S9<I?CQ(UR$U9"?,LE6"AP
MKW?_U8Y9I)NO)AR]7GJ5'8W@OJNIL-]5U]$;7>O:?.$_WBO;VLS,9$E351&=
M::J$L587AUDNK"U68.XNTS-($J8$I\0H[54I^6I/8R.+2M@R:].QN*"2-[3>
MS26 K]^318.M9ZKHC%B'.CA7T+BA'LZEE@>NBW-%P=/Z.-=>Z'"XMG6FR'S&
M+>7\0Z\>^.*Y/I?064%IIBT5Y*FE I((R!G)8:Z*5"$D15YX1=6T]C(V0M@+
M6BZ'M:@!!SX7T?0X+XN!4<^S_RP\70[&+N(4<!H6 Z^!CL#"OE9AQU[78&@[
MZ[KX[G '7-?$/SK5NOIP. &^MR):0GW2EU,NV>T2HH4SCP2R3%@H"8LLD9!A
MEIK4?IAHKYASO^[&1HE[B8^".0.RA'D@?)T=X^+6,TT>((N5&\P#0W_FC(OE
M0!1Z,Z9!K.H/40N]>C0R&,_Z*]0DW("WHAYA;=[PU>IYMOA:!G!.)<]TEDGN
M8BL32+3.88&E@:EA.DFS(N>!D1X^O8Z-A_>'--+]H ]R1SG1>H'X38=;W7%\
MK7.N"> ;L)/Z2NJU6&=>YU'J]_CK19]C. D[#X/GH=B%E[MQT<?54FJMUK]:
MT5W N'-<NS<?5[:WC;LVE>6MSI0:NRDVA$%CC4)()#&06\,0TAPE!<H1SG50
M"*E?MV-CHYW4P UTF77"R>TN*Q\KR5VVCTKT,'[R' 4_@HJ/;<\,=0SK^P:L
MM=#@XU58@PDJ#*5(#.79Z: 4%0;$2XX*?#N,I-:KS?23NUDN[YZX%)(G+(4)
MDA02DDLHJ) P4RKG.B\DIUYG<T>MCHUB2L&";NV.06JGB,ZJ]\P +O'N;+V9
M23X'OVONKI9K9X(X-W%G]6Z;T_:%QGRVOQWF\G%;@TS5L^+O9N+Y#\//A-[:
MN:L_6%OC][?_Z^WOO]SM=MB4Y5I0!A')#"1)AJ P+'>Y!XU46!C%O3S-+W<Q
MMBE82@F<F!/P^]L)^%_V_U98_W.+"TA>/^^Y'9^>Y^D%:#J<[5SZMGF?Y]R.
MU4!G.*%?IZ CFW846HYI+KPXV-%,N^#-XY@K3W;;]E2).LZD;3X45TVQA2S/
MH&4\"8E)-&1)+J!("ZZEM3NR(J@JW]4>QT:#E<!A^YCKL/IM8:*"U??U8)U<
MYVQR]E[<(;W1B;1KN=[?H!L6;_5/"M][O]C5U^C]PLY,V]#L2;_E&[Y+)$6E
M2!&6!$KEN 23%!8Y32$SF:%9@G*:>!WE7NMH;!12^\TTA 5.VJMYJ,+0;:>4
MF)CUS"1=X>K@9=2.Q0U.1A<:'MC'J%V]4Q>C*\]WLS%^X8M__S)[T&_UXW(]
MV^RB37F:"T1D E%N"D@X2V"1: 25QD3DJ)",!B5S/]_-V*C 20AV(H89%1=P
M3*A!B%H(,Y-:4F5)!@4NJ+72.%&&8*R4#,M.?3N2PZ2CCH^EGU5V.SX]$Z@3
M$!RATT,$=#L*D4RN"YT,:F>U*_K2N+KR=.?;J4>]VCR[^+W-W4*Y:[!'MV?_
M8ZW-=O[;S.BIYDF*4IQ 8ZI4: P6F>"0Y%P9))(,2Z]ZA@%]CHU<WZTWLX<R
M/FY;R@CF5L@R'?JSYJO0;.@^H'O?1,6$LO]KJ%+:21F?NRGOS/<23T E,W!"
M1[V%\D4HWA74U1Z'OG_RA>#,Y9/WJQW/B=3_V:XW9?S:!ZL.7W\K4Z]]67[2
M3KW97'_0F_<+N7S0ORW7]N_NLMZ*]3136OWR;.50[Q?W5DB^F2V^WCD+<[:9
MZ4/T:))GG,F,0<-*A_,TA8)2^U-JZ2Q)&.4LB+WZ%GALU-?0%VR6KGA[I258
MZ VPN_ORK^[GTH%HNZ[J=RQW"@*^U_!? H^Z^OYF>)Z4C6B\^SYH.Z@Z ;6R
M59;*B1ODO<+ :@PJE<%/3NF?W<>E]]-.<2">P4]_5%^&G\%>?7#0OY^#NX$&
M*]:Y7]_B#GML.!#X)Z>.0_7;L124GMM/O_Y#+VP/<[N(WJF'V6+FVBY]8'^X
M\&Z]/BE)1]*$944&$R$T)$AGL! 4P41BBH06><+#2M)U$F-LJU$M?FDZ'BL
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M\&[9A!F)(4D5X3A-.<F\O U;^A@;<5@Q824GV GJ;Z1<PO&ZO1<!G=[OH4Z
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MW]F_'U _.<ZWP9?*!AKCWEG/#4JE"*@T 94JDYW;X4&=ZK)DKQ X:!23)B,
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MI__Q7W9_L?^X<,C_\5_^+U!+ P04    " !@.VY7BUHEYT!K  #%T@0 %
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M<YW-1-L31-XM5NLP^W^FGS=.-5?2%$GG8!3HR:D."ER09 $#,V3^M*)#LQU
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M_3(LE]^F\Y/_&69G.$&;$W,E@)3!@1(4F_FH!4@6!2LV9&0/A;F'8&<GPGK
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M;[U@QT?:9W3Z QW1FF+3[,'57D<E!Z2S6R?VX$B)0P#U"$GC)M*'@51++70
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M>HJO\/-B-5U?<"%%9(4A[3/KZQ%?&Y,Y@Q!D02R2R>!;OP:ZFY)Q(]Z!(=1
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MFW_^<&NAB;_Z_<_D1I>$)[P!HJ6[N@.Z*8K+6Z ?#U?2SV&ZW$PAN^I9=-G
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MKHI)KO61^#/+Z>K4>!^Y/Q-4'\7R#GR3>Z1\P.7[Y:8.?%N;=+ME!F>%<R5
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M8FET,S(R+FAT;5!+ 0(4 Q0    ( & [;E=4+'5*2P<  ,0@   :
M      "  5H/  !I;75X+3EX,S R,WAE>&AI8FET,S$R+FAT;5!+ 0(4 Q0
M   ( & [;E>#LZHY8P0  %82   ;              "  =T6  !I;75X+3EX
M,S!X,C-X97AH:6)I=#,R,2YH=&U02P$"% ,4    " !@.VY7I37RGB0< 0#W
MZ0P $               @ %Y&P  =G1L+3(P,C,P.3,P+FAT;5!+ 0(4 Q0
M   ( & [;E>+0L,!PPX  .:5   0              "  <LW 0!V=&PM,C R
M,S Y,S N>'-D4$L! A0#%     @ 8#MN5_^#C&A8%   1+T  !0
M     ( !O$8! '9T;"TR,#(S,#DS,%]C86PN>&UL4$L! A0#%     @ 8#MN
M5^43 CQ3.P  Y*4" !0              ( !1EL! '9T;"TR,#(S,#DS,%]D
M968N>&UL4$L! A0#%     @ 8#MN5X+/\4);A0( R%(# !,
M ( !RY8! '9T;"TR,#(S,#DS,%]G,2YJ<&=02P$"% ,4    " !@.VY7*.LS
MN06L  "72 < %               @ %7' 0 =G1L+3(P,C,P.3,P7VQA8BYX
M;6Q02P$"% ,4    " !@.VY7BUHEYT!K  #%T@0 %               @ &.
MR 0 =G1L+3(P,C,P.3,P7W!R92YX;6Q02P4&      P #  F P   #0%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
